Page last updated: 2024-11-03

propranolol and Angioma

propranolol has been researched along with Angioma in 675 studies

Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.

Angioma: A vascular anomaly due to proliferation of blood or lymphatic vessels that forms a tumor-like mass. Vessels in the angioma may or may not be dilated.

Research Excerpts

ExcerptRelevanceReference
"Our primary objective was to review the current use of propranolol for treatment of infantile hemangioma (IH), specifically regarding 1) the age at initiation of therapy, 2) the method of initiation, 3) the use of other adjuvant therapy, 4) the duration of therapy and relapse rate, 5) the adverse events, and 6) the outcome."10.25Status of propranolol for treatment of infantile hemangioma and description of a randomized clinical trial. ( Bauman, NM; Greene, EA; McCarter, R; Menezes, MD, 2011)
"The initial recommendation propranolol usage in managing infantile hemangioma was in 2008 followed by various researches assessing the dosage, efficacy, and other parameters."9.51Itraconazole versus propranolol: therapeutic and pharmacologic effect on serum angiopoietin-2 in patients with infantile hemangioma. ( Bessar, H; Kandil, AH; Khattab, F; Nasr, NM, 2022)
"Although propranolol has been established as the gold standard when treatment is sought for infantile hemangioma, concerns over its side effect profile have led to increasing usage of atenolol, a beta-1 selective blocker."9.41Should Propranolol Remain the Gold Standard for Treatment of Infantile Hemangioma? A Systematic Review and Meta-Analysis of Propranolol Versus Atenolol. ( Carroll, W; Chen, T; Clemmens, C; Gudipudi, R; Nguyen, SA, 2023)
"With the emergence of propranolol as the first choice of treatment for problematic infantile haemangioma at many centres, the number of patients with a partial or non-response to propranolol has also been growing."9.27Role of intralesional bleomycin and intralesional triamcinolone therapy in residual haemangioma following propranolol. ( Kumar, R; Pandey, V; Sharma, SP; Singh, OP; Tiwari, P, 2018)
"There is no consensus on optimal treatment duration for propranolol in infantile hemangioma (IH)."9.27Efficacy of Propranolol Between 6 and 12 Months of Age in High-Risk Infantile Hemangioma. ( Baselga, E; Bouroubi, A; de Lucas-Laguna, R; Delarue, A; Dembowska-Baginska, B; Esteve-Martinez, A; Gautier, S; González-Enseñat, MA; Lebbé, G; López Gutiérrez, JC; Menon, Y; Przewratil, P; Roé, E; Rychłowska-Pruszyńska, M; Torrelo, A; Voisard, JJ; Wyrzykowski, D; Zaim, M, 2018)
"There are limited data from randomized clinical trials comparing propranolol and steroid medication for treatment of infantile hemangioma (IH)."9.24Comparison of Efficacy and Safety Between Propranolol and Steroid for Infantile Hemangioma: A Randomized Clinical Trial. ( Cheon, JE; Choe, YS; Choi, TH; Choi, Y; Hong, KY; Jeong, JH; Kang, HJ; Kim, DY; Kim, KH; Lee, H; Park, JB; Park, KD; Park, YW; Shin, HY, 2017)
"Although the efficacy of propranolol for the treatment of infantile hemangiomas (IHs) has been well documented, there is a paucity of clinical data regarding the safety and tolerance of propranolol in neonates."9.24Safety and tolerance of propranolol in neonates with severe infantile hemangiomas: a prospective study. ( Chen, S; Ji, Y; Qiu, L; Xiang, B; Yang, Y, 2017)
"The nonselective beta-blocker propranolol is the current criterion standard for treatment of infantile hemangiomas (IHs) and the first therapy that the U."9.24Atenolol Versus Propranolol for Treatment of Infantile Hemangiomas During the Proliferative Phase: A Retrospective Noninferiority Study. ( Bayart, CB; Golden, AB; Tamburro, JE; Vidimos, AT; Wang, L, 2017)
"Topical timolol and lasers are widely used for the treatment of infantile hemangioma (IH), and they can replace propranolol as the first-line treatment of IH."9.22Comparison of the efficacy and safety of lasers, topical timolol, and combination therapy for the treatment of infantile hemangioma: A meta-analysis of 10 studies. ( Cai, B; Chen, X; Huang, H; Wang, B; Yu, J, 2022)
"Propranolol is a valuable therapeutic alternative for treatment of ulcerated haemangiomas and effectively reduces pain."9.22Role of propranolol in ulcerated haemangioma of head and neck: a prospective comparative study. ( Gangopadhyay, AN; Gupta, DK; Pandey, V; Sharma, SP; Tiwari, P, 2016)
"The combination treatment for mix infantile hemangiomas (IHs) using oral propranolol with topical timolol maleate was not well documented in the literature."9.22Oral Propranolol With Topical Timolol Maleate Therapy for Mixed Infantile Hemangiomas in Oral and Maxillofacial Regions. ( Li, G; Sun, NN; Tong, S; Wang, XK; Xu, DP; Xue, L, 2016)
"Propranolol has been widely used in the treatment of infantile hemangiomas since 2008."9.22Effects of systemic propranolol treatment on physical growth of patients with infantile hemangiomas. ( Chang, L; Chen, H; Hu, L; Huang, H; Jin, Y; Li, W; Lin, X; Ma, G; Qiu, Y; Xu, X; Zhou, B, 2016)
"The objective of the present study is to formulate and characterize propranolol hydrochloride (PPL · HCl) gel, and to evaluate the efficacy of this formulation in transdermal treatment for superficial infantile hemangioma (IH)."9.20Formulation, characterization and clinical evaluation of propranolol hydrochloride gel for transdermal treatment of superficial infantile hemangioma. ( Chen, X; Ding, J; He, S; Jian, D; Yang, Y; Zhou, W, 2015)
"Oral propranolol has been used to treat complicated infantile hemangiomas, although data from randomized, controlled trials to inform its use are limited."9.20A randomized, controlled trial of oral propranolol in infantile hemangioma. ( Ballona, R; Barbarot, S; Baselga, E; Benjamin, L; Bernabeu-Wittel, J; Berul, CI; Birchall, N; Boccara, O; Boralevi, F; Buckova, H; Caceres, H; Cambazard, F; Delarue, A; Febrer Bosch, MI; Foelster-Holst, R; Frieden, IJ; Friedlander, SF; Glick, S; Grantzow, R; Guibaud, L; Heritier, S; Hoeger, P; Krol, A; Léauté-Labrèze, C; Lopez Gutierrez, JC; Mancini, AJ; Maruani, A; Mazereeuw-Hautier, J; Mehta, CR; Metz, B; Morgan, CC; Perek, D; Phillips, RJ; Pope, E; Posiunas, G; Powell, J; Prey, S; Przewratil, P; Roessler, J; Souteyrand, P; Su, J; Szalai, ZZ; Torrelo, A; Vabres, P; Valencia, AM; Voisard, JJ; Wargon, O; Wyrzykowski, D, 2015)
"Combining propranolol with corticosteroids gives a faster response and should be considered in treating life- or function-threatening hemangiomas."9.20Therapeutic superiority of combined propranolol with short steroids course over propranolol monotherapy in infantile hemangioma. ( Abdel Kader, HM; Aly, MM; Ghazy, MS; Hamza, AF; Ragab, IA; Saafan, HA, 2015)
"While propranolol is touted as superior to prednisolone for treating infantile hemangiomas (IH), a randomized clinical trial (RCT) comparing the outcome and tolerability of these medications for symptomatic, proliferating IH has not been reported."9.19Propranolol vs prednisolone for symptomatic proliferating infantile hemangiomas: a randomized clinical trial. ( Bauman, NM; Greene, EA; Guzzetta, PC; He, J; McCarter, RJ; Oh, AK; Preciado, DA; Puttgen, KB; Shin, JJ, 2014)
"Propranolol therapy is changing the treatment paradigm for infantile hemangioma."9.19Propranolol therapy for reducing the number of nasal infantile hemangioma invasive procedures. ( Chen, BS; Manning, SC; Parikh, SR; Perkins, JA; Saltzman, B, 2014)
"The combination of pulsed dye laser (PDL) and topical propranolol are used with variable effectiveness for the treatment of infantile hemangiomas (IH), particularly for superficial lesions."9.19Combination therapy of infantile hemangioma with pulsed dye laser with topical propranolol: a randomized clinical trial. ( Abdolreza, M; Arianian, Z; Balighi, K; Daklan, S; Ehsani, AH; Noormohammadpoor, P, 2014)
"The dramatic response of infantile hemangiomas to propranolol and few side effects suggest that early treatment of infantile hemangiomas could result in decreased disfigurement."9.17Propranolol is more effective than pulsed dye laser and cryosurgery for infantile hemangiomas. ( Aozasa, N; Araki, M; Inuzuka, R; Isomura, S; Kagami, S; Katori, T; Kuwano, Y; Masui, Y; Miyagawa, T; Miyamoto, A; Sato, S; Shibata, S; Takahashi, K; Uwajima, Y; Yamada, D; Yamamoto, M, 2013)
"To assess propranolol efficacy and safety in complicated infantile hemangiomas in two different age groups."9.17The use of propranolol for complicated infantile hemangiomas. ( Dalmonte, P; Occella, C; Pelegrini, M; Rimini, A; Romanini, MV; Vercellino, N, 2013)
"Propranolol has emerged as front-line therapy for infantile hemangiomas (IHs)."9.17Propranolol for infantile hemangioma (PINCH): an open-label trial to assess the efficacy of propranolol for treating infantile hemangiomas and for determining the decline in heart rate to predict response to propranolol. ( Patnaik, SK; Sondhi, V, 2013)
"The purpose of this study was to compare the efficacy of orally administered propranolol versus prednisolone versus both in the treatment of potentially disfiguring or functionally threatening infantile hemangiomas."9.17Effect of propranolol vs prednisolone vs propranolol with prednisolone in the management of infantile hemangioma: a randomized controlled study. ( Malik, MA; Menon, P; Rao, KL; Samujh, R, 2013)
"The mechanism of therapeutic success of propranolol for severe infantile haemangioma remains unclear."9.16Urinary matrix metalloproteinases-2/9 in healthy infants and haemangioma patients prior to and during propranolol therapy. ( Hinz, U; Holland-Cunz, S; Kleber, CJ; Kleber, JB; Spiess, A; Weiss, J, 2012)
"To observe the therapeutic effect of propranolol with 1 064 nm Nd:YAG laser on proliferating hemangioma in body surface."9.16[The therapeutic effect of propranolol with 1064 nm Nd: YAG laser on proliferating hemangioma in body surface]. ( Duan, B; Gong, H; Tan, M; Zhou, CM, 2012)
"Propranolol hydrochloride is a safe and effective medication for treating infantile hemangiomas (IHs), with decreases in IH volume, color, and elevation."9.15A randomized controlled trial of propranolol for infantile hemangiomas. ( Adams, S; Hogeling, M; Wargon, O, 2011)
"To investigate the clinical results of the treatment of severe infantile hemangioma with high-dose propranolol in Chinese."9.15[Preliminary clinical study on the treatment of severe infantile hemangioma with high-dose propranolol in China]. ( Chen, XS; Guo, ZH; Huang, BR; Li, M; Xie, YD; Yang, YC; Zhan, MK; Zhou, YK, 2011)
"To prospectively assess the efficacy and safety or propranolol as a first-line treatment for problematic infantile haemangioma in China."9.15[A prospective study of propranolol as first-line treatment for problematic infantile hemangioma in China]. ( Chen, H; Chen, XD; Da, C; Hu, XJ; Jiang, CH; Jin, YB; Lin, XX; Ma, G; Ye, XX, 2011)
"To evaluate the short-term efficacy and safety of propranolol for problematic infantile hemangiomas."9.15[Propranolol in the treatment of problematic infantile hemangiomas]. ( Chen, J; Huang, J; Li, S; Lu, J; Qin, G; Tna, L; Xiang, Y; Yang, S; Zhao, J; Zuo, C, 2011)
"Propranolol has recently been introduced as a novel pharmacologic treatment for infantile hemangiomas."9.14Propranolol for infantile hemangiomas: early experience at a tertiary vascular anomalies center. ( Buckmiller, LM; Dai, Y; Dyamenahalli, U; Munson, PD; Richter, GT, 2010)
"Propranolol has changed the management of infantile hemangiomas (IHs)."9.01Clinical and economic impact of surgery for treating infantile hemangiomas in the era of propranolol: overview of single-center experience from La Paz Hospital, Madrid. ( López-Gutiérrez, JC, 2019)
"Recently, several studies have reported their experience in using oral atenolol in patients with infantile haemangioma (IH), especially as an alternative to propranolol, but the efficacy and safety of oral atenolol has not been evaluated."9.01Efficacy and safety of oral atenolol for the treatment of infantile haemangioma: A systematic review. ( Chen, S; Ji, Y; Wang, Q; Xiang, B, 2019)
"We report a case presented in deep hypoglycemic coma during his treatment with propranolol for IH."9.01Deep coma in a child treated with propranolol for infantile hemangioma. ( Bakalli, I; Celaj, E; Gjeta, I; Klironomi, D; Kola, E; Lluka, R; Sala, D; Sallabanda, S, 2019)
"A number of clinical trials evaluated the effect of topical timolol in the treatment of infantile hemangioma and provided inconsistent results."8.98Effect of topical timolol on response rate and adverse events in infantile hemangioma: a meta-analysis. ( Li, Y; Zheng, L, 2018)
"Propranolol is a well tolerated and effective treatment for infantile hemangiomas."8.98Infantile hemangiomas: what have we learned from propranolol? ( Ghareeb, E; Hagen, R; Jalali, O; Zinn, Z, 2018)
"Five cases of subglottic hemangioma treated with systemic propranolol are presented."8.98[Tiempo de respuesta terapéutica al propranolol sistémico en el manejo de hemangiomas subglóticos pediátricos: serie de casos y revisión de la literatura]. ( Álvarez-Neri, H; Morera-Serna, E; Penchyna-Grub, J; Teyssier-Morales, G; Torre, C; Villamor, P, 2018)
"Propranolol has recently become the treatment of choice for management of subglottic and airway hemangiomas."8.95Efficacy and rebound rates in propranolol-treated subglottic hemangioma: A literature review. ( Chun, RH; Faria, J; Pawar, S; Schwartz, T; Siegel, D, 2017)
"Propranolol has become the first-line treatment for complicated Infantile Hemangioma (IH), showing so far a good risk-benefit profile."8.95Cardiac arrest in a toddler treated with propranolol for infantile Hemangioma: a case report. ( Cutrone, M; Dalle Carbonare, M; Perilongo, G; Pettenazzo, A; Sartori, S; Tosoni, A, 2017)
"EBSCO host and Ovid database search for key words of infantile hemangiomas, propranolol, vascular lesion, and proliferative lesion was utilized."8.93Infantile Hemangiomas: Pathogenesis and Review of Propranolol Use. ( Laken, PA, 2016)
"Given the widespread use of propranolol in infantile hemangioma (IH) it was considered essential to perform a systematic review of its safety."8.93Safety of Oral Propranolol for the Treatment of Infantile Hemangioma: A Systematic Review. ( Boccara, O; Degrugillier-Chopinet, C; Delarue, A; Gautier, S; Lafon, M; Léaute-Labrèze, C; Lebbé, G; Mazereeuw-Hautier, J; Montagne, A; Ortis, V; Prey, S; Voisard, JJ, 2016)
"1) Describe the origins of the use of propranolol in the treatment of subglottic hemangiomas, 2) Perform meta-analysis of all case reports and series in which propranolol was used to treat subglottic hemangiomas."8.93The use of propranolol in the treatment of subglottic hemangiomas: A literature review and meta-analysis. ( Dodson, KM; Hardison, S; Wan, W, 2016)
"Currently, propranolol is the preferred treatment for problematic proliferating infantile haemangiomas (IHs)."8.91The use of propranolol in the treatment of infantile haemangiomas: an update on potential mechanisms of action. ( Chen, S; Ji, Y; Li, L; Xiang, B; Xu, C, 2015)
"ince 2008, propranolol has become the first line therapy for infantile hemangiomas."8.91Propranolol induced hypoglycemia. ( Haim, A; Horev, A; Zvulunov, A, 2015)
"Propranolol may have shown excellent results as a first line therapy in infantile haemangiomas (IHs) at all sites in the body, but this conclusion remains controversial."8.90The effectiveness of propranolol in treating infantile haemangiomas: a meta-analysis including 35 studies. ( Cao, DS; Cao, Y; Li, HH; Lou, Y; Peng, WJ; Xie, J, 2014)
"The clinical efficacy and safety profile of propranolol 1% cream in treatment of superficial infantile hemangiomas (IHs) were determined in a preliminary randomized group of eight infants."8.90Topical propranolol cream in treatment of superficial infantile hemangiomas: a literature review and 4 years of clinical experience. ( Kovačević, M; Krnjević-Pezić, G; Lukinović Škudar, V; Maričić, G; Stanimirović, A, 2014)
"In 2008, the positive effects of propranolol on infantile hemangiomas (IH) have been discovered serendipitously by Léauté-Labrèze and her coworkers."8.89Propranolol in use for treatment of complex infant hemangiomas: literature review regarding current guidelines for preassessment and standards of care before initiation of therapy. ( Fette, A, 2013)
"Recent reports of propranolol for the treatment of hemangiomas have led many physicians to question the best treatment strategy for children with vision-threatening hemangiomas."8.89Hemangiomas treated with propranolol: do the rewards outweigh the risks? ( Haider, KM; Neely, DE; Plager, DA, 2013)
"Propranolol is a relatively recent therapy of hemangiomas with fewer side effects, a different mechanism of action, and greater efficacy than current first-line corticosteroid therapy."8.89Propranolol versus corticosteroids in the treatment of infantile hemangioma: a systematic review and meta-analysis. ( Belzile, E; Izadpanah, A; Kanevsky, J; Schwarz, K, 2013)
"Propranolol is a beta blocker which is safely used in the management of infantile hemangiomas."8.89Novel use of propranolol for management of pain in children with vertebral hemangioma: report of two cases. ( Celkan, T; Gungor, S; Hasiloglu, Z; Ozdemir, N; Saygin, C; Uzunaslan, D, 2013)
"To study the effectiveness of propranolol in infantile airway haemangiomas and compare the effectiveness of propranolol vs."8.87A meta-analysis on the effectiveness of propranolol for the treatment of infantile airway haemangiomas. ( Athanasopoulos, I; Parpounas, K; Peridis, S; Pilgrim, G, 2011)
"The objective of this study is to describe the initial use of propranolol as the sole treatment for focal infantile airway hemangiomas, and to report on available literature describing the use of propranolol for airway lesions."8.86Initial experience using propranolol as the sole treatment for infantile airway hemangiomas. ( Hartnick, C; Maturo, S, 2010)
"Propranolol, a nonselective beta-blocker, has recently been introduced as a novel modality for the treatment of proliferating haemangiomas."8.86Propranolol therapy for infantile haemangiomas: review of the literature. ( Eivazi, B; Werner, JA; Wiegand, S; Zimmermann, AP, 2010)
"Propranolol was serendipitously found to induce early involution in hemangiomas even during the proliferative phase of the hemangioma cycle."8.85Propranolol treatment for infantile hemangiomas. ( Buckmiller, LM, 2009)
"Propranolol has emerged as a first line agent in the management of hemangiomas."8.31Bleomycin-triamcinolone sclerotherapy in the management of propranolol resistant infantile hemangioma of the maxillofacial region: A single arm prospective evaluation of clinical outcome and Doppler ultrasound parameters. ( Bera, RN; Pandey, V; Tiwari, P, 2023)
"The purpose of this study was to compare long-term neurocognitive functioning (working memory, processing speed, and attention) between children who had been treated with either propranolol or atenolol for infantile hemangioma during infancy."8.31Long-term neurocognitive functioning of children treated with propranolol or atenolol for infantile hemangioma. ( Breugem, CC; Breur, JMPJ; de Graaf, M; de Laat, PCJ; de Wildt, SN; Hermans, MM; Langeveld, HR; Mendels, EJ; Pasmans, SGMA; Raphael, MF; Rietman, AB; Schappin, R, 2023)
"The introduction of propranolol as systemic therapy for infantile hemangiomas (IH) has changed the natural history of these tumors."8.31Propranolol and infantile hemangiomas: Outcome from a tricentric study. ( Benetton, C; Cimador, M; De Corti, F; Gamba, P; Midrio, P; Pace, MD, 2023)
"Despite its effectivity, there are reports of poor response to propranolol in the treatment of infantile hemangioma (IH)."8.31Intralesional steroid in the era of propranolol for infantile hemangioma-Do we need it? ( Pandey, A; Pant, N; Rawat, J; Singh, S; Srivastava, A, 2023)
"The distribution and response to propranolol of problematic facial infantile haemangiomas (IHs) has rarely been described in the literature."8.31Distribution of problematic localized facial infantile haemangiomas and their response to propranolol: a retrospective cohort study. ( Chang, L; Chang, SJ; Chen, J; Chen, Q; Gao, W; Li, H; Lin, X; Qiu, Y; Yu, Z; Zhou, L, 2023)
"We studied 95 patients with infantile hemangioma (IH) treated with propranolol at the Department of Dermatology, Kumamoto University Hospital, from November 2016 to January 2022, based on sex, site, clinical classification, duration of treatment, and residual lesions after treatment."8.31A study of 95 infantile hemangiomas treated with propranolol: A potentially efficacious combination with laser therapy. ( Amano, F; Aoi, J; Fukushima, S; Kajihara, I; Makino, K; Masuguchi, S; Nakayama, W; Nishimura, Y; Sawamura, S; Shimada, S; Yamada-Kanazawa, S, 2023)
"Although the efficacy of propranolol in the treatment of infantile hemangioma (IH) has been well established, clinical data on the safety and tolerability of propranolol in neonates are still lacking."8.31Safety of oral propranolol for neonates with problematic infantile hemangioma: a retrospective study in an Asian population. ( Bai, H; Cheng, J; Fu, R; Huan, X; Huang, M; Jin, P; Wu, Z; Yuan, H; Zou, Y, 2023)
"Between January 2016 and February 2019, dermatologists experienced hemangioma treatment and recommended propranolol treatment for 232 IHs."8.31Our experience with propranolol for infantile hemangioma. ( Dai, T; Lu, W; Song, W; Wang, L; Wu, Y; Zhao, P, 2023)
"Propranolol, a nonselective beta-blocker used in the medical treatment of infantile Hemangioma (IH), has been shown to decrease the levels of vascular endothelial growth factor and reduce angiogenesis with its antiproliferative and antiangiogenetic effects."8.31Can Propranolol Affect Platelet Indices in Infantile Hemangioma? ( Eker, I; Eroglu, N; Kar, YD; Pektas, A; Sen, HS, 2023)
"Propranolol is the first-line treatment for infantile hemangiomas (IH)."8.31Predictors of poor response to oral propranolol in infantile hemangiomas. ( Berrami, H; Chiheb, S; Hali, F; Moubine, I; Othmani, MB; Serhier, Z, 2023)
"Propranolol, a non-selective blocker of the β-adrenoceptor (AR), is a first-line treatment for infantile hemangioma (IH)."8.12Propranolol inhibits the angiogenic capacity of hemangioma endothelia via blocking β-adrenoceptor in mast cell. ( Dong, C; Dong, K; Dou, L; Gao, W; He, L; Li, J; Li, K; Lu, W; Song, W; Wang, L; Xia, C; Ye, Y; Zhong, H, 2022)
"Propranolol and atenolol, current therapies for problematic infantile hemangioma (IH), are composed of R(+) and S(-) enantiomers: the R(+) enantiomer is largely devoid of beta blocker activity."8.12Non-beta blocker enantiomers of propranolol and atenolol inhibit vasculogenesis in infantile hemangioma. ( Bischoff, J; Fontaine, F; Francois, M; Graus, MS; Huang, L; Karnezis, T; McCann, A; Meunier, F; Mulliken, JB; Seebauer, CT; Staffa, SJ; Wylie-Sears, J; Zurakowski, D, 2022)
"To evaluate the safety of initiating and maintaining propranolol therapy for infantile hemangioma (IH) and the safety of different doses."8.12Safety assessment of propranolol for infantile hemangioma: a study in an Asian population. ( Han, X; He, R; Li, L; Liu, Y; Ma, L; Qiu, L; Sun, Y; Wang, C; Wei, L; Xiu, B; Xu, Z; Yu, L; Zhang, B, 2022)
"The long-term evolution of children with segmental facial infantile haemangioma (SFIH) treated with propranolol remains unstudied."8.12Segmental facial infantile haemangiomas in the era of propranolol: evaluation at 6 years of age. ( Boccara, O; Boralevi, F; Léauté-Labrèze, C; Letertre, O; Pedespan, JM; Prey, S, 2022)
"Propranolol is a nonselective β-adrenergic receptor (AR) blocker that has been the first-line therapy for problematic infantile hemangioma (IH), the most frequent childhood vascular tumor."8.12A transcription factor is the target of propranolol treatment in infantile hemangioma. ( Boscolo, E; Schrenk, S, 2022)
"For infantile hemangiomas (IH) requiring treatment, including those in high-risk locations or in the setting of ulceration, oral propranolol is first-line therapy."8.12Worsening ulceration of infantile hemangioma after initiation or escalation of propranolol. ( Boull, C; Maguiness, S; Meyer-Mueller, C; Nicholson, C; Polcari, I, 2022)
"We report three infants with infantile hemangioma who experienced severe agitation and diarrhea following propranolol administration."8.12Propranolol therapy for hemangiomas in infants with neonatal abstinence syndrome may produce intolerable side effects. ( Chen, A; Poffenberger, P; Twist, J; Zinn, Z, 2022)
"Propranolol has evolved as a first line management of infantile haemangiomas."8.12Sandwich therapy in the management of propranolol resistant infantile hemangioma of the lip. ( Bera, RN; Mishra, A; Pandey, V; Sharma, SP; Tiwari, P; Tiwary, N, 2022)
"Propranolol is used to treat problematic infantile hemangiomas (IHs), but its safety in infants <5 weeks corrected age has not been established."8.12Safety of propranolol for infantile hemangioma in infants less than five weeks corrected age. ( Check, JF; Gatts, JE; McLean, TW; Rush, MC; Samelak, DM, 2022)
"Propranolol is used as the first-line treatment for infantile hemangiomas (IHs)."8.12Topical Formulations of Propranolol for Infantile Hemangiomas: Characteristics of Formulations and Three Cases of Infants Administered Topical Propranolol Cream. ( Endoh, A; Hakamata, A; Inui, N; Kashiwagura, Y; Namiki, N; Shirai, M; Tanaka, S; Uchida, S; Watanabe, H, 2022)
"Infantile haemangiomas are common benign tumours of infancy, which can be treated effectively with beta-blockers such as propranolol and atenolol."8.12Aesthetic Outcome of Propranolol vs Atenolol Treatment of Children with Infantile Haemangioma. ( Breugem, CC; Breur, JMPJ; De Graaf, M; De Laat, PCJ; De Wildt, SN; Hermans, MM; Jonge Poerink, E; Langeveld, HR; Mendels, EJ; Pasmans, SGMA; Ragamin, A; Raphael, MF; Rietman, AB; Schappin, R, 2022)
"Oral propranolol is recommended as the first-line agent for infantile hemangioma requiring systemic treatment."8.12Efficacy of intravenous propranolol for life-threatening diffuse neonatal hemangiomatosis. ( Ishikawa, T; Seki, K; Uchiyama, H, 2022)
"To assess the efficacy of transcatheter arterial embolization (TAE) plus propranolol treatment for infantile hepatic hemangioma (IHH)."8.12Clinical evaluation of transcatheter arterial embolization combined with propranolol orally treatment of infantile hepatic hemangioma. ( Guo, L; Li, J; Song, D; Wang, L, 2022)
"To analyze the therapeutic effect of oral propranolol combined with sclerotherapy of lauromacrogol and triamcinolone acetonide in the treatment of lip infantile hemangiomas (IHs)."8.12A Retrospective Study of Lip Hemangiomas: Curative Effect of Oral Propranolol Combined with Topical Sclerotherapy. ( Huo, R; Ling, J; Yang, K; Zhang, D, 2022)
"Propranolol is a first-line clinical drug for infantile haemangiomas (IH) therapy."8.12Circular RNA hsa_circ_0000915 promotes propranolol resistance of hemangioma stem cells in infantile haemangiomas. ( Chen, H; Li, Y, 2022)
"To investigate the effect of propranolol on urine bFGF, MMP-2, MMP-9 expression of children with proliferative infantile hemangioma(IH), so as to clarify the mechanism of propranolol in treating IH."8.12[Effects of oral propranolol on urine bFGF, MMP-2, MMP-9 expression in children with proliferative infantile hemangioma]. ( Wang, XK; Yuan, WL, 2022)
"To assess the adverse effects of propranolol therapy in infantile hemangioma."8.02Adverse Drug Reactions Following Propranolol in Infantile Hemangioma. ( Imran, M; Kumar, D; Mishra, A; Pandey, V; Sharma, SP; Tiwari, P, 2021)
"Propranolol is the first-line drug for infantile hemangioma (IH) therapy, whereas propranolol resistance is clinically observed."8.02Exosomal miR-27a-3p derived from tumor-associated macrophage suppresses propranolol sensitivity in infantile hemangioma. ( Fan, X; Guo, S; Liu, C; Zhang, L; Zhao, Z; Zheng, J, 2021)
"Oral propranolol accelerates the involution of infantile haemangiomas (IHs)."8.02Sequelae following infantile haemangiomas treated with propranolol. ( Baselga, E; Bassi, A; Bernabeu-Wittel, J; Carnevale, C; Diociaiuti, A; Downey, C; El Hachem, M; Gich, I; Gonzalez-Enseñat, MA; Knopfel, N; Leuzzi, M; Manunza, F; Mascaro, P; Monserrat-García, MT; Neri, I; Oranges, T; Ortiz-Prieto, A; Puig, L; Roe, E; Torrelo, A; Vercellino, N; Vicente, A, 2021)
"Oral propranolol is the treatment of choice for infantile hemangiomas."8.02Recurrence rate of infantile hemangioma after oral propranolol therapy. ( Byeon, JO; Frongia, G; Günther, P; Mehrabi, A, 2021)
"To report the effectiveness and safety of transcatheter arterial sclerosing embolization (TASE) for the treatment of parotid infantile hemangiomas that did not respond appreciably to propranolol."8.02Transcatheter Arterial Sclerosing Embolization for the Treatment of Giant Propranolol-Resistant Infantile Hemangiomas in the Parotid Region. ( Guo, L; Li, J; Song, D; Sun, J; Wang, L; Wu, C; Zhang, Y, 2021)
"To assess propranolol's impact on sleep when used in infants and toddlers with infantile hemangioma (80% under 6 months old)."8.02Propranolol's effects on the sleep of infants with hemangiomas: A prospective pilot study. ( Adams, S; Frost, S; Mallitt, KA; Saddi, V; Teng, A; Wargon, O; Williamson, B, 2021)
"Since 2008, oral propranolol has evolved as the first-line therapy for infantile hemangiomas (IHs)."8.02A survey on the application of oral propranolol and atenolol for the management of infantile hemangiomas in mainland China: Survey on propranolol atenolol hemangiomas. ( Liu, C; Shao, L; Wang, QZ; Wu, HW; Zhang, WB; Zhao, ZL; Zheng, JW, 2021)
"The outcomes of propranolol treatment remain controversial for parotid hemangiomas, which may be inferior to outcomes for infantile hemangiomas (IHs) at other sites."8.02Oral propranolol therapy in parotid hemangiomas: A retrospective comparison with other infantile hemangiomas. ( Bi, J; Gao, Q; Huo, R; Li, S; Li, X; Lv, R; Wang, L; Xu, G, 2021)
"Propranolol can inhibit the proliferation, migration, invasion, adhesion, and tube formation of hemangioma endothelial cells; block VEGF-mediated angiogenesis signaling pathway; suppress the expressions of downstream angiogenesis-related signaling molecules; and ultimately achieve the effect of treatment of IHs."8.02Propranolol Participates in the Treatment of Infantile Hemangioma by Inhibiting HUVECs Proliferation, Migration, Invasion, and Tube Formation. ( Wang, X; Yuan, W, 2021)
"To evaluate the prognostic value of ultrasound and MRI findings in patients with infantile hemangioma undergoing propranolol therapy."8.02Ultrasound and MRI findings as predictors of propranolol therapy response in patients with infantile hemangioma. ( Jung, HL; Lee, SY; Park, HJ; Rho, MH, 2021)
"Propranolol emerged as the first-line therapy for infantile hemangioma (IH)."8.02Propranolol for infantile hemangioma: Evaluating efficacy and predictors of response and rebound growth. ( Khamaysi, Z; Kridin, K; Pam, N, 2021)
"The beta-blocker propranolol is the standard medical therapy for subglottic hemangioma (SGH), but side effects and incomplete response rates require close monitoring."8.02Propranolol versus nadolol for treatment of pediatric subglottic hemangioma. ( Cushing, SL; Pope, E; Propst, EJ; Wolter, JK; Wolter, NE; Yang, W, 2021)
"Sleep problems are frequently reported in infants treated with propranolol for infantile hemangiomas, possibly serving as a marker for a negative impact on central nervous system function."8.02Sleep behavior of infants with infantile hemangioma treated with propranolol-a cohort study. ( Gnannt, R; Kernland-Lang, K; Knöpfel, N; Kohler, M; Kurth, S; Luchsinger, I; Neuhaus, K; Schoch, SF; Schwieger-Briel, A; Smith, A; Theiler, M; von der Heydt, S; Waelchli, R; Weibel, L, 2021)
"We presented the case of a child with infantile hemangioma of the lumbo-sacral region, treated with combination therapy with systemic propranolol and topical timolol, with satisfactory effect in the end."8.02Infantile Sacral Region Hemangioma and Combination Treatment with Propranolol and Topical Timolol: Case Review and Reference Review. ( Dinarevic, SM; Kardasevic, M, 2021)
"We present a case of a one-month-old female patient with severe hypertriglyceridaemia as a side effect of treating an ulcerating infantile hemangioma with systemic propranolol."8.02Transient hypertriglyceridaemia associated with propranolol for treatment of infantile hemangioma. ( Farshchian, M; Potts, GA, 2021)
"Oral propranolol has been widely used for problematic infantile hemangiomas (IHs)."7.96Lip Infantile Hemangiomas Involving the Vermillion Border Have Worse Outcomes and Prognosis to Oral Propranolol Than Lesions Confined to One Side of the Vermillion. ( Huang, H; Li, W; Xu, P; Yu, Q; Zhang, W, 2020)
"The highest efficacy of oral propranolol is for infantile hemangioma (IH) in the proliferative phase."7.96Oral propranolol administration is effective for infantile hemangioma in late infancy: A retrospective cohort study. ( Bergman, R; Khamaysi, Z; Kridin, K; Pam, N, 2020)
"The aim of this study is to evaluate the association of genetic polymorphisms in Cytochrome P450 2D6(CYP2D6) and the change in VEGF levels with the response to propranolol in patients with Infantile hemangiomas (IH)."7.96Influence of Cytochrome P450 2D6 Polymorphisms on the Efficacy of Oral Propranolol in Treating Infantile Hemangioma. ( Li, X; Wang, L; Wang, Y; Xu, Q; Zheng, K, 2020)
"Oral propranolol has become first-line treatment for infantile hemangiomas (IHs)."7.96Serum cytokine profiles in infants with infantile hemangiomas on oral propranolol treatment: VEGF and bFGF, potential biomarkers predicting clinical outcomes. ( Cheuh, HW; Choi, YB; Jung, HL; Kim, HS; Lee, JH; Lee, JM; Lee, MJ; Lim, YJ; Park, ES; Park, M; Park, SK; Shim, YJ; Yoon, HS, 2020)
"To study the clinical effect of oral propranolol in the treatment of respiratory hemangioma in infants and young children."7.96[Clinical effect of propranolol in the treatment of respiratory hemangioma in infants and young children]. ( Chen, YQ; Ding, XF; Zhong, LL, 2020)
"Infantile hemangiomas can be successfully treated by both systemic propranolol and neodymium:YAG (Nd:YAG)-dye laser combination therapy."7.96Combination therapy of oral propranolol and combined Nd:YAG/pulsed dye laser therapy in infantile hemangiomas: a retrospective analysis of 48 treated hemangiomas in 30 children. ( Hartmann, F; Hensen, J; Himpel, O; Kühnle, I; Lockmann, A; Schön, MP; Thoms, KM, 2020)
"Oral propranolol (OP) demonstrated high efficacy and safety profile for treatment of critical infantile hemangiomas (IHs)."7.96A new clinical and dermoscopic monitoring of infantile hemangiomas treated with oral propranolol. ( Caini, M; Cartocci, A; Cevenini, G; Cinotti, E; de Quattro, M; Fiorani, D; Ierardi, F; Oranges, T; Pianigiani, E; Rubegni, P; Tognetti, L, 2020)
"We describe a case of a 6-month-old female patient with a segmental, superficial, infantile hemangioma (IH) on the forehead being treated with propranolol 2 mg/kg/d for 5 months, who developed a symplastic hemangioma (SH) over the preexisting lesion, highlighting the need to consider SH in the differential diagnosis of vascular lesions arising over preexisting vascular anomalies in children."7.91Symplastic hemangioma developing over an infantile hemangioma during propranolol treatment. ( Cervilla, K; Downey, C; González, S; Kramer, D; Pino, G; Zambrano, MJ, 2019)
"There has been a paradigm shift from corticosteroid to propranolol treatment for infantile hemangiomas (IHs), with surgical resection reserved for complicated or persistent IHs."7.91Surgical resection of infantile hemangiomas following medical treatment with propranolol versus corticosteroids. ( Alvarez-Allende, CR; Crafton, T; Dasgupta, R; Hammill, AM; Jenkins, TM; Polites, SF; Watanabe, M, 2019)
"Concerns have been raised that propranolol treatment of infantile hemangioma (IH) may be associated with increased risks of adverse effects and growth impairment in preterm infants due to their immature development."7.91No Increased Risks Associated with Propranolol Treatment for Infantile Hemangioma in Preterm Infants were Identified at 3 Years of Age. ( Li, L; Ma, L; Wei, L; Xu, ZG, 2019)
"Propranolol is an effective method of treatment for infantile hemangiomas (IH)."7.91Safety assessment during initiation and maintenance of propranolol therapy for infantile hemangiomas. ( Babiak-Choroszczak, L; Bagłaj, M; Dawid, G; Gawrych, E; Giżewska-Kacprzak, K, 2019)
"Propranolol is the mainstay of treatment for infantile hemangiomas (IHs) benefited from its low complication in the present study."7.91Associations between short-term efficacy and clinical characteristics of infantile hemangioma treated by propranolol. ( Guo, L; Li, J; Song, D; Wang, C; Wang, L; Wu, C, 2019)
"We previously developed propranolol-encapsulated liposomes-in-microspheres (PLIM) to realize the sustained propranolol release for the treatment of hemangiomas."7.91The sustained and targeted treatment of hemangiomas by propranolol-loaded CD133 aptamers conjugated liposomes-in-microspheres. ( Dong, C; Guo, X; Liu, Q; Zhang, H; Zhu, X; Zuo, S, 2019)
"First-line therapy for infantile hemangiomas (IH) is oral propranolol, a systemic beta-blocker with the risk of rare but serious adverse effects."7.91Topical timolol as adjunct therapy to shorten oral propranolol therapy for infantile hemangiomas. ( Huang, AH; Lie, E; Mannschreck, DB; Psoter, K; Puttgen, K, 2019)
"Propranolol could repress infantile hemangioma cell growth and induce apoptosis."7.91Propranolol suppresses infantile hemangioma cell proliferation and promotes apoptosis by upregulating miR-125b expression. ( Huang, J; Jiang, D; Wang, A; Zhao, S, 2019)
"The use of propranolol for the treatment of subglottic haemangioma has become hugely popular due to its effectiveness and safety profile."7.91Treatment failure with propranolol for subglottic haemangioma. ( Jackson, C; Liu, Z; Trimble, K; Yeo, YH, 2019)
"To present the outcomes of fixed doses of propranolol tablets for the treatment of hemangiomas."7.91EFFECTIVENESS OF FIXED DOSES OF PROPRANOLOL IN THE TREATMENT OF HEMANGIOMAS REGARDLESS OF CHILD'S WEIGHT GAIN: A CASE REPORT. ( Anger, J; Gabel, J; Oliveira, EM, 2019)
"This was a retrospective study to analyze the clinical therapeutic efficacy of propranolol in patients with infantile hemangioma (IH)."7.91Therapeutic efficacy of propranolol for infantile hemangiomas. ( Chen, Y; Gao, Z; Hao, J; Li, F; Wang, H; Wu, W, 2019)
"The efficacy of lauromacrogol injection therapy and intralesional triamcinolone for infantile hemangiomas (IH) has been well documented recently, but with an increase in serious or rare adverse reactions."7.91Safety of intralesional injection of lauromacrogol combined with triamcinolone for infantile hemangiomas. ( Bi, J; Chai, Y; Huo, R; Li, X; Li, Z; Lv, R; Song, J; Xu, G; Zhou, Z, 2019)
"A prospective study was conducted on 25 patients with infantile hemangioma, who were treated with gradually increasing dose of propranolol starting from a lower dose of 1mg/kg/day."7.91Individualized dosing of oral propranolol for treatment of infantile hemangioma: a prospective study. ( Kumar, B; Kumari, M; Prasad, A; Sinha, AK, 2019)
"Propranolol is an approved non-selective β-adrenergic blocker that is first line therapy for infantile hemangioma."7.91R-propranolol is a small molecule inhibitor of the SOX18 transcription factor in a rare vascular syndrome and hemangioma. ( Andelfinger, G; Bischoff, J; Chiang, IK; Fontaine, F; Francois, M; Gambin, Y; Hamdan, M; Huang, L; Khosrotehrani, K; Lesieur, E; Meurer, M; Moustaqil, M; Overman, J; Pasquier, E; Patel, J; Sierecki, E; Wylie-Sears, J; Zuegg, J, 2019)
"BackgroundPropranolol is the first-choice treatment for severe infantile hemangioma (IH)."7.88Infantile hemangioma: factors causing recurrence after propranolol treatment. ( Chang, L; Chen, H; Gu, Y; Jin, Y; Lin, X; Lv, D; Ma, G; Qiu, Y; Ying, H; Yu, Z, 2018)
"The aim of this study was to examine whether oral propranolol has any effect on neurodevelopment outcomes in young children with problematic infantile hemangiomas (IHs)."7.88Effects of Propranolol on Neurodevelopmental Outcomes in Patients with Infantile Hemangioma: A Case-Control Study. ( Chen, S; Ji, Y; Wang, C; Wang, Q; Xiang, B; Xiong, F, 2018)
"Screening electrocardiography (ECG) before initiation of propranolol for treatment of infantile hemangiomas (IH) is controversial."7.88Utility of routine electrocardiographic screening before initiation of propranolol for infantile hemangiomas. ( Chamlin, SL; Lund, EB; Mancini, AJ, 2018)
"Infantile hemangiomas (IHs) are the most common benign vascular neoplasms of infancy, characterized by a rapid growth phase followed by a spontaneous involution, or triggered by propranolol treatment by poorly understood mechanisms."7.88Modulation of LIN28B/Let-7 Signaling by Propranolol Contributes to Infantile Hemangioma Involution. ( Akat, KM; Canfield, J; Lockhart, J; Matar, A; Mong, EF; Totary-Jain, H; Tsibris, JCM; Tuschl, T; VanWye, J; Wu, JK, 2018)
"The use of propranolol for the treatment of infantile hemangioma (IH) has been widely investigated in recent years."7.88Propranolol induces hemangioma endothelial cell apoptosis via a p53‑BAX mediated pathway. ( Du, JT; Ge, SM; Gu, XW; Li, QY; Pataer, P; Regmi, KP; Tu, JB; Yao, TH, 2018)
"Propranolol has become the treatment of choice for infantile hemangiomas (IH)."7.88Serum concentrations of VEGF and bFGF in the course of propranolol therapy of infantile hemangioma in children: Are we closer to understand the mechanism of action of propranolol on hemangiomas? ( Babiak-Choroszczak, L; Bagłaj, M; Fischer, K; Gawrych, E; Giżewska-Kacprzak, K; Puchalska-Niedbał, L; Rajewska-Majchrzak, J; Walecka, A, 2018)
"The safety of oral propranolol for infantile hemangioma has not yet been studied at population level since the pediatric use marketing authorization was obtained in Europe."7.88Safety of Oral Propranolol for Infantile Hemangioma. ( Botrel, MA; Droitcourt, C; Dupuy, A; Garlantezec, R; Guillot, B; Happe, A; Kerbrat, S; Oger, E; Rault, C; Schleich, JM, 2018)
"We aimed to evaluate the effects of oral propranolol for circumscribed choroidal hemangioma."7.88Effects of oral propranolol for circumscribed choroidal hemangioma. ( Gonçalves Júnior, I; Maia, M; Mattos Neto, RB; Morales, MC; Sancho, KFCB; Zett, C, 2018)
"There has been a paradigm shift from steroids to propranolol for the pharmacologic treatment of infantile hemangiomas (IH); however, the outcomes for ulcerated IH are not well studied."7.88Propranolol versus steroids for the treatment of ulcerated infantile hemangiomas. ( Chute, C; Dasgupta, R; Hammill, A; Polites, SF; Rodrigue, BB, 2018)
"Hemangioma is the most common vascular tumor in infantile period, and propranolol is the first choice, but there are still a few patients with poor curative effect."7.88[Effect of treatment of infant parotid hemangioma with no response to oral propranolol]. ( Guo, XS; Nan, J; Shen, G; Tian, Y; Wang, XL, 2018)
"Treating infantile haemangioma with propranolol is more cost-effective when initiated on an outpatient basis."7.88Cost-effectiveness of treating infantile haemangioma with propranolol in an outpatient setting. ( Chaturvedi, K; Snyder, CS; Steinberg, JS, 2018)
"We sought to evaluate effect of propranolol in the treatment of infantile hemangiomas by quantifying the amount of phosphatidylinositol 3-kinase (PI3K), protein kinase B (AKT), and hypoxia-inducible factor-1α (HIF-1α)."7.88Propranolol inhibits the activity of PI3K, AKT, and HIF-1α in infantile hemangiomas. ( Huang, G; Lin, H; Lin, Z; Wang, L; Wang, W, 2018)
"Propranolol is the treatment of choicefor complicated infantile hemangiomas (IH)."7.85Propranolol for infantile hemangiomas in developing countries. ( Lawley, LP; McMichael, J, 2017)
"There have been reports of the use of levothyroxine or levothyroxine plus liothyronine for consumptive hypothyroidism caused by hepatic hemangiomas."7.85Use of liothyronine without levothyroxine in the treatment of mild consumptive hypothyroidism caused by hepatic hemangiomas. ( Hasegawa, Y; Higuchi, S; Takagi, M, 2017)
"Despite not being licensed for the treatment of infantile hemangiomas (IH) in infants younger than 5 weeks or older than 5 months, propranolol is often used in these age groups to prevent or to treat potentially severe complications."7.85Safety and effectiveness of oral propranolol for infantile hemangiomas started before 5 weeks and after 5 months of age: an Italian multicenter experience. ( Berti, I; Boccaletti, V; Carnevale, C; Cutrone, M; Dalmonte, P; Diociaiuti, A; El Hachem, M; Gesualdo, F; Greco, A; Neri, I; Oranges, T; Porcedda, G; Vercellino, N, 2017)
"Oral propranolol is considered the first choice for the treatment of infantile hemangiomas (IHs)."7.85Study of Cognitive Function in Children Treated with Propranolol for Infantile Hemangioma. ( Del Olmo-Benito, I; Descalzo, MA; García-Doval, I; González-Llorente, N; Muñoz-Ollero, N; Torrelo, A, 2017)
" A cavernous hemangioma was suspected and treated with high doses of propranolol and prednisolone."7.85Unexpected Effect of Propranolol and Prednisolone on Infantile Facial Rhabdomyosarcoma. ( Bhandari, SB; Lemperle, G; Mentzel, T; Shakya, J; Shilpakar, R, 2017)
"To develop propranolol-loaded poly(lactic-co-glycolic acid) nanoparticle with CD133 aptamers (PPN-CD133) to treat infantile hemangioma."7.85PLGA nanoparticles with CD133 aptamers for targeted delivery and sustained release of propranolol to hemangioma. ( Dong, C; Gao, J; Guo, X; Jin, X; Liu, D; Zhu, X, 2017)
"The aim of this study was to investigate the mechanism of propranolol on the regression of hemangiomas."7.85Propranolol inhibits the proliferation, migration and tube formation of hemangioma cells through HIF-1α dependent mechanisms. ( Bai, N; Bi, JH; Chen, YZ; Huo, R; Li, XQ; Liu, XW; Xu, GQ; Zhang, LF, 2017)
"Propranolol hydrochloride has become the primary medical treatment for problematic infantile hemangioma; however, the expression of propranolol's target receptors during growth, involution, and treatment of hemangioma remains unclear."7.85Expression of β-Adrenergic Receptor Subtypes in Proliferative, Involuted, and Propranolol-Responsive Infantile Hemangiomas. ( Phillips, JD; Richter, GT; Wei, T; Zhang, H, 2017)
"Propranolol is becoming the treatment of choice for complicated infantile hemangioma."7.85Cardiovascular Profile of Propranolol after Multiple Dosing in Infantile Hemangioma. ( Cavalli, R; Giavarini, A; Giovanni Bianchetti, M; Gondoni, E; Lombardi, F; Maria Colli, A; Salice, P, 2017)
"Oral propranolol has been recently approved for infantile hemangiomas (IHs), but potential side effects stay a challenge."7.85Oral propranolol for infantile hemangiomas: a prospective study on the role of 48-hour Holter monitoring in additional safety assessment. ( Parezanović, V; Petrovic, J; Topalovic, M; Trajkovic, G; Trifunovic, B; Vukomanovic, G, 2017)
"Concern has been raised about the potential long-term effects of propranolol treatment for infantile hemangioma (IH)."7.85Propranolol treatment of infantile hemangioma is not associated with psychological problems at 7 years of age. ( Moyakine, AV; Spillekom-van Koulil, S; van der Vleuten, CJM, 2017)
"There is no definitive conclusion regarding the optimal timing for terminating propranolol treatment for infantile hemangioma (IH)."7.85When to stop propranolol for infantile hemangioma. ( Chang, L; Chen, H; Gu, Y; Jin, Y; Lin, X; Ma, G; Qiu, Y; Ying, H; Yu, Z, 2017)
"Propranolol is the treatment of choice for infantile hemangiomas requiring medical intervention."7.85Propranolol treatment for infantile hemangioma does not increase risk of childhood wheezing. ( Amitai, DB; Blau, H; Hoshen, M; Lapidoth, M; Mei-Zahav, M; Mussaffi, H; Prais, D; Stafler, P; Steuer, G; Zvulunov, A, 2017)
"Propranolol was first used in 2008 to treat hemangioma; its efficacy and safety have since changed the classical treatment indications."7.85A New Perspective for Infantile Hepatic Hemangioma in the Age of Propranolol: Experience at Baskent University. ( Boyvat, F; Demir, Ş; Erbay, A; Özçay, F; Sarıalioğlu, F; Uslu, N; Yazıcı, N, 2017)
"The purpose of the present study is to evaluate the efficacy and safety of propranolol for problematic infantile hemangiomas (IH), showing our experience on 24 children, with special focus on premature infants."7.83Efficacy of propranolol for cutaneous hemangiomas in premature children. ( Barruscotti, S; Borroni, G; Brazzelli, V; Codazzi, CA; Giorgini, C; Mannarino, S; Marseglia, GL; Stronati, M; Tzialla, C, 2016)
"A retrospective observational study was conducted on patients with ulcerated infantile haemangioma treated with pulsed dye laser in association with propranolol."7.83[Combination of pulsed dye laser and propranolol in the treatment of ulcerated infantile haemangioma]. ( del Pozo Losada, J; Rodríguez-Ruiz, M; Tellado, MG, 2016)
"To describe a case of diffuse choroidal hemangioma with exudative retinal detachment treated successfully with oral propranolol."7.83DIFFUSE CHOROIDAL HEMANGIOMA MASQUERADING AS CENTRAL SEROUS CHORIORETINOPATHY TREATED WITH ORAL PROPRANOLOL. ( Dave, T; Dave, VP; Pappuru, RR; Shah, G, 2016)
"We review the presentation, course, management and outcomes of all cases of genital infantile hemangiomas managed by propranolol administration at a single institution from April 2010 to July 2014."7.83Propranolol for Treatment of Genital Infantile Hemangioma. ( Golden, A; Rhee, A; Tamburro, J; Tran, C, 2016)
"Oral propranolol is widely prescribed as first-line treatment for infantile haemangiomas (IHs)."7.83Propranolol in the treatment of infantile haemangiomas: lessons from the European Propranolol In the Treatment of Complicated Haemangiomas (PITCH) Taskforce survey. ( Audrain, H; Baryschpolec, S; Baselga, E; Beattie, PE; Bhate, K; Bjerre, JV; Brown, SJ; Burrows, NP; Clayton, TH; Darne, S; Durack, A; Dvorakova, V; Flohr, C; Foelster-Holst, R; Gach, J; Glover, M; Goldstraw, N; Goodyear, H; Grabczynska, S; Greenblatt, D; Halpern, J; Hearn, RM; Hedelund, L; Hernandez-Martin, A; Hoeger, PH; Hoey, S; Hughes, B; Irvine, AD; Janmohamed, SR; Jayaraj, R; Johansson, EK; Laguda, B; Lam, M; Leech, S; McPherson, T; Morrison, D; Neri, I; O'Regan, GM; Oranje, AP; Patrizi, A; Porter, W; Ramesh, R; Ravenscroft, JC; Schill, T; Shahidullah, H; Shaw, L; Solman, L; Svensson, A; Taylor, AE; Taylor, R; Thomson, J; Tiffin, P; Tsakok, M; Wahlgren, CF; Wedgeworth, E, 2016)
"The present study investigated the action of propranolol in infantile hemangiomas (IHs)."7.83Propranolol Targets Hemangioma Stem Cells via cAMP and Mitogen-Activated Protein Kinase Regulation. ( Edwards, AK; England, RW; Kitajewski, AA; Kitajewski, JK; Kung, JE; Munabi, NC; Shawber, CJ; Tan, QK; Weinstein, A; Wilcox, M; Wu, JK, 2016)
"Despite the increasing popularity of propranolol for treatment of infantile hemangioma (IH), there is need for further evidence of efficacy and safety."7.83Treatment for Infantile Hemangiomas: Selection Criteria, Safety, and Outcomes Using Oral Propranolol During the Early Phase of Propranolol Use for Hemangiomas. ( Gehris, R; Geisler, S; Grunwaldt, LJ; MacIsaac, ZM; Mehta, D; Nayar, HS, 2016)
"Few specific reports have addressed propranolol as a treatment for parotid hemangioma, and its mechanism remains unclear."7.83Use of propranolol for parotid hemangioma. ( Chang, L; Chen, H; Jin, Y; Lin, X; Lv, D; Ma, G; Qiu, Y; Wang, T; Yang, X; Ying, H; Yu, W, 2016)
"The aim of this study was to explore the efficacy and safety of propranolol in treating infantile haemangiomas, the most common benign vascular tumours in children."7.83Propranolol was effective in treating cutaneous infantile haemangiomas in Thai children. ( Jetsrisuparb, C; Komwilaisak, P; Panombualert, S; Techasatian, L; Uppala, R, 2016)
"Propranolol is first-line therapy for problematic infantile hemangiomas (IHs)."7.83Rebound Growth of Infantile Hemangiomas After Propranolol Therapy. ( Adams, D; Baselga, E; Boon, LM; Chute, C; Coulie, J; Drolet, BA; Frieden, IJ; García-Romero, MT; Garzon, MC; Grimes, B; Haggstrom, AN; McCuaig, C; Newell, BD; Pope, E; Powell, J; Roe, E; Shah, SD; Siegel, DH, 2016)
"From October 2010 to June 2014, 31 infantile hemangioma patients admitted to our hospital, were administered propranolol combined with betamethasone injection treatment of lesions."7.83Treatment of infantile hemangioma by intralesional injection of propranolol combined with compound betamethasone. ( Li, J; Shao, RZ; Zhao, DH, 2016)
"Propranolol has recently been shown to be highly effective for infantile hemangioma (IH), but the mechanism of action of propranolol and the usefulness of measurement of vascular endothelial growth factor (VEGF) remain poorly understood."7.83Propranolol for infantile hemangioma: Effect on plasma vascular endothelial growth factor. ( Fukao, T; Hori, T; Kanda, K; Kawamoto, N; Kimura, T; Nozawa, A; Ozeki, M, 2016)
" The 31 patients had 32 hemangiomas (1 female patient had 2 lesions) and were treated with systemic propranolol at a high dose of 2 mg/kg per day."7.83Oral Propranolol for the Treatment of Infantile Hemangiomas in the Post-Proliferative Phase: A-Single Center Retrospective Study of 31 Cases. ( Liu, ZM; Tian, Y; Tong, S; Wang, XK; Xi, SL; Xu, DP, 2016)
"To investigate the effects of oral administration of low-dose propranolol on heart rate variability (HRV), acceleration capacity (AC), deceleration capacity (DC), and cardiac conduction in the treatment of infantile hemangioma."7.83[Changes in ambulatory electrocardiographic findings after oral administration of low-dose propranolol in infants with hemangioma]. ( Cao, XX; Huang, S; Qiu, M; Wen, HX; Yi, LF; Zhang, JY, 2016)
"In the last few years propranolol has revolutionized infantile hemangioma therapy."7.83Serum and tissue profile of VEGF and its receptors VGFR1/R2 in children with infantile hemangiomas on systemic propranolol treatment. ( Andrzejewska, E; Chrzanowska, B; Kobos, J; Przewratil, P; Szemraj, J; Taran, K; Wnęk, A; Wyrzykowski, D, 2016)
" The medical records of infants with periorbital hemangiomas who were treated with systemic propranolol at a dose of 1."7.83Clinical Outcomes of Infants With Periorbital Hemangiomas Treated With Oral Propranolol. ( Liu, ZM; Sun, C; Wang, XK; Xu, DP; Xue, L, 2016)
"To determine the efficacy of oral propranolol for the treatment of infantile subglottic hemangioma."7.83Role of oral propranolol in the treatment of infantile subglottic hemangioma. ( Chen, JR; Jin, L; Li, XY; Wang, Y, 2016)
"Propranolol, 2 mg/kg/day, is effective in the treatment of infantile hemangioma."7.83Response to propranolol in infantile hemangioma. ( Chunharas, A; Kadegasem, P; Lekanan, W; Sirachainan, N; Thammagasorn, Y; Wanitkun, S, 2016)
"An open observational prospective study was performed over 25 months in a group of pediatric patients diagnosed with infantile hemangioma treated with propranolol."7.83The Role of the Pharmacist in the Treatment of Patients with Infantile Hemangioma Using Propranolol. ( Castaneda, S; De la Cruz, H; Garcia, E; Melendez-Lopez, S; Sanchez-Palacio, J, 2016)
"There has been a dramatic increase in the off-label use of ophthalmic timolol maleate, a β-blocker used for infantile hemangioma (IH) treatment as a topical counterpart to oral propranolol."7.83Topical Timolol Maleate Treatment of Infantile Hemangiomas. ( Adams, D; Baselga, E; Drolet, B; Feigenbaum, D; Frieden, I; Garzon, MC; Holland, K; Horii, K; Lauren, C; Lucky, A; Mathes, E; McCuaig, C; Morel, KD; Newell, B; Nopper, A; Pope, E; Powell, J; Püttgen, K; Savva, Y; Siegel, D; Song, W, 2016)
"In recent years propranolol has become the treatment of choice for infantile hemangiomas (IHs)."7.83Is Routine Electrocardiography Necessary Before Initiation of Propranolol for Treatment of Infantile Hemangiomas? ( Krol, AL; Leitenberger, SL; MacArthur, CJ; Mann, JA; Tollefson, MM; Yarbrough, KB, 2016)
"Non-selective β-blocker propranolol has been proved by FDA as the first-line agent for infantile hemangioma (IH) with dramatic response."7.83[Chinese expert consensus on the use of topical timolol maleate treatment of infantile hemangiomas]. ( Fan, XD; Huo, R; Jiang, CH; Lei, SR; Liu, SH; Qin, ZP; Wang, XK; Wang, XY; Yang, YW; Zhao, JH; Zheng, JW; Zhou, DK, 2016)
"Although propranolol has been accepted as a first-line drug for infantile haemangioma (IH), no study has systematically characterized changes in heart rates during long-term propranolol treatment."7.81Safety profile of a divided dose of propranolol for heart rate in children with infantile haemangioma during 16 weeks of treatment. ( Chen, W; Shi, H; Song, H; Wang, J; Yu, Y; Zhang, X; Zhou, H, 2015)
"Propranolol is a valid treatment for large cranial hemangiomas, avoiding the risks involved in surgeries."7.81Giant cranial and cerebellar hemangioma treated with propranolol. ( Ben-Sira, L; Benvenisti, H; Constantini, S; Roth, J, 2015)
"The aim of this study was to investigate the therapeutic results and effects of propranolol on cardiovascular parameters in infants receiving systemic propranolol for complicated infantile hemangiomas (IHs), as well as to evaluate the adverse effects of propranolol throughout the course of treatment."7.81Treatment of severe infantile hemangiomas with propranolol: an evaluation of the efficacy and effects of cardiovascular parameters in 25 consecutive patients. ( Cao, RY; Sun, NN; Tong, S; Wang, XK; Xu, DP; Xue, L, 2015)
"The aim of our study was to assess the efficacy and safety of oral propranolol for the treatment of parotid infantile hemangiomas."7.81Oral propranolol for parotid infantile hemangiomas. ( Cheng, C; Li, G; Liu, ZM; Sun, HL; Wang, XK; Xi, SL; Xu, DP, 2015)
"The current study demonstrated the antiangiogenic properties of propranolol in vitro and that the drug was able to induce the regression of hemangioma cells via the inhibition of cell cycle progression, invasion, and tube formation, concomitantly with decreased NO and VEGF levels through the down-regulation of the PI3K/Akt/eNOS/VEGF pathway."7.81Propranolol induces regression of hemangioma cells via the down-regulation of the PI3K/Akt/eNOS/VEGF pathway. ( Gao, Y; Guo, ZT; Huang, Q; Li, P; Pan, WK, 2015)
"Propranolol has been recently approved by health authorities to treat infantile haemangiomas (IH)."7.81[Propranolol in infantile hemangiomas]. ( Léauté-Labrèze, C, 2015)
"Topical propranolol has been used for the therapy of superficial infantile hemangiomas (IH)."7.81A novel topical nano-propranolol for treatment of infantile hemangiomas. ( Chen, ZG; Yuan, ML; Yuan, WE; Zhang, L; Zheng, JW, 2015)
"Propranolol, as a non-selective blocker of the β-adrenergic receptor (AR), is utilised as the first-line treatment for infantile hemangiomas."7.81Propranolol represses infantile hemangioma cell growth through the β2-adrenergic receptor in a HIF-1α-dependent manner. ( Gao, Y; Guo, Z; Li, P; Pan, W, 2015)
"With the emergence of propranolol as the primary treatment for hemangiomas the indications for surgical intervention have been greatly reduced."7.81Open airway surgery for subglottic hemangioma in the era of propranolol: Is it still indicated? ( Mehta, D; Siegel, B, 2015)
"To evaluate the effectiveness of systemic propranolol in airway infantile hemangioma (AIH) treatment."7.81Multicenter Evaluation of the Effectiveness of Systemic Propranolol in the Treatment of Airway Hemangiomas. ( Darrow, DH; Elluru, RG; Friess, MR; Grimmer, JF; Perkins, JA; Richter, GT; Shin, JJ, 2015)
" Infantile hemangiomas which have numerous similarities with chorioangiomas are now usually treated with propranolol."7.81Propranolol during pregnancy for large chorioangioma. ( D'Hervé, D; Fouque, L; Le Duff, M; Padys, P; Poulain, P, 2015)
"I was asked to provide a commentary for "Shouldn't Propranolol be Used to Treat All Hemangiomas?" by Moodley et al."7.81Commentary on Moodley S et al. "Shouldn't Propranolol be Used to Treat All Hemangiomas?". ( Blei, F, 2015)
"This study suggests that propranolol become the first-line treatment of choice for all haemangiomas."7.81Shouldn't Propranolol Be Used to Treat All Haemangiomas? ( Adams, KG; Adams, S; Hudson, DA; Moodley, ST, 2015)
"Our aim was to compare in a prospective study the clinical effects and safety of propranolol given orally, timolol maleate applied locally, and the combination of the two, in the management of superficial infantile haemangiomas."7.81Evaluation of the efficacy and safety of propranolol, timolol maleate, and the combination of the two, in the treatment of superficial infantile haemangiomas. ( Cheng, C; Gong, H; Li, G; Li, YX; Wang, XK; Xu, DP, 2015)
"To investigate the effect of topical propranolol gel on the levels of plasma vascular endothelial growth factor (VEGF), basic fibroblastic growth factor (bFGF) and matrix metalloproteinases-9 (MMP-9) in proliferating infantile hemangiomas (IHs) of superficial type."7.81[Effect of propranolol gel on plasma VEGF, bFGF and MMP-9 in proliferating infantile hemangiomas of superficial type]. ( Guoliang, H; Lie, W; Shaoquan, C; Shuming, C; Yujuan, T; Zaizhong, Z, 2015)
"To explore the effect and safety of topical propranolol hydrochloride gel for treatment of infantile hemangioma."7.81[Effects of topical propranolol hydrochloride gel for treatment of infantile hemangioma in nude mice]. ( Chen, L; Chengjin, L; Lie, W; Qingjin, H; Shaoquan, C; Shuming, C; Yin, X; Zaizhong, Z, 2015)
"To summarize the subsequent therapy experiences for infantile hemangiomas after discontinuation of oral propranolol treatment, and explore the relationships between clinical interventions and types of infantile hemangioma."7.81[Subsequent therapy for infantile hemangiomas after discontinuation of oral propranolol]. ( Chen, T; Ge, CX; Li, KL; Liu, XJ; Qin, ZP; Tai, MZ, 2015)
"Propranolol is emerging as the treatment of choice for high-risk infantile haemangiomas."7.80Propranolol therapy for cutaneous infantile haemangiomas initiated safely as a day-case procedure. ( McSwiney, E; Murphy, M; Murray, D, 2014)
"Propranolol is an effective, safe treatment for complicated infantile haemangiomas (IH)."7.80Propranolol for the treatment of infantile haemangiomas: our experience with 44 patients. ( Lenane, P; Lynch, M; O'Donnell, BF, 2014)
"This study proved high efficiency of propranolol in treatment of infantile hemangioma, as assessed with the objective measures for the first time."7.80Treatment of infantile hemangiomas with propranolol: clinical guidelines. ( Anderson, W; Stewart, K; Szychta, P, 2014)
"Oral propranolol (PRN) has recently been shown to be highly effective for infantile hemangiomas (IHs), and is currently recommended as the first-line treatment of complicated IHs."7.80Propranolol inhibits angiogenesis via down-regulating the expression of vascular endothelial growth factor in hemangioma derived stem cell. ( Li, KL; Mai, HM; Qin, ZP; Wang, YA; Zhang, L; Zheng, J; Zheng, JW, 2014)
"Propranolol seemed to be effective for treatment of hemangiomas in children and adolescents, and not just in the proliferative stage, with responses in almost all the patients."7.80Treatment of children and adolescents with hemangioma using propranolol: preliminary results from a retrospective study. ( Albuquerque, JC; Bastos, MV; Felix, FH; Félix, JA; Fontenele, JB; Magalhães, RA; Trompieri, NM, 2014)
"Propranolol is highly effective in the treatment of infantile hemangioma (IH), but important clinical and pharmacological data are lacking."7.80Efficacy and safety of propranolol for the treatment of infantile hemangioma: a presentation of ninety-nine cases. ( Ben Amitai, D; Lapidoth, M; Sagi, L; Zvulunov, A, 2014)
"To highlight the importance of Magnetic Resonance Imaging (MRI) and the use of propranolol as both a final diagnostic tool and adequate treatment for orbital Infantile Haemangiomas (IHs)."7.80Propranolol as first-line treatment in orbital infantile haemangiomas: a case series. ( Coumou, AD; Freling, NJ; Groeneveld, L; Levitt, M; Saeed, P; van der Horst, CM, 2014)
"Propranolol, a β-adrenergic receptor (AR) antagonist, is an effective treatment for endangering infantile haemangioma (IH)."7.80Propranolol targets the contractility of infantile haemangioma-derived pericytes. ( Bischoff, J; Boscolo, E; Durham, JT; Herman, IM; Lee, D; Mulliken, JB, 2014)
"A small percentage of complicated infantile haemangiomas need early, safe and effective treatment, and the option of off-label systemic propranolol treatment has been in existence since 2008."7.80A retrospective analysis of systemic propranolol for the treatment of complicated infantile haemangiomas. ( Cremer, HJ; Ruef, P; Schneider, M, 2014)
"To prospectively assess the efficacy and safety of propranolol in children with infantile hemangioma."7.80The role of propranolol in the treatment of infantile hemangioma. ( Costa, G; Freitas, I; Laranjo, S; Martins, JD; Paramés, F; Pinto, FF; Trigo, C, 2014)
"Hemangioma stem cells (HemSCs) isolated from resected IH specimens were treated with adipogenic medium for 1 or 4 days in either propranolol or vehicle."7.80Propranolol promotes accelerated and dysregulated adipogenesis in hemangioma stem cells. ( England, RW; Hardy, KL; Kitajewski, AM; Kitajewski, JK; Shawber, CJ; Wong, A; Wu, JK, 2014)
"Propranolol has been widely used in treating infantile hemangiomas (IHs)."7.80Propranolol enhanced adipogenesis instead of induction of apoptosis of hemangiomas stem cells. ( Chang, M; Ma, X; Ma, Y; Ouyang, T; Xin, S; Zhao, T, 2014)
"To assess the safety and efficacy of systemic propranolol for the treatment of complicated infantile haemangiomas."7.80Propranolol for infantile haemangiomas: single centre experience of 250 cases and proposed therapeutic protocol. ( Glover, M; Gnarra, M; Harper, JI; Murabit, A; Solman, L; Syed, SB, 2014)
"To explore the indications of hemangiomas of different types by observing the clinical efficacy of oral propranolol."7.80[Clinical analysis for treatment of 1 080 cases of infantile hemangiomas with oral propranolol]. ( Ge, C; Li, K; Liu, X; Qin, Z; Tai, M, 2014)
"Propranolol is increasingly used to treat problematic infantile haemangioma (IH), although its molecular mechanisms remain unclear."7.80Increased apoptosis and secretion of tryptase by mast cells in infantile haemangioma treated with propranolol. ( Day, D; Steel, R, 2014)
"This study was aimed at assessing the efficacy of propranolol treatment in infantile hemangiomas (IHs) by ultrasound."7.80Ultrasound in assessing the efficacy of propranolol therapy for infantile hemangiomas. ( Shang, Y; Shi, H; Song, H; Wang, J; Xia, L; Yang, J; Zhou, H, 2014)
"To develop a tool for assessing amblyopic risk and monitoring the treatment effect of propranolol in periocular haemangioma management."7.80Monitoring propranolol treatment in periocular infantile haemangioma. ( Burne, R; Taylor, R, 2014)
"This study aims to investigate the expression levels of serum and urinary vascular endothelial growth factor-A (VEGF-A) and epidermal growth factor-like domain 7 (EGFL7) in proliferating infantile hemangioma patients under propranolol treatment."7.80[Expression of serum and urinary vascular endothelial growth factor-A and epidermal growth factor-like domain 7 in proliferating hemangioma treated with propranolol]. ( Bin, L; Jie, L; Manli, C; Xiaopeng, Y; Zhaoquan, L; Zhongcheng, G, 2014)
"Systemic treatment with propranolol is proven to be effective for patients with hemangiomas with less side-effect."7.80Topical treatment with propranolol gel as a supplement to the existing treatment of hemangiomas. ( Cremer, H; Reimer, A; Ruef, P; Schneider, M, 2014)
"To explore the new mechanism of propranolol for treatment of hemangioma and the effects of propranolol on proliferation of hemangioma-derived mesenchymal stem cells ( Hem- MSCs)."7.80[Effects of propranolol on proliferation of hemangioma-derived mesenchymal stem cells ]. ( Huiping, C; Tianxiang, O; Tinghui, Z; Xiaorong, M; Yan, X; Yingying, H, 2014)
"Clinical observation of conservative treatment of the left hemi-liver haemangioma by propranolol in the full-term newborn with initial symptoms of cardiac failure is presented."7.80[Clinical case of treatment of hepatic haemangioma by propranolol in the newborn]. ( Getman, AN; Ivleva, SA; Kucherov, IuI; Rekhviashvili, MG; Zhirkova, IuV, 2014)
"The β-blocker propranolol was discovered to be highly effective for the treatment of infantile hemangiomas (IHs), since 2008."7.80Adverse effects of propranolol treatment for infantile hemangiomas in China. ( Babajee, K; Chen, X; Hu, X; Jian, D; Li, J; Su, J; Xie, H, 2014)
"Propranolol has recently become a successful first-line therapy in the treatment of infantile hemangiomas (IHs)."7.80Effect of propranolol on the treatment of infantile hemangiomas: a single tertiary center 3-year experience. ( Choi, JW; Kim, DY; Kim, KH; Park, YW; Shin, H; Yeom, KB, 2014)
"This study provides multi-institutional practice guidelines for the initiation of propranolol hydrochloride treatment of routine infantile hemangiomas."7.79Propranolol use for infantile hemangiomas: American Society of Pediatric Otolaryngology Vascular Anomalies Task Force practice patterns. ( Darrow, DH; Grimmer, JF; Manning, SC; Parikh, SR; Perkins, JA; Richter, GT, 2013)
"Infantile hemangioma (IH) clearance may be slow or incomplete in response to pulsed dye laser (PDL) or propranolol alone."7.79Retrospective study of the treatment of infantile hemangiomas using a combination of propranolol and pulsed dye laser. ( Anolik, R; Bernstein, L; Blei, F; Brauer, JA; Brightman, L; Geronemus, RG; Hale, E; Karen, J; Reddy, KK; Waner, M; Weiss, E, 2013)
"Propranolol has been used successfully in a limited number of children with infantile hemangiomas (IHs)."7.79Use of propranolol for the treatment infantile hemangiomas in the maxillofacial region. ( Kasimova, KR; Metellmann, HR; Podmelle, F; Sadykov, RA; Sadykov, RR, 2013)
"Propranolol is now widely used to treat severe infantile haemangiomas (IHs)."7.79Propranolol-resistant infantile haemangiomas. ( Aubert, H; Barbarot, S; Boccara, O; Bursztejn, AC; Caussé, S; Chiaverini, C; Dreyfus, I; Eschard, C; Hadj-Rabia, S; Mahé, E; Maruani, A; Mazereeuw-Hautier, J; Miquel, J; Puzenat, E; Saint-Jean, M; Stalder, JF, 2013)
"Although propranolol has become the first-line therapy for infantile haemangiomas (IHs), no study has yet investigated factors associated with the risk of relapse in children with IH treated with propranolol after cessation of treatment."7.79Factors associated with the relapse of infantile haemangiomas in children treated with oral propranolol. ( Ahogo, CK; Boralevi, F; Colona, V; Diallo, A; Ezzedine, K; Léauté-Labrèze, C; Prey, S; Taïeb, A, 2013)
"Although propranolol can be an effective primary medical therapy for infantile hemangiomas of the head and neck, the duration of treatment and time to discontinue propranolol is unclear."7.79Successful discontinuation of propranolol for infantile hemangiomas of the head and neck at 12 months of age. ( Chiu, ES; Hong, P; Kluka, EA; Poole, JC; Simon, LM; Tammareddi, N; Walvekar, R, 2013)
"To evaluate the efficacy and safety of 1% propranolol ointment in the treatment of superficial infantile hemangiomas (IHs)."7.79[Treatment of superficial infantile hemangiomas with topical propranolol]. ( Huo, R; Lü, RR; Niu, JN; Xu, GQ, 2013)
"This case of a four and a half-month-old girl describes periocular infantile haemangioma which was treated successfully with propranolol."7.79Periocular infantile haemangioma and the role of propranolol. ( Ahmad, K; Chaudhry, TA; Kamal, M, 2013)
"Propranolol, a lipophilic non-selective beta-blocker, has proven to be effective in the treatment of infantile haemangioma (IH)."7.79Treatment of infantile haemangiomas with atenolol: comparison with a historical propranolol group. ( Breugem, CC; Breur, JM; Bruijnzeel-Koomen, CA; de Graaf, M; Knol, MJ; Kon, M; Pasmans, SG; Raphael, MF, 2013)
"Oral propranolol hydrochloride treatment has been proven effective for infantile hemangiomas."7.79Effects of oral propranolol on circumscribed choroidal hemangioma: a pilot study. ( Hirose, H; Kitano, T; Sahashi, K; Saito, AM; Tanabe, H; Tomita, Y, 2013)
"We sought to determine the effect of propranolol on cardiovascular and blood glucose parameters in infants with symptomatic infantile hemangiomas who were hospitalized for initiation of treatment, and to analyze adverse effects of propranolol throughout the course of inpatient and outpatient treatment."7.79Cardiovascular and blood glucose parameters in infants during propranolol initiation for treatment of symptomatic infantile hemangiomas. ( Bauman, NM; Boss, EF; Cohen, BA; Puttgen, KB; Schneider, J; Summerer, B, 2013)
"Propranolol had a rapid stabilizing effect leading to early regression of hemangiomas when administered orally at a dose of 3 mg/kg/day with good quality safety profile."7.79Propranolol for hemangiomas. ( Hasan, M; Hoque, S; Khondker, L; Rahman, M; Zahid Hossain, AK, 2013)
"We investigated the clinical efficacy of propranolol in treating proliferating infantile haemangiomas, and the serological changes in vascular endothelial growth factor (VEGF) and endothelial nitric oxide synthase (eNOS) during treatment."7.79Propranolol given orally for proliferating infantile haemangiomas: analysis of efficacy and serological changes in vascular endothelial growth factor and endothelial nitric oxide synthase in 35 patients. ( Jin, ZL; Liu, ZY; Wang, XK; Wei, JJ; Xue, L; Yuan, WL, 2013)
"We aimed to assess the efficacy and safety of low-dose propranolol for treatment of infantile hemangiomas (IHs) in China."7.79Preliminary experience on treatment of infantile hemangioma with low-dose propranolol in China. ( Chen, H; Huang, Y; Lin, J; Liu, J; Ma, X; Ouyang, T; Xiao, Y; Yu, J; Zhao, T, 2013)
"Treatment options for large subglottic haemangioma include steroids, laser ablation, open excision, tracheostomy and, more recently, propranolol."7.79Great Ormond Street Hospital treatment guidelines for use of propranolol in infantile isolated subglottic haemangioma. ( Albert, DM; Bajaj, Y; Harper, JI; Hartley, BE; Ifeacho, S; Jephson, CG; Kapoor, K, 2013)
"To evaluate the response of nasal tip hemangiomas to systemic propranolol."7.78Hemangiomas of the nasal tip treated with propranolol. ( Ben-Amitai, D; Halachmi, S; Kalish, E; Lapidoth, M; Raveh, E; Zvulunov, A, 2012)
"Propranolol was recently discovered to be an effective treatment for infantile haemangiomas, and varying doses and monitoring regimens have been proposed."7.78Propranolol for infantile haemangiomas: initiating treatment on an outpatient basis. ( Dyme, JL; Han, EJ; Kotb, ME; Nyirenda, TL; Shin, HT; Thampan, A, 2012)
"Thirty-seven infants with propranolol-treated problematic head and neck hemangiomas were included and all patients had a good response."7.78Propranolol for problematic head and neck hemangiomas: an analysis of 37 consecutive patients. ( Fan, XD; Lv, MM; Su, LX, 2012)
"To examine the location and degree of endothelial nitric oxide synthase (eNOS) protein expression in hemangioma growth, involution, and during propranolol therapy."7.78Decreased eNOS protein expression in involuting and propranolol-treated hemangiomas. ( Buckmiller, L; Dai, Y; Fan, CY; Hou, F; Richter, GT; Saad, A; Suen, J, 2012)
"Propranolol may be a promising therapeutic modality for infantile hemangioma."7.78Treatment with propranolol for infantile hemangioma in 13 Taiwanese newborns and young infants. ( Chang, TK; Chen, CH; Chou, CM; Hsu, TC; Lin, HK; Wang, JD; Wang, TM, 2012)
"To investigate the mechanism of propranolol on regression of infantile hemangiomas."7.78Propranolol induces regression of hemangioma cells through HIF-1α-mediated inhibition of VEGF-A. ( Armijo, BS; Chim, H; Gliniak, C; Gosain, AK; Miller, E; Serret, MA, 2012)
"Propranolol is a non-selective beta-adrenergic antagonist successfully used in a case of kaposiform hemangioendothelioma (KHE) associated with Kasabach-Merritt phenomenon (KMP)."7.78Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon. ( Blei, F; Carcao, M; Chiu, YE; Drolet, BA; Fangusaro, J; Kelly, ME; Krol, A; Lofgren, S; Mancini, AJ; Metry, DW; Pope, E; Recht, M; Silverman, RA; Tom, WL, 2012)
"To evaluate changes in infantile hemangioma tissue before and after propranolol therapy, using gray-scale and color Doppler ultrasound imaging."7.78Propranolol reduces infantile hemangioma volume and vessel density. ( Bingham, MM; Perkins, JA; Saltzman, B; Vo, NJ, 2012)
"Sixty-seven infantile hemangioma patients were included in propranolol protocol in two institutions from 2009 to 2011."7.78Propranolol as the first-line therapy for infantile hemangiomas: preliminary results of two centers. ( Celik, A; Ergun, O; Kismali, E; Levent, E; Musayev, A; Tiryaki, S, 2012)
"  To evaluate the effectiveness, safety and tolerability of propranolol as single-agent treatment in patients with problematic, proliferative-phase, infantile hemangiomas (IHs)."7.78Propranolol treatment for severe infantile hemangiomas: a single-centre 3-year experience. ( Georgountzou, A; Kakourou, T; Karavitakis, E; Klimentopoulou, A; Xaidara, A, 2012)
"Propranolol has recently emerged as an effective drug treatment for infantile haemangiomas."7.78Use of propranolol for treatment of infantile haemangiomas in an outpatient setting. ( Bekhor, PS; Crock, CM; Penington, AJ; Phillips, RJ, 2012)
"Discuss effect and dynamics of propranolol (PR) treatment in infantile haemangioma (IH) of head and neck in children during follow-up."7.78Propranolol for infantile haemangioma: striking effect in the first weeks. ( Csákányi, Z; Gács, E; Gerlinger, I; Katona, G; Ráth, G; Szalai, Z, 2012)
"Propranolol increased apoptosis of hemangioma endothelial cells, but not stem cells, and accelerated adipogenesis of hemangioma stem cells."7.78Propranolol accelerates adipogenesis in hemangioma stem cells and causes apoptosis of hemangioma endothelial cells. ( Hardy, KL; Kitajewski, AM; Kitajewski, JK; Shawber, CJ; Wong, A; Wu, JK, 2012)
"To observe the efficacy of oral Propranolol in the treatment of infantile subglottic hemangioma."7.78[Treatment of infantile subglottic hemangioma with oral propranolol]. ( Tang, LX; Wang, GX; Zhang, YM, 2012)
"Propranolol, a non-selective beta-blocker, has recently been introduced as a novel treatment modality for proliferating hemangiomas."7.78Effects of propranolol on the proliferation and apoptosis of hemangioma-derived endothelial cells. ( Chen, S; Ji, Y; Li, K; Xiao, X; Xu, T; Zheng, S, 2012)
"The clinical efficacy and safety of topical propranolol hydrochloride gel in the treatment of superficial infantile hemangiomas (IHs) were assessed."7.78Topical propranolol hydrochloride gel for superficial infantile hemangiomas. ( Li, C; Li, Y; Wang, L; Xia, Y; Zhai, Y, 2012)
"In 2008, propranolol was serendipitously observed to cause accelerated involution of infantile haemangioma."7.77Low-dose propranolol for infantile haemangioma. ( Itinteang, T; Leadbitter, P; Tan, ST, 2011)
"We report here the case of an infant with multiple hepatic and cutaneous infantile hemangiomas (IHs) associated with deranged liver function who was treated successfully with low-dose propranolol."7.77Low-dose propranolol for multiple hepatic and cutaneous hemangiomas with deranged liver function. ( Itinteang, T; Leadbitter, P; Tan, ST, 2011)
"I see many children with infantile hemangiomas and have read about new therapeutic options such as propranolol."7.77Use of propranolol in treating hemangiomas. ( Goldman, RD; Prendiville, JS; Shayan, YR, 2011)
"To outline a safe, standardized protocol for outpatient initiation of propranolol therapy for infantile hemangiomas."7.77Initial experience with a multidisciplinary strategy for initiation of propranolol therapy for infantile hemangiomas. ( Boucek, RJ; Cushing, SL; Manning, SC; Perkins, JA; Sidbury, R, 2011)
"Recent reports have described the successful use of propranolol to treat severe hemangiomas of infancy."7.77[Propranolol for the treatment of severe hemangiomas of infancy: results from a series of 28 patients]. ( Bernabeu-Wittel, J; Conejo-Mir, J; de Agustín, JC; Fernández-Pineda, I; Mantrana-Bermejo, ME; Pereyra-Rodríguez, JJ, 2011)
"To report the efficacy of propranolol as first-line treatment of head and neck hemangiomas in children and to present an optimized protocol for treating hemangiomas."7.77Propranolol as first-line treatment of head and neck hemangiomas. ( Ayari-Khalfallah, S; Froehlich, P; Fuchsmann, C; Giguere, C; Guibaud, L; McCone, C; Powell, J; Quintal, MC, 2011)
"A brief comment on efficacy and safety of propranolol in the treatment of parotid hemangioma is presented, with illustration of a typical case."7.77Comment on efficacy and safety of propranolol in the treatment of parotid hemangioma. ( Zheng, JW, 2011)
"To observe the efficacy and safety of oral propranolol in the treatment of periorbital proliferating phase infantile hemangioma."7.77[Oral propranolol in the management of periorbital proliferating phase infantile hemangioma]. ( Fu, HB; Guo, X; Huo, R; Lin, LL; Lü, RR; Wui, JC; Xu, GQ; Zhang, J; Zhao, ZF, 2011)
"To determine whether propranolol therapy is safe and effective and superior to oral corticosteroids for treating infantile hemangiomas (IHs)."7.77Propranolol vs corticosteroids for infantile hemangiomas: a multicenter retrospective analysis. ( Baum, B; Connelly, EA; Duarte, AM; Lattouf, C; McLeod, M; Price, CJ; Schachner, LA, 2011)
"Four children with haemangiomas of the head and neck were treated with propranolol at a tertiary referral centre."7.77Failure of propranolol in the treatment of childhood haemangiomas of the head and neck. ( Bruce, IA; Goswamy, J; Rothera, MP, 2011)
"There has been a dramatic evolution in the treatment of laryngotracheal hemangiomas during the past decade and recent accounts and case reports of propranolol treatment have been encouraging."7.77Evolving treatments in the management of laryngotracheal hemangiomas: will propranolol supplant steroids and surgery? ( Jacobs, IN; Javia, LR; Zur, KB, 2011)
"To study the level of serum vascular endothelial growth factor, matrix metalloproteinases-9 in the proliferative hemangioma before and after propranolol treatment."7.77[The change of serum vascular endothelial growth factor and matrix metalloproteinases-9 in proliferative hemangioma treated with propranolol]. ( Fu, HB; Huo, R; Lü, RR; Xu, GQ; Zhao, ZF, 2011)
"Four patients with ulcerated hemangioma aged 2, 4, 5 months and 5 weeks were treated with 2 mg/kg KG propranolol."7.76Successful treatment of ulcerated haemangioma with propranolol. ( Bross, F; Lorette, G; Maruani, A; Naouri, M; Rossler, J; Schill, T, 2010)
"To report our experience of using propranolol to treat an infantile airway haemangioma."7.76Use of propranolol to treat multicentric airway haemangioma. ( Mistry, N; Tzifa, K, 2010)
"We report the rapid and dramatic efficacy of propranolol in 8 infants with infantile hepatic hemangiomas."7.76Efficacy of propranolol in hepatic infantile hemangiomas with diffuse neonatal hemangiomatosis. ( Ammour, A; Benlahrech, S; Bodemer, C; Broue, P; Hoeger, PH; Labenne, M; Léauté-Labrèze, C; Mazereeuw-Hautier, J; Ohanessian, G; Rössler, J; Vabres, P; Vial, J, 2010)
"Propranolol is a novel therapeutic agent in the treatment of cutaneous infantile haemangiomas."7.76Successful treatment of infantile haemangiomas of the orbit with propranolol. ( Li, YC; Martin, FJ; Martin, PA; McCahon, E; Rowe, NA; Wilcsek, GA, 2010)
" Our main outcome measures were colour and size of infantile haemangioma before and after treatment, the change in astigmatism of our patients and the incidence of complications from propranolol."7.76Propranolol in the management of periorbital infantile haemangioma. ( Cheng, JF; Gole, GA; Sullivan, TJ, 2010)
"The successful management of subglottic hemangioma with propranolol has been reported."7.76Management of infantile subglottic hemangioma: acebutolol or propranolol? ( Amedro, P; Bigorre, M; Blanchet, C; Mondain, M; Nicollas, R, 2010)
"Propranolol has recently been reported to be useful in the treatment of infantile hemangiomas."7.76Outpatient treatment of periocular infantile hemangiomas with oral propranolol. ( Eikenberry, J; Haggstrom, A; Haider, KM; Neely, DE; Plager, DA, 2010)
"Propranolol hydrochloride has been prescribed for decades in the pediatric population for a variety of disorders, but its effectiveness in the treatment of infantile hemangiomas (IHs) was only recently discovered."7.76Hypoglycemia in children taking propranolol for the treatment of infantile hemangioma. ( Drolet, BA; Frieden, IJ; Frommelt, PC; Holland, KE; Mancini, AJ; Wyatt, D, 2010)
" She was given propranolol after her tracheotomy and had a significant reduction in her subglottic airway obstruction."7.76Propranolol in the management of airway infantile hemangiomas. ( Frieden, IJ; Maguiness, SM; Meyer, AK; Rosbe, KW; Suh, KY, 2010)
"To evaluate the short-term results and safety of propranolol for the treatment of infantile parotid hemangioma."7.76[Treatment of infantile parotid hemangioma with propranolol]. ( Ge, CX; Li, KL; Liu, XJ; Qin, ZP; Tai, MZ, 2010)
"Seven patients presenting with airway obstruction were treated with propranolol."7.76Propranolol for the treatment of airway hemangiomas: a case series and treatment algorithm. ( Chang, KW; Messner, AH; Perkins, JA; Truong, MT, 2010)
" Mean percentage of airway obstruction was 68% (15-90) before propranolol introduction."7.76Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma: A preliminary retrospective study of French experience. ( Ayari, S; Carrabin, L; Couloigner, V; Cox, A; Denoyelle, F; Fayoux, P; Froehlich, P; Garabédian, EN; Leboulanger, N; Lescanne, E; Marianowski, R; Marie, JP; Mom, T; Mondain, M; Nicollas, R; Roger, G; Teissier, N; Triglia, JM; Van Den Abbeele, T, 2010)
"To describe the use of propranolol as first-line treatment or as single therapy to control the proliferating phase of infantile haemangioma in Chinese children."7.76Use of propranolol in infantile haemangioma among Chinese children. ( Chan, HB; Chik, KK; Luk, CK; Tan, HY, 2010)
"Propranolol treatment was recently reported to be successful for the management of severe infantile hemangioma."7.76Hyperkalemia complicating propranolol treatment of an infantile hemangioma. ( Kietz, S; Lakomek, M; Lauerer, P; Pavlakovic, H; Zutt, M, 2010)
"There are recent reports of effective treatment of cutaneous hemangiomas with Propranolol."7.75Role of Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma. ( Denoyelle, F; Enjolras, O; Garabedian, EN; Harris, R; Leboulanger, N; Roger, G, 2009)
"To evaluate the short-term efficacy and safety of propranolol in the treatment of infantile hemangiomas."7.75[Treatment of infantile hemangiomas with low-dose propranolol: evaluation of short-term efficacy and safety]. ( Li, KL; Liu, XJ; Qin, ZP; Yang, XJ; Zheng, JW; Zhou, Q, 2009)
"Infantile hemangioma is a benign cutaneous tumor, which sometimes rapidly enlarges, causes cosmetic problem, destroys normal tissue, and possibly threatens life."6.94Change of serum cytokine profiles by propranolol treatment in patients with infantile hemangioma. ( Inaba, Y; Jinnin, M; Kakimoto, N; Kaminaka, C; Kanazawa, N; Kunimoto, K; Mikita, N; Suenaga, T; Suzuki, H; Takeuchi, T; Tani, S; Yamamoto, Y, 2020)
" Our study suggested that oral propranolol combined with topical timolol treatment is very effective and well-tolerated for compound IHs, which can be used as a first line treatment."6.82Oral propranolol combined with topical timolol for compound infantile hemangiomas: a retrospective study. ( Ge, J; Yuan, W; Zhang, L; Zhao, H; Zheng, J, 2016)
"Propranolol treatment decreases urinary excretion of MMP-9 in patients with IH."6.78Propranolol-mediated attenuation of MMP-9 excretion in infants with hemangiomas. ( Bauman, N; Brown, KJ; Movius, E; Preciado, D; Saieg, A; Thaivalappil, S, 2013)
"Infantile haemangioma is the commonest childhood tumour and approximately 10% requires treatment."6.76Propranolol as first-line treatment for rapidly proliferating infantile haemangiomas. ( Gorst, C; Holmes, WJ; Liew, SH; Mishra, A, 2011)
"Infantile hemangioma is one of the most common benign tumors of infancy."6.72Propranolol treatment of infantile subglottic hemangioma: a report of two cases and a literature review. ( Ganeva, K; Nikiforova, L; Sapundzhiev, N; Shivachev, P, 2021)
"Infantile haemangiomas are the most common tumour of infancy."6.58Topical propranolol for infantile haemangiomas: a systematic review. ( Birchall, JC; Elhassan, HA; Mcleod, RWJ; Price, A; Rai, S, 2018)
" The dosage was increased up to a maximum of 2 mg/kg/d and was maintained until the lesion had involuted or showed good result."6.53Treatment of rapidly proliferating haemangiomas in newborns with propranolol and review of the literature. ( Debek, W; Dzienis-Koronkiewicz, E; Hermanowicz, A; Matuszczak, E; Oksiuta, M, 2016)
"Propranolol was found to be a more effective modality in treating IHs (ORs = 0."6.52Effectiveness and Safety of Oral Propranolol versus Other Treatments for Infantile Hemangiomas: A Meta-Analysis. ( Liu, X; Qu, X; Zhang, L; Zheng, J, 2015)
"Infantile hepatic hemangioma is the most common benign liver tumor during infancy."6.48Multifocal infantile hepatic hemangiomas--imaging strategy and response to treatment after propranolol and steroids including review of the literature. ( Bosemani, T; Huisman, TA; Puttgen, KB; Tekes, A, 2012)
"Infantile haemangiomas are the most common benign tumour of infancy."6.47Propranolol for infantile haemangiomas: a review. ( Shahidullah, H; Starkey, E, 2011)
" Data from the literature and from our own patient cohort (n = 132) confirm the remarkable efficacy of propranolol in complicated IH, without significant adverse effects."6.47[Treatment of haemangiomas of infancy with propranolol; good results, few side effects]. ( Hermans, DJ; Ottenhof, MJ; van Beynum, IM; van der Horst, CM; van der Vleuten, CJ; Wijnen, MH, 2011)
"Oral propranolol is a very recent therapeutic option for complicated IH with impressive efficacy and generally good tolerance."6.46Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. ( Hoeger, PH; Storch, CH, 2010)
"Our primary objective was to review the current use of propranolol for treatment of infantile hemangioma (IH), specifically regarding 1) the age at initiation of therapy, 2) the method of initiation, 3) the use of other adjuvant therapy, 4) the duration of therapy and relapse rate, 5) the adverse events, and 6) the outcome."6.25Status of propranolol for treatment of infantile hemangioma and description of a randomized clinical trial. ( Bauman, NM; Greene, EA; McCarter, R; Menezes, MD, 2011)
"Propranolol treatment mostly leads to regression of hemangiomas with satisfactory aesthetic results, but unfortunately not in all cases."5.91Nd:YAG 1064-nm laser for residual infantile hemangioma after propranolol treatment. ( Avitan-Hersh, E; Khamaysi, Z; Pam, N; Zaaroura, H, 2023)
" To evaluate the correlation of clinical features between cutaneous IH and IHH, as well as efficacy of systemic propranolol in the treatment of cutaneous IH combined with IHH."5.91Clinical features of cutaneous infantile hemangioma combined with asymptomatic infantile hepatic hemangioma and efficacy of propranolol treatment. ( Han, X; Li, L; Ma, L; Sun, Y; Wei, L; Xu, Z; Yu, L; Zhang, B, 2023)
"Oral propranolol has not been shown to impact physical development, such as weight and height."5.91The impact of propranolol on the growth and development of children with proliferative infantile hemangioma during treatment. ( Chen, S; Chen, X; Deng, L; Gao, J; Huang, L; Lin, X; Liu, C; Wang, Q; Wang, T, 2023)
"Propranolol was successfully tapered over 3 weeks by reducing the dose by 50% weekly until it reached the therapeutic dose."5.91Excessively High Chronic Propranolol Overdose in Infantile Hemangioma: A Case Report. ( Alessa, A; Alghanem, A; Alhammad, AM; Alshammari, H; Elsharawy, Y, 2023)
" Adverse event and drug-related adverse event rates were 87."5.72Efficacy and safety of propranolol cream in infantile hemangioma: A prospective pilot study. ( Hakamata, A; Hayano, S; Inui, N; Iwashima, S; Kashiwagura, Y; Nagata, E; Nishida, M; Odagiri, K; Okada, E; Sano, S; Tanaka, S; Uchida, S; Umemura, K; Watanabe, H, 2022)
"Propranolol is a safe, effective and well-tolerated treatment in Australian children with IH."5.72Immediate possible adverse event rates in infants treated with oral propranolol for infantile haemangiomas at an Australian urban tertiary hospital between 2016 and 2019. ( Adams, L; Ryan, E, 2022)
"Severe hypoglycemia was common in infants aged >1 year, when PPL was used for ≥6 months."5.72Severe hypoglycemia in propranolol treatment for infantile hemangiomas. ( Baba, N; Kaneko, T; Kuwano, Y; Morimoto, A; Ozeki, M; Sasaki, S, 2022)
"Hepatic hemangioma is the most common benign liver tumor."5.62[Propranolol treatment in Kasabach-Merritt Syndrome secondary to congenital hepatic hemangioma. Clinical case]. ( Malla, I; Selzer Soria, EM, 2021)
"Oral propranolol has been well established as the first-line treatment of complicated hemangiomas; however, variability in the administration protocol remains."5.62Is prolonged monitoring necessary? An updated approach to infantile hemangioma treatment with oral propranolol. ( Johansen, ML; Lawley, LP; Mahendran, G, 2021)
"Hemangioma is one of the commonest benign vascular tumors among children."5.56Propranolol inhibits proliferation and induces apoptosis of hemangioma-derived endothelial cells via Akt pathway by down-regulating Ang-2 expression. ( Dong, C; Gong, Y; Lei, H; Li, M; Sun, B; Sun, L; Zhang, H; Zhang, Y, 2020)
"Infantile hemangioma is one of the most common vascular tumors, which might result in morbidity and mortality without timely intervention."5.56Enhanced efficacy of propranolol therapy for infantile hemangiomas based on a mesoporous silica nanoplatform through mediating autophagy dysfunction. ( Huang, S; Liang, H; Wang, X; Wu, H; Zhang, D; Zheng, J, 2020)
"Infantile hemangiomas are the most common benign vascular tumors in childhood."5.56Propranolol-resistant infantile hemangioma successfully treated with sirolimus. ( Baselga, E; Dávila-Osorio, VL; Iznardo, H; Puig, L; Roé, E, 2020)
" Although oral propranolol is currently first-line therapy, optimal dosing for treatment of IH remains debated."5.56Retrospective case series of increased oral propranolol dosage for infantile hemangiomas. ( Aggarwal, P; Cohen, BA; Huang, AH; Mahon, M; Mannschreck, D, 2020)
"The initial recommendation propranolol usage in managing infantile hemangioma was in 2008 followed by various researches assessing the dosage, efficacy, and other parameters."5.51Itraconazole versus propranolol: therapeutic and pharmacologic effect on serum angiopoietin-2 in patients with infantile hemangioma. ( Bessar, H; Kandil, AH; Khattab, F; Nasr, NM, 2022)
"Propranolol was started at the age of 3 months and 7 days old with an initial dosage of 1."5.51Efficacy of infantile hepatic hemangioma with propranolol treatment: A case report. ( Liu, HC; Tsai, MC; Yeung, CY, 2019)
"Propranolol is a well-documented medical therapy for cutaneous lesions, but surgical treatment dominates the literature on bladder haemangiomas."5.51Propranolol as an effective therapy for infantile haemangioma of the urinary bladder. ( Anwar, T; Malm-Buatsi, E, 2019)
"Infantile hemangioma is the most common soft tissue tumors in childhood."5.51MiR-187-3p Enhances Propranolol Sensitivity of Hemangioma Stem Cells. ( Ji, Z; Jiang, Y; Liu, C; Zhao, Z; Zheng, J, 2019)
"Infantile hemangiomas are the most common tumor of childhood and undergo rapid growth during early infancy followed by gradual involution."5.48Prolonged growth of infantile hemangioma after pulsed dye laser and oral propranolol treatment. ( Kagami, S; Kaneko, M; Katori, T; Kishi, A, 2018)
"The propranolol treatment for the patient with suspected of bronchial asthma was suspended for 4 months."5.48Oral propranolol for infantile hemangiomas beyond the proliferative phase. ( Kagami, S; Katori, T, 2018)
"Propranolol has been recently introduced for the treatment of IH."5.48Propranolol inhibits proliferation and invasion of hemangioma-derived endothelial cells by suppressing the DLL4/Notch1/Akt pathway. ( Dong, C; Gong, Y; Lei, H; Li, M; Sun, B; Sun, L; Zhang, H; Zhang, Y, 2018)
"Treatment with propranolol in this group of Moroccan pediatric patients proved to be safe and effective at a dose of 2 mg/kg/day, reducing the size and coloration of the hemangioma."5.48Effects of propranolol therapy in Moroccan children with infantile hemangioma. ( Baline, K; Chiheb, S; Fatoiki, FZE; Hali, F; Khadir, K; Lahrichi, A, 2018)
"Propranolol has been demonstrated to be effective for IHs; however, the factors affecting its therapeutic effect remain unknown."5.46Analysis of factors affecting the therapeutic effect of propranolol for infantile haemangioma of the head and neck. ( Dong, JY; Huang, YY; Li, K; Li, RH; Liu, C; Liu, SH; Ning, JX; Wang, XX; Yue, LL, 2017)
" The dosage of propranolol was increased from 0."5.46Successful Treatment of Infantile Hemangiomas With Propranolol in Low-Birth-Weight Infants. ( Hayashi, A; Kado, M; Matsumura, T; Mizuno, H; Mochizuki, M; Shimizu, A, 2017)
" During the involution phase, tapering propranolol dosage can be done to minimize side effects before discontinuing treatment."5.46Propranolol therapy for infantile hemangioma: our experience. ( Wu, HW; Yuan, W; Zhang, L; Zheng, JW, 2017)
"Diffuse hepatic hemangiomas are a challenging disease that can be life threatening."5.46Diffuse Hepatic Hemangiomas Successfully Treated Using Sirolimus and High-Dose Propranolol. ( Diaz, L; Levy, M; Warren, D, 2017)
"Infantile hemangiomas are the most common tumors affecting children."5.46Promotion of Propranolol Delivery to Hemangiomas by Using Anti-VEGFR Antibody-Conjugated Poly(lactic-co-glycolic acid) Nanoparticles. ( Dong, C; Gong, Y; Guo, X; Liu, D; Sun, J; Zhu, X, 2017)
"Hemangiomas are common skin lesion, affecting 10-12% of children <1year of age."5.43The treatment of problematic hemangiomas in children with propranolol and 940nm diode laser. ( Dementieva, N; Jones, S, 2016)
"Oral propranolol was successful in 95."5.43Propranolol treatment for infantile hemangioma: a case series of sixty-two patients. ( Barbato, G; Boccaletti, V; Carano, N; Cerasoli, G; Gritti, A; Lombardi, AA; Marchesi, M; Stringari, G; Tchana, B; Zanzucchi, M, 2016)
"Propranolol is the only treatment that the U."5.43Use of Propranolol for Treating Hemangiomas in Infants with Previously Diagnosed Hypoglycemic Conditions. ( De Léon, DD; McMahon, P; Treat, JR; Yang, TB, 2016)
" However, the appropriate drug dosage, dosing regimen, time for initiation, optimal duration, monitoring for side effects remains controversial."5.43[Chinese experts consensus on the use of oral propranolol for treatment of infantile hemangiomas]. ( Fan, XD; Huo, R; Li, K; Liu, SH; Qin, ZP; Wang, XK; Wang, XY; Yang, YW; Zhao, JH; Zheng, JW; Zhou, DK, 2016)
"Prior to propranolol the systemic treatment for haemangiomas was prednisolone and then the concern was the opposite, namely hypertension."5.42Propranolol and prednisolone combination for the treatment of segmental haemangioma in PHACES syndrome. ( Batul Syed, S; Gnarra, M; Harper, J; Solman, L, 2015)
"Infantile hemangiomas are the most common vascular tumors in childhood."5.42Delayed-onset of multiple cutaneous infantile hemangiomas due to propranolol: a case report. ( del Boz González, J; Navarro Morón, J; Porcel Chacón, R, 2015)
" The dosage of Propranolol was increased over the course of treatment, which initiated three days."5.42Large Doses of Propranolol for the Treatment of Infantile Cephalic and Facial Hemangiomas: A Clinical Report of 38 Cases. ( Jianguo, K; Mingkun, Z; Qiaoling, C; Wenjin, L; Xichun, W, 2015)
"Haemangiomas are benign vascular tumours that generally arise in the skin during the first days of life."5.42Propranolol (Hemangiol) and severe infantile haemangiomas. The drug of first choice. ( , 2015)
"Although propranolol has been established as the gold standard when treatment is sought for infantile hemangioma, concerns over its side effect profile have led to increasing usage of atenolol, a beta-1 selective blocker."5.41Should Propranolol Remain the Gold Standard for Treatment of Infantile Hemangioma? A Systematic Review and Meta-Analysis of Propranolol Versus Atenolol. ( Carroll, W; Chen, T; Clemmens, C; Gudipudi, R; Nguyen, SA, 2023)
"Pulmonary hemangioma is a rare benign tumor of the lungs."5.40Successful treatment of pulmonary hemangioma with propranolol. ( Akyüz, C; Emiralioğlu, N; Ersöz, DD; Kiper, N; Oğuz, B; Özçelik, U; Yalçın, B; Yalçın, E, 2014)
" The most important adverse effects were hypotension (3·4%), wheezing (9·2%), nocturnal restlessness (22·4%) and cold extremities (36·2%)."5.39Propranolol in a case series of 174 patients with complicated infantile haemangioma: indications, safety and future directions. ( Bauland, CG; Hermans, DJ; van Beynum, IM; van der Vleuten, CJ; Zweegers, J, 2013)
"Infantile hemangioma is a common benign pediatric tumor which shares many features with epulis, such as rich vascularity, high incidence of female patients, high hormone level and similar treatments."5.38New treatment strategy for granulomatous epulis: intralesional injection of propranolol. ( Fan, ZN; Li, KL; Liu, C; Liu, SH; Qin, ZP; Wang, YM; Wei, FC; Zhao, WJ, 2012)
"Propranolol has been recently discovered to shrink these lesions effectively."5.37Propranolol, infantile haemangiomas, and serendipity: new use for an old drug. ( Grech, V; Scerri, C, 2011)
"Infantile haemangioma is a benign tumour of the microvasculature characterised by excessive proliferation of immature endothelial cells."5.37Expression of components of the renin-angiotensin system in proliferating infantile haemangioma may account for the propranolol-induced accelerated involution. ( Brasch, HD; Day, DJ; Itinteang, T; Tan, ST, 2011)
"Propranolol was given to 20 patients with IH, who suffered from ulceration at the start of treatment (mean age at onset of treatment, 3."5.37Propranolol, a very promising treatment for ulceration in infantile hemangiomas: a study of 20 cases with matched historical controls. ( Hermans, DJ; Schultze Kool, LJ; van Beynum, IM; van de Kerkhof, PC; van der Vleuten, CJ; Wijnen, MH, 2011)
"Propranolol appears to be an effective and well-tolerated treatment for ulcerated IH."5.37Propranolol for treatment of ulcerated infantile hemangiomas. ( Barbarot, S; Bodak, N; Hadj-Rabia, S; Hamel-Teillac, D; Kupfer-Bessaguet, I; Lacour, JP; Léauté-Labrèze, C; Mazereeuw-Hautier, J; Naouri, M; Nguyen, JM; Saint-Jean, M; Stalder, JF; Vabres, P, 2011)
"Propranolol appears to be an effective treatment option for IH even in the nonproliferative phase and after the first year of life."5.37Adverse effects of propranolol when used in the treatment of hemangiomas: a case series of 28 infants. ( Breugem, CC; Breur, JMPJ; de Graaf, M; Pasmans, SGMA; Raphaël, MF; Vos, M, 2011)
"PHACE syndrome is a neurocutaneous disorder with large facial segmental hemangionas associated with anomalies of the brain, eye, heart and aorta."5.37Use of propranolol for treatment of hemangiomas in PHACE syndrome. ( Deming, D; Hopper, A; Merritt, TA; Ninnis, J; Solomon, T, 2011)
"Oral propranolol was given for a period of 6 months with monthly follow up."5.37Initial experiences with propranolol treatment of infantile hemangiomas: report of three cases. ( Halilbasic, A; Halilbasic, M; Hotic, N; Husaric, E; Husaric, S; Rahmanovic, E, 2011)
"Hemangiomas are the most common vascular tumors in children."5.36Successful treatment of a large hemangioma with propranolol. ( Haas, E; Kues, K; Lauerer, P; Mousa, W; Pavlakovic, H; Schön, MP; Zutt, M, 2010)
"Haemangiomas are the most common soft tissue tumours in infancy, occurring in approximately 5-10% of 1-year-old children."5.36Propranolol as a novel treatment for congenital visceral haemangioma. ( Cornette, L; Decaluwe, W; Van Geet, C; Vandelanotte, M; Vanlander, A, 2010)
"Propranolol was given to 32 children (21 girls; mean age at onset of treatment: 4."5.35Propranolol for severe infantile hemangiomas: follow-up report. ( Berge, J; Boralevi, F; de la Roque, ED; Dupuis, E; Ezzedine, K; Grenier, N; Léauté-Labrèze, C; Lipsker, D; Mazereeuw-Hautier, J; Sans, V; Taïeb, A; Vergnes, P, 2009)
"Subglottic haemangioma is a rare but potentially life threatening condition which requires intervention."5.35Successful treatment of isolated subglottic haemangioma with propranolol alone. ( Harper, J; Hartley, BE; Jephson, CG; Manunza, F; Mills, NA; Syed, S, 2009)
"Hemangioma is the most common tumor of infancy."5.35[Response to oral propranolol therapy for ulcerated hemangiomas in infancy]. ( Michel, JL; Patural, H, 2009)
"With the emergence of propranolol as the first choice of treatment for problematic infantile haemangioma at many centres, the number of patients with a partial or non-response to propranolol has also been growing."5.27Role of intralesional bleomycin and intralesional triamcinolone therapy in residual haemangioma following propranolol. ( Kumar, R; Pandey, V; Sharma, SP; Singh, OP; Tiwari, P, 2018)
"There are limited data from randomized clinical trials comparing propranolol and steroid medication for treatment of infantile hemangioma (IH)."5.24Comparison of Efficacy and Safety Between Propranolol and Steroid for Infantile Hemangioma: A Randomized Clinical Trial. ( Cheon, JE; Choe, YS; Choi, TH; Choi, Y; Hong, KY; Jeong, JH; Kang, HJ; Kim, DY; Kim, KH; Lee, H; Park, JB; Park, KD; Park, YW; Shin, HY, 2017)
"Topical timolol and lasers are widely used for the treatment of infantile hemangioma (IH), and they can replace propranolol as the first-line treatment of IH."5.22Comparison of the efficacy and safety of lasers, topical timolol, and combination therapy for the treatment of infantile hemangioma: A meta-analysis of 10 studies. ( Cai, B; Chen, X; Huang, H; Wang, B; Yu, J, 2022)
"Propranolol is a valuable therapeutic alternative for treatment of ulcerated haemangiomas and effectively reduces pain."5.22Role of propranolol in ulcerated haemangioma of head and neck: a prospective comparative study. ( Gangopadhyay, AN; Gupta, DK; Pandey, V; Sharma, SP; Tiwari, P, 2016)
"The combination treatment for mix infantile hemangiomas (IHs) using oral propranolol with topical timolol maleate was not well documented in the literature."5.22Oral Propranolol With Topical Timolol Maleate Therapy for Mixed Infantile Hemangiomas in Oral and Maxillofacial Regions. ( Li, G; Sun, NN; Tong, S; Wang, XK; Xu, DP; Xue, L, 2016)
"Propranolol has been widely used in the treatment of infantile hemangiomas since 2008."5.22Effects of systemic propranolol treatment on physical growth of patients with infantile hemangiomas. ( Chang, L; Chen, H; Hu, L; Huang, H; Jin, Y; Li, W; Lin, X; Ma, G; Qiu, Y; Xu, X; Zhou, B, 2016)
"Oral propranolol has been used to treat complicated infantile hemangiomas, although data from randomized, controlled trials to inform its use are limited."5.20A randomized, controlled trial of oral propranolol in infantile hemangioma. ( Ballona, R; Barbarot, S; Baselga, E; Benjamin, L; Bernabeu-Wittel, J; Berul, CI; Birchall, N; Boccara, O; Boralevi, F; Buckova, H; Caceres, H; Cambazard, F; Delarue, A; Febrer Bosch, MI; Foelster-Holst, R; Frieden, IJ; Friedlander, SF; Glick, S; Grantzow, R; Guibaud, L; Heritier, S; Hoeger, P; Krol, A; Léauté-Labrèze, C; Lopez Gutierrez, JC; Mancini, AJ; Maruani, A; Mazereeuw-Hautier, J; Mehta, CR; Metz, B; Morgan, CC; Perek, D; Phillips, RJ; Pope, E; Posiunas, G; Powell, J; Prey, S; Przewratil, P; Roessler, J; Souteyrand, P; Su, J; Szalai, ZZ; Torrelo, A; Vabres, P; Valencia, AM; Voisard, JJ; Wargon, O; Wyrzykowski, D, 2015)
"Combining propranolol with corticosteroids gives a faster response and should be considered in treating life- or function-threatening hemangiomas."5.20Therapeutic superiority of combined propranolol with short steroids course over propranolol monotherapy in infantile hemangioma. ( Abdel Kader, HM; Aly, MM; Ghazy, MS; Hamza, AF; Ragab, IA; Saafan, HA, 2015)
"Propranolol therapy is changing the treatment paradigm for infantile hemangioma."5.19Propranolol therapy for reducing the number of nasal infantile hemangioma invasive procedures. ( Chen, BS; Manning, SC; Parikh, SR; Perkins, JA; Saltzman, B, 2014)
"The dramatic response of infantile hemangiomas to propranolol and few side effects suggest that early treatment of infantile hemangiomas could result in decreased disfigurement."5.17Propranolol is more effective than pulsed dye laser and cryosurgery for infantile hemangiomas. ( Aozasa, N; Araki, M; Inuzuka, R; Isomura, S; Kagami, S; Katori, T; Kuwano, Y; Masui, Y; Miyagawa, T; Miyamoto, A; Sato, S; Shibata, S; Takahashi, K; Uwajima, Y; Yamada, D; Yamamoto, M, 2013)
"To assess propranolol efficacy and safety in complicated infantile hemangiomas in two different age groups."5.17The use of propranolol for complicated infantile hemangiomas. ( Dalmonte, P; Occella, C; Pelegrini, M; Rimini, A; Romanini, MV; Vercellino, N, 2013)
"The purpose of this study was to compare the efficacy of orally administered propranolol versus prednisolone versus both in the treatment of potentially disfiguring or functionally threatening infantile hemangiomas."5.17Effect of propranolol vs prednisolone vs propranolol with prednisolone in the management of infantile hemangioma: a randomized controlled study. ( Malik, MA; Menon, P; Rao, KL; Samujh, R, 2013)
"The mechanism of therapeutic success of propranolol for severe infantile haemangioma remains unclear."5.16Urinary matrix metalloproteinases-2/9 in healthy infants and haemangioma patients prior to and during propranolol therapy. ( Hinz, U; Holland-Cunz, S; Kleber, CJ; Kleber, JB; Spiess, A; Weiss, J, 2012)
"To observe the therapeutic effect of propranolol with 1 064 nm Nd:YAG laser on proliferating hemangioma in body surface."5.16[The therapeutic effect of propranolol with 1064 nm Nd: YAG laser on proliferating hemangioma in body surface]. ( Duan, B; Gong, H; Tan, M; Zhou, CM, 2012)
"Propranolol hydrochloride is a safe and effective medication for treating infantile hemangiomas (IHs), with decreases in IH volume, color, and elevation."5.15A randomized controlled trial of propranolol for infantile hemangiomas. ( Adams, S; Hogeling, M; Wargon, O, 2011)
"To evaluate the short-term efficacy and safety of propranolol for problematic infantile hemangiomas."5.15[Propranolol in the treatment of problematic infantile hemangiomas]. ( Chen, J; Huang, J; Li, S; Lu, J; Qin, G; Tna, L; Xiang, Y; Yang, S; Zhao, J; Zuo, C, 2011)
"Propranolol has recently been introduced as a novel pharmacologic treatment for infantile hemangiomas."5.14Propranolol for infantile hemangiomas: early experience at a tertiary vascular anomalies center. ( Buckmiller, LM; Dai, Y; Dyamenahalli, U; Munson, PD; Richter, GT, 2010)
"Propranolol has changed the management of infantile hemangiomas (IHs)."5.01Clinical and economic impact of surgery for treating infantile hemangiomas in the era of propranolol: overview of single-center experience from La Paz Hospital, Madrid. ( López-Gutiérrez, JC, 2019)
"Recently, several studies have reported their experience in using oral atenolol in patients with infantile haemangioma (IH), especially as an alternative to propranolol, but the efficacy and safety of oral atenolol has not been evaluated."5.01Efficacy and safety of oral atenolol for the treatment of infantile haemangioma: A systematic review. ( Chen, S; Ji, Y; Wang, Q; Xiang, B, 2019)
"We report a case presented in deep hypoglycemic coma during his treatment with propranolol for IH."5.01Deep coma in a child treated with propranolol for infantile hemangioma. ( Bakalli, I; Celaj, E; Gjeta, I; Klironomi, D; Kola, E; Lluka, R; Sala, D; Sallabanda, S, 2019)
"A number of clinical trials evaluated the effect of topical timolol in the treatment of infantile hemangioma and provided inconsistent results."4.98Effect of topical timolol on response rate and adverse events in infantile hemangioma: a meta-analysis. ( Li, Y; Zheng, L, 2018)
"Propranolol is a well tolerated and effective treatment for infantile hemangiomas."4.98Infantile hemangiomas: what have we learned from propranolol? ( Ghareeb, E; Hagen, R; Jalali, O; Zinn, Z, 2018)
"Five cases of subglottic hemangioma treated with systemic propranolol are presented."4.98[Tiempo de respuesta terapéutica al propranolol sistémico en el manejo de hemangiomas subglóticos pediátricos: serie de casos y revisión de la literatura]. ( Álvarez-Neri, H; Morera-Serna, E; Penchyna-Grub, J; Teyssier-Morales, G; Torre, C; Villamor, P, 2018)
"Propranolol has recently become the treatment of choice for management of subglottic and airway hemangiomas."4.95Efficacy and rebound rates in propranolol-treated subglottic hemangioma: A literature review. ( Chun, RH; Faria, J; Pawar, S; Schwartz, T; Siegel, D, 2017)
"Propranolol has become the first-line treatment for complicated Infantile Hemangioma (IH), showing so far a good risk-benefit profile."4.95Cardiac arrest in a toddler treated with propranolol for infantile Hemangioma: a case report. ( Cutrone, M; Dalle Carbonare, M; Perilongo, G; Pettenazzo, A; Sartori, S; Tosoni, A, 2017)
"We present a one-month old boy with an intracranial infantile hemangioma treated with propranolol."4.93Beta Blockade as Treatment for Intracranial Infantile Hemangioma: Case Report and Literature Review. ( Friedman, N; Golden, A; Kang, E; Mamoun, I; Tamburro, J, 2016)
"1) Describe the origins of the use of propranolol in the treatment of subglottic hemangiomas, 2) Perform meta-analysis of all case reports and series in which propranolol was used to treat subglottic hemangiomas."4.93The use of propranolol in the treatment of subglottic hemangiomas: A literature review and meta-analysis. ( Dodson, KM; Hardison, S; Wan, W, 2016)
"Currently, propranolol is the preferred treatment for problematic proliferating infantile haemangiomas (IHs)."4.91The use of propranolol in the treatment of infantile haemangiomas: an update on potential mechanisms of action. ( Chen, S; Ji, Y; Li, L; Xiang, B; Xu, C, 2015)
"The serendipitous demonstration that the nonselective β-adrenergic receptor (β-AR) antagonist propranolol promotes the regression of infantile hemangiomas (IHs) aroused interest around the involvement of the β-adrenergic system in angiogenic processes."4.91Infantile hemangiomas, retinopathy of prematurity and cancer: a common pathogenetic role of the β-adrenergic system. ( Bagnoli, P; Casini, G; Dal Monte, M; Daniotti, M; Filippi, L; Sereni, F, 2015)
"ince 2008, propranolol has become the first line therapy for infantile hemangiomas."4.91Propranolol induced hypoglycemia. ( Haim, A; Horev, A; Zvulunov, A, 2015)
"Propranolol has been recently adopted as the first-line medical treatment for complicated infantile hemangiomas."4.91Current trends in medical management of infantile hemangioma. ( Ames, JA; Sykes, JM, 2015)
"Propranolol may have shown excellent results as a first line therapy in infantile haemangiomas (IHs) at all sites in the body, but this conclusion remains controversial."4.90The effectiveness of propranolol in treating infantile haemangiomas: a meta-analysis including 35 studies. ( Cao, DS; Cao, Y; Li, HH; Lou, Y; Peng, WJ; Xie, J, 2014)
"Propranolol has replaced corticosteroids as preferred first-line therapy for the management of infantile hemangiomas (IH)."4.90Diagnosis and management of infantile hemangiomas. ( Püttgen, KB, 2014)
" The benefits with bedaquiline or Sirturo® are its ability to likely provide clinically relevant activity as part of multi-drug regimens against tuberculosis (TB) based on clinical data in multi-drug resistant tuberculosis (MDR TB) patients, who were defined as being at least resistant against the two major tuberculostatic medicines (isaoniazide and rifampicine)."4.90[Two news drugs (ivacaftor & bedaquiline), one biomarker (florbetapir) and a re-positioned drug (propranolol) on the market]. ( Monneret, C, 2014)
"Recent reports of propranolol for the treatment of hemangiomas have led many physicians to question the best treatment strategy for children with vision-threatening hemangiomas."4.89Hemangiomas treated with propranolol: do the rewards outweigh the risks? ( Haider, KM; Neely, DE; Plager, DA, 2013)
"Propranolol is a beta blocker which is safely used in the management of infantile hemangiomas."4.89Novel use of propranolol for management of pain in children with vertebral hemangioma: report of two cases. ( Celkan, T; Gungor, S; Hasiloglu, Z; Ozdemir, N; Saygin, C; Uzunaslan, D, 2013)
"To study the effectiveness of propranolol in infantile airway haemangiomas and compare the effectiveness of propranolol vs."4.87A meta-analysis on the effectiveness of propranolol for the treatment of infantile airway haemangiomas. ( Athanasopoulos, I; Parpounas, K; Peridis, S; Pilgrim, G, 2011)
"The objective of this study is to describe the initial use of propranolol as the sole treatment for focal infantile airway hemangiomas, and to report on available literature describing the use of propranolol for airway lesions."4.86Initial experience using propranolol as the sole treatment for infantile airway hemangiomas. ( Hartnick, C; Maturo, S, 2010)
"Propranolol, a nonselective beta-blocker, has recently been introduced as a novel modality for the treatment of proliferating haemangiomas."4.86Propranolol therapy for infantile haemangiomas: review of the literature. ( Eivazi, B; Werner, JA; Wiegand, S; Zimmermann, AP, 2010)
"Propranolol was serendipitously found to induce early involution in hemangiomas even during the proliferative phase of the hemangioma cycle."4.85Propranolol treatment for infantile hemangiomas. ( Buckmiller, LM, 2009)
" The present report describes a case of multifocal IHH associated with subcutaneous and lingual hemangiomas, complicated by consumptive hypothyroidism and successfully managed with oral propranolol and thyroid replacement therapy, without documented adverse effects."4.31Multifocal Infantile Hepatic Hemangiomas Complicated by Consumptive Hypothyroidism: The Benefits of Early Diagnosis and Treatment. ( Alves, I; Coelho, J; Do Bom-Sucesso, M; Morais, CG; Vilares, AT, 2023)
"Infantile hemangioma (IH), the most common benign tumor in infancy, is generally sensitive to propranolol treatment."4.31Apelin Receptor Can Act as a Specific Marker and Promising Therapeutic Target for Infantile Hemangioma. ( Chang, L; Chang, SJ; Chen, J; Chen, Q; Chen, Z; Lin, X; Qiu, Y; Ying, H; Yu, Z, 2023)
"Propranolol has emerged as a first line agent in the management of hemangiomas."4.31Bleomycin-triamcinolone sclerotherapy in the management of propranolol resistant infantile hemangioma of the maxillofacial region: A single arm prospective evaluation of clinical outcome and Doppler ultrasound parameters. ( Bera, RN; Pandey, V; Tiwari, P, 2023)
"The purpose of this study was to compare long-term neurocognitive functioning (working memory, processing speed, and attention) between children who had been treated with either propranolol or atenolol for infantile hemangioma during infancy."4.31Long-term neurocognitive functioning of children treated with propranolol or atenolol for infantile hemangioma. ( Breugem, CC; Breur, JMPJ; de Graaf, M; de Laat, PCJ; de Wildt, SN; Hermans, MM; Langeveld, HR; Mendels, EJ; Pasmans, SGMA; Raphael, MF; Rietman, AB; Schappin, R, 2023)
"The introduction of propranolol as systemic therapy for infantile hemangiomas (IH) has changed the natural history of these tumors."4.31Propranolol and infantile hemangiomas: Outcome from a tricentric study. ( Benetton, C; Cimador, M; De Corti, F; Gamba, P; Midrio, P; Pace, MD, 2023)
"Despite its effectivity, there are reports of poor response to propranolol in the treatment of infantile hemangioma (IH)."4.31Intralesional steroid in the era of propranolol for infantile hemangioma-Do we need it? ( Pandey, A; Pant, N; Rawat, J; Singh, S; Srivastava, A, 2023)
"The distribution and response to propranolol of problematic facial infantile haemangiomas (IHs) has rarely been described in the literature."4.31Distribution of problematic localized facial infantile haemangiomas and their response to propranolol: a retrospective cohort study. ( Chang, L; Chang, SJ; Chen, J; Chen, Q; Gao, W; Li, H; Lin, X; Qiu, Y; Yu, Z; Zhou, L, 2023)
"We studied 95 patients with infantile hemangioma (IH) treated with propranolol at the Department of Dermatology, Kumamoto University Hospital, from November 2016 to January 2022, based on sex, site, clinical classification, duration of treatment, and residual lesions after treatment."4.31A study of 95 infantile hemangiomas treated with propranolol: A potentially efficacious combination with laser therapy. ( Amano, F; Aoi, J; Fukushima, S; Kajihara, I; Makino, K; Masuguchi, S; Nakayama, W; Nishimura, Y; Sawamura, S; Shimada, S; Yamada-Kanazawa, S, 2023)
"This study aims to review how the introduction of propranolol as the primary treatment option for children with infantile hemangiomas (IHs) has affected the use of other treatment options at our institution and to determine the indications for surgical treatment of children with IHs in the propranolol era."4.31Indications for surgical resection of complicated infantile hemangiomas in the β-blocker's era: a single-institution experience from a retrospective cohort study. ( Beqo, BP; Flucher, C; Gasparella, P; Haxhija, EQ; Quehenberger, F; Spendel, S, 2023)
"Although the efficacy of propranolol in the treatment of infantile hemangioma (IH) has been well established, clinical data on the safety and tolerability of propranolol in neonates are still lacking."4.31Safety of oral propranolol for neonates with problematic infantile hemangioma: a retrospective study in an Asian population. ( Bai, H; Cheng, J; Fu, R; Huan, X; Huang, M; Jin, P; Wu, Z; Yuan, H; Zou, Y, 2023)
"Between January 2016 and February 2019, dermatologists experienced hemangioma treatment and recommended propranolol treatment for 232 IHs."4.31Our experience with propranolol for infantile hemangioma. ( Dai, T; Lu, W; Song, W; Wang, L; Wu, Y; Zhao, P, 2023)
"Propranolol is the first-line treatment for infantile hemangiomas (IH)."4.31Predictors of poor response to oral propranolol in infantile hemangiomas. ( Berrami, H; Chiheb, S; Hali, F; Moubine, I; Othmani, MB; Serhier, Z, 2023)
"Propranolol is the first choice for treating infantile hemangioma (IH)."4.31The effects of propranolol on the biology and Notch signaling pathway of human umbilical vein endothelial cells. ( Chen, J; Chen, S; Huang, J; Lin, C; Lin, N; Wang, L; Xu, Q; Zhang, Z; Zhao, X, 2023)
"Propranolol, a non-selective blocker of the β-adrenoceptor (AR), is a first-line treatment for infantile hemangioma (IH)."4.12Propranolol inhibits the angiogenic capacity of hemangioma endothelia via blocking β-adrenoceptor in mast cell. ( Dong, C; Dong, K; Dou, L; Gao, W; He, L; Li, J; Li, K; Lu, W; Song, W; Wang, L; Xia, C; Ye, Y; Zhong, H, 2022)
"Propranolol and atenolol, current therapies for problematic infantile hemangioma (IH), are composed of R(+) and S(-) enantiomers: the R(+) enantiomer is largely devoid of beta blocker activity."4.12Non-beta blocker enantiomers of propranolol and atenolol inhibit vasculogenesis in infantile hemangioma. ( Bischoff, J; Fontaine, F; Francois, M; Graus, MS; Huang, L; Karnezis, T; McCann, A; Meunier, F; Mulliken, JB; Seebauer, CT; Staffa, SJ; Wylie-Sears, J; Zurakowski, D, 2022)
"To evaluate the safety of initiating and maintaining propranolol therapy for infantile hemangioma (IH) and the safety of different doses."4.12Safety assessment of propranolol for infantile hemangioma: a study in an Asian population. ( Han, X; He, R; Li, L; Liu, Y; Ma, L; Qiu, L; Sun, Y; Wang, C; Wei, L; Xiu, B; Xu, Z; Yu, L; Zhang, B, 2022)
"The long-term evolution of children with segmental facial infantile haemangioma (SFIH) treated with propranolol remains unstudied."4.12Segmental facial infantile haemangiomas in the era of propranolol: evaluation at 6 years of age. ( Boccara, O; Boralevi, F; Léauté-Labrèze, C; Letertre, O; Pedespan, JM; Prey, S, 2022)
"Propranolol is a nonselective β-adrenergic receptor (AR) blocker that has been the first-line therapy for problematic infantile hemangioma (IH), the most frequent childhood vascular tumor."4.12A transcription factor is the target of propranolol treatment in infantile hemangioma. ( Boscolo, E; Schrenk, S, 2022)
"For infantile hemangiomas (IH) requiring treatment, including those in high-risk locations or in the setting of ulceration, oral propranolol is first-line therapy."4.12Worsening ulceration of infantile hemangioma after initiation or escalation of propranolol. ( Boull, C; Maguiness, S; Meyer-Mueller, C; Nicholson, C; Polcari, I, 2022)
"We report three infants with infantile hemangioma who experienced severe agitation and diarrhea following propranolol administration."4.12Propranolol therapy for hemangiomas in infants with neonatal abstinence syndrome may produce intolerable side effects. ( Chen, A; Poffenberger, P; Twist, J; Zinn, Z, 2022)
"Propranolol has evolved as a first line management of infantile haemangiomas."4.12Sandwich therapy in the management of propranolol resistant infantile hemangioma of the lip. ( Bera, RN; Mishra, A; Pandey, V; Sharma, SP; Tiwari, P; Tiwary, N, 2022)
"Propranolol is used to treat problematic infantile hemangiomas (IHs), but its safety in infants <5 weeks corrected age has not been established."4.12Safety of propranolol for infantile hemangioma in infants less than five weeks corrected age. ( Check, JF; Gatts, JE; McLean, TW; Rush, MC; Samelak, DM, 2022)
"Propranolol is used as the first-line treatment for infantile hemangiomas (IHs)."4.12Topical Formulations of Propranolol for Infantile Hemangiomas: Characteristics of Formulations and Three Cases of Infants Administered Topical Propranolol Cream. ( Endoh, A; Hakamata, A; Inui, N; Kashiwagura, Y; Namiki, N; Shirai, M; Tanaka, S; Uchida, S; Watanabe, H, 2022)
"Infantile haemangiomas are common benign tumours of infancy, which can be treated effectively with beta-blockers such as propranolol and atenolol."4.12Aesthetic Outcome of Propranolol vs Atenolol Treatment of Children with Infantile Haemangioma. ( Breugem, CC; Breur, JMPJ; De Graaf, M; De Laat, PCJ; De Wildt, SN; Hermans, MM; Jonge Poerink, E; Langeveld, HR; Mendels, EJ; Pasmans, SGMA; Ragamin, A; Raphael, MF; Rietman, AB; Schappin, R, 2022)
"Oral propranolol is recommended as the first-line agent for infantile hemangioma requiring systemic treatment."4.12Efficacy of intravenous propranolol for life-threatening diffuse neonatal hemangiomatosis. ( Ishikawa, T; Seki, K; Uchiyama, H, 2022)
"To assess the efficacy of transcatheter arterial embolization (TAE) plus propranolol treatment for infantile hepatic hemangioma (IHH)."4.12Clinical evaluation of transcatheter arterial embolization combined with propranolol orally treatment of infantile hepatic hemangioma. ( Guo, L; Li, J; Song, D; Wang, L, 2022)
"To analyze the therapeutic effect of oral propranolol combined with sclerotherapy of lauromacrogol and triamcinolone acetonide in the treatment of lip infantile hemangiomas (IHs)."4.12A Retrospective Study of Lip Hemangiomas: Curative Effect of Oral Propranolol Combined with Topical Sclerotherapy. ( Huo, R; Ling, J; Yang, K; Zhang, D, 2022)
"The mechanisms underlying the success of propranolol in the treatment of infantile hemangioma (IH) remain elusive and do not fully explain the rapid regression of hemangiomatous lesions following drug administration."4.12Β-blockers activate autophagy on infantile hemangioma-derived endothelial cells in vitro. ( Caputi, M; Cerasoli, G; Cerretani, E; Corradini, E; Falco, A; Frati, C; Gherli, A; Gnetti, L; Graiani, G; Lagrasta, C; Lorusso, B; Madeddu, D; Nogara, A; Pilato, FP; Quaini, F; Roti, G, 2022)
"Propranolol is a first-line clinical drug for infantile haemangiomas (IH) therapy."4.12Circular RNA hsa_circ_0000915 promotes propranolol resistance of hemangioma stem cells in infantile haemangiomas. ( Chen, H; Li, Y, 2022)
"To assess the adverse effects of propranolol therapy in infantile hemangioma."4.02Adverse Drug Reactions Following Propranolol in Infantile Hemangioma. ( Imran, M; Kumar, D; Mishra, A; Pandey, V; Sharma, SP; Tiwari, P, 2021)
"Propranolol has been used in the first-line therapy of infantile hemangioma (IH) for a number of years; however, the mechanisms through which propranolol regulates IH are not yet fully understood."4.02Propranolol Suppresses Proliferation and Migration of HUVECs through Regulation of the miR-206/VEGFA Axis. ( Hu, C; Li, W; Lu, H; Qian, H; Qian, Y; Wu, Y; Yuan, C; Zhang, T, 2021)
"Oral propranolol accelerates the involution of infantile haemangiomas (IHs)."4.02Sequelae following infantile haemangiomas treated with propranolol. ( Baselga, E; Bassi, A; Bernabeu-Wittel, J; Carnevale, C; Diociaiuti, A; Downey, C; El Hachem, M; Gich, I; Gonzalez-Enseñat, MA; Knopfel, N; Leuzzi, M; Manunza, F; Mascaro, P; Monserrat-García, MT; Neri, I; Oranges, T; Ortiz-Prieto, A; Puig, L; Roe, E; Torrelo, A; Vercellino, N; Vicente, A, 2021)
"Teledermatology can solve diagnostic and therapeutic problems in paediatrics, for example in infantile haemangiomas (IHs) requiring early treatment with propranolol."4.02Teledermatology in paediatrics: Health-care impact on the early treatment of infantile haemangiomas. ( Berbegal-DeGracia, L; Betlloch-Mas, I; Martínez-Miravete, MT; Sánchez-Payá, J; Sánchez-Vázquez, L, 2021)
" Of these, 14 were proliferating hemangiomas, 14 were stationary, 14 were involuted, and 13 had been treated with propranolol."4.02NOTCH pathway activation in infantile hemangiomas. ( Johnson, A; Richter, G; Strub, GM; Sun, R; Wei, T; Zhang, H, 2021)
"Oral propranolol is the treatment of choice for infantile hemangiomas."4.02Recurrence rate of infantile hemangioma after oral propranolol therapy. ( Byeon, JO; Frongia, G; Günther, P; Mehrabi, A, 2021)
"To report the effectiveness and safety of transcatheter arterial sclerosing embolization (TASE) for the treatment of parotid infantile hemangiomas that did not respond appreciably to propranolol."4.02Transcatheter Arterial Sclerosing Embolization for the Treatment of Giant Propranolol-Resistant Infantile Hemangiomas in the Parotid Region. ( Guo, L; Li, J; Song, D; Sun, J; Wang, L; Wu, C; Zhang, Y, 2021)
"The outcomes of propranolol treatment remain controversial for parotid hemangiomas, which may be inferior to outcomes for infantile hemangiomas (IHs) at other sites."4.02Oral propranolol therapy in parotid hemangiomas: A retrospective comparison with other infantile hemangiomas. ( Bi, J; Gao, Q; Huo, R; Li, S; Li, X; Lv, R; Wang, L; Xu, G, 2021)
"Propranolol emerged as the first-line therapy for infantile hemangioma (IH)."4.02Propranolol for infantile hemangioma: Evaluating efficacy and predictors of response and rebound growth. ( Khamaysi, Z; Kridin, K; Pam, N, 2021)
"Serum GLUT1, IGF-2, and VEGF-A levels were positively correlated with disease severity in patients with hemangioma, for example, in complicated hemangioma and hemangioma requiring propranolol treatment."4.02Evaluation of GLUT1, IGF-2, VEGF, FGF 1, and angiopoietin 2 in infantile hemangioma. ( Aydin Köker, S; Köker, A; Köksoy, AY; Kömüroğlu, AU; Şiraz, ÜG; Tekin, E, 2021)
"The beta-blocker propranolol is the standard medical therapy for subglottic hemangioma (SGH), but side effects and incomplete response rates require close monitoring."4.02Propranolol versus nadolol for treatment of pediatric subglottic hemangioma. ( Cushing, SL; Pope, E; Propst, EJ; Wolter, JK; Wolter, NE; Yang, W, 2021)
"Sleep problems are frequently reported in infants treated with propranolol for infantile hemangiomas, possibly serving as a marker for a negative impact on central nervous system function."4.02Sleep behavior of infants with infantile hemangioma treated with propranolol-a cohort study. ( Gnannt, R; Kernland-Lang, K; Knöpfel, N; Kohler, M; Kurth, S; Luchsinger, I; Neuhaus, K; Schoch, SF; Schwieger-Briel, A; Smith, A; Theiler, M; von der Heydt, S; Waelchli, R; Weibel, L, 2021)
"We present a case of a one-month-old female patient with severe hypertriglyceridaemia as a side effect of treating an ulcerating infantile hemangioma with systemic propranolol."4.02Transient hypertriglyceridaemia associated with propranolol for treatment of infantile hemangioma. ( Farshchian, M; Potts, GA, 2021)
"Oral propranolol has been widely used for problematic infantile hemangiomas (IHs)."3.96Lip Infantile Hemangiomas Involving the Vermillion Border Have Worse Outcomes and Prognosis to Oral Propranolol Than Lesions Confined to One Side of the Vermillion. ( Huang, H; Li, W; Xu, P; Yu, Q; Zhang, W, 2020)
"Oral propranolol is widely considered to be first-line therapy for complicated infantile hemangioma, but its use in patients with PHACE (posterior fossa malformations, hemangioma, arterial anomalies, cardiac defects, eye anomalies) syndrome has been debated owing to concerns that the cardiovascular effects of the drug may increase the risk for arterial ischemic stroke."3.96Evaluating the Safety of Oral Propranolol Therapy in Patients With PHACE Syndrome. ( Adams, D; Baselga, E; Chamlin, S; Drolet, BA; Frieden, IJ; Frommelt, P; Garzon, MC; Gupta, D; Hansen, LM; Horii, K; Klajn, J; Lauren, C; Maheshwari, M; Mancini, AJ; Mathes, E; McCuaig, CC; Newell, B; Nguyen, HL; Nopper, A; Olsen, GM; Powell, J; Puttgen, KB; Siegel, DH; Stefanko, NS; Tollefson, MM, 2020)
"Since the discovery of propranolol in the treatment of infantile hemangioma (IH), there has been emergent investigation of β-adrenergic receptor (β-AR) signaling in IH and the mechanisms of action for which β-AR blockers regulate hemangioma cell proliferation."3.96Rebound of Involuted Infantile Hemangioma After Administration of Salbutamol. ( Knöpfel, N; Oesch, V; Szello, P; Theiler, M; Weibel, L, 2020)
"Propranolol is approved for treatment of infantile hemangiomas (IH)."3.96Special management considerations for propranolol use in breastfed infants of mothers taking antihypertensives. ( Aizman, L; Kirkorian, AY; Krishnan, A; Tender, J; Van Den Anker, J, 2020)
"The highest efficacy of oral propranolol is for infantile hemangioma (IH) in the proliferative phase."3.96Oral propranolol administration is effective for infantile hemangioma in late infancy: A retrospective cohort study. ( Bergman, R; Khamaysi, Z; Kridin, K; Pam, N, 2020)
"To study the clinical effect of oral propranolol in the treatment of respiratory hemangioma in infants and young children."3.96[Clinical effect of propranolol in the treatment of respiratory hemangioma in infants and young children]. ( Chen, YQ; Ding, XF; Zhong, LL, 2020)
"Oral propranolol (OP) demonstrated high efficacy and safety profile for treatment of critical infantile hemangiomas (IHs)."3.96A new clinical and dermoscopic monitoring of infantile hemangiomas treated with oral propranolol. ( Caini, M; Cartocci, A; Cevenini, G; Cinotti, E; de Quattro, M; Fiorani, D; Ierardi, F; Oranges, T; Pianigiani, E; Rubegni, P; Tognetti, L, 2020)
"We describe a case of a 6-month-old female patient with a segmental, superficial, infantile hemangioma (IH) on the forehead being treated with propranolol 2 mg/kg/d for 5 months, who developed a symplastic hemangioma (SH) over the preexisting lesion, highlighting the need to consider SH in the differential diagnosis of vascular lesions arising over preexisting vascular anomalies in children."3.91Symplastic hemangioma developing over an infantile hemangioma during propranolol treatment. ( Cervilla, K; Downey, C; González, S; Kramer, D; Pino, G; Zambrano, MJ, 2019)
"Propranolol is an effective method of treatment for infantile hemangiomas (IH)."3.91Safety assessment during initiation and maintenance of propranolol therapy for infantile hemangiomas. ( Babiak-Choroszczak, L; Bagłaj, M; Dawid, G; Gawrych, E; Giżewska-Kacprzak, K, 2019)
"Propranolol is the mainstay of treatment for infantile hemangiomas (IHs) benefited from its low complication in the present study."3.91Associations between short-term efficacy and clinical characteristics of infantile hemangioma treated by propranolol. ( Guo, L; Li, J; Song, D; Wang, C; Wang, L; Wu, C, 2019)
"The main purpose of this study was to describe a unique case of retro-orbital infantile hemangioma (IH) simulating a congenital glaucoma requiring prompt management with systemic propranolol."3.91Secondary Congenital Glaucoma Associated With Retro-orbital Infantile Hemangioma: A Masquerade Syndrome. ( Beylerian, M; Dambricourt, L; Denis, D; Matonti, F; Ramtohul, P, 2019)
"The use of propranolol for the treatment of subglottic haemangioma has become hugely popular due to its effectiveness and safety profile."3.91Treatment failure with propranolol for subglottic haemangioma. ( Jackson, C; Liu, Z; Trimble, K; Yeo, YH, 2019)
"To present the outcomes of fixed doses of propranolol tablets for the treatment of hemangiomas."3.91EFFECTIVENESS OF FIXED DOSES OF PROPRANOLOL IN THE TREATMENT OF HEMANGIOMAS REGARDLESS OF CHILD'S WEIGHT GAIN: A CASE REPORT. ( Anger, J; Gabel, J; Oliveira, EM, 2019)
"This was a retrospective study to analyze the clinical therapeutic efficacy of propranolol in patients with infantile hemangioma (IH)."3.91Therapeutic efficacy of propranolol for infantile hemangiomas. ( Chen, Y; Gao, Z; Hao, J; Li, F; Wang, H; Wu, W, 2019)
"The efficacy of lauromacrogol injection therapy and intralesional triamcinolone for infantile hemangiomas (IH) has been well documented recently, but with an increase in serious or rare adverse reactions."3.91Safety of intralesional injection of lauromacrogol combined with triamcinolone for infantile hemangiomas. ( Bi, J; Chai, Y; Huo, R; Li, X; Li, Z; Lv, R; Song, J; Xu, G; Zhou, Z, 2019)
"Propranolol is an approved non-selective β-adrenergic blocker that is first line therapy for infantile hemangioma."3.91R-propranolol is a small molecule inhibitor of the SOX18 transcription factor in a rare vascular syndrome and hemangioma. ( Andelfinger, G; Bischoff, J; Chiang, IK; Fontaine, F; Francois, M; Gambin, Y; Hamdan, M; Huang, L; Khosrotehrani, K; Lesieur, E; Meurer, M; Moustaqil, M; Overman, J; Pasquier, E; Patel, J; Sierecki, E; Wylie-Sears, J; Zuegg, J, 2019)
"BackgroundPropranolol is the first-choice treatment for severe infantile hemangioma (IH)."3.88Infantile hemangioma: factors causing recurrence after propranolol treatment. ( Chang, L; Chen, H; Gu, Y; Jin, Y; Lin, X; Lv, D; Ma, G; Qiu, Y; Ying, H; Yu, Z, 2018)
"The primary management of infantile hemangioma (IH) has changed since 2008, with the initiation of propranolol."3.88Management trends of infantile hemangioma: A national perspective. ( Chun, RH; Espahbodi, M; McCormick, ME; Yan, K, 2018)
" The most common vascular tumor is infantile hemangioma, which treatment, when necessary, is propranolol."3.88[Benign aggressive vascular anomalies in children]. ( Boccara, O; Léauté-Labrèze, C; Maruani, A, 2018)
" Recently, the repurposing of the wide spectrum betablocker propranolol revolutionized the infantile hemangioma management."3.88[Repurposing of betablockers in dermatology]. ( Boehncke, WH; Le Gal, FA; Wrobel, LJ, 2018)
"Propranolol has become the treatment of choice for infantile hemangiomas (IH)."3.88Serum concentrations of VEGF and bFGF in the course of propranolol therapy of infantile hemangioma in children: Are we closer to understand the mechanism of action of propranolol on hemangiomas? ( Babiak-Choroszczak, L; Bagłaj, M; Fischer, K; Gawrych, E; Giżewska-Kacprzak, K; Puchalska-Niedbał, L; Rajewska-Majchrzak, J; Walecka, A, 2018)
"The safety of oral propranolol for infantile hemangioma has not yet been studied at population level since the pediatric use marketing authorization was obtained in Europe."3.88Safety of Oral Propranolol for Infantile Hemangioma. ( Botrel, MA; Droitcourt, C; Dupuy, A; Garlantezec, R; Guillot, B; Happe, A; Kerbrat, S; Oger, E; Rault, C; Schleich, JM, 2018)
"We aimed to evaluate the effects of oral propranolol for circumscribed choroidal hemangioma."3.88Effects of oral propranolol for circumscribed choroidal hemangioma. ( Gonçalves Júnior, I; Maia, M; Mattos Neto, RB; Morales, MC; Sancho, KFCB; Zett, C, 2018)
"There has been a paradigm shift from steroids to propranolol for the pharmacologic treatment of infantile hemangiomas (IH); however, the outcomes for ulcerated IH are not well studied."3.88Propranolol versus steroids for the treatment of ulcerated infantile hemangiomas. ( Chute, C; Dasgupta, R; Hammill, A; Polites, SF; Rodrigue, BB, 2018)
"Hemangioma is the most common vascular tumor in infantile period, and propranolol is the first choice, but there are still a few patients with poor curative effect."3.88[Effect of treatment of infant parotid hemangioma with no response to oral propranolol]. ( Guo, XS; Nan, J; Shen, G; Tian, Y; Wang, XL, 2018)
"Treating infantile haemangioma with propranolol is more cost-effective when initiated on an outpatient basis."3.88Cost-effectiveness of treating infantile haemangioma with propranolol in an outpatient setting. ( Chaturvedi, K; Snyder, CS; Steinberg, JS, 2018)
"Propranolol is the first-line drug for treatment of infantile hemangioma."3.88Role of Thrombospondin-1 and Nuclear Factor-κB Signaling Pathways in Antiangiogenesis of Infantile Hemangioma. ( An, W; Li, S; Sun, C; Wang, W; Xu, W; Yang, X; Yu, F; Zhang, Y, 2018)
"We sought to evaluate effect of propranolol in the treatment of infantile hemangiomas by quantifying the amount of phosphatidylinositol 3-kinase (PI3K), protein kinase B (AKT), and hypoxia-inducible factor-1α (HIF-1α)."3.88Propranolol inhibits the activity of PI3K, AKT, and HIF-1α in infantile hemangiomas. ( Huang, G; Lin, H; Lin, Z; Wang, L; Wang, W, 2018)
"Propranolol is the treatment of choicefor complicated infantile hemangiomas (IH)."3.85Propranolol for infantile hemangiomas in developing countries. ( Lawley, LP; McMichael, J, 2017)
"There have been reports of the use of levothyroxine or levothyroxine plus liothyronine for consumptive hypothyroidism caused by hepatic hemangiomas."3.85Use of liothyronine without levothyroxine in the treatment of mild consumptive hypothyroidism caused by hepatic hemangiomas. ( Hasegawa, Y; Higuchi, S; Takagi, M, 2017)
"Despite not being licensed for the treatment of infantile hemangiomas (IH) in infants younger than 5 weeks or older than 5 months, propranolol is often used in these age groups to prevent or to treat potentially severe complications."3.85Safety and effectiveness of oral propranolol for infantile hemangiomas started before 5 weeks and after 5 months of age: an Italian multicenter experience. ( Berti, I; Boccaletti, V; Carnevale, C; Cutrone, M; Dalmonte, P; Diociaiuti, A; El Hachem, M; Gesualdo, F; Greco, A; Neri, I; Oranges, T; Porcedda, G; Vercellino, N, 2017)
"Propranolol is a widely-known beta-blocker approved for treating infantile hemangiomas (IH)."3.85Tissue and serum mRNA profile of MMPs-2/9 as a potential novel biomarker for the most individual approach in infantile hemangiomas and cancer disease. ( Andrzejewska, E; Kobos, J; Przewratil, P; Taran, K; Wnęk, A, 2017)
" A cavernous hemangioma was suspected and treated with high doses of propranolol and prednisolone."3.85Unexpected Effect of Propranolol and Prednisolone on Infantile Facial Rhabdomyosarcoma. ( Bhandari, SB; Lemperle, G; Mentzel, T; Shakya, J; Shilpakar, R, 2017)
"Systemic propranolol is currently the first-line treatment modality for complicated infantile haemangiomas."3.85[Infantile haemangioma: clinical and demographic characteristics, experiences in the treatment]. ( Ábrahám, R; Csoma, ZR; Dalmády, S; Kemény, L; Rácz, K; Rózsa, T, 2017)
"Propranolol hydrochloride has become the primary medical treatment for problematic infantile hemangioma; however, the expression of propranolol's target receptors during growth, involution, and treatment of hemangioma remains unclear."3.85Expression of β-Adrenergic Receptor Subtypes in Proliferative, Involuted, and Propranolol-Responsive Infantile Hemangiomas. ( Phillips, JD; Richter, GT; Wei, T; Zhang, H, 2017)
"Oral propranolol has been recently approved for infantile hemangiomas (IHs), but potential side effects stay a challenge."3.85Oral propranolol for infantile hemangiomas: a prospective study on the role of 48-hour Holter monitoring in additional safety assessment. ( Parezanović, V; Petrovic, J; Topalovic, M; Trajkovic, G; Trifunovic, B; Vukomanovic, G, 2017)
"Concern has been raised about the potential long-term effects of propranolol treatment for infantile hemangioma (IH)."3.85Propranolol treatment of infantile hemangioma is not associated with psychological problems at 7 years of age. ( Moyakine, AV; Spillekom-van Koulil, S; van der Vleuten, CJM, 2017)
"There is no definitive conclusion regarding the optimal timing for terminating propranolol treatment for infantile hemangioma (IH)."3.85When to stop propranolol for infantile hemangioma. ( Chang, L; Chen, H; Gu, Y; Jin, Y; Lin, X; Ma, G; Qiu, Y; Ying, H; Yu, Z, 2017)
"Propranolol is the treatment of choice for infantile hemangiomas requiring medical intervention."3.85Propranolol treatment for infantile hemangioma does not increase risk of childhood wheezing. ( Amitai, DB; Blau, H; Hoshen, M; Lapidoth, M; Mei-Zahav, M; Mussaffi, H; Prais, D; Stafler, P; Steuer, G; Zvulunov, A, 2017)
"Propranolol was first used in 2008 to treat hemangioma; its efficacy and safety have since changed the classical treatment indications."3.85A New Perspective for Infantile Hepatic Hemangioma in the Age of Propranolol: Experience at Baskent University. ( Boyvat, F; Demir, Ş; Erbay, A; Özçay, F; Sarıalioğlu, F; Uslu, N; Yazıcı, N, 2017)
"The purpose of the present study is to evaluate the efficacy and safety of propranolol for problematic infantile hemangiomas (IH), showing our experience on 24 children, with special focus on premature infants."3.83Efficacy of propranolol for cutaneous hemangiomas in premature children. ( Barruscotti, S; Borroni, G; Brazzelli, V; Codazzi, CA; Giorgini, C; Mannarino, S; Marseglia, GL; Stronati, M; Tzialla, C, 2016)
"A retrospective observational study was conducted on patients with ulcerated infantile haemangioma treated with pulsed dye laser in association with propranolol."3.83[Combination of pulsed dye laser and propranolol in the treatment of ulcerated infantile haemangioma]. ( del Pozo Losada, J; Rodríguez-Ruiz, M; Tellado, MG, 2016)
"To describe a case of diffuse choroidal hemangioma with exudative retinal detachment treated successfully with oral propranolol."3.83DIFFUSE CHOROIDAL HEMANGIOMA MASQUERADING AS CENTRAL SEROUS CHORIORETINOPATHY TREATED WITH ORAL PROPRANOLOL. ( Dave, T; Dave, VP; Pappuru, RR; Shah, G, 2016)
"We review the presentation, course, management and outcomes of all cases of genital infantile hemangiomas managed by propranolol administration at a single institution from April 2010 to July 2014."3.83Propranolol for Treatment of Genital Infantile Hemangioma. ( Golden, A; Rhee, A; Tamburro, J; Tran, C, 2016)
"Oral propranolol is widely prescribed as first-line treatment for infantile haemangiomas (IHs)."3.83Propranolol in the treatment of infantile haemangiomas: lessons from the European Propranolol In the Treatment of Complicated Haemangiomas (PITCH) Taskforce survey. ( Audrain, H; Baryschpolec, S; Baselga, E; Beattie, PE; Bhate, K; Bjerre, JV; Brown, SJ; Burrows, NP; Clayton, TH; Darne, S; Durack, A; Dvorakova, V; Flohr, C; Foelster-Holst, R; Gach, J; Glover, M; Goldstraw, N; Goodyear, H; Grabczynska, S; Greenblatt, D; Halpern, J; Hearn, RM; Hedelund, L; Hernandez-Martin, A; Hoeger, PH; Hoey, S; Hughes, B; Irvine, AD; Janmohamed, SR; Jayaraj, R; Johansson, EK; Laguda, B; Lam, M; Leech, S; McPherson, T; Morrison, D; Neri, I; O'Regan, GM; Oranje, AP; Patrizi, A; Porter, W; Ramesh, R; Ravenscroft, JC; Schill, T; Shahidullah, H; Shaw, L; Solman, L; Svensson, A; Taylor, AE; Taylor, R; Thomson, J; Tiffin, P; Tsakok, M; Wahlgren, CF; Wedgeworth, E, 2016)
"Despite the increasing popularity of propranolol for treatment of infantile hemangioma (IH), there is need for further evidence of efficacy and safety."3.83Treatment for Infantile Hemangiomas: Selection Criteria, Safety, and Outcomes Using Oral Propranolol During the Early Phase of Propranolol Use for Hemangiomas. ( Gehris, R; Geisler, S; Grunwaldt, LJ; MacIsaac, ZM; Mehta, D; Nayar, HS, 2016)
"Few specific reports have addressed propranolol as a treatment for parotid hemangioma, and its mechanism remains unclear."3.83Use of propranolol for parotid hemangioma. ( Chang, L; Chen, H; Jin, Y; Lin, X; Lv, D; Ma, G; Qiu, Y; Wang, T; Yang, X; Ying, H; Yu, W, 2016)
"Propranolol-induced involution is a unique biological feature of some pediatric vascular tumors, for instance infantile hemangioma (IH), cerebral cavernoma or chorioangioma."3.83The embryo-placental CD15-positive "vasculogenic zones" as a source of propranolol-sensitive pediatric vascular tumors. ( Anspach, L; Roth, W; Seidmann, L, 2016)
"The aim of this study was to explore the efficacy and safety of propranolol in treating infantile haemangiomas, the most common benign vascular tumours in children."3.83Propranolol was effective in treating cutaneous infantile haemangiomas in Thai children. ( Jetsrisuparb, C; Komwilaisak, P; Panombualert, S; Techasatian, L; Uppala, R, 2016)
"From October 2010 to June 2014, 31 infantile hemangioma patients admitted to our hospital, were administered propranolol combined with betamethasone injection treatment of lesions."3.83Treatment of infantile hemangioma by intralesional injection of propranolol combined with compound betamethasone. ( Li, J; Shao, RZ; Zhao, DH, 2016)
" The 31 patients had 32 hemangiomas (1 female patient had 2 lesions) and were treated with systemic propranolol at a high dose of 2 mg/kg per day."3.83Oral Propranolol for the Treatment of Infantile Hemangiomas in the Post-Proliferative Phase: A-Single Center Retrospective Study of 31 Cases. ( Liu, ZM; Tian, Y; Tong, S; Wang, XK; Xi, SL; Xu, DP, 2016)
"In the last few years propranolol has revolutionized infantile hemangioma therapy."3.83Serum and tissue profile of VEGF and its receptors VGFR1/R2 in children with infantile hemangiomas on systemic propranolol treatment. ( Andrzejewska, E; Chrzanowska, B; Kobos, J; Przewratil, P; Szemraj, J; Taran, K; Wnęk, A; Wyrzykowski, D, 2016)
"Thirteen children with infantile haemangiomas presenting to the Vascular Anomalies Clinic, Royal Children's Hospital/Lady Cilento Children's Hospital treated with propranolol were included in the study."3.833D photography is a reliable method of measuring infantile haemangioma volume over time. ( Gee Kee, EL; Kimble, RM; Robertson, SA; Stockton, KA; Storey, KJ, 2016)
" The medical records of infants with periorbital hemangiomas who were treated with systemic propranolol at a dose of 1."3.83Clinical Outcomes of Infants With Periorbital Hemangiomas Treated With Oral Propranolol. ( Liu, ZM; Sun, C; Wang, XK; Xu, DP; Xue, L, 2016)
"To determine the efficacy of oral propranolol for the treatment of infantile subglottic hemangioma."3.83Role of oral propranolol in the treatment of infantile subglottic hemangioma. ( Chen, JR; Jin, L; Li, XY; Wang, Y, 2016)
"Propranolol, 2 mg/kg/day, is effective in the treatment of infantile hemangioma."3.83Response to propranolol in infantile hemangioma. ( Chunharas, A; Kadegasem, P; Lekanan, W; Sirachainan, N; Thammagasorn, Y; Wanitkun, S, 2016)
"An open observational prospective study was performed over 25 months in a group of pediatric patients diagnosed with infantile hemangioma treated with propranolol."3.83The Role of the Pharmacist in the Treatment of Patients with Infantile Hemangioma Using Propranolol. ( Castaneda, S; De la Cruz, H; Garcia, E; Melendez-Lopez, S; Sanchez-Palacio, J, 2016)
"There has been a dramatic increase in the off-label use of ophthalmic timolol maleate, a β-blocker used for infantile hemangioma (IH) treatment as a topical counterpart to oral propranolol."3.83Topical Timolol Maleate Treatment of Infantile Hemangiomas. ( Adams, D; Baselga, E; Drolet, B; Feigenbaum, D; Frieden, I; Garzon, MC; Holland, K; Horii, K; Lauren, C; Lucky, A; Mathes, E; McCuaig, C; Morel, KD; Newell, B; Nopper, A; Pope, E; Powell, J; Püttgen, K; Savva, Y; Siegel, D; Song, W, 2016)
"In recent years propranolol has become the treatment of choice for infantile hemangiomas (IHs)."3.83Is Routine Electrocardiography Necessary Before Initiation of Propranolol for Treatment of Infantile Hemangiomas? ( Krol, AL; Leitenberger, SL; MacArthur, CJ; Mann, JA; Tollefson, MM; Yarbrough, KB, 2016)
"Hemangiomas are tumors most commonly encountered in pediatric patients, and are frequently treated with propranolol."3.83Cardiac evaluation in children with hemangiomas. ( Erdoğan, İ; Sarıalioğlu, F, 2016)
"Non-selective β-blocker propranolol has been proved by FDA as the first-line agent for infantile hemangioma (IH) with dramatic response."3.83[Chinese expert consensus on the use of topical timolol maleate treatment of infantile hemangiomas]. ( Fan, XD; Huo, R; Jiang, CH; Lei, SR; Liu, SH; Qin, ZP; Wang, XK; Wang, XY; Yang, YW; Zhao, JH; Zheng, JW; Zhou, DK, 2016)
"Although propranolol has been accepted as a first-line drug for infantile haemangioma (IH), no study has systematically characterized changes in heart rates during long-term propranolol treatment."3.81Safety profile of a divided dose of propranolol for heart rate in children with infantile haemangioma during 16 weeks of treatment. ( Chen, W; Shi, H; Song, H; Wang, J; Yu, Y; Zhang, X; Zhou, H, 2015)
"Propranolol is a valid treatment for large cranial hemangiomas, avoiding the risks involved in surgeries."3.81Giant cranial and cerebellar hemangioma treated with propranolol. ( Ben-Sira, L; Benvenisti, H; Constantini, S; Roth, J, 2015)
"The successful use of nadolol as an alternative to propranolol therapy in three cases of infantile hemangioma is reported."3.81Nadolol for the treatment of infantile hemangioma. ( Bautista-Paloma, FJ; Cotrina-Luque, J; Del Vayo-Benito, CA; Flores-Moreno, S; Villalba-Moreno, AM, 2015)
"The aim of this study was to investigate the therapeutic results and effects of propranolol on cardiovascular parameters in infants receiving systemic propranolol for complicated infantile hemangiomas (IHs), as well as to evaluate the adverse effects of propranolol throughout the course of treatment."3.81Treatment of severe infantile hemangiomas with propranolol: an evaluation of the efficacy and effects of cardiovascular parameters in 25 consecutive patients. ( Cao, RY; Sun, NN; Tong, S; Wang, XK; Xu, DP; Xue, L, 2015)
"Although consensus guidelines for pretreatment evaluation and monitoring of propranolol therapy in patients with infantile hemangiomas (IH) have been formulated, little is known about the cardiovascular side effects."3.81Is cardiovascular evaluation necessary prior to and during beta-blocker therapy for infantile hemangiomas?: A cohort study. ( Breugem, CC; Breur, JM; de Graaf, M; Pasmans, SG; Raphael, MF; Slieker, MG; Vlasveld, FA, 2015)
"Intralesional compound betamethasone preparation is a feasible choice for the small-size hemangioma."3.81Intralesional injection of diprospan is effective for infantile hemangioma. ( Cui, L; Guo, Y; Hong, ZJ; Jiang, HQ; Yuan, SM; Zhang, M, 2015)
"The aim of our study was to assess the efficacy and safety of oral propranolol for the treatment of parotid infantile hemangiomas."3.81Oral propranolol for parotid infantile hemangiomas. ( Cheng, C; Li, G; Liu, ZM; Sun, HL; Wang, XK; Xi, SL; Xu, DP, 2015)
"The current study demonstrated the antiangiogenic properties of propranolol in vitro and that the drug was able to induce the regression of hemangioma cells via the inhibition of cell cycle progression, invasion, and tube formation, concomitantly with decreased NO and VEGF levels through the down-regulation of the PI3K/Akt/eNOS/VEGF pathway."3.81Propranolol induces regression of hemangioma cells via the down-regulation of the PI3K/Akt/eNOS/VEGF pathway. ( Gao, Y; Guo, ZT; Huang, Q; Li, P; Pan, WK, 2015)
"Propranolol has been recently approved by health authorities to treat infantile haemangiomas (IH)."3.81[Propranolol in infantile hemangiomas]. ( Léauté-Labrèze, C, 2015)
"Topical propranolol has been used for the therapy of superficial infantile hemangiomas (IH)."3.81A novel topical nano-propranolol for treatment of infantile hemangiomas. ( Chen, ZG; Yuan, ML; Yuan, WE; Zhang, L; Zheng, JW, 2015)
"With the emergence of propranolol as the primary treatment for hemangiomas the indications for surgical intervention have been greatly reduced."3.81Open airway surgery for subglottic hemangioma in the era of propranolol: Is it still indicated? ( Mehta, D; Siegel, B, 2015)
"To evaluate the effectiveness of systemic propranolol in airway infantile hemangioma (AIH) treatment."3.81Multicenter Evaluation of the Effectiveness of Systemic Propranolol in the Treatment of Airway Hemangiomas. ( Darrow, DH; Elluru, RG; Friess, MR; Grimmer, JF; Perkins, JA; Richter, GT; Shin, JJ, 2015)
" Infantile hemangiomas which have numerous similarities with chorioangiomas are now usually treated with propranolol."3.81Propranolol during pregnancy for large chorioangioma. ( D'Hervé, D; Fouque, L; Le Duff, M; Padys, P; Poulain, P, 2015)
"I was asked to provide a commentary for "Shouldn't Propranolol be Used to Treat All Hemangiomas?" by Moodley et al."3.81Commentary on Moodley S et al. "Shouldn't Propranolol be Used to Treat All Hemangiomas?". ( Blei, F, 2015)
"This study suggests that propranolol become the first-line treatment of choice for all haemangiomas."3.81Shouldn't Propranolol Be Used to Treat All Haemangiomas? ( Adams, KG; Adams, S; Hudson, DA; Moodley, ST, 2015)
"Our aim was to compare in a prospective study the clinical effects and safety of propranolol given orally, timolol maleate applied locally, and the combination of the two, in the management of superficial infantile haemangiomas."3.81Evaluation of the efficacy and safety of propranolol, timolol maleate, and the combination of the two, in the treatment of superficial infantile haemangiomas. ( Cheng, C; Gong, H; Li, G; Li, YX; Wang, XK; Xu, DP, 2015)
"To explore the effect and safety of topical propranolol hydrochloride gel for treatment of infantile hemangioma."3.81[Effects of topical propranolol hydrochloride gel for treatment of infantile hemangioma in nude mice]. ( Chen, L; Chengjin, L; Lie, W; Qingjin, H; Shaoquan, C; Shuming, C; Yin, X; Zaizhong, Z, 2015)
"To summarize the subsequent therapy experiences for infantile hemangiomas after discontinuation of oral propranolol treatment, and explore the relationships between clinical interventions and types of infantile hemangioma."3.81[Subsequent therapy for infantile hemangiomas after discontinuation of oral propranolol]. ( Chen, T; Ge, CX; Li, KL; Liu, XJ; Qin, ZP; Tai, MZ, 2015)
"Propranolol is emerging as the treatment of choice for high-risk infantile haemangiomas."3.80Propranolol therapy for cutaneous infantile haemangiomas initiated safely as a day-case procedure. ( McSwiney, E; Murphy, M; Murray, D, 2014)
"Propranolol is an effective, safe treatment for complicated infantile haemangiomas (IH)."3.80Propranolol for the treatment of infantile haemangiomas: our experience with 44 patients. ( Lenane, P; Lynch, M; O'Donnell, BF, 2014)
"This study proved high efficiency of propranolol in treatment of infantile hemangioma, as assessed with the objective measures for the first time."3.80Treatment of infantile hemangiomas with propranolol: clinical guidelines. ( Anderson, W; Stewart, K; Szychta, P, 2014)
"Oral propranolol (PRN) has recently been shown to be highly effective for infantile hemangiomas (IHs), and is currently recommended as the first-line treatment of complicated IHs."3.80Propranolol inhibits angiogenesis via down-regulating the expression of vascular endothelial growth factor in hemangioma derived stem cell. ( Li, KL; Mai, HM; Qin, ZP; Wang, YA; Zhang, L; Zheng, J; Zheng, JW, 2014)
"Propranolol seemed to be effective for treatment of hemangiomas in children and adolescents, and not just in the proliferative stage, with responses in almost all the patients."3.80Treatment of children and adolescents with hemangioma using propranolol: preliminary results from a retrospective study. ( Albuquerque, JC; Bastos, MV; Felix, FH; Félix, JA; Fontenele, JB; Magalhães, RA; Trompieri, NM, 2014)
"Propranolol is highly effective in the treatment of infantile hemangioma (IH), but important clinical and pharmacological data are lacking."3.80Efficacy and safety of propranolol for the treatment of infantile hemangioma: a presentation of ninety-nine cases. ( Ben Amitai, D; Lapidoth, M; Sagi, L; Zvulunov, A, 2014)
"To highlight the importance of Magnetic Resonance Imaging (MRI) and the use of propranolol as both a final diagnostic tool and adequate treatment for orbital Infantile Haemangiomas (IHs)."3.80Propranolol as first-line treatment in orbital infantile haemangiomas: a case series. ( Coumou, AD; Freling, NJ; Groeneveld, L; Levitt, M; Saeed, P; van der Horst, CM, 2014)
"Propranolol, a β-adrenergic receptor (AR) antagonist, is an effective treatment for endangering infantile haemangioma (IH)."3.80Propranolol targets the contractility of infantile haemangioma-derived pericytes. ( Bischoff, J; Boscolo, E; Durham, JT; Herman, IM; Lee, D; Mulliken, JB, 2014)
"A small percentage of complicated infantile haemangiomas need early, safe and effective treatment, and the option of off-label systemic propranolol treatment has been in existence since 2008."3.80A retrospective analysis of systemic propranolol for the treatment of complicated infantile haemangiomas. ( Cremer, HJ; Ruef, P; Schneider, M, 2014)
" Sixteen patients had recrudescence of IH off-treatment, with propranolol discontinued at a median age of 14 months (interquartile range 10-15 months)."3.80Retrospective analysis of beta-blocker instituted for treatment of hemangiomas (RABBIT study). ( Castelo-Soccio, L; Chu, DH; Gelfand, JM; Perman, MJ; Shaddy, RE; Shah, KN; Treat, JR; Wan, J; Yan, AC, 2014)
"Propranolol has been widely used in treating infantile hemangiomas (IHs)."3.80Propranolol enhanced adipogenesis instead of induction of apoptosis of hemangiomas stem cells. ( Chang, M; Ma, X; Ma, Y; Ouyang, T; Xin, S; Zhao, T, 2014)
"To assess the safety and efficacy of systemic propranolol for the treatment of complicated infantile haemangiomas."3.80Propranolol for infantile haemangiomas: single centre experience of 250 cases and proposed therapeutic protocol. ( Glover, M; Gnarra, M; Harper, JI; Murabit, A; Solman, L; Syed, SB, 2014)
"Propranolol is increasingly used to treat problematic infantile haemangioma (IH), although its molecular mechanisms remain unclear."3.80Increased apoptosis and secretion of tryptase by mast cells in infantile haemangioma treated with propranolol. ( Day, D; Steel, R, 2014)
"This study was aimed at assessing the efficacy of propranolol treatment in infantile hemangiomas (IHs) by ultrasound."3.80Ultrasound in assessing the efficacy of propranolol therapy for infantile hemangiomas. ( Shang, Y; Shi, H; Song, H; Wang, J; Xia, L; Yang, J; Zhou, H, 2014)
"Although propranolol is widely used in the treatment of infantile hemangiomas, the standard 40 mg tablet needs to be fractioned to obtain 10 mg parts, with even lower doses (i."3.80Is propranolol compounding from tablet safe for pediatric use? Results from an experimental test. ( Berti, I; Cardosi, L; Casiraghi, A; Franceschini, I; Minghetti, P; Musazzi, UM; Paragò, V, 2014)
"To develop a tool for assessing amblyopic risk and monitoring the treatment effect of propranolol in periocular haemangioma management."3.80Monitoring propranolol treatment in periocular infantile haemangioma. ( Burne, R; Taylor, R, 2014)
"Clinical observation of conservative treatment of the left hemi-liver haemangioma by propranolol in the full-term newborn with initial symptoms of cardiac failure is presented."3.80[Clinical case of treatment of hepatic haemangioma by propranolol in the newborn]. ( Getman, AN; Ivleva, SA; Kucherov, IuI; Rekhviashvili, MG; Zhirkova, IuV, 2014)
"The β-blocker propranolol was discovered to be highly effective for the treatment of infantile hemangiomas (IHs), since 2008."3.80Adverse effects of propranolol treatment for infantile hemangiomas in China. ( Babajee, K; Chen, X; Hu, X; Jian, D; Li, J; Su, J; Xie, H, 2014)
"This study provides multi-institutional practice guidelines for the initiation of propranolol hydrochloride treatment of routine infantile hemangiomas."3.79Propranolol use for infantile hemangiomas: American Society of Pediatric Otolaryngology Vascular Anomalies Task Force practice patterns. ( Darrow, DH; Grimmer, JF; Manning, SC; Parikh, SR; Perkins, JA; Richter, GT, 2013)
"Infantile hemangioma (IH) clearance may be slow or incomplete in response to pulsed dye laser (PDL) or propranolol alone."3.79Retrospective study of the treatment of infantile hemangiomas using a combination of propranolol and pulsed dye laser. ( Anolik, R; Bernstein, L; Blei, F; Brauer, JA; Brightman, L; Geronemus, RG; Hale, E; Karen, J; Reddy, KK; Waner, M; Weiss, E, 2013)
"Propranolol has been used successfully in a limited number of children with infantile hemangiomas (IHs)."3.79Use of propranolol for the treatment infantile hemangiomas in the maxillofacial region. ( Kasimova, KR; Metellmann, HR; Podmelle, F; Sadykov, RA; Sadykov, RR, 2013)
"Propranolol is now widely used to treat severe infantile haemangiomas (IHs)."3.79Propranolol-resistant infantile haemangiomas. ( Aubert, H; Barbarot, S; Boccara, O; Bursztejn, AC; Caussé, S; Chiaverini, C; Dreyfus, I; Eschard, C; Hadj-Rabia, S; Mahé, E; Maruani, A; Mazereeuw-Hautier, J; Miquel, J; Puzenat, E; Saint-Jean, M; Stalder, JF, 2013)
"Although propranolol has become the first-line therapy for infantile haemangiomas (IHs), no study has yet investigated factors associated with the risk of relapse in children with IH treated with propranolol after cessation of treatment."3.79Factors associated with the relapse of infantile haemangiomas in children treated with oral propranolol. ( Ahogo, CK; Boralevi, F; Colona, V; Diallo, A; Ezzedine, K; Léauté-Labrèze, C; Prey, S; Taïeb, A, 2013)
" The treatment of atopic dermatitis, exciting advances in the use of propranolol and other beta-blockers for the use of infantile hemangiomas, the use of rapamycin for vascular anomalies, the use of biologics in children, the central nervous system risks of general anesthesia in young children, side effects in the use of isotretinoin, the treatment of tinea capitis, treatment of herpes simplex infections, and the use of technologies such as texting and social media in medicine will be discussed."3.79What's new in pediatric dermatology?: part II. Treatment. ( Pride, HB; Silverman, R; Tollefson, M, 2013)
"Although propranolol can be an effective primary medical therapy for infantile hemangiomas of the head and neck, the duration of treatment and time to discontinue propranolol is unclear."3.79Successful discontinuation of propranolol for infantile hemangiomas of the head and neck at 12 months of age. ( Chiu, ES; Hong, P; Kluka, EA; Poole, JC; Simon, LM; Tammareddi, N; Walvekar, R, 2013)
"To evaluate the efficacy and safety of 1% propranolol ointment in the treatment of superficial infantile hemangiomas (IHs)."3.79[Treatment of superficial infantile hemangiomas with topical propranolol]. ( Huo, R; Lü, RR; Niu, JN; Xu, GQ, 2013)
"This case of a four and a half-month-old girl describes periocular infantile haemangioma which was treated successfully with propranolol."3.79Periocular infantile haemangioma and the role of propranolol. ( Ahmad, K; Chaudhry, TA; Kamal, M, 2013)
"Propranolol, a lipophilic non-selective beta-blocker, has proven to be effective in the treatment of infantile haemangioma (IH)."3.79Treatment of infantile haemangiomas with atenolol: comparison with a historical propranolol group. ( Breugem, CC; Breur, JM; Bruijnzeel-Koomen, CA; de Graaf, M; Knol, MJ; Kon, M; Pasmans, SG; Raphael, MF, 2013)
"Oral propranolol hydrochloride treatment has been proven effective for infantile hemangiomas."3.79Effects of oral propranolol on circumscribed choroidal hemangioma: a pilot study. ( Hirose, H; Kitano, T; Sahashi, K; Saito, AM; Tanabe, H; Tomita, Y, 2013)
"We sought to determine the effect of propranolol on cardiovascular and blood glucose parameters in infants with symptomatic infantile hemangiomas who were hospitalized for initiation of treatment, and to analyze adverse effects of propranolol throughout the course of inpatient and outpatient treatment."3.79Cardiovascular and blood glucose parameters in infants during propranolol initiation for treatment of symptomatic infantile hemangiomas. ( Bauman, NM; Boss, EF; Cohen, BA; Puttgen, KB; Schneider, J; Summerer, B, 2013)
"Propranolol had a rapid stabilizing effect leading to early regression of hemangiomas when administered orally at a dose of 3 mg/kg/day with good quality safety profile."3.79Propranolol for hemangiomas. ( Hasan, M; Hoque, S; Khondker, L; Rahman, M; Zahid Hossain, AK, 2013)
"We investigated the clinical efficacy of propranolol in treating proliferating infantile haemangiomas, and the serological changes in vascular endothelial growth factor (VEGF) and endothelial nitric oxide synthase (eNOS) during treatment."3.79Propranolol given orally for proliferating infantile haemangiomas: analysis of efficacy and serological changes in vascular endothelial growth factor and endothelial nitric oxide synthase in 35 patients. ( Jin, ZL; Liu, ZY; Wang, XK; Wei, JJ; Xue, L; Yuan, WL, 2013)
"We aimed to assess the efficacy and safety of low-dose propranolol for treatment of infantile hemangiomas (IHs) in China."3.79Preliminary experience on treatment of infantile hemangioma with low-dose propranolol in China. ( Chen, H; Huang, Y; Lin, J; Liu, J; Ma, X; Ouyang, T; Xiao, Y; Yu, J; Zhao, T, 2013)
"Treatment options for large subglottic haemangioma include steroids, laser ablation, open excision, tracheostomy and, more recently, propranolol."3.79Great Ormond Street Hospital treatment guidelines for use of propranolol in infantile isolated subglottic haemangioma. ( Albert, DM; Bajaj, Y; Harper, JI; Hartley, BE; Ifeacho, S; Jephson, CG; Kapoor, K, 2013)
"To evaluate the response of nasal tip hemangiomas to systemic propranolol."3.78Hemangiomas of the nasal tip treated with propranolol. ( Ben-Amitai, D; Halachmi, S; Kalish, E; Lapidoth, M; Raveh, E; Zvulunov, A, 2012)
"Propranolol was recently discovered to be an effective treatment for infantile haemangiomas, and varying doses and monitoring regimens have been proposed."3.78Propranolol for infantile haemangiomas: initiating treatment on an outpatient basis. ( Dyme, JL; Han, EJ; Kotb, ME; Nyirenda, TL; Shin, HT; Thampan, A, 2012)
" The beta-blocker propranolol, known for its effectiveness on cutaneous hemangiomas, is also proving useful for the treatment of subglottic or visceral hemangiomas."3.78[Pediatrics]. ( Chevallay, M; de Buys Roessingh, A; El Ezzi, O; Fischer, CJ; Gehri, M; Giannoni, E; Hauschild, M; Hohlfeld, J; Pauchard, JY; Seneggen, E; Tolsa, JF; Truttmann, AC, 2012)
"Thirty-seven infants with propranolol-treated problematic head and neck hemangiomas were included and all patients had a good response."3.78Propranolol for problematic head and neck hemangiomas: an analysis of 37 consecutive patients. ( Fan, XD; Lv, MM; Su, LX, 2012)
"To investigate the mechanism of propranolol on regression of infantile hemangiomas."3.78Propranolol induces regression of hemangioma cells through HIF-1α-mediated inhibition of VEGF-A. ( Armijo, BS; Chim, H; Gliniak, C; Gosain, AK; Miller, E; Serret, MA, 2012)
"Propranolol is a non-selective beta-adrenergic antagonist successfully used in a case of kaposiform hemangioendothelioma (KHE) associated with Kasabach-Merritt phenomenon (KMP)."3.78Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon. ( Blei, F; Carcao, M; Chiu, YE; Drolet, BA; Fangusaro, J; Kelly, ME; Krol, A; Lofgren, S; Mancini, AJ; Metry, DW; Pope, E; Recht, M; Silverman, RA; Tom, WL, 2012)
"To evaluate changes in infantile hemangioma tissue before and after propranolol therapy, using gray-scale and color Doppler ultrasound imaging."3.78Propranolol reduces infantile hemangioma volume and vessel density. ( Bingham, MM; Perkins, JA; Saltzman, B; Vo, NJ, 2012)
"  To evaluate the effectiveness, safety and tolerability of propranolol as single-agent treatment in patients with problematic, proliferative-phase, infantile hemangiomas (IHs)."3.78Propranolol treatment for severe infantile hemangiomas: a single-centre 3-year experience. ( Georgountzou, A; Kakourou, T; Karavitakis, E; Klimentopoulou, A; Xaidara, A, 2012)
"Propranolol has recently emerged as an effective drug treatment for infantile haemangiomas."3.78Use of propranolol for treatment of infantile haemangiomas in an outpatient setting. ( Bekhor, PS; Crock, CM; Penington, AJ; Phillips, RJ, 2012)
"Discuss effect and dynamics of propranolol (PR) treatment in infantile haemangioma (IH) of head and neck in children during follow-up."3.78Propranolol for infantile haemangioma: striking effect in the first weeks. ( Csákányi, Z; Gács, E; Gerlinger, I; Katona, G; Ráth, G; Szalai, Z, 2012)
"To observe the efficacy of oral Propranolol in the treatment of infantile subglottic hemangioma."3.78[Treatment of infantile subglottic hemangioma with oral propranolol]. ( Tang, LX; Wang, GX; Zhang, YM, 2012)
"Propranolol, a non-selective beta-blocker, has recently been introduced as a novel treatment modality for proliferating hemangiomas."3.78Effects of propranolol on the proliferation and apoptosis of hemangioma-derived endothelial cells. ( Chen, S; Ji, Y; Li, K; Xiao, X; Xu, T; Zheng, S, 2012)
"In 2008, propranolol was serendipitously observed to cause accelerated involution of infantile haemangioma."3.77Low-dose propranolol for infantile haemangioma. ( Itinteang, T; Leadbitter, P; Tan, ST, 2011)
"We report here the case of an infant with multiple hepatic and cutaneous infantile hemangiomas (IHs) associated with deranged liver function who was treated successfully with low-dose propranolol."3.77Low-dose propranolol for multiple hepatic and cutaneous hemangiomas with deranged liver function. ( Itinteang, T; Leadbitter, P; Tan, ST, 2011)
"To outline a safe, standardized protocol for outpatient initiation of propranolol therapy for infantile hemangiomas."3.77Initial experience with a multidisciplinary strategy for initiation of propranolol therapy for infantile hemangiomas. ( Boucek, RJ; Cushing, SL; Manning, SC; Perkins, JA; Sidbury, R, 2011)
"Recent reports have described the successful use of propranolol to treat severe hemangiomas of infancy."3.77[Propranolol for the treatment of severe hemangiomas of infancy: results from a series of 28 patients]. ( Bernabeu-Wittel, J; Conejo-Mir, J; de Agustín, JC; Fernández-Pineda, I; Mantrana-Bermejo, ME; Pereyra-Rodríguez, JJ, 2011)
"Propranolol has become first-line therapy for the treatment of infantile hemangiomas in many centers."3.77β-blockers for infantile hemangiomas: a single-institution experience. ( Blatt, J; Buck, S; Burkhart, CN; Gold, S; Morrell, DS; Powell, C; Stavas, J; Zdanski, C, 2011)
"To report the efficacy of propranolol as first-line treatment of head and neck hemangiomas in children and to present an optimized protocol for treating hemangiomas."3.77Propranolol as first-line treatment of head and neck hemangiomas. ( Ayari-Khalfallah, S; Froehlich, P; Fuchsmann, C; Giguere, C; Guibaud, L; McCone, C; Powell, J; Quintal, MC, 2011)
"A brief comment on efficacy and safety of propranolol in the treatment of parotid hemangioma is presented, with illustration of a typical case."3.77Comment on efficacy and safety of propranolol in the treatment of parotid hemangioma. ( Zheng, JW, 2011)
"To observe the efficacy and safety of oral propranolol in the treatment of periorbital proliferating phase infantile hemangioma."3.77[Oral propranolol in the management of periorbital proliferating phase infantile hemangioma]. ( Fu, HB; Guo, X; Huo, R; Lin, LL; Lü, RR; Wui, JC; Xu, GQ; Zhang, J; Zhao, ZF, 2011)
"To determine whether propranolol therapy is safe and effective and superior to oral corticosteroids for treating infantile hemangiomas (IHs)."3.77Propranolol vs corticosteroids for infantile hemangiomas: a multicenter retrospective analysis. ( Baum, B; Connelly, EA; Duarte, AM; Lattouf, C; McLeod, M; Price, CJ; Schachner, LA, 2011)
"Four children with haemangiomas of the head and neck were treated with propranolol at a tertiary referral centre."3.77Failure of propranolol in the treatment of childhood haemangiomas of the head and neck. ( Bruce, IA; Goswamy, J; Rothera, MP, 2011)
"There has been a dramatic evolution in the treatment of laryngotracheal hemangiomas during the past decade and recent accounts and case reports of propranolol treatment have been encouraging."3.77Evolving treatments in the management of laryngotracheal hemangiomas: will propranolol supplant steroids and surgery? ( Jacobs, IN; Javia, LR; Zur, KB, 2011)
"Four patients with ulcerated hemangioma aged 2, 4, 5 months and 5 weeks were treated with 2 mg/kg KG propranolol."3.76Successful treatment of ulcerated haemangioma with propranolol. ( Bross, F; Lorette, G; Maruani, A; Naouri, M; Rossler, J; Schill, T, 2010)
"To report our experience of using propranolol to treat an infantile airway haemangioma."3.76Use of propranolol to treat multicentric airway haemangioma. ( Mistry, N; Tzifa, K, 2010)
"We report the rapid and dramatic efficacy of propranolol in 8 infants with infantile hepatic hemangiomas."3.76Efficacy of propranolol in hepatic infantile hemangiomas with diffuse neonatal hemangiomatosis. ( Ammour, A; Benlahrech, S; Bodemer, C; Broue, P; Hoeger, PH; Labenne, M; Léauté-Labrèze, C; Mazereeuw-Hautier, J; Ohanessian, G; Rössler, J; Vabres, P; Vial, J, 2010)
"Propranolol is a novel therapeutic agent in the treatment of cutaneous infantile haemangiomas."3.76Successful treatment of infantile haemangiomas of the orbit with propranolol. ( Li, YC; Martin, FJ; Martin, PA; McCahon, E; Rowe, NA; Wilcsek, GA, 2010)
" Oral propranolol is currently the first choice in the treatment of alarming infantile hemangiomas."3.76Innovative therapeutics in pediatric dermatology. ( Frasin, A; Gelmetti, C; Restano, L, 2010)
" Our main outcome measures were colour and size of infantile haemangioma before and after treatment, the change in astigmatism of our patients and the incidence of complications from propranolol."3.76Propranolol in the management of periorbital infantile haemangioma. ( Cheng, JF; Gole, GA; Sullivan, TJ, 2010)
"The successful management of subglottic hemangioma with propranolol has been reported."3.76Management of infantile subglottic hemangioma: acebutolol or propranolol? ( Amedro, P; Bigorre, M; Blanchet, C; Mondain, M; Nicollas, R, 2010)
"Propranolol has recently been reported to be useful in the treatment of infantile hemangiomas."3.76Outpatient treatment of periocular infantile hemangiomas with oral propranolol. ( Eikenberry, J; Haggstrom, A; Haider, KM; Neely, DE; Plager, DA, 2010)
"Propranolol hydrochloride has been prescribed for decades in the pediatric population for a variety of disorders, but its effectiveness in the treatment of infantile hemangiomas (IHs) was only recently discovered."3.76Hypoglycemia in children taking propranolol for the treatment of infantile hemangioma. ( Drolet, BA; Frieden, IJ; Frommelt, PC; Holland, KE; Mancini, AJ; Wyatt, D, 2010)
" She was given propranolol after her tracheotomy and had a significant reduction in her subglottic airway obstruction."3.76Propranolol in the management of airway infantile hemangiomas. ( Frieden, IJ; Maguiness, SM; Meyer, AK; Rosbe, KW; Suh, KY, 2010)
"To evaluate the short-term results and safety of propranolol for the treatment of infantile parotid hemangioma."3.76[Treatment of infantile parotid hemangioma with propranolol]. ( Ge, CX; Li, KL; Liu, XJ; Qin, ZP; Tai, MZ, 2010)
"Seven patients presenting with airway obstruction were treated with propranolol."3.76Propranolol for the treatment of airway hemangiomas: a case series and treatment algorithm. ( Chang, KW; Messner, AH; Perkins, JA; Truong, MT, 2010)
" Mean percentage of airway obstruction was 68% (15-90) before propranolol introduction."3.76Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma: A preliminary retrospective study of French experience. ( Ayari, S; Carrabin, L; Couloigner, V; Cox, A; Denoyelle, F; Fayoux, P; Froehlich, P; Garabédian, EN; Leboulanger, N; Lescanne, E; Marianowski, R; Marie, JP; Mom, T; Mondain, M; Nicollas, R; Roger, G; Teissier, N; Triglia, JM; Van Den Abbeele, T, 2010)
"To describe the use of propranolol as first-line treatment or as single therapy to control the proliferating phase of infantile haemangioma in Chinese children."3.76Use of propranolol in infantile haemangioma among Chinese children. ( Chan, HB; Chik, KK; Luk, CK; Tan, HY, 2010)
"Propranolol treatment was recently reported to be successful for the management of severe infantile hemangioma."3.76Hyperkalemia complicating propranolol treatment of an infantile hemangioma. ( Kietz, S; Lakomek, M; Lauerer, P; Pavlakovic, H; Zutt, M, 2010)
"A case of a 4-month-old girl with a subglottic haemangioma successfully treated with propranolol is reported."3.76A clue on the face... ( Spinks, J, 2010)
"There are recent reports of effective treatment of cutaneous hemangiomas with Propranolol."3.75Role of Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma. ( Denoyelle, F; Enjolras, O; Garabedian, EN; Harris, R; Leboulanger, N; Roger, G, 2009)
" Our study suggested that oral propranolol combined with topical timolol treatment is very effective and well-tolerated for compound IHs, which can be used as a first line treatment."2.82Oral propranolol combined with topical timolol for compound infantile hemangiomas: a retrospective study. ( Ge, J; Yuan, W; Zhang, L; Zhao, H; Zheng, J, 2016)
"Propranolol treatment decreases urinary excretion of MMP-9 in patients with IH."2.78Propranolol-mediated attenuation of MMP-9 excretion in infants with hemangiomas. ( Bauman, N; Brown, KJ; Movius, E; Preciado, D; Saieg, A; Thaivalappil, S, 2013)
"Infantile haemangioma is the commonest childhood tumour and approximately 10% requires treatment."2.76Propranolol as first-line treatment for rapidly proliferating infantile haemangiomas. ( Gorst, C; Holmes, WJ; Liew, SH; Mishra, A, 2011)
"Infantile hemangioma is one of the most common benign tumors of infancy."2.72Propranolol treatment of infantile subglottic hemangioma: a report of two cases and a literature review. ( Ganeva, K; Nikiforova, L; Sapundzhiev, N; Shivachev, P, 2021)
" We review the indications, dosing regimens, duration of treatment, efficacy and adverse effects of propranolol, and therapeutic alternatives including oral atenolol, acebutolol, nadolol, intralesional propranolol injections, topical propranolol and timolol, and oral captopril."2.66β-blocker therapy for infantile hemangioma. ( Koh, SP; Leadbitter, P; Smithers, F; Tan, ST, 2020)
"Cutaneous hemangiomas are the most frequent benign tumors in children."2.61Role of Magnetic Resonance Image in Children with Lumbosacral and Perineal Hemangiomas: Case Reports and Review of the Literature. ( Barreda-Solana, M; Correa-González, N; García-Rabasco, A; Ortiz-Salvador, JM; Subiabre-Ferrer, D, 2019)
"Infantile hemangiomas are common; but they are extremely heterogeneous and cause a range of complications depending on their morphology, size, or location."2.58Infantile Hemangiomas in the Head and Neck Region. ( Adams, DM; Ricci, KW, 2018)
"Infantile haemangiomas are the most common tumour of infancy."2.58Topical propranolol for infantile haemangiomas: a systematic review. ( Birchall, JC; Elhassan, HA; Mcleod, RWJ; Price, A; Rai, S, 2018)
"Infantile haemangioma is a benign vascular tumour seen in 4-5% of infants."2.55[Medical treatment of children with infantile haemangiomas]. ( Bygum, A; Hartling, UB; Schuster, A; Velure, HK, 2017)
" The dosage was increased up to a maximum of 2 mg/kg/d and was maintained until the lesion had involuted or showed good result."2.53Treatment of rapidly proliferating haemangiomas in newborns with propranolol and review of the literature. ( Debek, W; Dzienis-Koronkiewicz, E; Hermanowicz, A; Matuszczak, E; Oksiuta, M, 2016)
"While options for treatment strategies for infantile hemangiomas (IH) are numerous, evidence-based information about agents, optimal dosage, adverse effects, treatment modality, pretreatment and treatment strategies remain limited."2.53Treatment of infantile hemangiomas: therapeutic options in regard to side effects and adverse events - a review of the literature. ( Breugem, CC; Breur, JM; Elbert, NJ; Kon, M; Liem, YT; Pasmans, SG; Raphael, MF; Vlasveld, FA, 2016)
"Consumptive hypothyroidism is a rare condition usually described in association with diffuse infantile hemangioma of the liver, over-expressing type 3 iodothyronine-deiodinase."2.52Consumptive hypothyroidism associated with parotid infantile hemangioma. ( Crivellaro, C; De Corti, F; Luzzatto, C; Zanon, GF, 2015)
"Infantile hemangioma is the most common vascular tumor of childhood."2.49[What's new about infantile hemangiomas?]. ( Dreyfus, I; Maza, A; Mazereeuw-Hautier, J, 2013)
"Haemangioma is a vascular tumour of infancy that is well known for its rapid growth during the first weeks to months of a child's life, followed by a spontaneous but slow involution."2.49Pathogenesis of infantile haemangioma. ( Bischoff, J; Greenberger, S, 2013)
"Propranolol has been suggested as the new standard of care for treatment of IH."2.49Infantile hemangioma: treatment with surgery or steroids. ( Mawn, LA, 2013)
"Infantile hepatic hemangioma is the most common benign liver tumor during infancy."2.48Multifocal infantile hepatic hemangiomas--imaging strategy and response to treatment after propranolol and steroids including review of the literature. ( Bosemani, T; Huisman, TA; Puttgen, KB; Tekes, A, 2012)
"Propranolol has become an effective first-line treatment, and protocols for its use as well as its potential risks are outlined."2.48Current management of infantile hemangiomas and their common associated conditions. ( Buckmiller, LM; Hartzell, LD, 2012)
"Propranolol has established itself as the first-line treatment."2.48[Treatment of hemangiomas]. ( Kalajoki-Helmiö, T; Lindahl, P; Overmark, M; Pitkäranta, A; Salminen, P; Vuola, P, 2012)
"Infantile haemangiomas are the most common benign tumour of infancy."2.47Propranolol for infantile haemangiomas: a review. ( Shahidullah, H; Starkey, E, 2011)
"Hemangiomas are benign neoplasms of the vasculature frequently encountered in children."2.47Hemangiomas - current therapeutic strategies. ( Mabeta, P; Pepper, MS, 2011)
" Data from the literature and from our own patient cohort (n = 132) confirm the remarkable efficacy of propranolol in complicated IH, without significant adverse effects."2.47[Treatment of haemangiomas of infancy with propranolol; good results, few side effects]. ( Hermans, DJ; Ottenhof, MJ; van Beynum, IM; van der Horst, CM; van der Vleuten, CJ; Wijnen, MH, 2011)
"Infantile hemangioma is the most common tumor in children, but its pathophysiology is still not well understood."2.46[Infantile hemangioma]. ( Léauté-Labrèze, C; Sans-Martin, V, 2010)
"Oral propranolol is a very recent therapeutic option for complicated IH with impressive efficacy and generally good tolerance."2.46Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. ( Hoeger, PH; Storch, CH, 2010)
"Infantile hemangiomas are benign vascular tumors that affect 8-12 % of infants."2.46[Propanolol used in treatment of infantile hemangioma]. ( Guldbakke, KK; Hanssen, HK; Huldt-Nystrøm, T; Høivik, F; Rørdam, OM, 2010)
"Propranolol was started in 30."1.91Management of infantile hemangiomas-experience of a tertiary hospital. ( Álvares, S; Banquart Leitão, J; Barbosa-Sequeira, J; Correia, MR; Fernandes, A; Fraga, C; Gomes, R; Paiva Coelho, M; Salazar, L, 2023)
"Propranolol treatment mostly leads to regression of hemangiomas with satisfactory aesthetic results, but unfortunately not in all cases."1.91Nd:YAG 1064-nm laser for residual infantile hemangioma after propranolol treatment. ( Avitan-Hersh, E; Khamaysi, Z; Pam, N; Zaaroura, H, 2023)
" To evaluate the correlation of clinical features between cutaneous IH and IHH, as well as efficacy of systemic propranolol in the treatment of cutaneous IH combined with IHH."1.91Clinical features of cutaneous infantile hemangioma combined with asymptomatic infantile hepatic hemangioma and efficacy of propranolol treatment. ( Han, X; Li, L; Ma, L; Sun, Y; Wei, L; Xu, Z; Yu, L; Zhang, B, 2023)
"Oral propranolol has not been shown to impact physical development, such as weight and height."1.91The impact of propranolol on the growth and development of children with proliferative infantile hemangioma during treatment. ( Chen, S; Chen, X; Deng, L; Gao, J; Huang, L; Lin, X; Liu, C; Wang, Q; Wang, T, 2023)
"Propranolol was successfully tapered over 3 weeks by reducing the dose by 50% weekly until it reached the therapeutic dose."1.91Excessively High Chronic Propranolol Overdose in Infantile Hemangioma: A Case Report. ( Alessa, A; Alghanem, A; Alhammad, AM; Alshammari, H; Elsharawy, Y, 2023)
"Propranolol (PROP) is a nonselective β-adrenergic receptor antagonist used to treat hypertension and cardiac arrhythmias."1.72Cyclosporin-A reduced the cytotoxicity of propranolol in HUVECs via p38 MAPK signaling. ( Chen, B; Cui, H; Lv, Z; Shao, C; Xie, G; Yao, Z; Yuan, W, 2022)
" Adverse event and drug-related adverse event rates were 87."1.72Efficacy and safety of propranolol cream in infantile hemangioma: A prospective pilot study. ( Hakamata, A; Hayano, S; Inui, N; Iwashima, S; Kashiwagura, Y; Nagata, E; Nishida, M; Odagiri, K; Okada, E; Sano, S; Tanaka, S; Uchida, S; Umemura, K; Watanabe, H, 2022)
"Infantile hemangiomas are the most common benign vascular tumours in infants."1.72Evaluation of cases with infantile hemangioma requiring treatment. ( Acipayam, C; Dalgiç, EF; Dinçer, S; Güllü, UU; Karaküçük, SN; Maraşli, H; Yurttutan, S, 2022)
"Propranolol is a safe, effective and well-tolerated treatment in Australian children with IH."1.72Immediate possible adverse event rates in infants treated with oral propranolol for infantile haemangiomas at an Australian urban tertiary hospital between 2016 and 2019. ( Adams, L; Ryan, E, 2022)
"Severe hypoglycemia was common in infants aged >1 year, when PPL was used for ≥6 months."1.72Severe hypoglycemia in propranolol treatment for infantile hemangiomas. ( Baba, N; Kaneko, T; Kuwano, Y; Morimoto, A; Ozeki, M; Sasaki, S, 2022)
"Propranolol therapy was interrupted for several months while patient was maintained on a diuretic regimen and treated with vincristine and high-dose corticosteroids."1.72Mediastinal infantile hemangioma with spinal canal extension and extensive gastrointestinal involvement complicated by respiratory failure. ( Anselmo, DM; Cohen-Cutler, S; Detterich, JA; Luu, M; Mascarenhas, L; Miller, JM, 2022)
"Hepatic hemangioma is the most common benign liver tumor."1.62[Propranolol treatment in Kasabach-Merritt Syndrome secondary to congenital hepatic hemangioma. Clinical case]. ( Malla, I; Selzer Soria, EM, 2021)
"Although infantile hemangiomas are occasional benign vascular tumors that appear predominantly on the skin, 1-2% of patients may have airway lesions that can sometimes cause potentially life-threatening respiratory condi-tions."1.62[Cranio-facial-cervical and subglottic hemangioma with respiratory symptoms. A therapeutic emergency]. ( Arredondo Montero, J; Bardají Pascual, C; Molina Caballero, AY; Moreno Alfonso, JC; Pérez Martínez, A; Zubicaray Ugarteche, J, 2021)
"Oral propranolol has been well established as the first-line treatment of complicated hemangiomas; however, variability in the administration protocol remains."1.62Is prolonged monitoring necessary? An updated approach to infantile hemangioma treatment with oral propranolol. ( Johansen, ML; Lawley, LP; Mahendran, G, 2021)
"Persistent cutaneous dysesthesias were present in seven patients, in most cases many years after completion of involution."1.62Persistent dysesthesias in involuted infantile hemangiomas: An uncommon complication in a common condition. ( Antaya, RJ; Braun, M; Frieden, IJ; Kohn, LL; Mancini, AJ; Metry, D, 2021)
"Placental chorioangioma (CA) is a benign placental tumor."1.56Giant placental chorioangioma followed by circulatory failure of the newborn and infantile hemangioma: Case report. ( Araki, S; Aramaki, S; Kusuhara, K; Shibata, E; Suga, S, 2020)
"Infantile hemangiomas are the most common benign vascular tumors in childhood."1.56Propranolol-resistant infantile hemangioma successfully treated with sirolimus. ( Baselga, E; Dávila-Osorio, VL; Iznardo, H; Puig, L; Roé, E, 2020)
"Consumptive hypothyroidism is a rare paraneoplastic syndrome characterized by excessive inactivation of the thyroid hormones due to increased type 3 iodothyronine deiodinase activity of tumors."1.56A Case of Consumptive Hypothyroidism in a 1-Month-Old Boy with Diffuse Infantile Hepatic Hemangiomas. ( Hong, KT; Kim, GB; Kim, YH; Ko, JS; Lee, YA; Lee, YJ; Shin, CH, 2020)
"Propranolol was interrupted after complete or almost complete resolution of infantile haemangiomas."1.56Cutaneous Infantile Haemangiomas with Intracranial and Intraspinal Involvement: A European Multicentre Experience and Review. ( Carnevale, C; Diociaiuti, A; El Hachem, M; Figà-Talamanca, L; Léauté-Labrèze, C; Neri, I; Rotunno, R; Torres, EB, 2020)
" Although oral propranolol is currently first-line therapy, optimal dosing for treatment of IH remains debated."1.56Retrospective case series of increased oral propranolol dosage for infantile hemangiomas. ( Aggarwal, P; Cohen, BA; Huang, AH; Mahon, M; Mannschreck, D, 2020)
"Infantile hemangiomas are the most common vascular tumors in childhood."1.56Evaluation of Clinical Properties and Treatment Responses of Infantile Hemangioma. ( Azizoglu, M; Corapcioglu, F; Demirsoy, U; Yildirimcakar, D, 2020)
"Propranolol was started at the age of 3 months and 7 days old with an initial dosage of 1."1.51Efficacy of infantile hepatic hemangioma with propranolol treatment: A case report. ( Liu, HC; Tsai, MC; Yeung, CY, 2019)
"Propranolol is a well-documented medical therapy for cutaneous lesions, but surgical treatment dominates the literature on bladder haemangiomas."1.51Propranolol as an effective therapy for infantile haemangioma of the urinary bladder. ( Anwar, T; Malm-Buatsi, E, 2019)
"Propranolol is the treatment of choice for complicated IH."1.51[Infantile haemangioma: an update]. ( Ott, H; Reimer, A, 2019)
"Propranolol is an effective, non-invasive treatment for life threatening infantile hemangiomas compressing the airway, should be used as a firstline treatment for subglottic hemangiomas when intervention is required."1.51A Life Threatening Subglottic and Mediastinal Hemangioma in an Infant. ( Gergin, O; Karabulut, B; Onder, SS, 2019)
"Treatment with propranolol, with or without dexamethasone, may result in a favorable prognosis."1.48Huge fetal hepatic Hemangioma: prenatal diagnosis on ultrasound and prognosis. ( Bo-Yang, Y; Jiao-Ling, L; Kun-Shan, C; Qian, F; Qiu-Ming, H; Xiao-Fen, L; Xiu-Ping, G, 2018)
"Hemangiomas are the most common tumors of childhood with an average incidence of 10%."1.48Cleft Palate Repair Using Single Flap Palatoplasty in Patient With Associated Palatal Hemangioma. ( Akyuz, C; Calis, M; Kara, M; Ozgur, F, 2018)
"Infantile hemangiomas are the most common tumor of childhood and undergo rapid growth during early infancy followed by gradual involution."1.48Prolonged growth of infantile hemangioma after pulsed dye laser and oral propranolol treatment. ( Kagami, S; Kaneko, M; Katori, T; Kishi, A, 2018)
"The propranolol treatment for the patient with suspected of bronchial asthma was suspended for 4 months."1.48Oral propranolol for infantile hemangiomas beyond the proliferative phase. ( Kagami, S; Katori, T, 2018)
"Subglottic hemangiomas are a rare presentation of infantile hemangiomas but with significant morbidity."1.48Subglottic hemangioma: Understanding the association with facial segmental hemangioma in a beard distribution. ( Azbell, C; Grunwaldt, L; Jabbour, N; McCormick, AA; Tarchichi, T, 2018)
"Tufted angioma is a benign vascular proliferation which presents most commonly in infants and children and could occasionally be complicated by Kasabach-Merritt syndrome."1.48Tufted angioma arising at the site of hepatitis B vaccination: A case report. ( Hajizadeh, J; Jowkar, F; Sari-Aslani, F; Sepaskhah, M, 2018)
"Hepatic hemangioma is the third most common pediatric tumor, and it is rare in the neonatal period."1.48Neonatal giant hepatic hemangioma: A case report. ( Cai, P; Chen, J; Gu, Z; Huang, S; Wang, J; Wu, B; Zhu, J; Zhu, Z, 2018)
"Propranolol has been demonstrated to be effective for IHs; however, the factors affecting its therapeutic effect remain unknown."1.46Analysis of factors affecting the therapeutic effect of propranolol for infantile haemangioma of the head and neck. ( Dong, JY; Huang, YY; Li, K; Li, RH; Liu, C; Liu, SH; Ning, JX; Wang, XX; Yue, LL, 2017)
" The dosage of propranolol was increased from 0."1.46Successful Treatment of Infantile Hemangiomas With Propranolol in Low-Birth-Weight Infants. ( Hayashi, A; Kado, M; Matsumura, T; Mizuno, H; Mochizuki, M; Shimizu, A, 2017)
"Diffuse hepatic hemangiomas are a challenging disease that can be life threatening."1.46Diffuse Hepatic Hemangiomas Successfully Treated Using Sirolimus and High-Dose Propranolol. ( Diaz, L; Levy, M; Warren, D, 2017)
"Hemangioma is a frequent disease which has a proliferative and involution phase."1.46Clinical features and treatment results in children with hemangioma. ( Artık, HA; Ataş, E; Koç, O, 2017)
"Infantile hemangiomas are the most common tumors affecting children."1.46Promotion of Propranolol Delivery to Hemangiomas by Using Anti-VEGFR Antibody-Conjugated Poly(lactic-co-glycolic acid) Nanoparticles. ( Dong, C; Gong, Y; Guo, X; Liu, D; Sun, J; Zhu, X, 2017)
"Hemangiomas are common skin lesion, affecting 10-12% of children <1year of age."1.43The treatment of problematic hemangiomas in children with propranolol and 940nm diode laser. ( Dementieva, N; Jones, S, 2016)
"Hemangiomas are the most common benign tumors of the liver."1.43Hepatic Hemangioma with Kasabach-Merritt Syndrome in an Adult Patient. ( Cho, EA; Cho, SB; Choi, SK; Joo, YE; Jun, CH; Kim, HS; Lee, DH; Oak, CY; Park, CH; Rew, JS, 2016)
"Oral treatment with propranolol (3 mg/kg/day) resulted in complete involution of the skin and hepatic haemangiomas over the period of treatment, which lasted until the child was aged 15 months."1.43Multifocal infantile haemangioma: a diagnostic challenge. ( Leaute-Labreze, C; Rosa, J; Soares-de-Almeida, L; Torres, E, 2016)
"Oral propranolol was successful in 95."1.43Propranolol treatment for infantile hemangioma: a case series of sixty-two patients. ( Barbato, G; Boccaletti, V; Carano, N; Cerasoli, G; Gritti, A; Lombardi, AA; Marchesi, M; Stringari, G; Tchana, B; Zanzucchi, M, 2016)
"Propranolol is the only treatment that the U."1.43Use of Propranolol for Treating Hemangiomas in Infants with Previously Diagnosed Hypoglycemic Conditions. ( De Léon, DD; McMahon, P; Treat, JR; Yang, TB, 2016)
" However, the appropriate drug dosage, dosing regimen, time for initiation, optimal duration, monitoring for side effects remains controversial."1.43[Chinese experts consensus on the use of oral propranolol for treatment of infantile hemangiomas]. ( Fan, XD; Huo, R; Li, K; Liu, SH; Qin, ZP; Wang, XK; Wang, XY; Yang, YW; Zhao, JH; Zheng, JW; Zhou, DK, 2016)
"Infantile hemangiomas are well known for their rapid growth during the first 6 to 9 months of life, followed by a spontaneous but slow involution."1.42Diode laser for the treatment of telangiectasias following hemangioma involution. ( Cerrati, EW; Chung, H; O, TM; Waner, M, 2015)
"Prior to propranolol the systemic treatment for haemangiomas was prednisolone and then the concern was the opposite, namely hypertension."1.42Propranolol and prednisolone combination for the treatment of segmental haemangioma in PHACES syndrome. ( Batul Syed, S; Gnarra, M; Harper, J; Solman, L, 2015)
"Infantile hemangiomas are the most common vascular tumors in childhood."1.42Delayed-onset of multiple cutaneous infantile hemangiomas due to propranolol: a case report. ( del Boz González, J; Navarro Morón, J; Porcel Chacón, R, 2015)
" The dosage of Propranolol was increased over the course of treatment, which initiated three days."1.42Large Doses of Propranolol for the Treatment of Infantile Cephalic and Facial Hemangiomas: A Clinical Report of 38 Cases. ( Jianguo, K; Mingkun, Z; Qiaoling, C; Wenjin, L; Xichun, W, 2015)
"Haemangiomas are benign vascular tumours that generally arise in the skin during the first days of life."1.42Propranolol (Hemangiol) and severe infantile haemangiomas. The drug of first choice. ( , 2015)
"Cardiac hemangiomas are benign tumors with an unpredictable natural history."1.42Conservative Management of Cardiac Hemangioma for 11 Years. ( Boughzela, E; Gribaa, R; Neffati, E; Slim, M, 2015)
"Pulmonary hemangioma is a rare benign tumor of the lungs."1.40Successful treatment of pulmonary hemangioma with propranolol. ( Akyüz, C; Emiralioğlu, N; Ersöz, DD; Kiper, N; Oğuz, B; Özçelik, U; Yalçın, B; Yalçın, E, 2014)
"Propranolol, has been quickly adopted as the first line medical treatment for complicated infantile hemangioma; and it is the only treatment to have a marketing authorization in this indication."1.40[Infantile hemangiomas: the revolution of beta-blockers]. ( Leaute-Labreze, C, 2014)
" The most important adverse effects were hypotension (3·4%), wheezing (9·2%), nocturnal restlessness (22·4%) and cold extremities (36·2%)."1.39Propranolol in a case series of 174 patients with complicated infantile haemangioma: indications, safety and future directions. ( Bauland, CG; Hermans, DJ; van Beynum, IM; van der Vleuten, CJ; Zweegers, J, 2013)
"Infantile hemangioma is a common benign pediatric tumor which shares many features with epulis, such as rich vascularity, high incidence of female patients, high hormone level and similar treatments."1.38New treatment strategy for granulomatous epulis: intralesional injection of propranolol. ( Fan, ZN; Li, KL; Liu, C; Liu, SH; Qin, ZP; Wang, YM; Wei, FC; Zhao, WJ, 2012)
"Consumptive hypothyroidism is a rare condition related to massive infantile hemangiomas producing an excess of the thyroid-hormone-inactivating enzyme type 3 iodothyronine deiodinase."1.38Difficult treatment of consumptive hypothyroidism in a child with massive parotid hemangioma. ( Chiumello, G; Cortinovis, F; Di Frenna, M; Gelmetti, C; Passoni, A; Persani, L; Rabbiosi, S; Vigone, MC; Weber, G, 2012)
"Adult hemangiomas are usually benign vascular tumors presenting as painless progressive proptosis, sometimes accompanied by serious visual loss due to compression of the optic nerve."1.38Management of adult onset orbital hemangioma by oral propranalol: a case report. ( Goswami, M; Murthy, GJ, 2012)
"Propranolol has been recently discovered to shrink these lesions effectively."1.37Propranolol, infantile haemangiomas, and serendipity: new use for an old drug. ( Grech, V; Scerri, C, 2011)
"Infantile haemangioma is a benign tumour of the microvasculature characterised by excessive proliferation of immature endothelial cells."1.37Expression of components of the renin-angiotensin system in proliferating infantile haemangioma may account for the propranolol-induced accelerated involution. ( Brasch, HD; Day, DJ; Itinteang, T; Tan, ST, 2011)
"Propranolol was given to 20 patients with IH, who suffered from ulceration at the start of treatment (mean age at onset of treatment, 3."1.37Propranolol, a very promising treatment for ulceration in infantile hemangiomas: a study of 20 cases with matched historical controls. ( Hermans, DJ; Schultze Kool, LJ; van Beynum, IM; van de Kerkhof, PC; van der Vleuten, CJ; Wijnen, MH, 2011)
"Propranolol appears to be an effective and well-tolerated treatment for ulcerated IH."1.37Propranolol for treatment of ulcerated infantile hemangiomas. ( Barbarot, S; Bodak, N; Hadj-Rabia, S; Hamel-Teillac, D; Kupfer-Bessaguet, I; Lacour, JP; Léauté-Labrèze, C; Mazereeuw-Hautier, J; Naouri, M; Nguyen, JM; Saint-Jean, M; Stalder, JF; Vabres, P, 2011)
"Propranolol appears to be an effective treatment option for IH even in the nonproliferative phase and after the first year of life."1.37Adverse effects of propranolol when used in the treatment of hemangiomas: a case series of 28 infants. ( Breugem, CC; Breur, JMPJ; de Graaf, M; Pasmans, SGMA; Raphaël, MF; Vos, M, 2011)
"PHACE syndrome is a neurocutaneous disorder with large facial segmental hemangionas associated with anomalies of the brain, eye, heart and aorta."1.37Use of propranolol for treatment of hemangiomas in PHACE syndrome. ( Deming, D; Hopper, A; Merritt, TA; Ninnis, J; Solomon, T, 2011)
"Oral propranolol was given for a period of 6 months with monthly follow up."1.37Initial experiences with propranolol treatment of infantile hemangiomas: report of three cases. ( Halilbasic, A; Halilbasic, M; Hotic, N; Husaric, E; Husaric, S; Rahmanovic, E, 2011)
"Hemangiomas are the most common vascular tumors in children."1.36Successful treatment of a large hemangioma with propranolol. ( Haas, E; Kues, K; Lauerer, P; Mousa, W; Pavlakovic, H; Schön, MP; Zutt, M, 2010)
"Haemangiomas are the most common soft tissue tumours in infancy, occurring in approximately 5-10% of 1-year-old children."1.36Propranolol as a novel treatment for congenital visceral haemangioma. ( Cornette, L; Decaluwe, W; Van Geet, C; Vandelanotte, M; Vanlander, A, 2010)
"Subglottic hemangioma is a rare, potentially life threatening tumor of infancy which poses serious treatment challenges."1.36Case report: Treatment failure using propanolol for treatment of focal subglottic hemangioma. ( Baum, ED; Canadas, KT; Lee, S; Ostrower, ST, 2010)
"Propranolol was given to 32 children (21 girls; mean age at onset of treatment: 4."1.35Propranolol for severe infantile hemangiomas: follow-up report. ( Berge, J; Boralevi, F; de la Roque, ED; Dupuis, E; Ezzedine, K; Grenier, N; Léauté-Labrèze, C; Lipsker, D; Mazereeuw-Hautier, J; Sans, V; Taïeb, A; Vergnes, P, 2009)
"Subglottic haemangioma is a rare but potentially life threatening condition which requires intervention."1.35Successful treatment of isolated subglottic haemangioma with propranolol alone. ( Harper, J; Hartley, BE; Jephson, CG; Manunza, F; Mills, NA; Syed, S, 2009)
"Hemangioma is the most common tumor of infancy."1.35[Response to oral propranolol therapy for ulcerated hemangiomas in infancy]. ( Michel, JL; Patural, H, 2009)

Research

Studies (675)

TimeframeStudies, this research(%)All Research%
pre-19901 (0.15)18.7374
1990's0 (0.00)18.2507
2000's12 (1.78)29.6817
2010's519 (76.89)24.3611
2020's143 (21.19)2.80

Authors

AuthorsStudies
Lin, Q1
Hai, Y1
Chen, S13
Feng, N1
Mo, Z1
Wei, Y1
Luo, Q1
Huang, X1
Fan, L1
Chen, J6
Xiang, W1
Pandey, V5
Tiwari, P5
Imran, M1
Mishra, A7
Kumar, D1
Sharma, SP4
Cotter, C1
Solman, L5
Flohr, C3
Makkeyah, SM1
Elseedawy, ME1
Abdel-Kader, HM1
Mokhtar, GM1
Ragab, IA2
Yüksel, H1
Yaşar, A1
Gürbüz, N1
Bizbirlik, ZI1
Yilmaz, Ö1
Liu, C6
Zhao, Z3
Guo, S1
Zhang, L7
Fan, X2
Zheng, J7
Ye, Y1
Zhong, H1
Dou, L1
Song, W3
Dong, C7
Lu, W3
Dong, K2
Li, K8
Li, J7
He, L1
Gao, W4
Xia, C1
Wang, L12
Colmant, C1
Powell, J6
Zhang, T1
Qian, Y1
Yuan, C1
Wu, Y2
Qian, H1
Lu, H1
Hu, C1
Li, W4
Schmid, F1
Hoeger, PH8
Nikfarjam, U1
Wegner, J1
Grabbe, S1
Schepler, H1
Juchems, E1
Seebauer, CT1
Graus, MS1
Huang, L4
McCann, A1
Wylie-Sears, J2
Fontaine, F2
Karnezis, T1
Zurakowski, D1
Staffa, SJ1
Meunier, F1
Mulliken, JB3
Bischoff, J6
Francois, M2
Yu, L2
Wei, L3
Xu, Z3
Zhang, B2
Han, X2
Sun, Y2
Liu, Y2
Wang, C3
Qiu, L2
Xiu, B1
He, R1
Li, L6
Ma, L5
Pahl, KS1
McLean, TW3
Letertre, O1
Boccara, O7
Prey, S7
Pedespan, JM1
Boralevi, F4
Léauté-Labrèze, C23
Lv, Z1
Xie, G1
Cui, H1
Yao, Z2
Shao, C1
Yuan, W4
Chen, B1
Schrenk, S1
Boscolo, E2
Baselga, E12
El Hachem, M4
Diociaiuti, A3
Carnevale, C3
Downey, C2
Roe, E5
Mascaro, P1
Neri, I5
Leuzzi, M1
Bernabeu-Wittel, J3
Monserrat-García, MT1
Ortiz-Prieto, A1
Torrelo, A6
Knopfel, N3
Vercellino, N3
Manunza, F2
Oranges, T3
Bassi, A2
Gonzalez-Enseñat, MA2
Vicente, A1
Gich, I1
Puig, L2
Meyer-Mueller, C1
Nicholson, C1
Polcari, I1
Boull, C1
Maguiness, S1
Twist, J1
Chen, A1
Poffenberger, P1
Zinn, Z2
Bera, RN2
Tiwary, N1
Der Sarkissian, S1
Ge, L1
Sun, HY1
Chen, MKY1
Sebaratnam, DF1
Gatts, JE1
Rush, MC1
Check, JF1
Samelak, DM1
D'Ambrosio, PD1
Cardoso, PFG1
Silva, PLD1
Fernandes, PMP1
Minamoto, H1
Bleve, C1
Conighi, ML1
Valerio, E1
Cutrone, M3
Iannucci, G1
Segna, A1
Chiarenza, SF1
Kashiwagura, Y2
Hakamata, A2
Shirai, M1
Endoh, A1
Tanaka, S2
Inui, N2
Watanabe, H2
Namiki, N1
Uchida, S2
Chen, T3
Gudipudi, R1
Nguyen, SA1
Carroll, W1
Clemmens, C1
Chang, SJ5
Chang, HF2
Qiu, Y11
Chang, L10
Jin, Y7
Lin, X12
Colmenero, M1
Del Boz, J1
Bernabeu Wittel, J1
Feito-Rodríguez, M1
Vicente-Villa, MA1
Martín-Santiago, A1
Palencia Pérez, SI1
Azon, A1
Valdivielso-Ramos, M1
Sánchez Moya, AI1
Campos-Domínguez, M1
Garnacho-Saucedo, G1
Azaña Defez, JM1
Vera Casaño, Á1
Tercedor-Sánchez, J1
Alcalá, R1
González-Enseyat, MA1
Giacaman, A1
Hernández-Martin, Á2
Monserrat García, MT1
Bauzá, A1
Domínguez-Cruz, J1
García-Doval, I2
Grau-Pérez, M1
Hermans, MM3
Breugem, CC8
Schappin, R3
Jonge Poerink, E1
Mendels, EJ3
Ragamin, A1
Breur, JMPJ5
Langeveld, HR3
Raphael, MF8
De Laat, PCJ3
De Wildt, SN3
Rietman, AB3
Pasmans, SGMA5
De Graaf, M7
Nagata, E1
Okada, E1
Sano, S1
Nishida, M1
Hayano, S1
Iwashima, S1
Odagiri, K1
Umemura, K1
Odaman Al, I1
Demirağ, B1
Erdem, M1
Genç, S1
Karapinar, TH1
Kaulanjan-Checkmodine, P1
Oucherif, S1
Gontier, E1
Lacomme, S1
Loot, M1
Miljkovic-Licina, M1
Cario, M1
Taieb, A4
Moisan, F1
Rezvani, HR1
Ishikawa, T1
Seki, K1
Uchiyama, H1
Song, D3
Guo, L3
Hung, YT1
Chung, WH1
Chen, CB1
Ganeva, K1
Shivachev, P1
Sapundzhiev, N1
Nikiforova, L1
Maraşli, H1
Acipayam, C1
Güllü, UU1
Dinçer, S1
Dalgiç, EF1
Karaküçük, SN1
Yurttutan, S1
Morais, CG1
Alves, I1
Coelho, J1
Vilares, AT1
Do Bom-Sucesso, M1
Ling, J1
Yang, K4
Huo, R10
Zhang, D3
Adams, L1
Ryan, E1
Morimoto, A1
Ozeki, M4
Sasaki, S1
Baba, N1
Kuwano, Y2
Kaneko, T2
Cohen-Cutler, S1
Detterich, JA1
Miller, JM1
Anselmo, DM1
Luu, M2
Mascarenhas, L1
Lorusso, B1
Cerasoli, G2
Falco, A1
Frati, C1
Graiani, G1
Madeddu, D1
Nogara, A1
Corradini, E1
Roti, G1
Cerretani, E1
Gherli, A1
Caputi, M1
Gnetti, L1
Pilato, FP1
Quaini, F1
Lagrasta, C1
Chen, H7
Li, Y4
Kleinman, EP1
Blei, F6
Adams, D4
Greenberger, S3
Tirelli, LL1
Luna, PC1
Panizzardi, AA1
Larralde, M1
Huang, H3
Chen, X6
Cai, B1
Yu, J2
Wang, B1
Chen, Q3
Ying, H4
Yu, Z5
Chen, Z2
Hasbani, DJ1
Hamie, L1
Zamil, DH1
Fernandez, JK1
Brown, DN1
Kralik, SF1
Herd, TJ1
Yang, E1
Wang, X4
Huang, S4
Li, M5
Geng, Y1
Liu, X6
Wu, H3
Frieden, I3
Delarue, A9
Benetton, C2
Pace, MD2
De Corti, F3
Cimador, M2
Gamba, P2
Midrio, P2
Pandey, A1
Srivastava, A1
Pant, N1
Singh, S1
Rawat, J1
Gomes, R1
Salazar, L1
Fraga, C1
Correia, MR1
Barbosa-Sequeira, J1
Fernandes, A1
Álvares, S1
Banquart Leitão, J1
Paiva Coelho, M1
Yuan, WL2
Wang, XK10
Zhou, L1
Li, H1
Yamada-Kanazawa, S1
Shimada, S1
Nakayama, W1
Sawamura, S1
Nishimura, Y1
Kajihara, I1
Makino, K1
Aoi, J1
Masuguchi, S1
Amano, F1
Fukushima, S1
Beqo, BP1
Gasparella, P1
Flucher, C1
Spendel, S1
Quehenberger, F1
Haxhija, EQ1
Mahmoud, I1
Kotirkova, D1
Gospodinova, K1
Darlenski, R1
Kazandjieva, J1
Fu, R1
Zou, Y1
Wu, Z2
Jin, P1
Cheng, J2
Bai, H1
Huang, M2
Huan, X1
Yuan, H1
Höger, PH2
Hamm, H1
Zhao, P1
Dai, T1
Arredondo Montero, J2
Molina Caballero, AY2
Moreno, JC1
Antona, G1
Gonzalez Martinez, OG1
Langer, PD1
Milman, T1
Khamaysi, Z3
Pam, N3
Zaaroura, H1
Avitan-Hersh, E1
Panda, SK1
Nikhila, GP1
Kavya, PS1
Eroglu, N1
Sen, HS2
Kar, YD1
Pektas, A1
Eker, I1
Wang, T2
Deng, L1
Wang, Q4
Gao, J2
Hali, F2
Moubine, I1
Berrami, H1
Serhier, Z1
Othmani, MB1
Chiheb, S2
Zhao, X1
Huang, J4
Lin, N1
Xu, Q2
Lin, C1
Zhang, Z1
Borst, AJ1
Hammill, AM2
Iacobas, I1
Atkinson, A1
Shah, T1
Margolin, JF1
Bayliff, SL1
Blatt, J2
Shang, Y2
Li, X6
Qiu, T2
Zhou, J2
Gong, X1
Lan, Y1
Ji, Y11
Alshammari, H1
Alessa, A1
Elsharawy, Y1
Alghanem, A1
Alhammad, AM1
Pino, G1
Zambrano, MJ1
Kramer, D1
Cervilla, K1
González, S1
Singh, P1
Chamlin, S2
Hignett, E1
Silverberg, JI1
Lekwuttikarn, R1
Josephs, S1
Teng, JM1
Qiao, C2
Ma, G7
Janmohamed, SR5
Harris, J1
Phillips, JD2
de Wild, SR1
Moyakine, AV3
van der Vleuten, CJM3
Li, HH2
Lou, Y2
Zhang, RR1
Xie, J3
Cao, DS2
Xu, P1
Yu, Q1
Zhang, W2
Lim, TH1
Yap, E1
Norhatizah, BS1
Bessar, H1
Kandil, AH1
Nasr, NM1
Khattab, F1
Kotlukova, NP1
Osmanov, IM1
Konstantinova, NK1
Trunina, II1
Lavrova, TR1
Karelina, EV1
Grishkin, AN1
Mosin, IM1
Tripathy, D1
Olsen, GM1
Hansen, LM1
Stefanko, NS1
Mathes, E2
Puttgen, KB8
Tollefson, MM3
Lauren, C2
Mancini, AJ8
McCuaig, CC1
Frieden, IJ13
Gupta, D1
Frommelt, P1
Garzon, MC5
Horii, K2
Klajn, J1
Maheshwari, M1
Newell, B2
Nguyen, HL1
Nopper, A2
Siegel, DH3
Drolet, BA8
Sun, B2
Lei, H2
Gong, Y4
Zhang, Y5
Zhang, H5
Sun, L2
Tan, JMC1
Lim, HW1
Koh, MJ1
Xerfan, EMS1
Andersen, ML1
Facina, AS1
Tufik, S1
Tomimori, J1
Oesch, V1
Theiler, M3
Szello, P1
Weibel, L4
Aizman, L1
Van Den Anker, J1
Tender, J1
Krishnan, A1
Kirkorian, AY1
Liang, H1
Duell, K1
McNab, S1
Betlloch-Mas, I1
Martínez-Miravete, MT1
Berbegal-DeGracia, L1
Sánchez-Vázquez, L1
Sánchez-Payá, J1
Kridin, K2
Bergman, R1
Zheng, K1
Wang, Y2
Robert, J1
Tavernier, E1
Mashiah, J1
Mazereeuw-Hautier, J9
Maruani, A5
Suga, S1
Araki, S1
Aramaki, S1
Shibata, E1
Kusuhara, K1
Joshi, K1
Bolia, R1
Poddar, U1
Dabadgao, P1
Park, M1
Jung, HL2
Shim, YJ1
Kim, HS3
Yoon, HS1
Park, SK1
Cheuh, HW1
Lee, MJ1
Lee, JM1
Park, ES1
Lee, JH1
Lim, YJ1
Choi, YB1
Dávila-Osorio, VL1
Iznardo, H1
Tani, S1
Kunimoto, K1
Inaba, Y1
Mikita, N1
Kaminaka, C1
Kanazawa, N1
Yamamoto, Y2
Kakimoto, N1
Suenaga, T1
Takeuchi, T1
Suzuki, H1
Jinnin, M1
Goto, K1
Yasue, S1
Endo, S1
Fukao, T2
Kim, YH1
Lee, YA1
Shin, CH1
Hong, KT1
Kim, GB1
Ko, JS1
Lee, YJ1
Yang, J2
Azzarelli, A1
Vaccaro, A1
Mazzatenta, C1
Koh, SP1
Leadbitter, P4
Smithers, F1
Tan, ST5
Chen, YQ1
Zhong, LL1
Ding, XF1
Bonafede, L1
Go, M1
Belcastro, AA1
Bellet, JS1
Gabr, H1
Freedman, SF1
Velez, FG1
Hanson, T1
Hanson, J1
Torres, EB1
Rotunno, R1
Figà-Talamanca, L1
Wei, T2
Johnson, A1
Sun, R1
Richter, G1
Strub, GM1
Hartmann, F2
Lockmann, A2
Himpel, O1
Kühnle, I2
Hensen, J1
Schön, MP3
Thoms, KM2
Huang, AH2
Mannschreck, D1
Aggarwal, P1
Mahon, M1
Cohen, BA2
Tognetti, L1
Pianigiani, E1
Ierardi, F1
Cartocci, A1
Fiorani, D1
de Quattro, M1
Caini, M1
Cinotti, E1
Cevenini, G1
Rubegni, P1
Macdonald, A1
Durkin, N1
Deganello, A1
Sellars, ME1
Makin, E1
Davenport, M1
Czechowicz, JA1
Benjamin, T1
Bly, RA1
Ganti, SN1
Balkin, DM1
Perkins, JA7
Rosbe, KW4
Galdeano, F1
Herón, A1
Moreno, S1
Aprea, G1
Meneses, M1
Liao, S1
Wu, J1
Li, Z2
Cheng, G1
Lu, B1
Liu, G1
Frongia, G1
Byeon, JO1
Mehrabi, A1
Günther, P1
Wu, C2
Sun, J3
Yildirimcakar, D1
Demirsoy, U1
Azizoglu, M1
Corapcioglu, F1
Frost, S1
Saddi, V1
Teng, A1
Mallitt, KA1
Adams, S5
Williamson, B1
Wargon, O6
Yalçın, B2
Canpınar, H1
Ocak, S1
Akyüz, C3
Zhao, ZL1
Wang, QZ1
Zhang, WB1
Shao, L1
Wu, HW2
Zheng, JW10
Selzer Soria, EM1
Malla, I1
Li, S3
Gao, Q1
Lv, R3
Xu, G3
Bi, J2
Park, HJ1
Lee, SY1
Rho, MH1
Aydin Köker, S1
Kömüroğlu, AU1
Köksoy, AY1
Şiraz, ÜG1
Tekin, E1
Köker, A1
Yang, W1
Wolter, NE1
Cushing, SL2
Pope, E7
Wolter, JK1
Propst, EJ1
Sun, X1
Fang, Y1
Ma, Y2
Moreno Alfonso, JC1
Pérez Martínez, A1
Zubicaray Ugarteche, J1
Bardají Pascual, C1
Zhang, X2
Xiang, B6
Jiang, X2
Xu, X2
Dai, S1
Kong, F1
Lu, G2
Qiu, Q1
Nagoba, B1
Davane, M1
Warad, B1
Jamadar, N1
Gavkare, AM1
Konstantinidou, S1
Butler, CR1
Hartley, B1
Frauenfelder, C1
Miyazaki, T1
Sasai, H1
Ohnishi, H1
Johansen, ML1
Mahendran, G1
Lawley, LP2
von der Heydt, S1
Schwieger-Briel, A1
Luchsinger, I1
Smith, A1
Kernland-Lang, K1
Waelchli, R1
Neuhaus, K2
Kohler, M1
Gnannt, R1
Schoch, SF1
Kurth, S1
Kardasevic, M1
Dinarevic, SM1
Farshchian, M1
Potts, GA1
Braun, M1
Metry, D3
Antaya, RJ2
Kohn, LL1
McMichael, J1
Dong, JY1
Ning, JX1
Wang, XX1
Li, RH1
Yue, LL1
Huang, YY1
Liu, SH4
Velure, HK1
Hartling, UB1
Schuster, A1
Bygum, A1
Higuchi, S1
Takagi, M1
Hasegawa, Y1
Kim, KH2
Choi, TH1
Choi, Y1
Park, YW2
Hong, KY1
Kim, DY2
Choe, YS1
Lee, H1
Cheon, JE1
Park, JB1
Park, KD1
Kang, HJ1
Shin, HY1
Jeong, JH1
Gesualdo, F1
Berti, I2
Boccaletti, V2
Porcedda, G1
Greco, A1
Dalmonte, P2
Kado, M1
Shimizu, A1
Matsumura, T1
Mochizuki, M1
Mizuno, H1
Hayashi, A1
Yang, Y2
Charny, JW1
Moon, AT1
Treat, JR3
Oberlin, KE1
Keller, RG2
Stevens, S1
Hochman, M2
Goldberg, V1
Martinez, B1
Cnop, K1
Rohloff, P1
Bayart, CB1
Tamburro, JE1
Vidimos, AT1
Golden, AB1
Taran, K3
Wnęk, A3
Kobos, J3
Andrzejewska, E3
Przewratil, P5
Mahamadou, G2
Saka, B2
Mouhari-Toure, A2
Tchaou, M1
Pessinaba, S1
Gnassingbé, W1
Kombaté, K2
Pitché, P2
Yazici, N2
Sarialioglu, F3
Erbay, A2
Paul, SP1
Boyd, GM1
Warren, D1
Diaz, L1
Levy, M1
González-Llorente, N1
Del Olmo-Benito, I1
Muñoz-Ollero, N1
Descalzo, MA1
Shilpakar, R1
Lemperle, G1
Mentzel, T1
Shakya, J1
Bhandari, SB1
Herwegen, B1
Schwartz, T1
Faria, J1
Pawar, S1
Siegel, D2
Chun, RH3
Chong, JH1
Mya, HT1
Labreze, C2
Csoma, ZR1
Dalmády, S1
Ábrahám, R1
Rózsa, T1
Rácz, K1
Kemény, L1
Guo, X5
Zhu, X4
Liu, D3
Jin, X1
Chen, YZ1
Bai, N1
Bi, JH1
Liu, XW1
Xu, GQ4
Zhang, LF1
Li, XQ1
Lv, D2
Gu, Y3
Abdellaoui, T1
Laaribi, N1
Zerrouk, R1
Elasri, F1
Reda, K1
Oubaaz, A1
Tosoni, A1
Dalle Carbonare, M1
Pettenazzo, A1
Perilongo, G1
Sartori, S1
Rotter, A2
de Oliveira, ZNP1
Darrow, DH4
Adams, DM2
Ricci, KW1
Espinel, AG1
Bauman, NM6
Bangiyev, JN1
Gurgel, R1
Vanderhooft, SL1
Grimmer, JF3
Roncone, K1
Kindley, KJ1
Zlotoff, B1
Espahbodi, M1
Yan, K1
McCormick, ME1
Jiao-Ling, L1
Xiu-Ping, G1
Kun-Shan, C1
Qiu-Ming, H1
Xiao-Fen, L1
Bo-Yang, Y1
Qian, F1
Mahon, C1
Heron, G1
Perkins, D1
Drage, A1
Zheng, L1
Ataş, E1
Koç, O1
Artık, HA1
Price, A1
Rai, S1
Mcleod, RWJ1
Birchall, JC1
Elhassan, HA1
Wrobel, LJ1
Boehncke, WH1
Le Gal, FA1
Kagami, S4
Kaneko, M2
Katori, T4
Kara, M1
Calis, M1
Ozgur, F1
Zhu, L1
Liu, Z2
Huang, Z1
Yin, H1
Qi, W1
Yang, Z1
Zhou, T1
Gao, G1
Zhang, J3
Yang, X3
Kumar, R1
Singh, OP1
Xiong, F1
Lund, EB1
Chamlin, SL2
Mong, EF1
Akat, KM1
Canfield, J1
Lockhart, J1
VanWye, J1
Matar, A1
Tsibris, JCM1
Wu, JK4
Tuschl, T1
Totary-Jain, H1
Del Frari, L1
Guibaud, L3
Barbarot, S4
Lacour, JP2
Chaumont, C1
Voisard, JJ7
Brunner, V1
Takechi, T1
Kumokawa, T1
Kato, R1
Higuchi, T1
Ieiri, I1
Lopez, T1
Miraglia, E2
Schiavetti, A3
Varrasso, G3
Calvieri, S2
Giustini, S2
Yao, TH1
Pataer, P1
Regmi, KP1
Gu, XW1
Li, QY1
Du, JT1
Ge, SM1
Tu, JB1
Glover, M3
Beattie, PE2
Buckley, H1
Clark, S1
Gach, JE1
Giardini, A1
Helbling, I1
Hewitt, RJ1
Laguda, B2
Langan, SM1
Martinez, AE1
Murphy, R1
Proudfoot, L1
Ravenscroft, J1
Shahidullah, H3
Shaw, L2
Syed, SB2
Wells, L1
Babiak-Choroszczak, L2
Giżewska-Kacprzak, K2
Gawrych, E2
Fischer, K1
Walecka, A1
Puchalska-Niedbał, L1
Rajewska-Majchrzak, J1
Bagłaj, M2
Droitcourt, C1
Kerbrat, S1
Rault, C1
Botrel, MA1
Happe, A1
Garlantezec, R1
Guillot, B1
Schleich, JM1
Oger, E1
Dupuy, A2
Hagen, R1
Ghareeb, E1
Jalali, O1
Sancho, KFCB1
Zett, C1
Gonçalves Júnior, I1
Morales, MC1
Maia, M1
Mattos Neto, RB1
Samorano, LP1
Rivitti-Machado, MC1
Oliveira, ZNP1
Gontijo, B1
Polites, SF2
Rodrigue, BB1
Chute, C2
Hammill, A1
Dasgupta, R2
Kishi, A1
Tian, Y2
Guo, XS1
Nan, J1
Wang, XL1
Shen, G1
Gültekin, ND1
Yilmaz, FH1
Altunhan, H1
Findik, S1
Tokgöz, H1
Çalişkan, Ü1
Chaturvedi, K1
Steinberg, JS1
Snyder, CS1
Dembowska-Baginska, B1
Wyrzykowski, D3
López Gutiérrez, JC3
Rychłowska-Pruszyńska, M1
de Lucas-Laguna, R1
Esteve-Martinez, A1
Zaim, M1
Menon, Y1
Gautier, S2
Lebbé, G3
Bouroubi, A1
Xu, W1
Yu, F1
An, W1
Wang, W2
Sun, C2
McCormick, AA1
Tarchichi, T1
Azbell, C1
Grunwaldt, L1
Jabbour, N1
Tangtatco, JA1
Freedman, C1
Phillips, J1
Lin, Z1
Huang, G1
Lin, H1
Watanabe, M1
Crafton, T1
Jenkins, TM1
Alvarez-Allende, CR1
Martin, JM1
Sanchez, S1
González, V1
Cordero, P1
Ramon, D1
Sepaskhah, M1
Hajizadeh, J1
Sari-Aslani, F1
Jowkar, F1
Zhu, Z1
Cai, P1
Zhu, J1
Wu, B1
Gu, Z1
Wang, J3
Lahrichi, A1
Baline, K1
Fatoiki, FZE1
Khadir, K1
Álvarez-Neri, H1
Penchyna-Grub, J1
Teyssier-Morales, G1
Morera-Serna, E1
Torre, C1
Villamor, P1
Novoa, M1
Beltran, S1
Giraldo, L1
Shahbaz, A1
Pardo-Hernandez, H1
Arevalo-Rodriguez, I1
López-Gutiérrez, JC1
Subiabre-Ferrer, D1
García-Rabasco, A1
Correa-González, N1
Ortiz-Salvador, JM1
Barreda-Solana, M1
Lee, SM1
Khwarg, SI1
Ahn, JH1
Campanelli, R1
Codazzi, AC1
Poletto, V1
Abbà, C1
Catarsi, P1
Fois, G1
Avanzini, MA1
Brazzelli, V2
Tzialla, C2
De Silvestri, A1
Tinelli, C1
Licari, A1
Berra-Romani, R1
Zuccolo, E1
Moccia, F1
Mannarino, S2
Rosti, V1
Massa, M1
Xu, ZG1
Dawid, G1
Tsai, MC1
Liu, HC1
Yeung, CY1
Anwar, T1
Malm-Buatsi, E1
Ji, Z1
Jiang, Y1
Welfringer-Morin, A1
Fraitag, S1
Balguerie, X1
Laaengh-Massoni, C1
Leclerc-Mercier, S1
Hadj-Rabia, S3
Bodemer, C2
Mellerio, JE1
Feng, L1
Yuan, WE2
Ramtohul, P1
Beylerian, M1
Dambricourt, L1
Matonti, F1
Denis, D1
Düzenli Kar, Y1
Özdemir, ZC1
Acu, B1
Bör, Ö1
Cai, R1
Moro, R1
Fabiano, A1
Mangeri, F1
Di Buduo, A1
Manerba, A1
Rossini, M1
Calzavara-Pinton, PG1
Gualdi, G1
Celli, M1
Akakpo, AS1
Téclessou, JN1
Djalogue, L1
Gottara, WS1
Tchangai-Walla, K1
O'Bryhim, BE1
Li, AS1
Bayliss, SJ1
Tychsen, L1
Lueder, GT1
Rajagopal, R1
Liu, Q1
Zuo, S1
Mannschreck, DB1
Lie, E2
Psoter, K1
Puttgen, K2
Jiang, D1
Zhao, S1
Wang, A1
Rokugo, Y1
Ota, C1
Kimura, M1
Sasahara, Y1
Yeo, YH1
Jackson, C1
Trimble, K1
Anger, J1
Oliveira, EM1
Gabel, J1
Reimer, A2
Ott, H1
Wu, W1
Wang, H2
Hao, J1
Gao, Z1
Li, F1
Chen, Y1
Bakalli, I1
Kola, E1
Lluka, R1
Celaj, E1
Sala, D1
Gjeta, I1
Sallabanda, S1
Klironomi, D1
Chai, Y1
Zhou, Z1
Song, J1
Onder, SS1
Gergin, O1
Karabulut, B1
Prasad, A2
Sinha, AK1
Kumar, B1
Kumari, M1
Overman, J1
Moustaqil, M1
Meurer, M1
Chiang, IK1
Lesieur, E1
Patel, J1
Zuegg, J1
Pasquier, E1
Sierecki, E1
Gambin, Y1
Hamdan, M1
Khosrotehrani, K1
Andelfinger, G1
Fernández Ibieta, M1
Méndez Aguirre, NA1
Girón Vallejo, O1
Ruiz Jiménez, JI1
Ben-Amitai, D1
Halachmi, S1
Zvulunov, A5
Raveh, E1
Kalish, E1
Lapidoth, M3
Parikh, SR2
Manning, SC3
Richter, GT7
Craiglow, BG1
Reddy, KK1
Brauer, JA1
Waner, M4
Anolik, R1
Bernstein, L1
Brightman, L1
Hale, E1
Karen, J1
Weiss, E1
Geronemus, RG2
Sadykov, RR1
Podmelle, F1
Sadykov, RA1
Kasimova, KR1
Metellmann, HR1
McGee, P1
Miller, S1
Black, C1
Hoey, S2
Dreyfus, I2
Maza, A1
Caussé, S1
Aubert, H1
Saint-Jean, M2
Puzenat, E1
Bursztejn, AC1
Eschard, C1
Mahé, E1
Miquel, J2
Chiaverini, C1
Stalder, JF2
Ahogo, CK1
Ezzedine, K4
Colona, V1
Diallo, A1
Mendiratta, V1
Varghese, B1
Chander, R1
Parakh, A1
Solanki, RS1
Pride, HB1
Tollefson, M1
Silverman, R1
Hong, P1
Tammareddi, N1
Walvekar, R1
Chiu, ES1
Poole, JC1
Kluka, EA1
Simon, LM1
Block, SL1
Blackmon, L1
Wang, HW1
Zhang, N1
Zhang, JL2
Fette, A1
Chandran, S1
Ari, D1
Jose, J1
Niu, JN1
Lü, RR3
Tlougan, BE1
Lee, MT1
Shibata, S1
Uwajima, Y1
Yamada, D1
Miyamoto, A1
Miyagawa, T1
Araki, M1
Takahashi, K1
Isomura, S1
Aozasa, N1
Masui, Y1
Yamamoto, M1
Inuzuka, R1
Sato, S1
Romanini, MV1
Pelegrini, M1
Rimini, A1
Occella, C1
Ferrandiz, L1
Toledo-Pastrana, T1
Moreno-Ramirez, D1
Bardallo-Cruzado, L1
Perez-Bertolez, S1
Luna-Lagares, S1
Rios-Martin, JJ1
Engberg Damsgaard, T1
Vandborg Bjerre, J1
Huoh, KC2
Frost, G1
Relic, J1
Sondhi, V1
Patnaik, SK1
Chaudhry, TA1
Kamal, M1
Ahmad, K1
McSwiney, E1
Murray, D1
Murphy, M1
Cavalli, R2
Novotna, V1
Buffon, RB1
Gelmetti, C3
Knol, MJ1
Bruijnzeel-Koomen, CA1
Kon, M2
Breur, JM3
Pasmans, SG3
Xiao, X4
Xu, T2
Zheng, S4
Peng, WJ1
Cao, Y1
Thaivalappil, S1
Bauman, N1
Saieg, A1
Movius, E1
Brown, KJ1
Preciado, D1
Ng, SY1
Kader Ibrahim, SB1
Tanabe, H1
Sahashi, K1
Kitano, T1
Tomita, Y1
Saito, AM1
Hirose, H1
Theunissen, CI1
van der Horst, CM3
Summerer, B1
Schneider, J1
Boss, EF1
Biesbroeck, L1
Brandling-Bennett, HA1
Haider, KM2
Neely, DE2
Plager, DA2
Mawn, LA1
Puligadda, RK1
Vijayalakshmi, B1
Lynch, M1
Lenane, P1
O'Donnell, BF2
Kum, JJ1
Khan, ZA1
Malik, MA1
Menon, P1
Rao, KL1
Samujh, R1
Gu, MZ1
Wu, JL1
Zhao, LM1
Ni, K1
Chen, SM1
Chen, JR2
Chen, F1
Li, XY2
Szychta, P1
Stewart, K1
Anderson, W1
Chim, H2
Mai, HM1
Wang, YA1
Qin, ZP7
Li, KL5
Rössler, J4
Braunschweiger, F1
Schill, T4
Albuquerque, JC1
Magalhães, RA1
Félix, JA1
Bastos, MV1
Fontenele, JB1
Trompieri, NM1
Felix, FH1
Wang, Z1
Andersen, IG1
Rechnitzer, C1
Charabi, B1
McCarter, RJ1
Guzzetta, PC1
Shin, JJ2
Oh, AK1
Preciado, DA1
He, J1
Greene, EA2
Sagi, L1
Ben Amitai, D1
Chen, BS1
Saltzman, B2
Levitt, M1
Coumou, AD1
Groeneveld, L1
Freling, NJ1
Saeed, P1
Chang, TC1
Estes, R1
Emiralioğlu, N1
Oğuz, B1
Kiper, N1
Ersöz, DD1
Yalçın, E1
Özçelik, U1
Soldatskiĭ, IuL1
Timofeeva, MIu1
Koltukova, NP1
Strygina, IuV1
Gasparian, SF1
Kislenko, OA1
Bruneau, B1
Lee, D1
Durham, JT1
Herman, IM1
Schneider, M2
Cremer, HJ2
Ruef, P2
Chu, DH1
Castelo-Soccio, L1
Wan, J1
Gelfand, JM1
Shaddy, RE1
Shah, KN1
Perman, MJ1
Yan, AC1
Laranjo, S1
Costa, G1
Paramés, F1
Freitas, I1
Martins, JD1
Trigo, C1
Pinto, FF1
Zhou, H3
Li, QF1
Cao, GL1
Ling, HZ1
Dai, HR1
Chen, XH1
Monneret, C1
Song, H2
Shi, H2
Yu, Y1
Chen, W1
England, RW2
Hardy, KL2
Kitajewski, AM2
Wong, A2
Kitajewski, JK3
Shawber, CJ3
Ma, X2
Zhao, T2
Ouyang, T2
Xin, S1
Chang, M1
Murabit, A1
Gnarra, M2
Harper, JI4
Jacobson, D1
Nayan, S1
Macnay, R1
Maclean, J1
Qi, M1
Xie, HF1
Ding, JS1
Jian, D3
Zhou, W1
He, S1
Ding, J1
Crivellaro, C1
Zanon, GF1
Luzzatto, C1
Tai, M1
Qin, Z1
Ge, C1
Steel, R1
Day, D1
Nakayama, H1
Klagsbrun, M1
Xu, C1
Kaushik, S1
Kaur, S1
Pandav, SS1
Gupta, A1
Xia, L1
Bonifazi, E1
Milano, A1
Foti, C1
Casiraghi, A2
Musazzi, UM2
Franceschini, I1
Paragò, V1
Cardosi, L1
Minghetti, P2
Lind, H1
Zaharov, T1
Godballe, C1
Ehsani, AH1
Noormohammadpoor, P1
Abdolreza, M1
Balighi, K1
Arianian, Z1
Daklan, S1
Burne, R1
Taylor, R2
Sterker, I1
Tegetmeyer, H1
Sorge, I1
Weißer, M1
Böhm, R1
Goelz, R1
Poets, CF1
Oksiuta, M1
Matuszczak, E1
Debek, W1
Dzienis-Koronkiewicz, E1
Hermanowicz, A1
Kounami, S1
Okuhira, H1
Nakamura, Y1
Furukawa, F1
Hoff, SR1
Rastatter, JC1
Cerrati, EW1
O, TM1
Chung, H1
Benvenisti, H1
Ben-Sira, L1
Constantini, S1
Roth, J1
Bin, L1
Manli, C1
Jie, L1
Xiaopeng, Y1
Zhaoquan, L1
Zhongcheng, G1
Korownyk, C1
Ross, D1
Fiorillo, L1
Villalba-Moreno, AM1
Cotrina-Luque, J1
Del Vayo-Benito, CA1
Flores-Moreno, S1
Bautista-Paloma, FJ1
Su, L1
Wang, D1
Cremer, H3
Tinghui, Z1
Xiaorong, M1
Yingying, H1
Huiping, C1
Yan, X1
Tianxiang, O1
Filippi, L1
Dal Monte, M1
Casini, G1
Daniotti, M1
Sereni, F1
Bagnoli, P1
Kovačević, M1
Lukinović Škudar, V1
Maričić, G1
Krnjević-Pezić, G1
Stanimirović, A1
Xu, DP6
Cao, RY1
Xue, L4
Sun, NN2
Tong, S3
Kucherov, IuI1
Zhirkova, IuV1
Getman, AN1
Ivleva, SA1
Rekhviashvili, MG1
Vlasveld, FA2
Slieker, MG1
Harper, J2
Batul Syed, S1
Yuan, SM1
Zhang, M1
Guo, Y1
Cui, L1
Hong, ZJ1
Jiang, HQ1
Giorgini, C1
Barruscotti, S1
Codazzi, CA1
Stronati, M1
Marseglia, GL1
Borroni, G1
Li, G3
Sun, HL1
Cheng, C2
Liu, ZM3
Xi, SL2
Hoeger, P1
Posiunas, G1
Phillips, RJ4
Caceres, H1
Ballona, R1
Friedlander, SF2
Perek, D1
Metz, B1
Szalai, ZZ1
Krol, A2
Foelster-Holst, R2
Febrer Bosch, MI1
Su, J2
Buckova, H1
Cambazard, F1
Grantzow, R1
Roessler, J1
Valencia, AM1
Glick, S1
Birchall, N1
Benjamin, L1
Vabres, P3
Souteyrand, P1
Berul, CI1
Mehta, CR1
Morgan, CC1
Heritier, S1
Pan, WK1
Li, P3
Guo, ZT1
Huang, Q1
Gao, Y2
Porcel Chacón, R1
del Boz González, J1
Navarro Morón, J1
Chen, ZG1
Yuan, ML1
Okuno, T1
Tokuriki, S1
Yoshino, T1
Tanaka, N1
Ohshima, Y1
Guo, Z2
Pan, W2
You, HS1
Kim, BS1
Kim, MB1
Ko, HC1
Horev, A2
Haim, A2
Aly, MM1
Hamza, AF1
Abdel Kader, HM1
Saafan, HA1
Ghazy, MS1
Rodríguez-Ruiz, M1
Tellado, MG1
del Pozo Losada, J1
Bonnet, D1
Boon, LM2
Ciofi Degli Atti, M1
Oranje, AP4
Rubin, AT1
Siegel, B1
Mehta, D2
Lockman, JL1
Schwartz, AJ1
Ames, JA1
Sykes, JM1
Baena-Gómez, MA1
Priego Ruiz, MP1
Mateos González, E1
Peña Rosa, MJ1
Muñoz Sánchez, R1
Elluru, RG1
Friess, MR1
Moore, N3
Padys, P1
Fouque, L1
Le Duff, M1
D'Hervé, D1
Poulain, P1
Dave, T1
Dave, VP1
Shah, G1
Pappuru, RR1
Tozzi, A1
Jianguo, K1
Xichun, W1
Mingkun, Z1
Qiaoling, C1
Wenjin, L1
Patel, KG1
El Rassi, E1
MacArthur, CJ2
Zhu, JY1
Ren, JG1
Chen, G1
Zhao, YF1
Reinhardt, D1
Qu, X1
Moodley, ST1
Hudson, DA1
Adams, KG1
Tran, C1
Tamburro, J2
Rhee, A1
Golden, A2
Gong, H2
Li, YX1
Vergine, G2
Sorci, M1
Rosafio, C1
Bigucci, B1
Filippini, B1
Ancora, G1
Yang, B1
Zhang, LX1
Sun, YJ1
Wedgeworth, E1
Irvine, AD1
Clayton, TH1
Bjerre, JV1
Burrows, NP1
Hedelund, L1
Audrain, H1
Bhate, K1
Brown, SJ1
Baryschpolec, S1
Darne, S1
Durack, A1
Dvorakova, V1
Gach, J1
Goldstraw, N1
Goodyear, H1
Grabczynska, S1
Greenblatt, D1
Halpern, J1
Hearn, RM1
Hughes, B1
Jayaraj, R1
Johansson, EK1
Lam, M1
Leech, S1
O'Regan, GM1
Morrison, D1
Porter, W1
Ramesh, R1
Taylor, AE1
Thomson, J1
Tiffin, P1
Tsakok, M1
McPherson, T1
Patrizi, A2
Ravenscroft, JC1
Svensson, A1
Wahlgren, CF1
Méchineaud, M1
Nicaise, D1
Martin, L1
Gangopadhyay, AN1
Gupta, DK1
Gribaa, R1
Slim, M1
Neffati, E1
Boughzela, E1
Munabi, NC1
Edwards, AK1
Kitajewski, AA1
Tan, QK1
Weinstein, A1
Kung, JE1
Wilcox, M1
Elbert, NJ1
Liem, YT1
Yujuan, T1
Shaoquan, C2
Zaizhong, Z2
Shuming, C2
Guoliang, H1
Lie, W2
MacIsaac, ZM1
Nayar, HS1
Gehris, R1
Geisler, S1
Grunwaldt, LJ1
Yu, W1
Zaher, H1
Rasheed, H1
El-Komy, MM1
Hegazy, RA2
Gawdat, HI1
Abdel Halim, DM1
Abdel Hay, RM1
Mohy, AM1
Chinnadurai, S1
Fonnesbeck, C1
Snyder, KM1
Sathe, NA1
Morad, A1
Likis, FE1
McPheeters, ML1
Krstulovic, C1
Ibañez-Alcañiz, I1
Alamar-Velázquez, A1
López-Andreu, J1
Evoli-Buselli, M1
Neckman, JP1
Ge, J1
Zhao, H1
Seidmann, L1
Anspach, L1
Roth, W1
Techasatian, L1
Komwilaisak, P1
Panombualert, S1
Uppala, R1
Jetsrisuparb, C1
Laken, PA1
Hu, L1
Zhou, B1
Shah, SD1
McCuaig, C2
Coulie, J1
Haggstrom, AN1
Newell, BD1
García-Romero, MT1
Grimes, B1
Shao, RZ1
Zhao, DH1
Dementieva, N1
Jones, S1
Nozawa, A1
Hori, T1
Kanda, K1
Kimura, T1
Kawamoto, N1
Chengjin, L1
Yin, X1
Chen, L1
Qingjin, H1
Tai, MZ2
Liu, XJ3
Ge, CX2
Kang, E1
Friedman, N1
Mamoun, I1
Yi, LF1
Wen, HX1
Qiu, M1
Zhang, JY1
Cao, XX1
Oak, CY1
Jun, CH1
Cho, EA1
Lee, DH1
Cho, SB1
Park, CH1
Joo, YE1
Rew, JS1
Choi, SK1
Szemraj, J1
Chrzanowska, B1
Robertson, SA1
Kimble, RM1
Storey, KJ1
Gee Kee, EL1
Stockton, KA1
Jin, L1
Torres, E1
Rosa, J1
Soares-de-Almeida, L1
Danchin, M1
Boyce, SL1
Phuong, L1
Cooper, E1
Vidmar, S1
Stringari, G1
Barbato, G1
Zanzucchi, M1
Marchesi, M1
Tchana, B1
Gritti, A1
Lombardi, AA1
Carano, N1
Streicher, JL1
Riley, EB1
Castelo-Soccio, LA1
Sirachainan, N1
Lekanan, W1
Thammagasorn, Y1
Wanitkun, S1
Kadegasem, P1
Chunharas, A1
Castaneda, S1
Melendez-Lopez, S1
Garcia, E1
De la Cruz, H1
Sanchez-Palacio, J1
Furuta, S1
Sato, H1
Tsuji, S1
Murakami, F1
Kitagawa, H1
Lucky, A1
Feigenbaum, D1
Savva, Y1
Holland, K1
Drolet, B1
Morel, KD1
Yang, L1
Rocco, P1
Franzè, S1
Yang, TB1
McMahon, P1
De Léon, DD1
Yarbrough, KB1
Krol, AL1
Leitenberger, SL1
Mann, JA1
Cheng, CE1
Fan, XD3
Yang, YW2
Zhao, JH2
Wang, XY2
Zhou, DK2
Erdoğan, İ1
Degrugillier-Chopinet, C1
Ortis, V1
Lafon, M1
Montagne, A1
Slaughter, KA1
Williams, E1
Hardison, S1
Wan, W1
Dodson, KM1
Salice, P1
Giovanni Bianchetti, M1
Giavarini, A1
Gondoni, E1
Maria Colli, A1
Lombardi, F1
Grönemeyer, LL1
Haenssle, HA1
Zutt, M3
von Fintel, H1
Petrovic, J1
Trifunovic, B1
Vukomanovic, G1
Topalovic, M1
Trajkovic, G1
Parezanović, V1
Lanciotti, S1
Sapio, M1
Ferrara, E1
De Grazia, A1
Clerico, A1
He, A1
Khanna, R1
Kwatra, SG1
Li, D1
Grech, V1
Scerri, C1
Spillekom-van Koulil, S1
Yu, X1
Liu, M1
Chen, R1
Crock, CM2
Penington, AJ2
Bekhor, PS2
Piccolo, V2
Moscarella, E1
Ametrano, O1
Picciocchi, R1
Russo, T2
Mei-Zahav, M1
Blau, H1
Hoshen, M1
Mussaffi, H1
Prais, D1
Stafler, P1
Steuer, G1
Amitai, DB1
Jiang, CH2
Lei, SR1
Matsuura, T1
Kadono, T1
Koizumi, H1
Kawakami, T1
Soma, Y1
Boyvat, F1
Demir, Ş1
Özçay, F1
Uslu, N1
Fraser, K1
Theletsane, T1
Redfern, A1
Raynham, O1
Harris, T1
Prose, NS1
Khumalo, NP1
Denoyelle, F4
Leboulanger, N3
Enjolras, O1
Harris, R1
Roger, G2
Garabedian, EN4
Pérez, RS1
Mora, PC1
Rodríguez, JD1
Sánchez, FR1
de Torres, Jde L1
Buckmiller, L2
Dyamenahalli, U2
Sans, V1
de la Roque, ED1
Berge, J1
Grenier, N2
Lipsker, D1
Dupuis, E1
Vergnes, P1
Eivazi, B3
Teymoortash, A2
Stiller, S1
Werner, JA3
Mousa, W1
Kues, K1
Haas, E1
Lauerer, P2
Pavlakovic, H2
Jephson, CG2
Syed, S1
Mills, NA1
Hartley, BE2
Buckmiller, LM3
Löffler, H1
Kosel, C1
Kachel, W1
Michel, JL1
Patural, H1
Holmes, WJM3
Gorst, C5
Liew, SH4
Naouri, M3
Lorette, G2
Maturo, S1
Hartnick, C1
Truong, MT2
Chang, KW2
Berk, DR1
Heerema-McKenney, A1
Bruckner, AL1
Munson, PD1
Dai, Y2
Zimmermann, AP1
Wiegand, S2
Fay, A1
Nguyen, J1
Jakobiec, FA1
Meyer-Junghaenel, L1
Zhou, Q1
Yang, XJ1
Sans-Martin, V1
Akhavan, A1
Zippin, JH1
Baetz, J1
Eigelshoven, S1
Marquard, J1
Bruch-Gerharz, D1
Homey, B1
Meissner, T1
Bross, F1
Mistry, N1
Tzifa, K1
Vanlander, A1
Decaluwe, W1
Vandelanotte, M1
Van Geet, C1
Cornette, L1
Fölster-Holst, R1
Storch, CH1
Benlahrech, S1
Ammour, A1
Broue, P1
Vial, J1
Ohanessian, G1
Labenne, M1
Li, YC1
McCahon, E1
Rowe, NA1
Martin, PA1
Wilcsek, GA1
Martin, FJ1
Frasin, A1
Restano, L1
Cheng, JF1
Gole, GA1
Sullivan, TJ1
Blanchet, C1
Nicollas, R2
Bigorre, M1
Amedro, P1
Mondain, M2
Schwartz, RA1
Sidor, MI1
Musumeci, ML1
Lin, RL1
Micali, G1
Eikenberry, J1
Haggstrom, A2
Itinteang, T4
Meyer, L1
Graffstaedt, H1
Giest, H1
Truebenbach, J1
Holland, KE2
Frommelt, PC2
Wyatt, D1
Suh, KY1
Meyer, AK2
Maguiness, SM1
Messner, AH1
Fusilli, G1
Merico, G1
Gurrado, R1
Rosa, T1
Acquafredda, A1
Cavallo, L1
Holmes, WJ1
Fayoux, P1
Teissier, N1
Cox, A2
Van Den Abbeele, T1
Carrabin, L1
Couloigner, V1
Triglia, JM1
Ayari, S1
Froehlich, P2
Lescanne, E1
Marianowski, R1
Mom, T1
Marie, JP1
Arneja, JS1
Pappas, PN1
Shwayder, TA1
Cullen, ML1
Becker, CJ1
Hamzavi, FH1
Roarty, JD1
Madgy, DN1
Baker, JD1
Canadas, KT1
Baum, ED1
Lee, S1
Ostrower, ST1
Brasch, HD1
Day, DJ1
Fretheim, A1
Guldbakke, KK1
Rørdam, OM1
Huldt-Nystrøm, T1
Hanssen, HK1
Høivik, F1
Ho, KM1
Chik, KK1
Luk, CK1
Chan, HB1
Tan, HY1
Schiestl, C1
Zoller, S1
Subotic, U1
Forster-Kuebler, I1
Michels, R1
Balmer, C1
Krause, H1
Haß, HJ1
Kroker, S1
Meyer, F1
Halloul, Z1
Wagemann, W1
O'Loughlin, A1
Watson, R1
Kietz, S1
Lakomek, M1
Muthamilselvan, S1
Vinoth, PN1
Vilvanathan, V1
Ninan, B1
Amboiram, P1
Sai, V1
Anand, V1
Scott, JX1
Mangold, C1
Guye, E1
Chollet-Rivier, M1
Schröder, D1
Sandu, K1
Hohlfeld, J2
de Buys Roessingh, A2
Cuccaro, P1
Rapacciuolo, A1
Vitiello, R1
di Pietro, E1
Montaldo, P1
Esposito, F1
Maresca, G1
Correra, A1
Bonanno, C1
Paccanaro, M1
Fontanellilea, A1
Freshwater, MF1
Peridis, S1
Pilgrim, G1
Athanasopoulos, I1
Parpounas, K1
Morais, P1
Magina, S1
Mateus, M1
Trindade, E1
Jesus, JM1
Azevedo, F1
Hermans, DJ3
van Beynum, IM3
Schultze Kool, LJ1
van de Kerkhof, PC1
Wijnen, MH2
van der Vleuten, CJ4
Bodak, N1
Hamel-Teillac, D1
Kupfer-Bessaguet, I1
Nguyen, JM1
Shayan, YR1
Prendiville, JS1
Goldman, RD1
Holmes, W1
Liew, S2
Martínez-Escanamé, M1
Castillo-Martínez, C1
Torres-Álvarez, B1
González, FJ1
Oros-Valle, C1
Moncada, B1
Boucek, RJ2
Sidbury, R2
Kim, LHC1
Hogeling, M2
Jiwane, A1
Pereyra-Rodríguez, JJ1
Mantrana-Bermejo, ME1
Fernández-Pineda, I1
de Agustín, JC1
Conejo-Mir, J1
Morrell, DS1
Buck, S1
Zdanski, C1
Gold, S1
Stavas, J1
Powell, C1
Burkhart, CN1
Schöni, MH1
Kernland Lang, K1
Fuchsmann, C1
Quintal, MC1
Giguere, C1
Ayari-Khalfallah, S1
McCone, C1
Sierpina, DI1
Chaudhary, HM1
Walner, DL1
Aljadeff, G1
Dubrow, IW1
Ghosh, PS1
Ghosh, D1
Vos, M1
Restrepo, R1
Palani, R1
Cervantes, LF1
Duarte, AM2
Amjad, I1
Altman, NR1
Starkey, E1
Azzopardi, S1
Wright, TC1
Chun, YH1
Moon, CJ1
Yoon, JS1
Kim, HH1
Kim, JT1
Lee, JS1
Zide, BM1
Levine, SM1
Greenhill, NB1
Deacon, GB1
Zhan, MK1
Xie, YD1
Guo, ZH1
Huang, BR1
Zhou, YK1
Chen, XS1
Yang, YC1
Jin, YB1
Lin, XX1
Ye, XX1
Da, C1
Chen, XD1
Hu, XJ1
Zhao, ZF2
Fu, HB2
Wui, JC1
Lin, LL1
Price, CJ1
Lattouf, C1
Baum, B1
McLeod, M1
Schachner, LA1
Connelly, EA1
Goswamy, J1
Rothera, MP1
Bruce, IA1
Mabeta, P1
Pepper, MS1
Javia, LR1
Zur, KB1
Jacobs, IN1
Raol, N1
Edmonds, J1
Chandy, B1
Sulek, M1
Larrier, D1
Arevalo, JF1
Arias, JD1
Serrano, MA1
Ottenhof, MJ1
Bähr, A1
Truckenmüller, W1
Noellke, P1
Niemeyer, CM1
Solomon, T1
Ninnis, J1
Deming, D1
Merritt, TA1
Hopper, A1
Menezes, MD1
McCarter, R1
El-Shabrawi, M1
Hassanin, F1
Fan, ZN1
Zhao, WJ1
Wang, YM1
Wei, FC1
Dyme, JL1
Thampan, A1
Han, EJ1
Nyirenda, TL1
Kotb, ME1
Shin, HT1
Lu, J1
Qin, G1
Zhao, J1
Xiang, Y1
Zuo, C1
Yang, S1
Tna, L1
Shepherd, D1
Jaffe, A1
Nunn, A1
Shah, U1
Ford, J1
Madern, GC2
Nieuwenhuis, K1
de Laat, PC2
Kleber, CJ1
Spiess, A1
Kleber, JB1
Hinz, U1
Holland-Cunz, S1
Weiss, J1
Bosemani, T1
Huisman, TA1
Tekes, A1
Constantinides, J1
Prowse, P1
Didi, MA1
Mahadevan, M1
Cheng, A1
Barber, C1
Halilbasic, A1
Hotic, N1
Husaric, E1
Rahmanovic, E1
Halilbasic, M1
Husaric, S1
Fischer, CJ1
Giannoni, E1
Truttmann, AC1
Tolsa, JF1
Chevallay, M1
El Ezzi, O1
Seneggen, E1
Pauchard, JY1
Gehri, M1
Hauschild, M1
Küpeli, S1
Lv, MM1
Su, LX1
Hou, F1
Fan, CY1
Saad, A1
Suen, J1
Thayal, PK1
Bhandari, PS1
Sarin, YK1
Talaat, AA1
Elbasiouny, MS1
Elgendy, DS1
Elwakil, TF1
Hsu, TC1
Wang, JD1
Chen, CH1
Chang, TK1
Wang, TM1
Chou, CM1
Lin, HK1
Prashanth, GP1
Vigone, MC1
Cortinovis, F1
Rabbiosi, S1
Di Frenna, M1
Passoni, A1
Persani, L1
Chiumello, G1
Weber, G1
Armijo, BS1
Miller, E1
Gliniak, C1
Serret, MA1
Gosain, AK1
Hartzell, LD1
Chiu, YE2
Carcao, M1
Fangusaro, J1
Kelly, ME1
Lofgren, S1
Metry, DW1
Recht, M1
Silverman, RA1
Tom, WL1
Bingham, MM1
Vo, NJ1
Spinks, J1
Chakkittakandiyil, A1
Lara-Corrales, I1
Maki, E1
Weinstein, M1
Celik, A1
Tiryaki, S1
Musayev, A1
Kismali, E1
Levent, E1
Ergun, O1
Dorresteijn, EM1
Jan Danser, AH1
Georgountzou, A1
Karavitakis, E1
Klimentopoulou, A1
Xaidara, A1
Kakourou, T1
Zweegers, J2
Durr, ML1
Tan, M1
Duan, B1
Zhou, CM1
Murthy, GJ1
Goswami, M1
Marsciani, A1
Pedini, A1
Brocchi, S1
Marsciani, M1
Desiderio, E1
Bertelli, S1
Vecchi, V1
Katona, G1
Csákányi, Z1
Gács, E1
Szalai, Z1
Ráth, G1
Gerlinger, I1
Salminen, P1
Vuola, P1
Overmark, M1
Lindahl, P1
Kalajoki-Helmiö, T1
Pitkäranta, A1
Loizzi, M1
De Palma, A1
Pagliarulo, V1
Quaranta, N1
Tang, LX1
Zhang, YM1
Wang, GX1
Izadpanah, A2
Kanevsky, J1
Belzile, E1
Schwarz, K1
Baranowski, S1
Winkler, A1
Kunzi-Rapp, K1
Schaal, M1
Hempel, S1
Debatin, KM1
Posovszky, C1
Babajee, K1
Hu, X1
Xie, H1
Hasan, M1
Rahman, M1
Hoque, S1
Zahid Hossain, AK1
Khondker, L1
Liberman, L1
MacLellan-Tobert, S1
Seefeldt, M2
Ward, KM1
Cassidy, L1
Joachim, S1
Kwon, EK2
Martin, K1
Perkins, J1
Xia, Y1
Zhai, Y1
Li, C1
Yeom, KB1
Choi, JW1
Shin, H1
Bauland, CG1
Jin, ZL1
Wei, JJ1
Liu, ZY1
Dumas de la Roque, E1
Nacka, F1
Abouelfath, A1
Rebola, M1
Uzunaslan, D1
Saygin, C1
Gungor, S1
Hasiloglu, Z1
Ozdemir, N1
Celkan, T1
Xiao, Y1
Huang, Y1
Liu, J1
Lin, J1
Bajaj, Y1
Kapoor, K1
Ifeacho, S1
Albert, DM1
Liu, L1
Wang, G1
Gao, T1
Bianchi, A1
Daniel, RH1
Hubler, WR1
Wolf, JE1
Holder, WR1

Clinical Trials (16)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Safety and Efficiency of Propranolol as an Initial Treatment for Pediatric Hemangioma[NCT01908972]Phase 434 participants (Actual)Interventional2013-06-30Completed
Sirolimus in the Treatment for Propranolol-resistant Infantile Hepatic Hemangioendothelioma[NCT04406870]Phase 436 participants (Anticipated)Interventional2020-07-31Not yet recruiting
Efficacy and Safety of Propranolol Versus Atenolol on the Proliferative Phase of Infantile Hemangioma[NCT02342275]Phase 3377 participants (Actual)Interventional2013-10-31Completed
Propranolol vs Prednisolone for Infant Hemangiomas-A Clinical and Molecular Study[NCT00967226]Phase 219 participants (Actual)Interventional2009-07-31Terminated (stopped due to Serious adverse events with prednisolone, primarily temporary growth retardation, <5th percentile.)
Natural Berry Extract Treatment of Hemangiomas[NCT04020419]Early Phase 112 participants (Actual)Interventional2020-12-01Terminated (stopped due to Study ending early due to program transferring to another site.)
A Randomised, Controlled, Multidose, Multicentre, Adaptive Phase II/III Study in Infants With Proliferating Infantile Hemangiomas (IHs) Requiring Systemic Therapy to Compare 4 Regimens of Propranolol (1 or 3 mg/kg/Day for 3 or 6 Months) to Placebo (Double[NCT01056341]Phase 2/Phase 3512 participants (Actual)Interventional2010-01-31Completed
Influence of Systemic Propranolol Treatment on the Physical Development of Paediatric Patients With Infantile Hemangiomas[NCT04651049]128 participants (Actual)Observational2010-07-15Completed
"'' Efficacy of Propranolol in the Treatment of Infantile Hemangioma"[NCT04684667]Phase 2100 participants (Anticipated)Interventional2021-01-01Not yet recruiting
A Comparative Study of the Use of Beta Blocker and Oral Corticosteroid in the Treatment of Proliferative and Involuting Cutaneous Infantile Hemangioma[NCT01072045]Phase 250 participants (Actual)Interventional2010-01-31Completed
Phase 2 Study of Sildenafil for the Treatment of Lymphatic Malformations[NCT02335242]Phase 222 participants (Actual)Interventional2015-05-23Completed
The Efficacy of Timolol 0.5% Gel Forming Solution for the Treatment of Ulcerated Hemangiomas[NCT01408056]Phase 20 participants (Actual)Interventional2011-02-28Withdrawn (stopped due to Difficulty with recruitment)
Propanolol Effect on Red Cell Adhesion in Non-Asthmatic Children With Sickle Cell Disease: A Dose Finding Study[NCT02012777]Phase 19 participants (Actual)Interventional2010-06-30Terminated (stopped due to Inability to recruit patients into the study.)
Open-label, Uncontrolled Study of the Off Label Use of Propranolol for Infancy Hemangiomas to Identify Side Effects[NCT01211080]72 participants (Actual)Observational2008-08-31Completed
A Phase II, Randomized, Double-Blind Comparison of Corticosteroid and Corticosteroids With Propranolol Treatment of Infantile Hemangiomas (IH)[NCT01074437]Phase 29 participants (Actual)Interventional2010-02-28Terminated (stopped due to Insufficient enrollment)
Role of Propranolol as Compared to Bleomycin in Management of Hemangioma[NCT05327309]90 participants (Actual)Interventional2015-05-08Completed
Propanolol for Primary Prophylaxis for Variceal Bleed in Biliary Atresia - An Open Label Randomized Controlled Study[NCT04494763]92 participants (Anticipated)Interventional2020-08-15Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Number of Participants in Which, Facial Edema Occurs, Anytime During the 16 Weeks

Number of Participants in Which, facial edema occurs, Anytime During the 16 Weeks.. (NCT01908972)
Timeframe: up to 16weeks

InterventionParticipants (Count of Participants)
Prednisolone5
Propranolol0

Number of Participants in Which, Glucose Levels Fall (to <50mg/dl), Anytime During the 16 Weeks

Number of Participants in Which, Glucose levels fall (to <50mg/dl), Anytime During the 16 Weeks.. (NCT01908972)
Timeframe: up to 16weeks

InterventionParticipants (Count of Participants)
Prednisolone0
Propranolol0

Number of Participants in Which, the Heart Rate Fell to <70% of Acceptable Age Related Minimum Post-dose With Child Awake, Anytime During the 16 Weeks

Number of Participants in which, the Heart rate fell to <70% of acceptable age related minimum post-dose with child awake, anytime during the 16 weeks Count of patients whose Heart rate fall to <70% of acceptable age related minimum post-dose with child awake (NCT01908972)
Timeframe: up to 16weeks

InterventionParticipants (Count of Participants)
Prednisolone1
Propranolol5

Number of Participants in Which, the Systolic Blood Pressure Fall of >25% of Baseline Postdose With Child Awake, Anytime During the 16 Weeks

Number of Participants in Which, the Systolic blood pressure fall of >25% of baseline postdose with child awake, Anytime During the 16 Weeks.. (NCT01908972)
Timeframe: up to 16weeks

InterventionParticipants (Count of Participants)
Prednisolone1
Propranolol5

Number of Participants With Adverse Drug Reaction

All symptoms associated adverse drug reaction will be checked (NCT01908972)
Timeframe: up to 16weeks

InterventionParticipants (Count of Participants)
Prednisolone15
Propranolol16

Number of Participants With Clinical Response From Baseline in Hemangioma Volume Measured by MRI or SONO

The primary efficacy variable was the clinical response at 16 weeks, classified as follows: when the volume did not increase or decreased by less than 25% after treatment began, we defined it as stop of progression; when the volume decreased by 25% or more compared with the original size, we defined it as regression. Both stop of progression and regressionwere defined as reaction. If the volume at the primary efficacy evaluation point was greater than the size measured when treatment started,we called it an increase. Increase was defined as a nonreaction. (NCT01908972)
Timeframe: After 16weeks

InterventionParticipants (Count of Participants)
Prednisolone14
Propranolol16

Number of Participants With Drug Compliance Within 16 Weeks

We checked Number of participants with Drug compliance within 16 weeks (NCT01908972)
Timeframe: After 16 weeks

InterventionParticipants (Count of Participants)
Prednisolone15
Propranolol17

Number of Participants With Gastroesophageal Reflux Within 16 Weeks

Number of Participants With Gastroesophageal reflux within 16 weeks.. (NCT01908972)
Timeframe: up to 16weeks

InterventionParticipants (Count of Participants)
Prednisolone0
Propranolol0

Number of Participants With Growth Retardation Within 16 Weeks

Number of Participants with Growth Retardation within 16 weeks.. (NCT01908972)
Timeframe: up to 16weeks

InterventionParticipants (Count of Participants)
Prednisolone2
Propranolol0

Number of Participants With Reepithelialzation in 16weeks

Number of participants with Reepithelialzation in 16weeks.. (NCT01908972)
Timeframe: After 16 weeks

InterventionParticipants (Count of Participants)
Prednisolone4
Propranolol8

Number of Participants With Regression

Number of participants whose hemangioma showed regression in 16 weeks. (NCT01908972)
Timeframe: Within 16 weeks

InterventionParticipants (Count of Participants)
Prednisolone9
Propranolol13

Number of Participants With Size Reduction of Ulceration

size was measure the horizontal and vertical size (2-dimension) of ulceration (from baseline to 16 weeks after medication) (NCT01908972)
Timeframe: After 16 weeks

InterventionParticipants (Count of Participants)
Prednisolone2
Propranolol1

Number of Participants With Stop of Proliferation

Number of participants whose hemangioma stop proliferating in 16weeks (NCT01908972)
Timeframe: After 16 weeks

InterventionParticipants (Count of Participants)
Prednisolone15
Propranolol17

Percent Reduction in Hemangioma Volume From Baseline

Percent Reduction in Hemangioma Volume from Baseline (measured by MRI or Sono (from basline to 16 weeks)) (NCT01908972)
Timeframe: After 16 weeks

Intervention% from baseline (Mean)
Prednisolone46.52
Propranolol55.87

Number of Participants With Change in Color as Compared to Baseline

Participants were observed for any change in color. The possible change in colors included change to Red/Purple/Blue/Gray/Apricot. Reported are the number of participants who experienced a change in color by the type of color (NCT01908972)
Timeframe: After 16 weeks

,
InterventionParticipants (Count of Participants)
RedPurple
Prednisolone130
Propranolol140

Complete Ulceration Healing Time

The complete healing time of the ulceration was defined as the time from the first dosage of propranolol or atenolol until complete healing of the hemangioma ulceration (assessed up to 6 months). Ulceration is defined as a break in the integrity of the hemangioma surface epithelium (or skin) with or without infection. The information included the extent of ulceration, complications of ulceration, prior duration of ulceration (before treatment), concurrent treatments, and complete healing time. Prior duration of ulceration was defined as the time from the first sign of ulceration until before β-blocker treatment. The complete healing time of the ulceration was defined as the time from the first dosage of propranolol or atenolol until complete healing of the hemangioma ulceration. Concurrent treatments, including oral pain medication, oral antibiotics, topical ointment antibiotics and/or wound dressings, were permitted to treat ulcerated IH and were recorded. (NCT02342275)
Timeframe: from the first dosage of propranolol or atenolol until complete healing ofthe hemangioma ulceration.

Interventionweeks (Mean)
Propranolol4.94
Atenolol4.82

Number of Participants With Complete/Nearly Complete Response (96 Week)

A complete/nearly complete response at week 96 was considered median-term efficacy. (NCT02342275)
Timeframe: 96 week

InterventionParticipants (Count of Participants)
Propranolol156
Atenolol149

Rebound Rate

Regrowth of more than 20% in hemangioma appearance (including changes in color and/or volume) after stopping the medication was considered significant rebound. The inclusion criteria for rebound analysis were as follows: (1) patients who completed 6 months of treatment and (2) patients who discontinued therapy or were tapering treatment after achieving an any response. The exclusion criteria were as follows: (1) patients who were noncompliant with treatment and (2) patients who did not respond to treatment. Whether a patient had hemangioma rebound was based on the site investigators' assessments after the week 24 treatment. In patients with significant rebound, reinitiation of systemic therapy (either propranolol or atenolol) was recommended. Minor rebound, which was defined as those patients in whose rebound was noted but no reinitiation of systemic therapy or further treatment was necessary, was not included in the analysis. (NCT02342275)
Timeframe: between weeks 24 and 96

InterventionParticipants (Count of Participants)
Propranolol19
Atenolol12

Successful Initial Response

"A successful initial response was defined as a HAS score decrease at 1 week after treatment.~A successful initial response was assessed by using HAS in the intention-to-treat population. Previous studies demonstrated that HAS decreases over time after β-blocker treatment, with a dramatic drop occurring in the first week, indicating an immediate therapeutic response. HAS can reflect the rapid effect of β-blocker (either propranolol or atenolol) therapy shortly after initiation." (NCT02342275)
Timeframe: 1 week after treatment

InterventionParticipants (Count of Participants)
Propranolol171
Atenolol163

The Primary Outcome Measure Was Any Response at 6 Months

"Changes in IH size and color were classified as a complete response, nearly complete response, partial response or no response. The primary outcome measure was any response at 6 months in the intention-to-treat population of all patients who underwent randomization. The any response included compete, nearly complete and partial responses.~A complete response was defined as no redundant tissue or telangiectasia was identified.~A nearly complete response was defined as a minimal degree of telangiectasis, erythema and skin thickening.~A partial response was defined as a size reduction or change in color that did not meet the nearly complete resolution criteria." (NCT02342275)
Timeframe: 6 month

InterventionParticipants (Count of Participants)
Propranolol178
Atenolol173

Hemangioma Activity Score (HAS)

"HAS was measured at baseline and at 1, 4, 12, and 24 weeks, including the degree of deep swelling, the color of the hemangioma, and the ulceration assessment:~Assessment of the degree of swelling. It was scored as follows:~6 points if the swelling was tense;~4 points if the swelling was'neutral;~2 points when the swelling was reduced by 50% or more at follow-up; or~0 point when there was no more visible swelling at a follow-up.~Assessment of the color of the IH.~5 points if the hemangioma lesion was bright red all over;~3 points if the hemangioma lesion was matte red or reddish-purple;~1 point if the hemangioma lesion was totally or partially gray;~0 points if the hemangioma lesion was totally or partially skin-colored after involution.~(2) Assessment of the ulceration. -0.5 point for an ulcer ≤1.0 cm2;~One point for an ulcer >1.0 cm2 but <25 cm2;~Two points for an ulcer ≥25 cm2. The HAS score= (Swelling score + color score)/2 +Ulceration score." (NCT02342275)
Timeframe: Baseline and at 1, 4, 12, and 24 weeks

,
Interventionscore on a scale (Mean)
BaselineWeek 1Week 4Week 12Week 24
Atenolol4.543.472.331.540.82
Propranolol4.613.312.421.540.82

Allergy/Immunology Adverse Events

Number of allergy/immunology AE per study arm (NCT00967226)
Timeframe: enrollment through study closeout or study withdrawal up to 9 months

InterventionAdverse Events (Number)
Allergy/Immunology Events Propranolol1
Allergy/Immunology Events Prednisolone1

Constitutional Adverse Events

Number of constitutional AEs in each study arm. (NCT00967226)
Timeframe: enrollment to study close out or withdrawal up to 9 months

InterventionAdverse Events (Number)
Constitutional AEs Propranolol2
Constitutional AEs Prednisolone3

Decrease in Size of Hemangioma (Length x Width) in Square mm

A priori primary outcome was proportional change in the total surface area as measured by lesion's outer margin length x width at baseline minus the same measure at 4 months with surrogate data used at 5 months if 4 months not available. (NCT00967226)
Timeframe: 4-5 months after initiating therapy

Interventionmm squared (Mean)
Propranolol0.57
Prednisolone0.63

Dermatologic Adverse Events

Number of Dermatologic Adverse Events in each study arm. (NCT00967226)
Timeframe: enrollment to study close out or withdrawal up to 9 months

InterventionAdverse Events (Number)
Dermatologic AEs Propranolol2
Dermatologic AEs Prednisolone1

Endocrinologic Adverse Events

Number of Endocrinologic AEs (of which adrenal crisis does not overlap). (NCT00967226)
Timeframe: enrollment to close out or study withdrawal up to 9 months

InterventionAdverse Events (Number)
Endocrine AEs Propranolol0
Endocrinologic AEs Prednisolone7

Gastrointestinal Adverse Events

Number of Gastrointestinal AEs in each arm (NCT00967226)
Timeframe: enrollment to study withdrawal or study close out up to 9 months

InterventionAdverse Events (Number)
Gastrointestinal AEs Propranolol6
Gastrointestinal AEs Prednisolone6

Growth and Development Adverse Events

Number of Growth and Development AEs in each study arm (NCT00967226)
Timeframe: enrollment to study withdrawal or close out up to 9 months

InterventionAdverse Events (Number)
Growth/Developoment AEs Propranolol0
Growth/Development AEs Prednisolone1

Infectious Adverse Events

Number of infectious AEs in each study arm (i.e. conjunctivitis, thrush, fever) (NCT00967226)
Timeframe: enrollment to study withdrawal or close out up to 9 months

InterventionAdverse Events (Number)
Infectious AEs Propranolol5
Infectious AEs Prednisolone3

Metabolic or Laboratory AEs

Number of Metabolic or Laboratory AEs in each study arm. (NCT00967226)
Timeframe: enrollment to study withdrawal or close out up to 9 months

InterventionAdverse Events (Number)
Metabolic/Laboratory AEs Propranolol1
Metabolic/Laboratory AEs Prednisolone0

Number of Serious Adverse Events (SAEs)

Number of serious adverse events experienced by the participants in each treatment arm within the categories adrenal crisis, growth/development, constitutional. Serious adverse events are defined as events that result in death, require either inpatient hospitalization or the prolongation of hospitalization, are life-threatening, result in a persistent or significant disability/incapacity, or result in a congenital anomaly/birth defect. Other important medical events, based upon appropriate medical judgment, may also be considered Serious Adverse Events if a trial participant's health is at risk and intervention is required to prevent an outcome mentioned. (NCT00967226)
Timeframe: enrollment until study close out or withdrawal up to 9 months

InterventionSerious Adverse Events (Number)
Number of Serious Adverse Events in Propranolol1
Number of Serious Adverse Events in Prednisolone11

Pulmonary/Respiratory Adverse Events

Number of pulmonary/respiratory adverse events (CTCAE 22) in each study arm (NCT00967226)
Timeframe: enrollment through study close out or withdrawal, up to 9 months

InterventionAdverse Events (Number)
Pulmonary/Respiratory AEs Propranolol14
Pulmonary/Respiratory AEs Prednisolone4

Vascular Adverse Events

Number of Vascular AEs in each study arm. (NCT00967226)
Timeframe: enrollment to study withdrawal or close out up to 9 months

InterventionAdverse Events (Number)
Vascular AEs Propranolol3
Vascular AEs Prednisolone4

Tolerability of Medication

All adverse events relating to medication tolerability including: adrenal crisis, growth/development, constitutional (dehydration), allergy/immunology, dermatologic, endocrine, GI, infection, metabolism/labs, pulmonary, vascular. (NCT00967226)
Timeframe: enrollment until study close out or withdrawal up to 9 months

,
InterventionEvents (Number)
Adverse EventsSerious Adverse Events
Overall Number of Adverse Events in Prednisolone3011
Overall Number of Adverse Events in Propranolol341

Interim Analysis : Complete/Nearly Complete Resolution of the Target Infantile Hemangioma at Week 24 Compared to Baseline Based on the Intra-patient Blinded Centralized Independent Qualitative Assessments of Week 24 Photographs.

(NCT01056341)
Timeframe: 6 months

Interventionpercentage of participants (Number)
Placebo8.0
Propranolol 1mg/kg/d 3 Months9.8
Propranolol 1 mg/kg/d 6 Months37.5
Propranolol 3 mg/kg/d 3 Months7.7
Propranolol 3 mg/kg/d 6 Months62.8

Primary Analysis : Complete/Nearly Complete Resolution of the Target Infantile Hemangioma at W24 Compared to Baseline Based on the Intra-patient Blinded Centralized Independent Qualitative Assessments of W24 Photographs.

(NCT01056341)
Timeframe: 6 months

Interventionpercentage of participants (Number)
Placebo3.6
Propranolol 3mg/kg/d 6 Months60.4

Change in Lesion Volume of the Test Medication as Evaluated by MRI Examination.

Participants will be followed for the duration of the study, an expected average of 20 weeks. (NCT02335242)
Timeframe: Baseline, week 20

Interventionpercentage of volume (Mean)
Double-Blind Placebo5.89
Open-Label Sildenafil-8.54
Double-blind Sildenafil-0.642

Change in Subject's Assessment of Change in Lymphatic Malformation Overall Score

"Subject's evaluation of the overall change in lymphatic malformation. Participants will be followed from baseline to 20 weeks.~Patients rated change as no improvement, minimal improvement (1-25% change), fair improvement (25-50% change), good improvement (50-75% change), and excellent improvement (75-100% change)." (NCT02335242)
Timeframe: Baseline, week 20

,
InterventionParticipants (Count of Participants)
No improvementMinimal improvementFair improvementGood improvementExcellent improvement
Double-Blind Placebo12020
Double-Blind Sildenafil24110

Reviews

101 reviews available for propranolol and Angioma

ArticleYear
Mediastinal and subglottic hemangioma in an infant: a case report and literature review.
    The Journal of international medical research, 2021, Volume: 49, Issue:8

    Topics: Hemangioma; Humans; Infant; Laryngeal Neoplasms; Male; Mediastinum; Propranolol; Retrospective Studi

2021
Medical Management of Infantile Hemangiomas: An Update.
    Paediatric drugs, 2022, Volume: 24, Issue:1

    Topics: Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Hemangioma; Humans; Infant; Propranolol; Skin

2022
Infantile Hemangioma: A Current Review.
    Journal of pediatric hematology/oncology, 2022, 03-01, Volume: 44, Issue:2

    Topics: Adrenergic beta-Antagonists; Child; Hemangioma; Humans; Infant; Propranolol; Skin Neoplasms; Timolol

2022
Should Propranolol Remain the Gold Standard for Treatment of Infantile Hemangioma? A Systematic Review and Meta-Analysis of Propranolol Versus Atenolol.
    The Annals of otology, rhinology, and laryngology, 2023, Volume: 132, Issue:3

    Topics: Adrenergic beta-Antagonists; Atenolol; Drug-Related Side Effects and Adverse Reactions; Hemangioma;

2023
Propranolol treatment of infantile subglottic hemangioma: a report of two cases and a literature review.
    Folia medica, 2021, Aug-31, Volume: 63, Issue:4

    Topics: Child; Hemangioma; Hemangioma, Capillary; Humans; Infant; Laryngeal Neoplasms; Laryngoscopy; Propran

2021
Sirolimus for diffuse intestinal infantile hemangioma with PHACE features: systematic review.
    Pediatric research, 2023, Volume: 93, Issue:6

    Topics: Aortic Coarctation; Eye Abnormalities; Female; Hemangioma; Hemangioma, Capillary; Humans; Infant; Pr

2023
Comparison of the efficacy and safety of lasers, topical timolol, and combination therapy for the treatment of infantile hemangioma: A meta-analysis of 10 studies.
    Dermatologic therapy, 2022, Volume: 35, Issue:12

    Topics: Administration, Topical; Adrenergic beta-Antagonists; Combined Modality Therapy; Hemangioma; Humans;

2022
Infantile Hemangiomas.
    Dermatologic clinics, 2022, Volume: 40, Issue:4

    Topics: Hemangioma; Hemangioma, Capillary; Humans; Infant; Propranolol; Skin Neoplasms; Treatment Outcome

2022
[Infantile hemangioma : Clinical manifestation, treatment, and differential diagnoses].
    Dermatologie (Heidelberg, Germany), 2023, Volume: 74, Issue:5

    Topics: Child; Diagnosis, Differential; Hemangioma; Hemangioma, Capillary; Humans; Neoplasms, Vascular Tissu

2023
Sleep disturbances as an adverse effect of propranolol use in children with infantile hemangioma.
    World journal of pediatrics : WJP, 2020, Volume: 16, Issue:5

    Topics: Adrenergic beta-Antagonists; Hemangioma; Humans; Infant; Propranolol; Sleep Wake Disorders

2020
β-blocker therapy for infantile hemangioma.
    Expert review of clinical pharmacology, 2020, Volume: 13, Issue:8

    Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Hemangioma; Humans;

2020
[Medical treatment of children with infantile haemangiomas].
    Ugeskrift for laeger, 2017, Feb-20, Volume: 179, Issue:8

    Topics: Adrenergic beta-Antagonists; Algorithms; Diagnosis, Differential; Hemangioma; Humans; Infant; Propra

2017
Efficacy and rebound rates in propranolol-treated subglottic hemangioma: A literature review.
    The Laryngoscope, 2017, Volume: 127, Issue:11

    Topics: Hemangioma; Humans; Propranolol; Tracheal Diseases; Treatment Outcome; Vasodilator Agents

2017
Cardiac arrest in a toddler treated with propranolol for infantile Hemangioma: a case report.
    Italian journal of pediatrics, 2017, Nov-17, Volume: 43, Issue:1

    Topics: Administration, Oral; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow

2017
Infantile hemangioma: pathogenesis and mechanisms of action of propranolol.
    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2017, Volume: 15, Issue:12

    Topics: Angiogenesis Inducing Agents; Cell Proliferation; Female; Hemangioma; Humans; Infant, Newborn; Matri

2017
Management of Infantile Hemangiomas of the Airway.
    Otolaryngologic clinics of North America, 2018, Volume: 51, Issue:1

    Topics: Airway Obstruction; Hemangioma; Humans; Infant; Laser Therapy; Propranolol; Respiratory Tract Neopla

2018
Infantile Hemangiomas in the Head and Neck Region.
    Otolaryngologic clinics of North America, 2018, Volume: 51, Issue:1

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Head and Neck Neoplasms; Hemangioma; Humans; Infa

2018
Psychosocial Impact of Vascular Anomalies on Children and Their Families.
    Otolaryngologic clinics of North America, 2018, Volume: 51, Issue:1

    Topics: Adaptation, Psychological; Adult; Arteriovenous Malformations; Child; Head and Neck Neoplasms; Heman

2018
Effect of topical timolol on response rate and adverse events in infantile hemangioma: a meta-analysis.
    Archives of dermatological research, 2018, Volume: 310, Issue:4

    Topics: Administration, Topical; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Reactions;

2018
Topical propranolol for infantile haemangiomas: a systematic review.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2018, Volume: 32, Issue:12

    Topics: Administration, Cutaneous; Antineoplastic Agents; Gels; Hemangioma; Humans; Ointments; Propranolol;

2018
Infantile hemangiomas: what have we learned from propranolol?
    Current opinion in pediatrics, 2018, Volume: 30, Issue:4

    Topics: Adrenergic beta-Antagonists; Hemangioma; Humans; Infant; Propranolol; Skin Neoplasms; Treatment Outc

2018
PHACE syndrome: clinical manifestations, diagnostic criteria, and management.
    Anais brasileiros de dermatologia, 2018, Volume: 93, Issue:3

    Topics: Aortic Coarctation; Brain; Eye Abnormalities; Face; Facial Neoplasms; Hemangioma; Humans; Infant; Ma

2018
[Tiempo de respuesta terapéutica al propranolol sistémico en el manejo de hemangiomas subglóticos pediátricos: serie de casos y revisión de la literatura].
    Boletin medico del Hospital Infantil de Mexico, 2018, Volume: 75, Issue:6

    Topics: Administration, Oral; Antineoplastic Agents; Female; Hemangioma; Humans; Infant; Laryngeal Neoplasms

2018
Interventions for infantile haemangiomas of the skin: abridged Cochrane systematic review and GRADE assessments.
    The British journal of dermatology, 2019, Volume: 180, Issue:3

    Topics: Administration, Cutaneous; Administration, Oral; Adrenergic beta-Antagonists; Bradycardia; GRADE App

2019
Clinical and economic impact of surgery for treating infantile hemangiomas in the era of propranolol: overview of single-center experience from La Paz Hospital, Madrid.
    European journal of pediatrics, 2019, Volume: 178, Issue:1

    Topics: Adrenergic beta-Antagonists; Child; Female; Glucocorticoids; Health Care Costs; Hemangioma; Humans;

2019
Role of Magnetic Resonance Image in Children with Lumbosacral and Perineal Hemangiomas: Case Reports and Review of the Literature.
    Actas dermo-sifiliograficas, 2019, Volume: 110, Issue:9

    Topics: Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Lipoma; Lumbosacral Region; Male; P

2019
Efficacy and safety of oral atenolol for the treatment of infantile haemangioma: A systematic review.
    The Australasian journal of dermatology, 2019, Volume: 60, Issue:3

    Topics: Administration, Oral; Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Atenolol;

2019
[What's new in pediatric dermatology?]
    Annales de dermatologie et de venereologie, 2018, Volume: 145 Suppl 7

    Topics: Arteriovenous Malformations; Dermatology; Hemangioma; Humans; Pediatrics; Propranolol; Risk Factors;

2018
Deep coma in a child treated with propranolol for infantile hemangioma.
    BMC pediatrics, 2019, 07-02, Volume: 19, Issue:1

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Coma; Glucose; Hemangioma; Humans; Hypoglycemia;

2019
Management of infantile hemangiomas : current and potential pharmacotherapeutic approaches.
    Paediatric drugs, 2013, Volume: 15, Issue:2

    Topics: Administration, Oral; Administration, Topical; Adrenal Cortex Hormones; Aminoquinolines; Hemangioma;

2013
[Infantile hemangioma: update and treatment].
    Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 2013, Volume: 20, Issue:5

    Topics: Abnormalities, Multiple; Adrenergic beta-Antagonists; Early Medical Intervention; Esthetics; Follow-

2013
[What's new about infantile hemangiomas?].
    Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 2013, Volume: 20, Issue:7

    Topics: Hemangioma; Humans; Infant, Newborn; Propranolol; Skin Neoplasms; Skin Ulcer; Vasodilator Agents

2013
Pathogenesis of infantile haemangioma.
    The British journal of dermatology, 2013, Volume: 169, Issue:1

    Topics: Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Angiopoietins; Embryonic Stem Cells; Endotheli

2013
Haemangioma: clinical course, complications and management.
    The British journal of dermatology, 2013, Volume: 169, Issue:1

    Topics: Administration, Cutaneous; Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Cicatrix; Congenita

2013
Propranolol in use for treatment of complex infant hemangiomas: literature review regarding current guidelines for preassessment and standards of care before initiation of therapy.
    TheScientificWorldJournal, 2013, Volume: 2013

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Child; Evidence-Based Medicine; Guideline Adherence;

2013
Use of propanolol for treatment of large infantile haemangiomas-a report of two cases and review of the literature.
    Annals of the Academy of Medicine, Singapore, 2013, Volume: 42, Issue:5

    Topics: Antineoplastic Agents; Child, Preschool; Facial Neoplasms; Female; Follow-Up Studies; Forearm; Hand;

2013
Infantile hemangiomas of the head and neck.
    Pediatric clinics of North America, 2013, Volume: 60, Issue:4

    Topics: Diagnostic Imaging; Head and Neck Neoplasms; Hemangioma; Humans; Infant; Propranolol; Vasodilator Ag

2013
Multiple cutaneous and hepatic infantile hemangiomas having a successful response to propranolol as monotherapy at neonatal period.
    Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia, 2013, Volume: 148, Issue:5

    Topics: Adrenergic beta-Antagonists; Disease Management; Female; Hemangioma; Humans; Infant, Newborn; Liver

2013
The effectiveness of propranolol in treating infantile haemangiomas: a meta-analysis including 35 studies.
    British journal of clinical pharmacology, 2014, Volume: 78, Issue:1

    Topics: Antineoplastic Agents; Hemangioma; Humans; Infant; Propranolol

2014
Hemangiomas treated with propranolol: do the rewards outweigh the risks?
    The American orthoptic journal, 2013, Volume: 63

    Topics: Adrenergic beta-Antagonists; Child; Hemangioma; Humans; Orbital Neoplasms; Propranolol; Treatment Ou

2013
Infantile hemangioma: treatment with surgery or steroids.
    The American orthoptic journal, 2013, Volume: 63

    Topics: Adrenergic beta-Antagonists; Glucocorticoids; Hemangioma; Humans; Infant; Ophthalmologic Surgical Pr

2013
Diagnosis and management of infantile hemangiomas.
    Pediatric clinics of North America, 2014, Volume: 61, Issue:2

    Topics: Adrenergic beta-Antagonists; Diagnosis, Differential; Hemangioma; Humans; Infant; Propranolol; Skin

2014
[Two news drugs (ivacaftor & bedaquiline), one biomarker (florbetapir) and a re-positioned drug (propranolol) on the market].
    Annales pharmaceutiques francaises, 2014, Volume: 72, Issue:4

    Topics: Adrenergic beta-Antagonists; Adult; Alzheimer Disease; Aminophenols; Aniline Compounds; Antitubercul

2014
Intra-thyroidal hemangioma--a rare congenital anomaly: case presentation and literature review.
    International journal of pediatric otorhinolaryngology, 2014, Volume: 78, Issue:10

    Topics: Adrenergic beta-Antagonists; Bronchoscopy; Dexamethasone; Female; Glucocorticoids; Hemangioma; Human

2014
Consumptive hypothyroidism associated with parotid infantile hemangioma.
    Journal of pediatric endocrinology & metabolism : JPEM, 2015, Volume: 28, Issue:3-4

    Topics: Administration, Oral; Hemangioma; Humans; Hypothyroidism; Infant; Male; Parotid Neoplasms; Propranol

2015
The use of propranolol in the treatment of infantile haemangiomas: an update on potential mechanisms of action.
    The British journal of dermatology, 2015, Volume: 172, Issue:1

    Topics: Adrenergic beta-Antagonists; Angiogenesis Inhibitors; Apoptosis; Catecholamines; Hemangioma; Humans;

2015
[Propranolol therapy for periocular and orbital infantile haemangiomas].
    Klinische Monatsblatter fur Augenheilkunde, 2014, Volume: 231, Issue:10

    Topics: Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant, Newborn; Male; Orbital Neoplasms; P

2014
Incidence and treatment of infantile haemangioma in preterm infants.
    Archives of disease in childhood. Fetal and neonatal edition, 2015, Volume: 100, Issue:1

    Topics: Adrenergic beta-Antagonists; Cryotherapy; Hemangioma; Humans; Incidence; Infant, Premature; Infant,

2015
Treatment of rapidly proliferating haemangiomas in newborns with propranolol and review of the literature.
    The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 2016, Volume: 29, Issue:1

    Topics: Adrenergic beta-Antagonists; Facial Neoplasms; Female; Hemangioma; Humans; Infant, Newborn; Male; Pr

2016
Head and neck vascular lesions.
    Otolaryngologic clinics of North America, 2015, Volume: 48, Issue:1

    Topics: Arteriovenous Malformations; Biopsy, Needle; Child; Child, Preschool; Female; Follow-Up Studies; Hea

2015
Novel treatment for infantile hemangiomas.
    Canadian family physician Medecin de famille canadien, 2014, Volume: 60, Issue:12

    Topics: Adrenergic beta-Antagonists; Hemangioma; Humans; Infant; Infant, Newborn; Propranolol; Timolol

2014
Infantile hemangiomas, retinopathy of prematurity and cancer: a common pathogenetic role of the β-adrenergic system.
    Medicinal research reviews, 2015, Volume: 35, Issue:3

    Topics: Adrenergic beta-Antagonists; Animals; Cell Line, Tumor; Child, Preschool; Hemangioma; Humans; Hypoxi

2015
Topical propranolol cream in treatment of superficial infantile hemangiomas: a literature review and 4 years of clinical experience.
    Acta dermatovenerologica Alpina, Pannonica, et Adriatica, 2014, Volume: 23, Issue:4

    Topics: Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Male; Propranolol; Skin Cream; Trea

2014
Propranolol induced hypoglycemia.
    Pediatric endocrinology reviews : PER, 2015, Volume: 12, Issue:3

    Topics: Adrenergic beta-Antagonists; Hemangioma; Humans; Hypoglycemia; Infant; Practice Guidelines as Topic;

2015
Treatment of infantile haemangiomas: recommendations of a European expert group.
    European journal of pediatrics, 2015, Volume: 174, Issue:7

    Topics: Administration, Topical; Adrenergic beta-Antagonists; Aortic Coarctation; Cryotherapy; Diagnosis, Di

2015
Current trends in medical management of infantile hemangioma.
    Current opinion in otolaryngology & head and neck surgery, 2015, Volume: 23, Issue:4

    Topics: Adrenergic beta-Antagonists; Dermatologic Agents; Early Medical Intervention; Esthetics; Glucocortic

2015
Evidence-Based Medicine in the Treatment of Infantile Hemangiomas.
    Facial plastic surgery clinics of North America, 2015, Volume: 23, Issue:3

    Topics: Evidence-Based Medicine; Hemangioma; Humans; Infant; Laser Therapy; Propranolol; Steroids

2015
Effectiveness and Safety of Oral Propranolol versus Other Treatments for Infantile Hemangiomas: A Meta-Analysis.
    PloS one, 2015, Volume: 10, Issue:9

    Topics: Adrenergic beta-Antagonists; Antineoplastic Agents; Hemangioma; Humans; Infant; Propranolol; Safety

2015
"Cyrano nose" associated with hepatic hemangiomas successfully treated with propranolol.
    Dermatology online journal, 2015, Jul-15, Volume: 21, Issue:7

    Topics: Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Liver Neoplasms;

2015
Treatment of infantile hemangiomas: therapeutic options in regard to side effects and adverse events - a review of the literature.
    Expert opinion on drug safety, 2016, Volume: 15, Issue:2

    Topics: Adrenergic beta-Antagonists; Drug-Related Side Effects and Adverse Reactions; Hemangioma; Humans; In

2016
Pharmacologic Interventions for Infantile Hemangioma: A Meta-analysis.
    Pediatrics, 2016, Volume: 137, Issue:2

    Topics: Administration, Oral; Administration, Topical; Adrenergic beta-Antagonists; Glucocorticoids; Hemangi

2016
Infantile Hemangiomas: Pathogenesis and Review of Propranolol Use.
    Advances in neonatal care : official journal of the National Association of Neonatal Nurses, 2016, Volume: 16, Issue:2

    Topics: Adrenergic beta-Antagonists; Hemangioma; Humans; Infant; Infant, Newborn; Propranolol

2016
Beta Blockade as Treatment for Intracranial Infantile Hemangioma: Case Report and Literature Review.
    Pediatric neurology, 2016, Volume: 59

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Antineoplastic Agents; Brain Neoplasms; Hemangiom

2016
Infantile hemangiomas, complications and treatments.
    Seminars in cutaneous medicine and surgery, 2016, Volume: 35, Issue:3

    Topics: Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Airway Obstruction; Drug Therapy, Combination;

2016
Safety of Oral Propranolol for the Treatment of Infantile Hemangioma: A Systematic Review.
    Pediatrics, 2016, Volume: 138, Issue:4

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Male; Propranolol; Tr

2016
Vascular Lesions.
    Facial plastic surgery clinics of North America, 2016, Volume: 24, Issue:4

    Topics: Adrenergic beta-Antagonists; Combined Modality Therapy; Hemangioma; Humans; Plastic Surgery Procedur

2016
The use of propranolol in the treatment of subglottic hemangiomas: A literature review and meta-analysis.
    International journal of pediatric otorhinolaryngology, 2016, Volume: 90

    Topics: Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Airway Obstruction; Endoscopy; Hemangioma; Hum

2016
Infantile haemangioma.
    Lancet (London, England), 2017, 07-01, Volume: 390, Issue:10089

    Topics: Adrenergic beta-Antagonists; Heart Failure; Hemangioma; Humans; Infant; Propranolol; Respiratory Dis

2017
LUMBAR syndrome: A case manifesting as cutaneous infantile hemangiomas of the lower extremity, perineum and gluteal region, and a review of published work.
    The Journal of dermatology, 2017, Volume: 44, Issue:7

    Topics: Abnormalities, Multiple; Adrenergic beta-Antagonists; Biopsy; Buttocks; Female; Hemangioma; Humans;

2017
Propranolol treatment for infantile hemangiomas.
    Current opinion in otolaryngology & head and neck surgery, 2009, Volume: 17, Issue:6

    Topics: Adrenergic beta-Antagonists; Head and Neck Neoplasms; Hemangioma; Humans; Infant; Propranolol

2009
Initial experience using propranolol as the sole treatment for infantile airway hemangiomas.
    International journal of pediatric otorhinolaryngology, 2010, Volume: 74, Issue:3

    Topics: Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Laryngeal Neoplasms; Magnetic Reson

2010
Propranolol therapy for infantile haemangiomas: review of the literature.
    International journal of pediatric otorhinolaryngology, 2010, Volume: 74, Issue:4

    Topics: Adrenergic beta-Antagonists; Apoptosis; Down-Regulation; Endothelial Cells; Fibroblast Growth Factor

2010
[Infantile hemangioma].
    Presse medicale (Paris, France : 1983), 2010, Volume: 39, Issue:4

    Topics: Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Antineoplastic Agents, Phytogenic; Child; Chil

2010
Current treatments for infantile hemangiomas.
    Journal of drugs in dermatology : JDD, 2010, Volume: 9, Issue:2

    Topics: Adrenal Cortex Hormones; Aminoquinolines; Hemangioma; Humans; Imiquimod; Infant; Infant, Newborn; In

2010
Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action.
    The British journal of dermatology, 2010, Volume: 163, Issue:2

    Topics: Adrenergic beta-Antagonists; Angiogenesis Inhibitors; Apoptosis; Female; Fibroblast Growth Factors;

2010
Infantile haemangiomas: a challenge in paediatric dermatology.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2010, Volume: 24, Issue:6

    Topics: Adrenergic beta-Antagonists; Cell Proliferation; Hemangioma; Humans; Infant, Newborn; Neovasculariza

2010
[Propanolol used in treatment of infantile hemangioma].
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2010, Sep-23, Volume: 130, Issue:18

    Topics: Adrenergic beta-Antagonists; Eye Neoplasms; Female; Hemangioma; Humans; Infant; Neoplasms, Multiple

2010
[Therapeutic options for haemangiomas of infancy].
    Zentralblatt fur Chirurgie, 2012, Volume: 137, Issue:5

    Topics: Adrenergic beta-Antagonists; Cryotherapy; Hemangioma; Humans; Infant; Infant, Newborn; Laser Therapy

2012
A meta-analysis on the effectiveness of propranolol for the treatment of infantile airway haemangiomas.
    International journal of pediatric otorhinolaryngology, 2011, Volume: 75, Issue:4

    Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hemangioma; Humans; Infant;

2011
Infantile haemangioma and β-blockers in otolaryngology.
    European annals of otorhinolaryngology, head and neck diseases, 2011, Volume: 128, Issue:5

    Topics: Acebutolol; Adrenergic beta-Antagonists; Dose-Response Relationship, Drug; Hemangioma; Humans; Infan

2011
An infantile bronchial hemangioma unresponsive to propranolol therapy: case report and literature review.
    Archives of otolaryngology--head & neck surgery, 2011, Volume: 137, Issue:5

    Topics: Adrenergic beta-Antagonists; Beclomethasone; Bronchial Neoplasms; Bronchoscopy; Child, Preschool; Di

2011
Hemangiomas revisited: the useful, the unusual and the new. Part 2: endangering hemangiomas and treatment.
    Pediatric radiology, 2011, Volume: 41, Issue:7

    Topics: Child; Child, Preschool; Contrast Media; Diagnostic Imaging; Hemangioma; Humans; Infant; Infant, New

2011
Propranolol for infantile haemangiomas: a review.
    Archives of disease in childhood, 2011, Volume: 96, Issue:9

    Topics: Adrenergic beta-Antagonists; Child, Preschool; Drug Administration Schedule; Hemangioma; Humans; Inf

2011
Novel strategies for managing infantile hemangiomas: a review.
    Annals of plastic surgery, 2012, Volume: 68, Issue:2

    Topics: Adrenergic beta-Antagonists; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Bleomyc

2012
Hemangioma update: pearls from 30 years of treatment.
    Annals of plastic surgery, 2012, Volume: 69, Issue:1

    Topics: Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Age Factors; Antibiotics, Antineoplastic; Bleo

2012
Hemangiomas - current therapeutic strategies.
    The International journal of developmental biology, 2011, Volume: 55, Issue:4-5

    Topics: Angiogenesis Inhibitors; Bleomycin; Child; Cyclophosphamide; Hemangioma; Humans; Interferons; Neovas

2011
[Treatment of haemangiomas of infancy with propranolol; good results, few side effects].
    Nederlands tijdschrift voor geneeskunde, 2011, Volume: 155, Issue:40

    Topics: Adrenergic beta-Antagonists; Child; Child, Preschool; Disease Progression; Hemangioma; Humans; Infan

2011
Propranolol for proliferating infantile haemangioma is superior to corticosteroid therapy--a retrospective, single centre study.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2012, Volume: 26, Issue:9

    Topics: Adrenal Cortex Hormones; Female; Hemangioma; Humans; Infant; Male; Propranolol; Retrospective Studie

2012
Status of propranolol for treatment of infantile hemangioma and description of a randomized clinical trial.
    The Annals of otology, rhinology, and laryngology, 2011, Volume: 120, Issue:10

    Topics: Age Factors; Child; Child, Preschool; Hemangioma; Humans; Prednisolone; Propranolol; Recurrence; Tre

2011
Propranolol safety profile in children.
    Current drug safety, 2011, Sep-01, Volume: 6, Issue:4

    Topics: Adrenergic beta-Antagonists; Age Factors; Angina Pectoris; Central Nervous System Diseases; Child; D

2011
Infantile hemangioma-mechanism(s) of drug action on a vascular tumor.
    Cold Spring Harbor perspectives in medicine, 2011, Volume: 1, Issue:1

    Topics: Adrenergic beta-Antagonists; Biomarkers; Cell Differentiation; Cell Proliferation; Glucocorticoids;

2011
Multifocal infantile hepatic hemangiomas--imaging strategy and response to treatment after propranolol and steroids including review of the literature.
    European journal of pediatrics, 2012, Volume: 171, Issue:7

    Topics: Adrenergic beta-Antagonists; Drug Therapy, Combination; Female; Glucocorticoids; Heart Failure; Hema

2012
Current management of infantile hemangiomas and their common associated conditions.
    Otolaryngologic clinics of North America, 2012, Volume: 45, Issue:3

    Topics: Adrenergic beta-Antagonists; Antineoplastic Agents, Phytogenic; Antiviral Agents; Bronchoscopy; Cong

2012
The psychosocial impact of an infantile haemangioma on children and their parents.
    Archives of disease in childhood, 2012, Volume: 97, Issue:10

    Topics: Adrenergic beta-Antagonists; Child; Child Behavior; Child, Preschool; Hemangioma; Humans; Infant; In

2012
[Treatment of hemangiomas].
    Duodecim; laaketieteellinen aikakauskirja, 2012, Volume: 128, Issue:17

    Topics: Adrenal Cortex Hormones; Angiography; Embolization, Therapeutic; Hemangioma; Humans; Infant; Infant,

2012
Propranolol versus corticosteroids in the treatment of infantile hemangioma: a systematic review and meta-analysis.
    Plastic and reconstructive surgery, 2013, Volume: 131, Issue:3

    Topics: Adrenal Cortex Hormones; Hemangioma; Humans; Infant; Propranolol

2013
Medical management of vascular anomalies.
    Facial plastic surgery : FPS, 2012, Volume: 28, Issue:6

    Topics: Adrenergic beta-Antagonists; Hemangioendothelioma; Hemangioma; Humans; Kasabach-Merritt Syndrome; Pr

2012
Management of vascular tumors.
    Facial plastic surgery : FPS, 2012, Volume: 28, Issue:6

    Topics: Adrenergic beta-Antagonists; Child; Granuloma, Pyogenic; Hemangioendothelioma; Hemangioma; Humans; K

2012
Initiation and use of propranolol for infantile hemangioma: report of a consensus conference.
    Pediatrics, 2013, Volume: 131, Issue:1

    Topics: Consensus Development Conferences as Topic; Hemangioma; Humans; Infant; Propranolol; Research Report

2013
Novel use of propranolol for management of pain in children with vertebral hemangioma: report of two cases.
    Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 2013, Volume: 29, Issue:5

    Topics: Adolescent; Adrenergic beta-Antagonists; Back Pain; Child; Female; Follow-Up Studies; Hemangioma; Hu

2013
Infantile hemangiomas: an update.
    American journal of clinical dermatology, 2013, Volume: 14, Issue:2

    Topics: Adrenal Cortex Hormones; Biopsy, Needle; Combined Modality Therapy; Dermatologic Surgical Procedures

2013

Trials

38 trials available for propranolol and Angioma

ArticleYear
Early initiation of treatment with oral propranolol for infantile hemangioma improves success rate.
    Pediatric dermatology, 2023, Volume: 40, Issue:2

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Hemangioma, Capillary; Humans; Infant

2023
Early initiation of treatment with oral propranolol for infantile hemangioma improves success rate.
    Pediatric dermatology, 2023, Volume: 40, Issue:2

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Hemangioma, Capillary; Humans; Infant

2023
Early initiation of treatment with oral propranolol for infantile hemangioma improves success rate.
    Pediatric dermatology, 2023, Volume: 40, Issue:2

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Hemangioma, Capillary; Humans; Infant

2023
Early initiation of treatment with oral propranolol for infantile hemangioma improves success rate.
    Pediatric dermatology, 2023, Volume: 40, Issue:2

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Hemangioma, Capillary; Humans; Infant

2023
Itraconazole versus propranolol: therapeutic and pharmacologic effect on serum angiopoietin-2 in patients with infantile hemangioma.
    The Journal of dermatological treatment, 2022, Volume: 33, Issue:1

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Angiopoietin-2; Antifungal Agents; Child; Hemangi

2022
Change of serum cytokine profiles by propranolol treatment in patients with infantile hemangioma.
    Drug discoveries & therapeutics, 2020, Volume: 14, Issue:2

    Topics: Cytokines; Female; Hemangioma; Humans; Infant; Male; Propranolol

2020
Comparison of Efficacy and Safety Between Propranolol and Steroid for Infantile Hemangioma: A Randomized Clinical Trial.
    JAMA dermatology, 2017, 06-01, Volume: 153, Issue:6

    Topics: Female; Glucocorticoids; Hemangioma; Humans; Infant; Infant, Newborn; Magnetic Resonance Imaging; Ma

2017
Safety and tolerance of propranolol in neonates with severe infantile hemangiomas: a prospective study.
    Scientific reports, 2017, 05-04, Volume: 7, Issue:1

    Topics: Administration, Oral; Blood Glucose; Blood Pressure; Female; Heart Rate; Hemangioma; Humans; Infant,

2017
Atenolol Versus Propranolol for Treatment of Infantile Hemangiomas During the Proliferative Phase: A Retrospective Noninferiority Study.
    Pediatric dermatology, 2017, Volume: 34, Issue:4

    Topics: Adrenergic beta-Antagonists; Atenolol; Case-Control Studies; Female; Hemangioma; Humans; Infant; Inf

2017
Thirty-two Japanese cases of infantile hemangiomas treated with oral propranolol.
    The Journal of dermatology, 2018, Volume: 45, Issue:6

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Body Image; Female; Follow-Up Studies; Hemangioma

2018
Role of intralesional bleomycin and intralesional triamcinolone therapy in residual haemangioma following propranolol.
    International journal of oral and maxillofacial surgery, 2018, Volume: 47, Issue:7

    Topics: Antibiotics, Antineoplastic; Bleomycin; Child, Preschool; Female; Glucocorticoids; Hemangioma; Human

2018
Efficacy of Propranolol Between 6 and 12 Months of Age in High-Risk Infantile Hemangioma.
    Pediatrics, 2018, Volume: 142, Issue:3

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Drug Administration Schedule; Female; Hemangioma;

2018
Propranolol is more effective than pulsed dye laser and cryosurgery for infantile hemangiomas.
    European journal of pediatrics, 2013, Volume: 172, Issue:11

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Cryosurgery; Drug Administration Schedule; Female

2013
The use of propranolol for complicated infantile hemangiomas.
    International journal of dermatology, 2013, Volume: 52, Issue:9

    Topics: Administration, Oral; Child, Preschool; Facial Dermatoses; Female; Follow-Up Studies; Hemangioma; Hu

2013
Propranolol for infantile hemangioma (PINCH): an open-label trial to assess the efficacy of propranolol for treating infantile hemangiomas and for determining the decline in heart rate to predict response to propranolol.
    Journal of pediatric hematology/oncology, 2013, Volume: 35, Issue:7

    Topics: Child; Child, Preschool; Female; Heart Rate; Hemangioma; Humans; Infant; Infant, Newborn; Male; Prog

2013
Propranolol-mediated attenuation of MMP-9 excretion in infants with hemangiomas.
    JAMA otolaryngology-- head & neck surgery, 2013, Volume: 139, Issue:10

    Topics: Adrenergic beta-Antagonists; Age Factors; Antineoplastic Agents, Hormonal; Cohort Studies; Female; H

2013
Effect of propranolol vs prednisolone vs propranolol with prednisolone in the management of infantile hemangioma: a randomized controlled study.
    Journal of pediatric surgery, 2013, Volume: 48, Issue:12

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Anti-Inflammatory Agents; Drug Administration Sch

2013
Propranolol vs prednisolone for symptomatic proliferating infantile hemangiomas: a randomized clinical trial.
    JAMA otolaryngology-- head & neck surgery, 2014, Volume: 140, Issue:4

    Topics: Administration, Oral; Antineoplastic Agents, Hormonal; Female; Hemangioma; Humans; Infant; Infant, N

2014
Propranolol vs prednisolone for symptomatic proliferating infantile hemangiomas: a randomized clinical trial.
    JAMA otolaryngology-- head & neck surgery, 2014, Volume: 140, Issue:4

    Topics: Administration, Oral; Antineoplastic Agents, Hormonal; Female; Hemangioma; Humans; Infant; Infant, N

2014
Propranolol vs prednisolone for symptomatic proliferating infantile hemangiomas: a randomized clinical trial.
    JAMA otolaryngology-- head & neck surgery, 2014, Volume: 140, Issue:4

    Topics: Administration, Oral; Antineoplastic Agents, Hormonal; Female; Hemangioma; Humans; Infant; Infant, N

2014
Propranolol vs prednisolone for symptomatic proliferating infantile hemangiomas: a randomized clinical trial.
    JAMA otolaryngology-- head & neck surgery, 2014, Volume: 140, Issue:4

    Topics: Administration, Oral; Antineoplastic Agents, Hormonal; Female; Hemangioma; Humans; Infant; Infant, N

2014
Propranolol therapy for reducing the number of nasal infantile hemangioma invasive procedures.
    JAMA otolaryngology-- head & neck surgery, 2014, Volume: 140, Issue:3

    Topics: Adolescent; Adrenergic beta-Antagonists; Child; Child, Preschool; Female; Hemangioma; Humans; Laser

2014
Formulation, characterization and clinical evaluation of propranolol hydrochloride gel for transdermal treatment of superficial infantile hemangioma.
    Drug development and industrial pharmacy, 2015, Volume: 41, Issue:7

    Topics: Administration, Cutaneous; Adrenergic beta-Antagonists; Animals; Chemistry, Pharmaceutical; Child, P

2015
Combination therapy of infantile hemangioma with pulsed dye laser with topical propranolol: a randomized clinical trial.
    Archives of Iranian medicine, 2014, Volume: 17, Issue:10

    Topics: Administration, Topical; Combined Modality Therapy; Female; Hemangioma; Humans; Infant; Lasers, Dye;

2014
A randomized, controlled trial of oral propranolol in infantile hemangioma.
    The New England journal of medicine, 2015, Feb-19, Volume: 372, Issue:8

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Dose-Response Relationship, Drug; Double-Blind Me

2015
A randomized, controlled trial of oral propranolol in infantile hemangioma.
    The New England journal of medicine, 2015, Feb-19, Volume: 372, Issue:8

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Dose-Response Relationship, Drug; Double-Blind Me

2015
A randomized, controlled trial of oral propranolol in infantile hemangioma.
    The New England journal of medicine, 2015, Feb-19, Volume: 372, Issue:8

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Dose-Response Relationship, Drug; Double-Blind Me

2015
A randomized, controlled trial of oral propranolol in infantile hemangioma.
    The New England journal of medicine, 2015, Feb-19, Volume: 372, Issue:8

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Dose-Response Relationship, Drug; Double-Blind Me

2015
Therapeutic superiority of combined propranolol with short steroids course over propranolol monotherapy in infantile hemangioma.
    European journal of pediatrics, 2015, Volume: 174, Issue:11

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Drug Therapy, Combination; Female; Follow-Up Stud

2015
Role of propranolol in ulcerated haemangioma of head and neck: a prospective comparative study.
    Oral and maxillofacial surgery, 2016, Volume: 20, Issue:1

    Topics: Acetaminophen; Administration, Oral; Drug Therapy, Combination; Female; Head and Neck Neoplasms; Hem

2016
Propranolol versus captopril in the treatment of infantile hemangioma (IH): A randomized controlled trial.
    Journal of the American Academy of Dermatology, 2016, Volume: 74, Issue:3

    Topics: Angiotensin-Converting Enzyme Inhibitors; Captopril; Female; Hemangioma; Humans; Infant; Male; Pepti

2016
Oral Propranolol With Topical Timolol Maleate Therapy for Mixed Infantile Hemangiomas in Oral and Maxillofacial Regions.
    The Journal of craniofacial surgery, 2016, Volume: 27, Issue:1

    Topics: Administration, Oral; Administration, Topical; Antineoplastic Agents; Drug Therapy, Combination; Fac

2016
Oral propranolol combined with topical timolol for compound infantile hemangiomas: a retrospective study.
    Scientific reports, 2016, Jan-28, Volume: 6

    Topics: Administration, Oral; Administration, Topical; Aftercare; Female; Hemangioma; Humans; Infant; Infant

2016
Effects of systemic propranolol treatment on physical growth of patients with infantile hemangiomas.
    The Journal of dermatology, 2016, Volume: 43, Issue:10

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Blood Glucose; Body Height; Body Weight; Child; C

2016
Clinical features and management of multifocal hepatic hemangiomas in children: a retrospective study.
    Scientific reports, 2016, 08-17, Volume: 6

    Topics: Administration, Oral; Child, Preschool; Female; Hemangioma; Humans; Infant; Liver Neoplasms; Male; P

2016
Propranolol for infantile hemangiomas: early experience at a tertiary vascular anomalies center.
    The Laryngoscope, 2010, Volume: 120, Issue:4

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Arkansas; Child, Preschool; Dose-Response Relatio

2010
Propranolol as first-line treatment for rapidly proliferating infantile haemangiomas.
    Journal of plastic, reconstructive & aesthetic surgery : JPRAS, 2011, Volume: 64, Issue:4

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Facial Neoplasms; Female; Hemangioma; Humans; Inf

2011
A randomized controlled trial of propranolol for infantile hemangiomas.
    Pediatrics, 2011, Volume: 128, Issue:2

    Topics: Bronchiolitis; Child, Preschool; Double-Blind Method; Female; Gastroenteritis; Hemangioma; Humans; I

2011
[Preliminary clinical study on the treatment of severe infantile hemangioma with high-dose propranolol in China].
    Zhonghua zheng xing wai ke za zhi = Zhonghua zhengxing waike zazhi = Chinese journal of plastic surgery, 2011, Volume: 27, Issue:3

    Topics: China; Female; Hemangioma; Humans; Infant; Male; Propranolol; Treatment Outcome

2011
[A prospective study of propranolol as first-line treatment for problematic infantile hemangioma in China].
    Zhonghua zheng xing wai ke za zhi = Zhonghua zhengxing waike zazhi = Chinese journal of plastic surgery, 2011, Volume: 27, Issue:3

    Topics: Female; Follow-Up Studies; Hemangioma; Humans; Infant; Male; Propranolol; Prospective Studies; Treat

2011
Status of propranolol for treatment of infantile hemangioma and description of a randomized clinical trial.
    The Annals of otology, rhinology, and laryngology, 2011, Volume: 120, Issue:10

    Topics: Age Factors; Child; Child, Preschool; Hemangioma; Humans; Prednisolone; Propranolol; Recurrence; Tre

2011
[Propranolol in the treatment of problematic infantile hemangiomas].
    Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2011, Volume: 36, Issue:11

    Topics: Female; Hemangioma; Humans; Infant; Male; Propranolol; Prospective Studies; Skin Neoplasms; Subcutan

2011
Evaluation of intra-lesional corticosteroids in the treatment of peri-ocular haemangioma of infancy: still an alternative besides propranolol.
    Pediatric surgery international, 2012, Volume: 28, Issue:4

    Topics: Adrenal Cortex Hormones; Eyelid Neoplasms; Female; Hemangioma; Humans; Infant, Newborn; Injections,

2012
Urinary matrix metalloproteinases-2/9 in healthy infants and haemangioma patients prior to and during propranolol therapy.
    European journal of pediatrics, 2012, Volume: 171, Issue:6

    Topics: Adrenergic beta-Antagonists; Age Factors; Biomarkers; Case-Control Studies; Drug Administration Sche

2012
Propranolol treatment of infantile hemangioma: clinical and radiologic evaluations.
    Journal of pediatric surgery, 2012, Volume: 47, Issue:4

    Topics: Adrenergic beta-Antagonists; Drug Administration Schedule; Female; Follow-Up Studies; Hemangioma; Hu

2012
[The therapeutic effect of propranolol with 1064 nm Nd: YAG laser on proliferating hemangioma in body surface].
    Zhonghua zheng xing wai ke za zhi = Zhonghua zhengxing waike zazhi = Chinese journal of plastic surgery, 2012, Volume: 28, Issue:3

    Topics: Angiogenesis Inhibitors; Combined Modality Therapy; Hemangioma; Humans; Lasers, Solid-State; Propran

2012
Double-blind randomized pilot trial evaluating the efficacy of oral propranolol on infantile haemangiomas in infants < 4 months of age.
    The British journal of dermatology, 2013, Volume: 169, Issue:1

    Topics: Antineoplastic Agents; Cicatrix; Double-Blind Method; Female; Head and Neck Neoplasms; Hemangioma; H

2013

Other Studies

537 other studies available for propranolol and Angioma

ArticleYear
Adverse Drug Reactions Following Propranolol in Infantile Hemangioma.
    Indian pediatrics, 2021, 08-15, Volume: 58, Issue:8

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Child; Child, Preschool; Drug-Related Side Effect

2021
A national audit of oral propranolol for the treatment of infantile haemangiomas.
    The British journal of dermatology, 2022, Volume: 186, Issue:1

    Topics: Adrenergic beta-Antagonists; Hemangioma; Humans; Infant; Propranolol; Skin Neoplasms; Treatment Outc

2022
Vascular endothelial growth factor response with propranolol therapy in patients with infantile hemangioma.
    Pediatric hematology and oncology, 2022, Volume: 39, Issue:3

    Topics: Hemangioma; Humans; Infant; Propranolol; Prospective Studies; Vascular Endothelial Growth Factor A

2022
Infantile Glottic Hemangioma: Bronchoscopic Evaluation and Propranolol Treatment.
    Journal of bronchology & interventional pulmonology, 2021, Oct-01, Volume: 28, Issue:4

    Topics: Hemangioma; Hemangioma, Capillary; Humans; Infant; Propranolol; Treatment Outcome

2021
Exosomal miR-27a-3p derived from tumor-associated macrophage suppresses propranolol sensitivity in infantile hemangioma.
    Cellular immunology, 2021, Volume: 370

    Topics: Animals; Drug Resistance, Neoplasm; Exosomes; Gene Expression Regulation, Neoplastic; Hemangioma; He

2021
Propranolol inhibits the angiogenic capacity of hemangioma endothelia via blocking β-adrenoceptor in mast cell.
    Pediatric research, 2022, Volume: 92, Issue:2

    Topics: Cell Proliferation; Cytokines; Endothelial Cells; Hemangioma; Hemangioma, Capillary; Humans; Mast Ce

2022
Propranolol Suppresses Proliferation and Migration of HUVECs through Regulation of the miR-206/VEGFA Axis.
    BioMed research international, 2021, Volume: 2021

    Topics: Apoptosis; Cell Proliferation; Cell Survival; Cells, Cultured; Hemangioma; Human Umbilical Vein Endo

2021
Propranolol response in patients with segmental versus focal facial hemangiomas: A retrospective case-control study.
    Journal of the American Academy of Dermatology, 2022, Volume: 87, Issue:2

    Topics: Adrenergic beta-Antagonists; Case-Control Studies; Facial Neoplasms; Hemangioma; Humans; Infant; Pro

2022
Significance of the pulsed dye laser in treatment of acral infantile hemangioma.
    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2022, Volume: 20, Issue:1

    Topics: Hemangioma; Humans; Infant; Laser Therapy; Lasers, Dye; Propranolol; Skin Neoplasms

2022
Non-beta blocker enantiomers of propranolol and atenolol inhibit vasculogenesis in infantile hemangioma.
    The Journal of clinical investigation, 2022, 02-01, Volume: 132, Issue:3

    Topics: Animals; Atenolol; Hemangioma; Humans; Mice; Neoplastic Stem Cells; Neovascularization, Pathologic;

2022
Safety assessment of propranolol for infantile hemangioma: a study in an Asian population.
    Expert review of clinical pharmacology, 2022, Volume: 15, Issue:2

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Humans; Infant; Propranolol; Retrospe

2022
Segmental facial infantile haemangiomas in the era of propranolol: evaluation at 6 years of age.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2022, Volume: 36, Issue:4

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Child; Face; Hemangioma; Humans; Infant; Infant,

2022
Cyclosporin-A reduced the cytotoxicity of propranolol in HUVECs via p38 MAPK signaling.
    Medicine, 2022, Jan-28, Volume: 101, Issue:4

    Topics: Antioxidants; Apoptosis; Cell Proliferation; Cyclosporine; Hemangioma; Human Umbilical Vein Endothel

2022
A transcription factor is the target of propranolol treatment in infantile hemangioma.
    The Journal of clinical investigation, 2022, 02-01, Volume: 132, Issue:3

    Topics: Adrenergic beta-Antagonists; Animals; Child; Hemangioma; Humans; Mice; Propranolol; SOXF Transcripti

2022
Sequelae following infantile haemangiomas treated with propranolol.
    European journal of dermatology : EJD, 2021, Dec-01, Volume: 31, Issue:6

    Topics: Administration, Oral; Antineoplastic Agents; Female; Hemangioma; Humans; Infant; Male; Propranolol;

2021
Worsening ulceration of infantile hemangioma after initiation or escalation of propranolol.
    Pediatric dermatology, 2022, Volume: 39, Issue:2

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Hemangioma, Capillary; Humans; Infant

2022
Propranolol therapy for hemangiomas in infants with neonatal abstinence syndrome may produce intolerable side effects.
    Pediatric dermatology, 2022, Volume: 39, Issue:2

    Topics: Adrenergic beta-Antagonists; Hemangioma; Hemangioma, Capillary; Humans; Iatrogenic Disease; Infant;

2022
Sandwich therapy in the management of propranolol resistant infantile hemangioma of the lip.
    Journal of stomatology, oral and maxillofacial surgery, 2022, Volume: 123, Issue:5

    Topics: Bleomycin; Hemangioma; Humans; Lip; Propranolol

2022
Atenolol as treatment for hepatic hemangiomas in a premature infant.
    Pediatrics and neonatology, 2022, Volume: 63, Issue:3

    Topics: Atenolol; Hemangioma; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, Premature, Disease

2022
Safety of propranolol for infantile hemangioma in infants less than five weeks corrected age.
    Pediatric dermatology, 2022, Volume: 39, Issue:3

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Child, Preschool; Female; Hemangioma; Hemangioma,

2022
Management of infantile subglottic hemangioma with T-tube placement and propranolol.
    Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia, 2022, 03-14, Volume: 48, Issue:1

    Topics: Hemangioma; Humans; Infant; Laryngeal Neoplasms; Propranolol; Treatment Outcome

2022
Surgical management of large scalp infantile hemangioma in 30-month-old infant.
    La Pediatria medica e chirurgica : Medical and surgical pediatrics, 2022, Mar-21, Volume: 44, Issue:1

    Topics: Child, Preschool; Female; Hemangioma; Hemorrhage; Humans; Infant; Infant, Newborn; Propranolol; Scal

2022
Topical Formulations of Propranolol for Infantile Hemangiomas: Characteristics of Formulations and Three Cases of Infants Administered Topical Propranolol Cream.
    Chemical & pharmaceutical bulletin, 2022, Volume: 70, Issue:4

    Topics: Child; Hemangioma; Humans; Hypromellose Derivatives; Infant; Propranolol; Skin; Skin Neoplasms

2022
Does Oral Propranolol Improve the Final Outcome of All Involuted Infantile Hemangiomas? A Matched Retrospective Comparative Study.
    Annals of plastic surgery, 2022, 08-01, Volume: 89, Issue:2

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Disease Progression; Hemangioma; Hemangioma, Capi

2022
Inter- and intra-observer variability in the selection of therapy for infantile hemangiomas among pediatric dermatologists in Spain.
    Pediatric dermatology, 2022, Volume: 39, Issue:4

    Topics: Child; Cross-Sectional Studies; Dermatologists; Hemangioma; Hemangioma, Capillary; Humans; Observer

2022
Aesthetic Outcome of Propranolol vs Atenolol Treatment of Children with Infantile Haemangioma.
    Acta dermato-venereologica, 2022, Oct-11, Volume: 102

    Topics: Adrenergic beta-Antagonists; Atenolol; Cross-Sectional Studies; Esthetics; Hemangioma; Hemangioma, C

2022
Efficacy and safety of propranolol cream in infantile hemangioma: A prospective pilot study.
    Journal of pharmacological sciences, 2022, Volume: 149, Issue:2

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Hemangioma, Capillary; Humans; Infant

2022
A Retrospective Analysis of Clinical Characteristics, Treatment Modalities and Outcome of the Patients With Infantile Hepatic Hemangiomas: Single-center Experience From Turkey.
    Journal of pediatric hematology/oncology, 2023, 03-01, Volume: 45, Issue:2

    Topics: Adrenal Cortex Hormones; Hemangioma; Humans; Infant; Infant, Newborn; Liver Neoplasms; Propranolol;

2023
Is Infantile Hemangioma a Neuroendocrine Tumor?
    International journal of molecular sciences, 2022, May-05, Volume: 23, Issue:9

    Topics: Adrenergic beta-Antagonists; Endothelial Cells; Hemangioma; Humans; Infant; Infant, Newborn; Neuroen

2022
Efficacy of intravenous propranolol for life-threatening diffuse neonatal hemangiomatosis.
    Pediatric dermatology, 2022, Volume: 39, Issue:4

    Topics: Hemangioma; Hemangioma, Capillary; Humans; Infant; Infant, Newborn; Liver Neoplasms; Propranolol; Tr

2022
Clinical evaluation of transcatheter arterial embolization combined with propranolol orally treatment of infantile hepatic hemangioma.
    Pediatric surgery international, 2022, Volume: 38, Issue:8

    Topics: Child; Embolization, Therapeutic; Female; Heart Failure; Hemangioma; Hemangioma, Capillary; Humans;

2022
A premonitory mark of segmental infantile hemangioma.
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2022, 07-11, Volume: 194, Issue:26

    Topics: Hemangioma; Humans; Infant; Propranolol; Skin Neoplasms

2022
Evaluation of cases with infantile hemangioma requiring treatment.
    Folia medica, 2022, Feb-28, Volume: 64, Issue:1

    Topics: Administration, Oral; Hemangioma; Hemangioma, Capillary; Humans; Infant; Propranolol; Skin Neoplasms

2022
Multifocal Infantile Hepatic Hemangiomas Complicated by Consumptive Hypothyroidism: The Benefits of Early Diagnosis and Treatment.
    Journal of pediatric hematology/oncology, 2023, 03-01, Volume: 45, Issue:2

    Topics: Child; Early Diagnosis; Hemangioma; Humans; Hypothyroidism; Infant; Liver Neoplasms; Propranolol

2023
A Retrospective Study of Lip Hemangiomas: Curative Effect of Oral Propranolol Combined with Topical Sclerotherapy.
    BioMed research international, 2022, Volume: 2022

    Topics: Hemangioma; Humans; Lip; Propranolol; Retrospective Studies; Sclerotherapy

2022
Immediate possible adverse event rates in infants treated with oral propranolol for infantile haemangiomas at an Australian urban tertiary hospital between 2016 and 2019.
    The Australasian journal of dermatology, 2022, Volume: 63, Issue:4

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Australia; Hemangioma; Hemangioma, Capillary; Hos

2022
Severe hypoglycemia in propranolol treatment for infantile hemangiomas.
    Pediatrics international : official journal of the Japan Pediatric Society, 2022, Volume: 64, Issue:1

    Topics: Adrenergic beta-Antagonists; Child; Female; Hemangioma; Hemangioma, Capillary; Humans; Hypoglycemia;

2022
Mediastinal infantile hemangioma with spinal canal extension and extensive gastrointestinal involvement complicated by respiratory failure.
    Pediatric blood & cancer, 2022, Volume: 69, Issue:11

    Topics: Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Diuretics; Hemangioma; Hemangioma, Capillary;

2022
Β-blockers activate autophagy on infantile hemangioma-derived endothelial cells in vitro.
    Vascular pharmacology, 2022, Volume: 146

    Topics: Adrenergic beta-Antagonists; Amines; Atenolol; Autophagy; Cell Proliferation; Child; Endothelial Cel

2022
Circular RNA hsa_circ_0000915 promotes propranolol resistance of hemangioma stem cells in infantile haemangiomas.
    Human genomics, 2022, 09-27, Volume: 16, Issue:1

    Topics: Biotin; Caspase 3; Cell Movement; Gene Expression Regulation, Neoplastic; Hemangioma; Humans; Interl

2022
[Management of ulcers on a segmental hemangioma: A combination of systemic and topical therapies in two pediatric cases].
    Archivos argentinos de pediatria, 2022, Volume: 120, Issue:5

    Topics: Administration, Oral; Child; Hemangioma; Humans; Infant; Propranolol; Skin Neoplasms; Skin Ulcer; Tr

2022
Apelin Receptor Can Act as a Specific Marker and Promising Therapeutic Target for Infantile Hemangioma.
    The Journal of investigative dermatology, 2023, Volume: 143, Issue:4

    Topics: Animals; Apelin Receptors; Cell Proliferation; Endothelial Cells; Hemangioma; Humans; Mice; Proprano

2023
Bleomycin-triamcinolone sclerotherapy in the management of propranolol resistant infantile hemangioma of the maxillofacial region: A single arm prospective evaluation of clinical outcome and Doppler ultrasound parameters.
    Journal of stomatology, oral and maxillofacial surgery, 2023, Volume: 124, Issue:1S

    Topics: Bleomycin; Hemangioma; Humans; Neoplasm Recurrence, Local; Propranolol; Sclerotherapy; Treatment Out

2023
Intracranial hemangioma-associated cranial nerve VII palsy treated with propranolol in an infant with possible PHACE syndrome.
    Pediatric dermatology, 2022, Volume: 39, Issue:6

    Topics: Brain Neoplasms; Facial Nerve; Facial Paralysis; Female; Hemangioma; Humans; Infant; Propranolol; Sy

2022
Shikonin reverses pyruvate kinase isoform M2-mediated propranolol resistance in infantile hemangioma through reactive oxygen species-induced autophagic dysfunction.
    Cancer science, 2023, Volume: 114, Issue:3

    Topics: Adrenergic beta-Antagonists; Animals; Endothelial Cells; Hemangioma; Propranolol; Pyruvate Kinase; R

2023
Long-term neurocognitive functioning of children treated with propranolol or atenolol for infantile hemangioma.
    European journal of pediatrics, 2023, Volume: 182, Issue:2

    Topics: Adrenergic beta-Antagonists; Atenolol; Child; Cross-Sectional Studies; Female; Hemangioma; Hemangiom

2023
Long-term neurocognitive functioning of children treated with propranolol or atenolol for infantile hemangioma.
    European journal of pediatrics, 2023, Volume: 182, Issue:2

    Topics: Adrenergic beta-Antagonists; Atenolol; Child; Cross-Sectional Studies; Female; Hemangioma; Hemangiom

2023
Long-term neurocognitive functioning of children treated with propranolol or atenolol for infantile hemangioma.
    European journal of pediatrics, 2023, Volume: 182, Issue:2

    Topics: Adrenergic beta-Antagonists; Atenolol; Child; Cross-Sectional Studies; Female; Hemangioma; Hemangiom

2023
Long-term neurocognitive functioning of children treated with propranolol or atenolol for infantile hemangioma.
    European journal of pediatrics, 2023, Volume: 182, Issue:2

    Topics: Adrenergic beta-Antagonists; Atenolol; Child; Cross-Sectional Studies; Female; Hemangioma; Hemangiom

2023
Propranolol and infantile hemangiomas: Outcome from a tricentric study.
    Journal of plastic, reconstructive & aesthetic surgery : JPRAS, 2023, Volume: 76

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Humans; Infant; Propranolol; Skin Neo

2023
Propranolol and infantile hemangiomas: Outcome from a tricentric study.
    Journal of plastic, reconstructive & aesthetic surgery : JPRAS, 2023, Volume: 76

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Humans; Infant; Propranolol; Skin Neo

2023
Propranolol and infantile hemangiomas: Outcome from a tricentric study.
    Journal of plastic, reconstructive & aesthetic surgery : JPRAS, 2023, Volume: 76

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Humans; Infant; Propranolol; Skin Neo

2023
Propranolol and infantile hemangiomas: Outcome from a tricentric study.
    Journal of plastic, reconstructive & aesthetic surgery : JPRAS, 2023, Volume: 76

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Humans; Infant; Propranolol; Skin Neo

2023
Intralesional steroid in the era of propranolol for infantile hemangioma-Do we need it?
    Journal of plastic, reconstructive & aesthetic surgery : JPRAS, 2023, Volume: 77

    Topics: Adrenergic beta-Antagonists; Hemangioma; Humans; Infant; Propranolol; Prospective Studies; Skin Neop

2023
Management of infantile hemangiomas-experience of a tertiary hospital.
    European journal of pediatrics, 2023, Volume: 182, Issue:4

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Child; Female; Hemangioma; Humans; Infant; Male;

2023
[Effects of oral propranolol on urine bFGF, MMP-2, MMP-9 expression in children with proliferative infantile hemangioma].
    Shanghai kou qiang yi xue = Shanghai journal of stomatology, 2022, Volume: 31, Issue:4

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Endothelial Cells; Hemangioma; Humans; Infant; Ma

2022
Distribution of problematic localized facial infantile haemangiomas and their response to propranolol: a retrospective cohort study.
    Clinical and experimental dermatology, 2023, Mar-01, Volume: 48, Issue:3

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Hemangioma, Capillary; Humans; Infant

2023
A study of 95 infantile hemangiomas treated with propranolol: A potentially efficacious combination with laser therapy.
    Drug discoveries & therapeutics, 2023, Mar-11, Volume: 17, Issue:1

    Topics: Administration, Oral; Erythema; Hemangioma; Humans; Infant; Laser Therapy; Propranolol; Skin Neoplas

2023
Indications for surgical resection of complicated infantile hemangiomas in the β-blocker's era: a single-institution experience from a retrospective cohort study.
    International journal of surgery (London, England), 2023, Apr-01, Volume: 109, Issue:4

    Topics: Adrenergic beta-Antagonists; Child; Health Facilities; Hemangioma; Humans; Infant; Propranolol; Retr

2023
Allergic contact dermatitis caused by topical propranolol therapy for infantile haemangioma.
    Contact dermatitis, 2023, Volume: 89, Issue:1

    Topics: Adrenergic beta-Antagonists; Dermatitis, Allergic Contact; Hemangioma; Humans; Infant; Propranolol

2023
Safety of oral propranolol for neonates with problematic infantile hemangioma: a retrospective study in an Asian population.
    Scientific reports, 2023, 04-12, Volume: 13, Issue:1

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Hemangioma, Capillary; Humans; Infant

2023
Our experience with propranolol for infantile hemangioma.
    Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI), 2023, Volume: 29, Issue:4

    Topics: Administration, Oral; Child; Hemangioma; Humans; Infant; Propranolol; Skin Neoplasms; Treatment Outc

2023
Intratracheal infantile haemangioma: an infrequent cause of lower airway obstruction in early infancy.
    Anales de pediatria, 2023, Volume: 98, Issue:6

    Topics: Hemangioma; Humans; Propranolol

2023
Propranolol-induced Involution of Infantile Hemangioma.
    Ophthalmology, 2023, Volume: 130, Issue:12

    Topics: Adrenergic beta-Antagonists; Hemangioma; Hemangioma, Capillary; Humans; Infant; Propranolol; Skin Ne

2023
Nd:YAG 1064-nm laser for residual infantile hemangioma after propranolol treatment.
    Scientific reports, 2023, 05-08, Volume: 13, Issue:1

    Topics: Hemangioma; Hemangioma, Capillary; Humans; Infant; Lasers, Solid-State; Propranolol; Prospective Stu

2023
Propranolol in Congenital Hepatic Arteriovenous Malformation.
    Indian journal of pediatrics, 2023, Volume: 90, Issue:9

    Topics: Arteriovenous Malformations; Hemangioma; Humans; Liver Diseases; Propranolol

2023
Can Propranolol Affect Platelet Indices in Infantile Hemangioma?
    Journal of pediatric hematology/oncology, 2023, 10-01, Volume: 45, Issue:7

    Topics: Blood Platelets; Hemangioma; Humans; Mean Platelet Volume; Propranolol; Vascular Endothelial Growth

2023
Clinical features of cutaneous infantile hemangioma combined with asymptomatic infantile hepatic hemangioma and efficacy of propranolol treatment.
    Journal of cosmetic dermatology, 2023, Volume: 22, Issue:12

    Topics: Child, Preschool; Hemangioma; Humans; Infant; Liver Neoplasms; Propranolol; Retrospective Studies; S

2023
The impact of propranolol on the growth and development of children with proliferative infantile hemangioma during treatment.
    Medicine, 2023, Jun-09, Volume: 102, Issue:23

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Child; Growth and Development; Hemangioma; Hemang

2023
Predictors of poor response to oral propranolol in infantile hemangiomas.
    Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 2023, Volume: 30, Issue:7

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Child; Female; Hemangioma; Humans; Infant; Male;

2023
The effects of propranolol on the biology and Notch signaling pathway of human umbilical vein endothelial cells.
    Medicine, 2023, Aug-11, Volume: 102, Issue:32

    Topics: Biology; Cell Proliferation; Hemangioma; Human Umbilical Vein Endothelial Cells; Humans; Propranolol

2023
Practice Variations in Managing Infantile Hemangiomas.
    Journal of pediatric hematology/oncology, 2023, 11-01, Volume: 45, Issue:8

    Topics: Adrenergic beta-Antagonists; Child; Hemangioma; Humans; Infant; Propranolol; Skin Neoplasms; Treatme

2023
Intralesional betamethasone versus oral propranolol for localized infantile hemangiomas of the lip.
    Journal of plastic, reconstructive & aesthetic surgery : JPRAS, 2023, Volume: 87

    Topics: Adrenergic beta-Antagonists; Betamethasone; Child; Hemangioma; Humans; Infant; Lip; Propranolol; Pro

2023
Effects of propranolol on glucose metabolism in hemangioma-derived endothelial cells.
    Biochemical pharmacology, 2023, Volume: 218

    Topics: Cell Proliferation; Child; Endothelial Cells; Glucose; Hemangioma; Humans; Phosphates; Propranolol;

2023
Excessively High Chronic Propranolol Overdose in Infantile Hemangioma: A Case Report.
    The American journal of case reports, 2023, Nov-27, Volume: 24

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Child; Drug Overdose; Female; Hemangioma; Hemangi

2023
Symplastic hemangioma developing over an infantile hemangioma during propranolol treatment.
    Pediatric dermatology, 2019, Volume: 36, Issue:6

    Topics: Female; Hemangioma; Humans; Infant; Neoplasms, Second Primary; Propranolol; Skin Neoplasms; Vasodila

2019
Trends in healthcare utilization for infantile haemangioma in the U.S.A.
    The British journal of dermatology, 2020, Volume: 182, Issue:2

    Topics: Hemangioma; Humans; Infant; Patient Acceptance of Health Care; Propranolol

2020
Successful Medical Management of Life-threatening Hepatic Hemangioma in Neonates.
    Pediatrics, 2019, Volume: 144, Issue:4

    Topics: Drug Therapy, Combination; Embolization, Therapeutic; Female; Glucocorticoids; Hemangioma; Hepatic A

2019
A 7-year follow-up study on untreated deep or mixed facial infantile hemangioma in East-Asian patients: When propranolol was not yet an option.
    The Journal of dermatology, 2019, Volume: 46, Issue:11

    Topics: Asian People; Cardiovascular Agents; Child; Child, Preschool; Conservative Treatment; Disease Progre

2019
Comment on "Topical timolol as adjunct therapy to shorten oral propranolol therapy for infantile hemangiomas".
    Pediatric dermatology, 2019, Volume: 36, Issue:5

    Topics: Hemangioma; Hemangioma, Capillary; Humans; Propranolol; Timolol

2019
Evaluating the Clinical Outcomes of Parotid Hemangiomas in the Pediatric Patient Population.
    Ear, nose, & throat journal, 2021, Volume: 100, Issue:5

    Topics: Adrenal Cortex Hormones; Drug Administration Schedule; Female; Hemangioma; Hemangioma, Capillary; Hu

2021
Does treatment with propranolol affect quality of life in infantile hemangioma patients and their parents?
    Pediatric dermatology, 2019, Volume: 36, Issue:6

    Topics: Child, Preschool; Cohort Studies; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Male; Paren

2019
Propranolol Accelerats Hemangioma Stem Cell Transformation Into Adipocyte.
    Annals of plastic surgery, 2019, Volume: 83, Issue:5

    Topics: Adipocytes; Cell Differentiation; Cells, Cultured; Child; Hemangioma; Humans; Neoplastic Stem Cells;

2019
Lip Infantile Hemangiomas Involving the Vermillion Border Have Worse Outcomes and Prognosis to Oral Propranolol Than Lesions Confined to One Side of the Vermillion.
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2020, Volume: 78, Issue:3

    Topics: Hemangioma; Humans; Infant; Lip; Prognosis; Propranolol; Retrospective Studies; Treatment Outcome

2020
Facial segmental haemangioma with PHACE Syndrome successfully treated with oral propranolol.
    The Medical journal of Malaysia, 2019, Volume: 74, Issue:5

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Aortic Coarctation; Disease Progression; Eye Abno

2019
[Modern Approach and Successful Experience of Conservative Treatment of Infantile Hemangiomas with Non-Selective Beta-Blocker Propranolol].
    Problemy sotsial'noi gigieny, zdravookhraneniia i istorii meditsiny, 2019, Volume: 27, Issue:Special Is

    Topics: Adrenergic beta-Antagonists; Algorithms; Conservative Treatment; Hemangioma; Humans; Infant; Propran

2019
Commentary: Propranolol for infantile hemangiomas - The intralesional route.
    Indian journal of ophthalmology, 2019, Volume: 67, Issue:12

    Topics: Eyelid Neoplasms; Hemangioma; Hemangioma, Capillary; Humans; Propranolol

2019
Evaluating the Safety of Oral Propranolol Therapy in Patients With PHACE Syndrome.
    JAMA dermatology, 2020, 02-01, Volume: 156, Issue:2

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Aortic Coarctation; Cohort Studies; Eye Abnormali

2020
Propranolol inhibits proliferation and induces apoptosis of hemangioma-derived endothelial cells via Akt pathway by down-regulating Ang-2 expression.
    Chemico-biological interactions, 2020, Jan-25, Volume: 316

    Topics: Angiopoietin-2; Apoptosis; Cell Line; Cell Proliferation; Down-Regulation; Endothelial Cells; Hemang

2020
Oral propranolol for the treatment of infantile haemangiomas in Singapore.
    Singapore medical journal, 2021, Volume: 62, Issue:3

    Topics: Adrenergic beta-Antagonists; Child; Female; Hemangioma; Humans; Infant; Infant, Newborn; Infant, Pre

2021
Rebound of Involuted Infantile Hemangioma After Administration of Salbutamol.
    Pediatrics, 2020, Volume: 145, Issue:3

    Topics: Adrenergic beta-2 Receptor Agonists; Albuterol; Bronchitis; Child, Preschool; Female; Hemangioma; Hu

2020
Special management considerations for propranolol use in breastfed infants of mothers taking antihypertensives.
    Pediatric dermatology, 2020, Volume: 37, Issue:3

    Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Breast Feeding; Female; Hemangioma; Humans; In

2020
Enhanced efficacy of propranolol therapy for infantile hemangiomas based on a mesoporous silica nanoplatform through mediating autophagy dysfunction.
    Acta biomaterialia, 2020, 04-15, Volume: 107

    Topics: Animals; Antineoplastic Agents; Autophagy; Drug Carriers; Endoplasmic Reticulum Stress; Hemangioma;

2020
Propranolol and topical timolol for infantile haemangiomas of the skin.
    Journal of paediatrics and child health, 2020, Volume: 56, Issue:3

    Topics: Hemangioma; Hemangioma, Capillary; Humans; Propranolol; Skin; Timolol

2020
Teledermatology in paediatrics: Health-care impact on the early treatment of infantile haemangiomas.
    Journal of telemedicine and telecare, 2021, Volume: 27, Issue:7

    Topics: Child; Female; Hemangioma; Humans; Infant; Male; Pediatrics; Propranolol; Referral and Consultation;

2021
Oral propranolol administration is effective for infantile hemangioma in late infancy: A retrospective cohort study.
    Dermatologic therapy, 2020, Volume: 33, Issue:3

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Child; Hemangioma; Humans; Infant; Propranolol; R

2020
Influence of Cytochrome P450 2D6 Polymorphisms on the Efficacy of Oral Propranolol in Treating Infantile Hemangioma.
    BioMed research international, 2020, Volume: 2020

    Topics: Administration, Oral; Cytochrome P-450 CYP2D6; Female; Genotype; Hemangioma; Humans; Infant; Male; P

2020
Modalities of use of oral propranolol in proliferative infantile haemangiomas: an international survey among practitioners.
    The British journal of dermatology, 2020, Volume: 183, Issue:3

    Topics: Adrenergic beta-Antagonists; Hemangioma; Humans; Infant; Propranolol; Skin Neoplasms

2020
Giant placental chorioangioma followed by circulatory failure of the newborn and infantile hemangioma: Case report.
    Journal of neonatal-perinatal medicine, 2020, Volume: 13, Issue:1

    Topics: Adrenergic beta-Antagonists; Anemia, Hemolytic; Disseminated Intravascular Coagulation; Edema; Eryth

2020
Consumptive Hypothyroidism Due to Diffuse Hepatic Hemangiomas Treated With Propranolol Therapy.
    Indian pediatrics, 2020, 04-15, Volume: 57, Issue:4

    Topics: Hemangioma; Humans; Hypothyroidism; Infant; Liver Neoplasms; Propranolol; Thyroid Hormones; Treatmen

2020
Serum cytokine profiles in infants with infantile hemangiomas on oral propranolol treatment: VEGF and bFGF, potential biomarkers predicting clinical outcomes.
    Pediatric research, 2020, Volume: 88, Issue:5

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Antineoplastic Agents; Biomarkers, Tumor; Chemoki

2020
Propranolol-resistant infantile hemangioma successfully treated with sirolimus.
    Pediatric dermatology, 2020, Volume: 37, Issue:4

    Topics: Adrenergic beta-Antagonists; Child; Hemangioma; Hemangioma, Capillary; Humans; Infant; Prednisolone;

2020
A retrospective study of 2 or 3 mg/kg/day propranolol for infantile hemangioma.
    Pediatrics international : official journal of the Japan Pediatric Society, 2020, Volume: 62, Issue:6

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Male; Propran

2020
A Case of Consumptive Hypothyroidism in a 1-Month-Old Boy with Diffuse Infantile Hepatic Hemangiomas.
    Journal of Korean medical science, 2020, Jun-08, Volume: 35, Issue:22

    Topics: Adrenergic beta-Antagonists; Anti-Inflammatory Agents; Cholestasis; Drug Therapy, Combination; Heart

2020
Successful treatment of infantile hemangioma with high risk of severe sequelae by microneedle radiofrequency.
    Dermatologic therapy, 2020, Volume: 33, Issue:6

    Topics: Disease Progression; Hemangioma; Humans; Infant; Propranolol

2020
At-home dose escalation of propranolol for infantile hemangiomas during the COVID-19 pandemic.
    Dermatologic therapy, 2020, Volume: 33, Issue:6

    Topics: COVID-19; Hemangioma; Humans; Infant; Propranolol; SARS-CoV-2

2020
[Clinical effect of propranolol in the treatment of respiratory hemangioma in infants and young children].
    Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 2020, Volume: 22, Issue:7

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Child; Child, Preschool; Hemangioma; Humans; Infa

2020
Periocular infantile hemangioma masquerading as dacryocele.
    Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus, 2020, Volume: 24, Issue:5

    Topics: Hemangioma; Hemangioma, Capillary; Humans; Infant; Lacrimal Duct Obstruction; Male; Nasolacrimal Duc

2020
Strawberry mark: our daughter's journey with an infantile hemangioma.
    Pediatric research, 2020, Volume: 88, Issue:5

    Topics: Adaptation, Psychological; Adrenergic beta-Antagonists; Antineoplastic Agents; Female; Health Knowle

2020
Cutaneous Infantile Haemangiomas with Intracranial and Intraspinal Involvement: A European Multicentre Experience and Review.
    Acta dermato-venereologica, 2020, Sep-08, Volume: 100, Issue:16

    Topics: Adrenergic beta-Antagonists; Hemangioma; Hemangioma, Capillary; Humans; Infant; Propranolol; Retrosp

2020
NOTCH pathway activation in infantile hemangiomas.
    Journal of vascular surgery. Venous and lymphatic disorders, 2021, Volume: 9, Issue:2

    Topics: Adrenergic beta-Antagonists; Angiogenesis Inhibitors; Cell Proliferation; Child, Preschool; DNA-Bind

2021
Combination therapy of oral propranolol and combined Nd:YAG/pulsed dye laser therapy in infantile hemangiomas: a retrospective analysis of 48 treated hemangiomas in 30 children.
    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2020, Volume: 18, Issue:9

    Topics: Administration, Oral; Hemangioma; Humans; Infant; Laser Therapy; Lasers, Dye; Propranolol; Retrospec

2020
Retrospective case series of increased oral propranolol dosage for infantile hemangiomas.
    Pediatric dermatology, 2020, Volume: 37, Issue:6

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Child; Hemangioma; Humans; Infant; Propranolol; R

2020
A new clinical and dermoscopic monitoring of infantile hemangiomas treated with oral propranolol.
    Dermatologic therapy, 2020, Volume: 33, Issue:6

    Topics: Hemangioma; Humans; Infant; Infant, Newborn; Neoplasm Recurrence, Local; Propranolol; Skin Neoplasms

2020
Historical and Contemporary Management of Infantile Hepatic Hemangioma: A 30-year Single-center Experience.
    Annals of surgery, 2022, 01-01, Volume: 275, Issue:1

    Topics: Adolescent; Adrenergic beta-Antagonists; Child; Child, Preschool; Embolization, Therapeutic; Female;

2022
Airway Hemangiomas in PHACE Syndrome: A Multicenter Experience.
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2021, Volume: 165, Issue:1

    Topics: Aortic Coarctation; Eye Abnormalities; Female; Hemangioma; Humans; Infant; Infant, Newborn; Male; Ne

2021
Multiple pulmonary infantile hemangiomas responsive to oral propranolol.
    Pediatric dermatology, 2021, Volume: 38, Issue:1

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Hemangioma, Capillary; Humans; Infant

2021
Study on the Mechanism of Targeted Poly(lactic-coglycolic acid) Nano-Delivery Carriers in the Treatment of Hemangiomas.
    Journal of nanoscience and nanotechnology, 2021, 02-01, Volume: 21, Issue:2

    Topics: Apoptosis; Cell Proliferation; Child; Child, Preschool; Drug Carriers; Hemangioma; Humans; Infant; N

2021
Recurrence rate of infantile hemangioma after oral propranolol therapy.
    European journal of pediatrics, 2021, Volume: 180, Issue:2

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Humans; Infant; Neoplasm Recurrence,

2021
Transcatheter Arterial Sclerosing Embolization for the Treatment of Giant Propranolol-Resistant Infantile Hemangiomas in the Parotid Region.
    Journal of vascular and interventional radiology : JVIR, 2021, Volume: 32, Issue:2

    Topics: Antineoplastic Agents; Bleomycin; Drug Resistance, Neoplasm; Embolization, Therapeutic; Ethiodized O

2021
Evaluation of Clinical Properties and Treatment Responses of Infantile Hemangioma.
    Journal of drugs in dermatology : JDD, 2020, Dec-01, Volume: 19, Issue:12

    Topics: Age Factors; Esthetics; Facial Neoplasms; Female; Glucocorticoids; Hemangioma; Hemorrhage; Humans; I

2020
Propranolol's effects on the sleep of infants with hemangiomas: A prospective pilot study.
    Pediatric dermatology, 2021, Volume: 38, Issue:2

    Topics: Adrenergic beta-Antagonists; Child; Child, Preschool; Hemangioma; Humans; Infant; Infant, Newborn; P

2021
Serum levels of VEGF and bFGF in infantile hemangiomas treated with propranolol.
    The Turkish journal of pediatrics, 2020, Volume: 62, Issue:6

    Topics: Fibroblast Growth Factor 2; Hemangioma; Humans; Infant; Propranolol; Prospective Studies; Vascular E

2020
A survey on the application of oral propranolol and atenolol for the management of infantile hemangiomas in mainland China: Survey on propranolol atenolol hemangiomas.
    Medicine, 2021, Jan-08, Volume: 100, Issue:1

    Topics: Administration, Oral; Antihypertensive Agents; Atenolol; China; Female; Hemangioma; Humans; Infant;

2021
[Propranolol treatment in Kasabach-Merritt Syndrome secondary to congenital hepatic hemangioma. Clinical case].
    Archivos argentinos de pediatria, 2021, Volume: 119, Issue:1

    Topics: Hemangioma; Humans; Infant, Newborn; Kasabach-Merritt Syndrome; Liver Neoplasms; Propranolol

2021
Oral propranolol therapy in parotid hemangiomas: A retrospective comparison with other infantile hemangiomas.
    Head & neck, 2021, Volume: 43, Issue:5

    Topics: Administration, Oral; Hemangioma; Humans; Infant; Neoplasm Recurrence, Local; Propranolol; Retrospec

2021
Propranolol Participates in the Treatment of Infantile Hemangioma by Inhibiting HUVECs Proliferation, Migration, Invasion, and Tube Formation.
    BioMed research international, 2021, Volume: 2021

    Topics: Cell Adhesion; Cell Movement; Cell Proliferation; Cells, Cultured; Hemangioma; Human Umbilical Vein

2021
Ultrasound and MRI findings as predictors of propranolol therapy response in patients with infantile hemangioma.
    PloS one, 2021, Volume: 16, Issue:3

    Topics: Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Magnetic Resonan

2021
Propranolol for infantile hemangioma: Evaluating efficacy and predictors of response and rebound growth.
    Dermatologic therapy, 2021, Volume: 34, Issue:3

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Cohort Studies; Hemangioma; Humans; Infant; Infan

2021
Evaluation of GLUT1, IGF-2, VEGF, FGF 1, and angiopoietin 2 in infantile hemangioma.
    Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 2021, Volume: 28, Issue:4

    Topics: Angiopoietin-2; Biomarkers; Child; Child, Preschool; Cross-Sectional Studies; Enzyme-Linked Immunoso

2021
Propranolol versus nadolol for treatment of pediatric subglottic hemangioma.
    International journal of pediatric otorhinolaryngology, 2021, Volume: 144

    Topics: Adrenergic beta-Antagonists; Child; Female; Hemangioma; Humans; Infant; Male; Nadolol; Propranolol;

2021
[Applied value of color Doppler flow imaging in diagnosis of congenital subglottic haemangioma in infant].
    Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery, 2021, Volume: 35, Issue:4

    Topics: Child; Glottis; Hemangioma; Humans; Infant; Laryngeal Neoplasms; Propranolol; Retrospective Studies;

2021
[Cranio-facial-cervical and subglottic hemangioma with respiratory symptoms. A therapeutic emergency].
    Anales del sistema sanitario de Navarra, 2021, Apr-28, Volume: 44, Issue:1

    Topics: Adrenergic beta-Antagonists; Child; Hemangioma; Humans; Infant; Laryngeal Neoplasms; Propranolol; Tr

2021
Propranolol for the treatment of ulcerated infantile hemangiomas: A prospective study.
    Journal of the American Academy of Dermatology, 2022, Volume: 86, Issue:5

    Topics: Adrenergic beta-Antagonists; Hemangioma; Hemangioma, Capillary; Humans; Infant; Propranolol; Prospec

2022
Using Topical Citric Acid to Treat an Infected Ulcerated Hemangioma in an Infant: A Case Study.
    Wounds : a compendium of clinical research and practice, 2021, Volume: 33, Issue:2

    Topics: Child; Citric Acid; Hemangioma; Humans; Infant; Propranolol; Skin Neoplasms; Treatment Outcome; Ulce

2021
Subglottic ectopic thymus mimicking airway haemangioma.
    BMJ case reports, 2021, May-19, Volume: 14, Issue:5

    Topics: Hemangioma; Humans; Infant; Infant, Newborn; Laryngeal Neoplasms; Lymphatic Diseases; Propranolol; R

2021
Propranolol for infantile hemangiomas with hyperinsulinemic hypoglycemia.
    Pediatrics international : official journal of the Japan Pediatric Society, 2021, Volume: 63, Issue:6

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Hemangioma, Capillary; Humans; Hypogl

2021
Is prolonged monitoring necessary? An updated approach to infantile hemangioma treatment with oral propranolol.
    Pediatric dermatology, 2021, Volume: 38, Issue:4

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Humans; Infant; Propranolol; Retrospe

2021
Sleep behavior of infants with infantile hemangioma treated with propranolol-a cohort study.
    European journal of pediatrics, 2021, Volume: 180, Issue:8

    Topics: Adrenergic beta-Antagonists; Cohort Studies; Hemangioma; Humans; Infant; Propranolol; Skin Neoplasms

2021
Infantile Sacral Region Hemangioma and Combination Treatment with Propranolol and Topical Timolol: Case Review and Reference Review.
    Medical archives (Sarajevo, Bosnia and Herzegovina), 2021, Volume: 75, Issue:2

    Topics: Administration, Topical; Adrenergic beta-Antagonists; Bosnia and Herzegovina; Female; Hemangioma; Hu

2021
Transient hypertriglyceridaemia associated with propranolol for treatment of infantile hemangioma.
    The Australasian journal of dermatology, 2021, Volume: 62, Issue:4

    Topics: Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Hypertriglyceridemia; Infant; Propranolol;

2021
Persistent dysesthesias in involuted infantile hemangiomas: An uncommon complication in a common condition.
    Pediatric dermatology, 2021, Volume: 38, Issue:5

    Topics: Administration, Cutaneous; Adolescent; Adult; Child; Child, Preschool; Hemangioma; Hemangioma, Capil

2021
Propranolol for infantile hemangiomas in developing countries.
    Dermatology online journal, 2017, Mar-15, Volume: 23, Issue:3

    Topics: Afghanistan; Developing Countries; Facial Neoplasms; Female; Hemangioma; Humans; Infant; Male; Propr

2017
Analysis of factors affecting the therapeutic effect of propranolol for infantile haemangioma of the head and neck.
    Scientific reports, 2017, 03-23, Volume: 7, Issue:1

    Topics: Administration, Oral; Antineoplastic Agents; Female; Head and Neck Neoplasms; Hemangioma; Humans; In

2017
Use of liothyronine without levothyroxine in the treatment of mild consumptive hypothyroidism caused by hepatic hemangiomas.
    Endocrine journal, 2017, Jun-29, Volume: 64, Issue:6

    Topics: Hemangioma; Hormone Replacement Therapy; Humans; Hypothyroidism; Infant; Liver; Liver Neoplasms; Mal

2017
Safety and effectiveness of oral propranolol for infantile hemangiomas started before 5 weeks and after 5 months of age: an Italian multicenter experience.
    Italian journal of pediatrics, 2017, Apr-19, Volume: 43, Issue:1

    Topics: Administration, Oral; Age Factors; Cohort Studies; Dose-Response Relationship, Drug; Drug Administra

2017
Successful Treatment of Infantile Hemangiomas With Propranolol in Low-Birth-Weight Infants.
    The Journal of craniofacial surgery, 2017, Volume: 28, Issue:3

    Topics: Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant, Low Birth Weight; Infant, Newborn;

2017
Scalp Infantile Hemangioma Complicated by Life-Threatening Bleeding.
    Pediatric dermatology, 2017, Volume: 34, Issue:4

    Topics: Adrenergic beta-Antagonists; Female; Glucocorticoids; Hemangioma; Hemorrhage; Humans; Infant; Predni

2017
Expanding uses of propranolol in dermatology.
    Cutis, 2017, Volume: 99, Issue:4

    Topics: Administration, Cutaneous; Administration, Oral; Dermatology; Hemangioma; Humans; Practice Patterns,

2017
Modern Management of Nasal Hemangiomas.
    JAMA facial plastic surgery, 2017, Jul-01, Volume: 19, Issue:4

    Topics: Adolescent; Adrenal Cortex Hormones; Adult; Algorithms; Child; Child, Preschool; Combined Modality T

2017
Propranolol therapy for infantile hemangioma: our experience.
    Drug design, development and therapy, 2017, Volume: 11

    Topics: Administration, Oral; Hemangioma; Humans; Propranolol; Retrospective Studies

2017
Use of propranolol in a remote region of rural Guatemala to treat a large facial infantile haemangioma.
    BMJ case reports, 2017, May-16, Volume: 2017

    Topics: Aortic Coarctation; Diagnosis, Differential; Eye Abnormalities; Face; Female; Guatemala; Hemangioma;

2017
Tissue and serum mRNA profile of MMPs-2/9 as a potential novel biomarker for the most individual approach in infantile hemangiomas and cancer disease.
    Immunobiology, 2017, Volume: 222, Issue:11

    Topics: Biomarkers, Tumor; Child, Preschool; Female; Hemangioma; Humans; Immunohistochemistry; Infant; Infan

2017
[Benign neonatal hemangiomatosis: An observation in a child in Togo].
    Annales de dermatologie et de venereologie, 2017, Volume: 144, Issue:10

    Topics: Female; Hemangioma; Humans; Infant; Propranolol; Skin Neoplasms; Togo; Vasodilator Agents

2017
Use of proporanolol compounding from tablet in infantile hemangiomas.
    Minerva pediatrica, 2017, Volume: 69, Issue:4

    Topics: Adrenergic beta-Antagonists; Chemistry, Pharmaceutical; Drug Compounding; Hemangioma; Humans; Infant

2017
Efficacy and Safety of 2% Topical Propranolol Cream for the Treatment of Proliferating Infantile Strawberry Hemangiomas: Correspondence.
    Indian journal of pediatrics, 2017, Volume: 84, Issue:11

    Topics: Adrenergic beta-Antagonists; Hemangioma; Hemangioma, Cavernous; Humans; Infant; Propranolol; Skin Ne

2017
Diffuse Hepatic Hemangiomas Successfully Treated Using Sirolimus and High-Dose Propranolol.
    Pediatric dermatology, 2017, Volume: 34, Issue:5

    Topics: Adrenergic beta-Antagonists; Hemangioma; Humans; Immunosuppressive Agents; Infant, Newborn; Liver; L

2017
Study of Cognitive Function in Children Treated with Propranolol for Infantile Hemangioma.
    Pediatric dermatology, 2017, Volume: 34, Issue:5

    Topics: Adrenergic beta-Antagonists; Child; Child, Preschool; Cognition; Female; Hemangioma; Humans; Infant;

2017
Unexpected Effect of Propranolol and Prednisolone on Infantile Facial Rhabdomyosarcoma.
    Journal of pediatric hematology/oncology, 2017, Volume: 39, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Diagnosis, Differential; Facial Neoplasms; F

2017
Use of the Hemangioma Severity Scale to facilitate treatment decisions for infantile hemangiomas.
    Journal of the American Academy of Dermatology, 2017, Volume: 77, Issue:5

    Topics: Clinical Decision-Making; Cohort Studies; Databases, Factual; Female; Follow-Up Studies; Hemangioma;

2017
Can the extent of heart rate reduction predict the clinical response of infantile haemangiomas to propranolol?
    The British journal of dermatology, 2018, Volume: 178, Issue:3

    Topics: Anti-Arrhythmia Agents; Bradycardia; Drug Administration Schedule; Female; Heart Rate; Hemangioma; H

2018
[Infantile haemangioma: clinical and demographic characteristics, experiences in the treatment].
    Orvosi hetilap, 2017, Volume: 158, Issue:39

    Topics: Adrenergic beta-Antagonists; Child, Preschool; Follow-Up Studies; Hemangioma; Humans; Hungary; Infan

2017
PLGA nanoparticles with CD133 aptamers for targeted delivery and sustained release of propranolol to hemangioma.
    Nanomedicine (London, England), 2017, Volume: 12, Issue:21

    Topics: AC133 Antigen; Animals; Aptamers, Nucleotide; Cell Proliferation; Cell Survival; Delayed-Action Prep

2017
Propranolol inhibits the proliferation, migration and tube formation of hemangioma cells through HIF-1α dependent mechanisms.
    Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2017, Oct-02, Volume: 50, Issue:12

    Topics: Apoptosis; Cell Movement; Cell Proliferation; Hemangioma; Humans; Hypoxia-Inducible Factor 1, alpha

2017
Infantile hemangioma: factors causing recurrence after propranolol treatment.
    Pediatric research, 2018, Volume: 83, Issue:1-1

    Topics: Biomarkers; Female; Hemangioma; Hemodynamics; Humans; Infant; Infant, Newborn; Male; MicroRNAs; Prop

2018
[Giant infantile hemangioma of the eyelid].
    Journal francais d'ophtalmologie, 2017, Volume: 40, Issue:10

    Topics: Abdominal Neoplasms; Eyelid Neoplasms; Eyelids; Female; Hemangioma; Humans; Infant; Propranolol; Tum

2017
Significant inhibition of infantile hemangioma growth by sustained delivery of urea from liposomes-in-microspheres.
    Oncology reports, 2018, Volume: 39, Issue:1

    Topics: Administration, Oral; Animals; Cell Proliferation; Cells, Cultured; Delayed-Action Preparations; Dis

2018
Reversible profound sensorineural hearing loss due to propranolol sensitive hemangioma in an infant with PHACE syndrome.
    International journal of pediatric otorhinolaryngology, 2017, Volume: 103

    Topics: Adrenergic beta-Antagonists; Aortic Coarctation; Eye Abnormalities; Hearing Loss, Sensorineural; Hem

2017
Eczematous dermatitis in an infantile hemangioma with minimal or arrested growth.
    Pediatric dermatology, 2018, Volume: 35, Issue:2

    Topics: Adrenergic beta-Antagonists; Eczema; Glucocorticoids; Hemangioma; Humans; Hydrocortisone; Infant; Ma

2018
Management trends of infantile hemangioma: A national perspective.
    International journal of pediatric otorhinolaryngology, 2018, Volume: 104

    Topics: Biopsy; Child; Child, Preschool; Databases, Factual; Endoscopy; Female; Hemangioma; Hospital Charges

2018
Huge fetal hepatic Hemangioma: prenatal diagnosis on ultrasound and prognosis.
    BMC pregnancy and childbirth, 2018, 01-02, Volume: 18, Issue:1

    Topics: Adult; Contrast Media; Dexamethasone; Female; Glucocorticoids; Hemangioma; Humans; Infant, Newborn;

2018
Oral propranolol for infantile haemangioma may be associated with transient gross motor delay.
    The British journal of dermatology, 2018, Volume: 178, Issue:6

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Child, Preschool; Female; Hemangioma; Humans; Inf

2018
Clinical features and treatment results in children with hemangioma.
    The Turkish journal of pediatrics, 2017, Volume: 59, Issue:3

    Topics: Adolescent; Adrenergic beta-Antagonists; Child; Child, Preschool; Female; Glucocorticoids; Hemangiom

2017
Promotion of Propranolol Delivery to Hemangiomas by Using Anti-VEGFR Antibody-Conjugated Poly(lactic-co-glycolic acid) Nanoparticles.
    Journal of biomedical nanotechnology, 2017, Dec-01, Volume: 13, Issue:12

    Topics: Drug Delivery Systems; Hemangioma; Humans; Infant; Lactic Acid; Nanoparticles; Polyglycolic Acid; Po

2017
[Benign aggressive vascular anomalies in children].
    Bulletin du cancer, 2018, Volume: 105, Issue:6

    Topics: Adolescent; Adrenergic alpha-1 Receptor Antagonists; Arteriovenous Malformations; Child; Child, Pres

2018
[Repurposing of betablockers in dermatology].
    Revue medicale suisse, 2018, Mar-28, Volume: 14, Issue:600

    Topics: Adrenergic beta-Antagonists; Cell Proliferation; Dermatology; Hemangioma; Humans; Infant; Propranolo

2018
Cleft Palate Repair Using Single Flap Palatoplasty in Patient With Associated Palatal Hemangioma.
    The Journal of craniofacial surgery, 2018, Volume: 29, Issue:5

    Topics: Cleft Palate; Comorbidity; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Palatal Neoplasms;

2018
Pigment epithelium-derived factor/vascular endothelial growth factor ratio plays a crucial role in the spontaneous regression of infant hemangioma and in the therapeutic effect of propranolol.
    Cancer science, 2018, Volume: 109, Issue:6

    Topics: Apoptosis; Cell Movement; Cell Proliferation; Cells, Cultured; Endothelial Cells; Eye Proteins; Hema

2018
Effects of Propranolol on Neurodevelopmental Outcomes in Patients with Infantile Hemangioma: A Case-Control Study.
    BioMed research international, 2018, Volume: 2018

    Topics: Administration, Oral; Case-Control Studies; Central Nervous System; Female; Hemangioma; Humans; Infa

2018
Utility of routine electrocardiographic screening before initiation of propranolol for infantile hemangiomas.
    Pediatric dermatology, 2018, Volume: 35, Issue:4

    Topics: Adrenergic beta-Antagonists; Electrocardiography; Female; Hemangioma; Humans; Infant; Male; Mass Scr

2018
Modulation of LIN28B/Let-7 Signaling by Propranolol Contributes to Infantile Hemangioma Involution.
    Arteriosclerosis, thrombosis, and vascular biology, 2018, Volume: 38, Issue:6

    Topics: Antineoplastic Agents; Case-Control Studies; Cell Proliferation; Cellular Senescence; Epithelial-Mes

2018
Propranolol pharmacokinetics in infants treated for Infantile Hemangiomas requiring systemic therapy: Modeling and dosing regimen recommendations.
    Pharmacology research & perspectives, 2018, Volume: 6, Issue:3

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Body Weight; Drug Administration Schedule; Drug D

2018
Population Pharmacokinetics and Pharmacodynamics of Oral Propranolol in Pediatric Patients With Infantile Hemangioma.
    Journal of clinical pharmacology, 2018, Volume: 58, Issue:10

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Area Under Curve; Computer Simulation; Dose-Respo

2018
Effectiveness of oral propranolol for infantile hemangiomas started after 5 months of age.
    Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia, 2020, Volume: 155, Issue:1

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Propranolol;

2020
Propranolol induces hemangioma endothelial cell apoptosis via a p53‑BAX mediated pathway.
    Molecular medicine reports, 2018, Volume: 18, Issue:1

    Topics: Apoptosis; bcl-2-Associated X Protein; Endothelial Cells; Female; Hemangioma; Humans; Male; Mitochon

2018
Oral propranolol in the treatment of proliferating infantile haemangiomas: British Society for Paediatric Dermatology consensus guidelines.
    The British journal of dermatology, 2018, Volume: 179, Issue:3

    Topics: Administration, Oral; Aortic Coarctation; Clinical Decision-Making; Consensus; Delphi Technique; Der

2018
Serum concentrations of VEGF and bFGF in the course of propranolol therapy of infantile hemangioma in children: Are we closer to understand the mechanism of action of propranolol on hemangiomas?
    Advances in clinical and experimental medicine : official organ Wroclaw Medical University, 2018, Volume: 27, Issue:5

    Topics: Child; Fibroblast Growth Factor 2; Hemangioma; Humans; Infant; Neovascularization, Pathologic; Propr

2018
Safety of Oral Propranolol for Infantile Hemangioma.
    Pediatrics, 2018, Volume: 141, Issue:6

    Topics: Administration, Oral; Bradycardia; Bronchitis; Child, Preschool; Cohort Studies; Databases, Factual;

2018
Effects of oral propranolol for circumscribed choroidal hemangioma.
    Arquivos brasileiros de oftalmologia, 2018, Volume: 81, Issue:3

    Topics: Adult; Choroid Neoplasms; Hemangioma; Humans; Longitudinal Studies; Middle Aged; Propranolol; Prospe

2018
Propranolol versus steroids for the treatment of ulcerated infantile hemangiomas.
    Pediatric blood & cancer, 2018, Volume: 65, Issue:10

    Topics: Adrenal Cortex Hormones; Child, Preschool; Female; Hemangioma; Humans; Infant; Male; Propranolol; Re

2018
Prolonged growth of infantile hemangioma after pulsed dye laser and oral propranolol treatment.
    The Journal of dermatology, 2018, Volume: 45, Issue:9

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Lasers, Dye;

2018
[Effect of treatment of infant parotid hemangioma with no response to oral propranolol].
    Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese journal of stomatology, 2018, Jan-09, Volume: 53, Issue:1

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Embolization, Therapeutic; Hemangioma; Humans; In

2018
Coexistence of Kasabach-Merritt Syndrome and placental chorioangioma in a premature infant.
    Journal of neonatal-perinatal medicine, 2018, Volume: 11, Issue:2

    Topics: Anti-Inflammatory Agents; Comorbidity; Fatal Outcome; Female; Hemangioma; Humans; Infant, Newborn; K

2018
Cost-effectiveness of treating infantile haemangioma with propranolol in an outpatient setting.
    Cardiology in the young, 2018, Volume: 28, Issue:10

    Topics: Adrenergic beta-Antagonists; Cost of Illness; Cost-Benefit Analysis; Female; Hemangioma; Humans; Inf

2018
Oral propranolol for infantile hemangiomas beyond the proliferative phase.
    The Journal of dermatology, 2018, Volume: 45, Issue:10

    Topics: Administration, Oral; Asthma; Exanthema Subitum; Female; Hemangioma; Humans; Infant; Male; Photograp

2018
Propranolol inhibits proliferation and invasion of hemangioma-derived endothelial cells by suppressing the DLL4/Notch1/Akt pathway.
    Chemico-biological interactions, 2018, Oct-01, Volume: 294

    Topics: Adaptor Proteins, Signal Transducing; Calcium-Binding Proteins; Cell Movement; Cell Proliferation; C

2018
Role of Thrombospondin-1 and Nuclear Factor-κB Signaling Pathways in Antiangiogenesis of Infantile Hemangioma.
    Plastic and reconstructive surgery, 2018, Volume: 142, Issue:3

    Topics: Adrenergic beta-Antagonists; Animals; Cell Proliferation; Endothelial Cells; Female; Hemangioma; Hum

2018
Subglottic hemangioma: Understanding the association with facial segmental hemangioma in a beard distribution.
    International journal of pediatric otorhinolaryngology, 2018, Volume: 113

    Topics: Antineoplastic Agents; Combined Modality Therapy; Facial Neoplasms; Female; Hemangioma; Humans; Infa

2018
Surgical treatment outcomes of infantile hemangioma in children: Does prior medical treatment matter.
    Pediatric dermatology, 2018, Volume: 35, Issue:6

    Topics: Adrenergic beta-Antagonists; Canada; Child; Child, Preschool; Cohort Studies; Female; Glucocorticoid

2018
Minimizing differences in treatment: expert- and evidence-based guidelines for propranolol treatment of infantile haemangiomas in the U.K. and beyond.
    The British journal of dermatology, 2018, Volume: 179, Issue:3

    Topics: Adrenergic beta-Antagonists; Child; Consensus; Dermatology; Hemangioma; Humans; Propranolol

2018
Propranolol inhibits the activity of PI3K, AKT, and HIF-1α in infantile hemangiomas.
    Pediatric surgery international, 2018, Volume: 34, Issue:11

    Topics: Animals; Disease Models, Animal; Hemangioma; Hypoxia-Inducible Factor 1, alpha Subunit; Mice, Nude;

2018
Surgical resection of infantile hemangiomas following medical treatment with propranolol versus corticosteroids.
    Journal of pediatric surgery, 2019, Volume: 54, Issue:4

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Child, Preschool; Female; Glucocorticoids; Hemang

2019
Infantile hemangiomas with minimal or arrested growth: A retrospective case series.
    Pediatric dermatology, 2019, Volume: 36, Issue:1

    Topics: Adrenergic beta-Antagonists; Child; Child, Preschool; Disease Progression; Female; Hemangioma; Human

2019
Tufted angioma arising at the site of hepatitis B vaccination: A case report.
    The Turkish journal of pediatrics, 2018, Volume: 60, Issue:2

    Topics: Adrenergic beta-Antagonists; Female; Glucocorticoids; Hemangioma; Hepatitis B Vaccines; Humans; Infa

2018
Neonatal giant hepatic hemangioma: A case report.
    Medicine, 2018, Volume: 97, Issue:42

    Topics: Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant, Newborn; Liver; Liver Neoplasms; Ma

2018
Effects of propranolol therapy in Moroccan children with infantile hemangioma.
    Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 2018, Volume: 25, Issue:8

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Male; Morocco

2018
Epithelioid hemangioma of the orbit treated with oral propranolol in adult.
    Canadian journal of ophthalmology. Journal canadien d'ophtalmologie, 2018, Volume: 53, Issue:6

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Dose-Response Relationship, Drug; Hemangioma; Hum

2018
Kinetic and Angiogenic Activity of Circulating Endothelial Colony Forming Cells in Patients with Infantile Haemangioma Receiving Propranolol.
    Thrombosis and haemostasis, 2019, Volume: 119, Issue:2

    Topics: Adrenergic beta-Antagonists; Antigens, CD34; Calcium; Calcium Signaling; Cell Movement; Chemokine CX

2019
No Increased Risks Associated with Propranolol Treatment for Infantile Hemangioma in Preterm Infants were Identified at 3 Years of Age.
    American journal of clinical dermatology, 2019, Volume: 20, Issue:2

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Child, Preschool; Female; Hemangioma; Humans; Inf

2019
Safety assessment during initiation and maintenance of propranolol therapy for infantile hemangiomas.
    Advances in clinical and experimental medicine : official organ Wroclaw Medical University, 2019, Volume: 28, Issue:3

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Blood Pressure; Child; Heart Rate; Hemangioma; Hu

2019
Efficacy of infantile hepatic hemangioma with propranolol treatment: A case report.
    Medicine, 2019, Volume: 98, Issue:4

    Topics: Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Liver Neoplasms; Propranolol

2019
Propranolol as an effective therapy for infantile haemangioma of the urinary bladder.
    BMJ case reports, 2019, Feb-01, Volume: 12, Issue:2

    Topics: Female; Hemangioma; Humans; Infant, Newborn; Propranolol; Treatment Outcome; Urinary Bladder Neoplas

2019
MiR-187-3p Enhances Propranolol Sensitivity of Hemangioma Stem Cells.
    Cell structure and function, 2019, Mar-20, Volume: 44, Issue:1

    Topics: Base Sequence; Cell Cycle Proteins; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm;

2019
Late ulceration of residual abortive infantile haemangioma: a rare complication.
    The British journal of dermatology, 2019, Volume: 181, Issue:2

    Topics: Adolescent; Bandages; Biopsy; Female; Hemangioma; Humans; Leg Ulcer; Propranolol; Skin; Time Factors

2019
Associations between short-term efficacy and clinical characteristics of infantile hemangioma treated by propranolol.
    Medicine, 2019, Volume: 98, Issue:6

    Topics: Adrenergic beta-Antagonists; Age Factors; Drug Administration Schedule; Female; Hemangioma; Humans;

2019
Beta blockers for infantile haemangiomas: where should we go from here?
    The British journal of dermatology, 2019, Volume: 180, Issue:3

    Topics: Adrenergic beta-Antagonists; Hemangioma; Humans; Propranolol; Skin

2019
Progressive infantile hepatic hemangioma not responding to propranolol.
    The Journal of dermatology, 2019, Volume: 46, Issue:8

    Topics: Adrenergic beta-Antagonists; Age of Onset; Child, Preschool; Disease Progression; Fatal Outcome; Fem

2019
Propranolol-Loaded Mesoporous Silica Nanoparticles for Treatment of Infantile Hemangiomas.
    Advanced healthcare materials, 2019, Volume: 8, Issue:9

    Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Carriers; Drug Delivery Systems; Hema

2019
Secondary Congenital Glaucoma Associated With Retro-orbital Infantile Hemangioma: A Masquerade Syndrome.
    Journal of glaucoma, 2019, Volume: 28, Issue:6

    Topics: Diagnosis, Differential; Female; Glaucoma; Hemangioma; Humans; Hydrophthalmos; Infant; Intraocular P

2019
Infantile hemangioma: Efficacy of low-dose propranolol and of intralesional bleomycin injection for propranolol non-response.
    Pediatrics international : official journal of the Japan Pediatric Society, 2019, Volume: 61, Issue:5

    Topics: Administration, Oral; Antibiotics, Antineoplastic; Bleomycin; Female; Hemangioma; Humans; Infant; In

2019
Clinical and radiological outcomes of infantile hemangioma treated with oral propranolol: A long-term follow-up study.
    The Journal of dermatology, 2019, Volume: 46, Issue:5

    Topics: Administration, Oral; Child, Preschool; Disease Progression; Erythema; Female; Follow-Up Studies; He

2019
Objective evaluation of the response of infantile haemangiomas to propranolol treatment using a three-dimensional imaging system.
    The British journal of dermatology, 2019, Volume: 181, Issue:4

    Topics: Administration, Oral; Feasibility Studies; Female; Follow-Up Studies; Hemangioma; Humans; Imaging, T

2019
Effectiveness of oral propranolol in a patient with neurofibromatosis type 1 and infantile hemangiomas.
    Italian journal of dermatology and venereology, 2021, Volume: 156, Issue:Suppl. 1 t

    Topics: Hemangioma; Hemangioma, Capillary; Humans; Infant; Neurofibromatosis 1; Propranolol

2021
[Vascular Cutaneous Abnormalities in Togo: a 120-Case Study].
    Bulletin de la Societe de pathologie exotique (1990), 2018, Volume: 111, Issue:5

    Topics: Adrenal Cortex Hormones; Child, Preschool; Cohort Studies; Female; Hemangioma; Humans; Infant; Klipp

2018
Successful treatment of an exudative choroidal hemangioma with oral propranolol in a 10-year-old boy.
    Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus, 2019, Volume: 23, Issue:4

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Child; Choroid; Choroid Neoplasms; Dose-Response

2019
The sustained and targeted treatment of hemangiomas by propranolol-loaded CD133 aptamers conjugated liposomes-in-microspheres.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2019, Volume: 114

    Topics: AC133 Antigen; Animals; Aptamers, Nucleotide; Cell Proliferation; Cells, Cultured; Delayed-Action Pr

2019
Topical timolol as adjunct therapy to shorten oral propranolol therapy for infantile hemangiomas.
    Pediatric dermatology, 2019, Volume: 36, Issue:3

    Topics: Administration, Oral; Administration, Topical; Adrenergic beta-Antagonists; Combined Modality Therap

2019
Propranolol suppresses infantile hemangioma cell proliferation and promotes apoptosis by upregulating miR-125b expression.
    Anti-cancer drugs, 2019, Volume: 30, Issue:5

    Topics: Adrenergic beta-Antagonists; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Gene Expression Regul

2019
Preoperative administration of propranolol reduced the surgical risks of PHACES syndrome in a 14-month-old girl.
    BMJ case reports, 2019, Apr-29, Volume: 12, Issue:4

    Topics: Abnormalities, Multiple; Administration, Oral; Adrenergic beta-Antagonists; Airway Obstruction; Aort

2019
Treatment failure with propranolol for subglottic haemangioma.
    BMJ case reports, 2019, May-13, Volume: 12, Issue:5

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Humans; Infant; Laryngeal Neoplasms;

2019
EFFECTIVENESS OF FIXED DOSES OF PROPRANOLOL IN THE TREATMENT OF HEMANGIOMAS REGARDLESS OF CHILD'S WEIGHT GAIN: A CASE REPORT.
    Revista paulista de pediatria : orgao oficial da Sociedade de Pediatria de Sao Paulo, 2019, May-07, Volume: 37, Issue:3

    Topics: Adrenergic beta-Antagonists; Child; Dose-Response Relationship, Drug; Female; Hemangioma; Humans; Pr

2019
[Infantile haemangioma: an update].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2019, Volume: 70, Issue:6

    Topics: Child; Face; Hemangioma; Humans; Infant; Propranolol; Skin Neoplasms; Treatment Outcome

2019
Therapeutic efficacy of propranolol for infantile hemangiomas.
    Oral surgery, oral medicine, oral pathology and oral radiology, 2019, Volume: 128, Issue:2

    Topics: Administration, Oral; Hemangioma; Humans; Infant; Logistic Models; Propranolol; Retrospective Studie

2019
Safety of intralesional injection of lauromacrogol combined with triamcinolone for infantile hemangiomas.
    The Journal of dermatology, 2019, Volume: 46, Issue:9

    Topics: Adrenergic beta-Antagonists; Body Height; Body Weight; Child Development; Dose-Response Relationship

2019
A Life Threatening Subglottic and Mediastinal Hemangioma in an Infant.
    The Journal of craniofacial surgery, 2019, Volume: 30, Issue:5

    Topics: Female; Hemangioma; Hemangioma, Capillary; Humans; Infant; Laryngeal Neoplasms; Mediastinal Neoplasm

2019
Individualized dosing of oral propranolol for treatment of infantile hemangioma: a prospective study.
    The Pan African medical journal, 2019, Volume: 32

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Child, Preschool; Dose-Response Relationship, Dru

2019
R-propranolol is a small molecule inhibitor of the SOX18 transcription factor in a rare vascular syndrome and hemangioma.
    eLife, 2019, 07-30, Volume: 8

    Topics: Adrenergic beta-Antagonists; Animals; Disease Models, Animal; Enzyme Inhibitors; Hemangioma; Humans;

2019
[Rapid response of a multifocal liver hemangioma to propranolol treatment].
    Anales de pediatria (Barcelona, Spain : 2003), 2013, Volume: 79, Issue:2

    Topics: Female; Hemangioma; Humans; Infant; Liver Neoplasms; Propranolol; Remission Induction; Time Factors

2013
Hemangiomas of the nasal tip treated with propranolol.
    Dermatology (Basel, Switzerland), 2012, Volume: 225, Issue:4

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Israel; Male;

2012
Propranolol use for infantile hemangiomas: American Society of Pediatric Otolaryngology Vascular Anomalies Task Force practice patterns.
    JAMA otolaryngology-- head & neck surgery, 2013, Volume: 139, Issue:2

    Topics: Adrenergic beta-Antagonists; Blood Glucose; Blood Pressure; Dose-Response Relationship, Drug; Drug A

2013
Retrospective study of the treatment of infantile hemangiomas using a combination of propranolol and pulsed dye laser.
    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2013, Volume: 39, Issue:6

    Topics: Combined Modality Therapy; Hemangioma; Humans; Infant; Infant, Newborn; Lasers, Dye; Propranolol; Re

2013
Use of propranolol for the treatment infantile hemangiomas in the maxillofacial region.
    International journal of oral and maxillofacial surgery, 2013, Volume: 42, Issue:7

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Child, Preschool; Face; Female; Hemangioma; Human

2013
Propranolol for infantile haemangioma: a review of current dosing regime in a regional paediatric hospital.
    The Ulster medical journal, 2013, Volume: 82, Issue:1

    Topics: Adrenergic beta-Antagonists; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hemangioma

2013
Propranolol-resistant infantile haemangiomas.
    The British journal of dermatology, 2013, Volume: 169, Issue:1

    Topics: Age of Onset; Antineoplastic Agents; Child, Preschool; Drug Resistance, Neoplasm; Facial Neoplasms;

2013
Factors associated with the relapse of infantile haemangiomas in children treated with oral propranolol.
    The British journal of dermatology, 2013, Volume: 169, Issue:6

    Topics: Administration, Oral; Antineoplastic Agents; Child; Child, Preschool; Female; Head and Neck Neoplasm

2013
Propranolol for infantile haemangiomas: initiating treatment on an outpatient basis.
    Cardiology in the young, 2013, Volume: 23, Issue:5

    Topics: Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Male; Propranolol; Skin Neoplasms

2013
Successful management of airway hemangioma with propranolol.
    International journal of dermatology, 2013, Volume: 52, Issue:6

    Topics: Adrenergic beta-Antagonists; Airway Obstruction; Epiglottis; Female; Head and Neck Neoplasms; Hemang

2013
What's new in pediatric dermatology?: part II. Treatment.
    Journal of the American Academy of Dermatology, 2013, Volume: 68, Issue:6

    Topics: Acyclovir; Antiviral Agents; Dermatitis, Atopic; Dermatology; Hemangioma; Humans; Internet; Proprano

2013
Successful discontinuation of propranolol for infantile hemangiomas of the head and neck at 12 months of age.
    International journal of pediatric otorhinolaryngology, 2013, Volume: 77, Issue:7

    Topics: Adrenergic beta-Antagonists; Age Factors; Female; Follow-Up Studies; Head and Neck Neoplasms; Hemang

2013
Treating infantile hemangiomatosis: a case study.
    Pediatric annals, 2013, Jun-01, Volume: 42, Issue:6

    Topics: Antineoplastic Agents; Female; Hemangioma; Humans; Infant; Propranolol; Skin Neoplasms

2013
[A case of congenital subglottic hemangiomas].
    Zhonghua er ke za zhi = Chinese journal of pediatrics, 2013, Volume: 51, Issue:3

    Topics: Administration, Oral; Bronchoscopy; Female; Glottis; Hemangioma; Humans; Infant, Newborn; Laryngeal

2013
[Treatment of superficial infantile hemangiomas with topical propranolol].
    Zhonghua zheng xing wai ke za zhi = Zhonghua zhengxing waike zazhi = Chinese journal of plastic surgery, 2013, Volume: 29, Issue:2

    Topics: Female; Hemangioma; Humans; Infant; Male; Ointments; Propranolol; Skin Neoplasms; Treatment Outcome

2013
Medical management of tumors associated with Kasabach-Merritt phenomenon: an expert survey.
    Journal of pediatric hematology/oncology, 2013, Volume: 35, Issue:8

    Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Data Collection; Hemangioendothelioma; Hemangioma; H

2013
An update on infantile haemangiomas.
    The British journal of dermatology, 2013, Volume: 169, Issue:1

    Topics: Antineoplastic Agents; Hemangioma; Humans; Infant; Propranolol; Skin Neoplasms

2013
Diffuse neonatal hemangiomatosis with partial response to propranolol.
    International journal of dermatology, 2014, Volume: 53, Issue:4

    Topics: Female; Hemangioma; Humans; Infant, Newborn; Liver Neoplasms; Propranolol; Skin Neoplasms; Vasodilat

2014
Haemangioma and propranolol.
    Journal of plastic surgery and hand surgery, 2014, Volume: 48, Issue:1

    Topics: Adrenergic beta-Antagonists; Cardiovascular Agents; Combined Modality Therapy; Facial Neoplasms; Fem

2014
Dangers of propranolol in preterm infants.
    The Australasian journal of dermatology, 2013, Volume: 54, Issue:3

    Topics: Apnea; Bradycardia; Hemangioma; Humans; Infant; Infant, Premature; Mouth Neoplasms; Propranolol; Ski

2013
Periocular infantile haemangioma and the role of propranolol.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2013, Volume: 23, Issue:8

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Eyelid Neoplasms; Female; Hemangioma; Humans; Inf

2013
Propranolol therapy for cutaneous infantile haemangiomas initiated safely as a day-case procedure.
    European journal of pediatrics, 2014, Volume: 173, Issue:1

    Topics: Adrenergic beta-Antagonists; Day Care, Medical; Female; Hemangioma; Humans; Infant; Male; Propranolo

2014
Treatment of infantile haemangiomas with atenolol: comparison with a historical propranolol group.
    Journal of plastic, reconstructive & aesthetic surgery : JPRAS, 2013, Volume: 66, Issue:12

    Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Atenolol; Facial Neoplasms; Fem

2013
Upregulated autocrine vascular endothelial growth factor (VEGF)/VEGF receptor-2 loop prevents apoptosis in haemangioma-derived endothelial cells.
    The British journal of dermatology, 2014, Volume: 170, Issue:1

    Topics: Adrenergic beta-Antagonists; Angiogenesis Inhibitors; Apoptosis; Cell Survival; Culture Media, Serum

2014
A Case of PHACES Syndrome with Successful Treatment of Facial Haemangioma With Propranolol.
    The Medical journal of Malaysia, 2013, Volume: 68, Issue:4

    Topics: Hemangioma; Humans; Infant; Propranolol; Syndrome

2013
Effects of oral propranolol on circumscribed choroidal hemangioma: a pilot study.
    JAMA ophthalmology, 2013, Volume: 131, Issue:12

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Choroid Neoplasms; Coloring Agents; Female

2013
Propranolol as diagnostic tool for infantile hemangiomas.
    The Journal of craniofacial surgery, 2013, Volume: 24, Issue:6

    Topics: Diagnosis, Differential; Facial Neoplasms; Hemangioma; Humans; Infant; Male; Myofibroma; Propranolol

2013
Cardiovascular and blood glucose parameters in infants during propranolol initiation for treatment of symptomatic infantile hemangiomas.
    The Annals of otology, rhinology, and laryngology, 2013, Volume: 122, Issue:9

    Topics: Adrenergic beta-Antagonists; Blood Glucose; Blood Pressure; Cardiovascular System; Dose-Response Rel

2013
Propranolol for infantile haemangiomas: review of report of a consensus conference.
    Archives of disease in childhood. Education and practice edition, 2014, Volume: 99, Issue:3

    Topics: Congresses as Topic; Hemangioma; Humans; Infant; Patient Selection; Propranolol; Vasodilator Agents

2014
Large orbital hemangioma: managed with systemic propranolol.
    Indian journal of pediatrics, 2014, Volume: 81, Issue:8

    Topics: Administration, Oral; Hemangioma; Humans; Infant; Male; Orbital Neoplasms; Propranolol

2014
Propranolol for the treatment of infantile haemangiomas: our experience with 44 patients.
    Clinical and experimental dermatology, 2014, Volume: 39, Issue:2

    Topics: Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Infant, Newborn; Male; Propranolol

2014
Propranolol inhibits growth of hemangioma-initiating cells but does not induce apoptosis.
    Pediatric research, 2014, Volume: 75, Issue:3

    Topics: Adrenergic beta-Antagonists; Apoptosis; Caspase 3; Cell Count; Cell Proliferation; Cyclin D1; Hemang

2014
[Controlling therapy with propranolol for infants with parotid gland hemangiomas].
    Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery, 2013, Volume: 48, Issue:9

    Topics: Hemangioma; Humans; Infant; Parotid Gland; Parotid Neoplasms; Propranolol

2013
Treatment of infantile hemangiomas with propranolol: clinical guidelines.
    Plastic and reconstructive surgery, 2014, Volume: 133, Issue:4

    Topics: Adrenergic beta-Antagonists; Child, Preschool; Clinical Protocols; Facial Neoplasms; Female; Hemangi

2014
Propranolol: a novel antihemangioma agent with multiple potential mechanisms of action.
    Annals of surgery, 2015, Volume: 261, Issue:2

    Topics: Adrenergic beta-Antagonists; Endothelial Cells; Hemangioma; Humans; Hypoxia-Inducible Factor 1, alph

2015
Reply to letter: "propranolol: a novel antihemangioma agent with multiple potential mechanisms of action".
    Annals of surgery, 2015, Volume: 261, Issue:2

    Topics: Adrenergic beta-Antagonists; Endothelial Cells; Hemangioma; Humans; Hypoxia-Inducible Factor 1, alph

2015
Propranolol inhibits angiogenesis via down-regulating the expression of vascular endothelial growth factor in hemangioma derived stem cell.
    International journal of clinical and experimental pathology, 2014, Volume: 7, Issue:1

    Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Blotting, Western; Cell Proliferation; Cells, Cultured;

2014
[Medication-based therapy of infantile hemangioma and lymphatic malformations].
    HNO, 2014, Volume: 62, Issue:1

    Topics: Antibiotics, Antineoplastic; Female; Head and Neck Neoplasms; Hemangioma; Humans; Infant; Infant, Ne

2014
Treatment of children and adolescents with hemangioma using propranolol: preliminary results from a retrospective study.
    Sao Paulo medical journal = Revista paulista de medicina, 2014, Volume: 132, Issue:1

    Topics: Adolescent; Adrenergic beta-Antagonists; Age Factors; Chi-Square Distribution; Child; Child, Prescho

2014
Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon.
    Pediatric blood & cancer, 2014, Volume: 61, Issue:8

    Topics: Adrenergic beta-Antagonists; Female; Hemangioendothelioma; Hemangioma; Humans; Kasabach-Merritt Synd

2014
Effectiveness of propanolol for treatment of infantile haemangioma.
    Danish medical journal, 2014, Volume: 61, Issue:2

    Topics: Adrenergic beta-Antagonists; Drug Administration Schedule; Female; Hemangioma; Humans; Infant; Infan

2014
Efficacy and safety of propranolol for the treatment of infantile hemangioma: a presentation of ninety-nine cases.
    Dermatology (Basel, Switzerland), 2014, Volume: 228, Issue:2

    Topics: Administration, Oral; Dermatologic Agents; Female; Follow-Up Studies; Hemangioma; Hospitals, Univers

2014
Propranolol as first-line treatment in orbital infantile haemangiomas: a case series.
    Orbit (Amsterdam, Netherlands), 2014, Volume: 33, Issue:3

    Topics: Administration, Oral; Contrast Media; Female; Hemangioma; Humans; Infant; Magnetic Resonance Imaging

2014
Beta blocker treatment of infantile conjunctival hemangiomas--observations from 2 cases.
    Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus, 2014, Volume: 18, Issue:1

    Topics: Adrenergic beta-Antagonists; Conjunctival Neoplasms; Female; Hemangioma; Humans; Infant; Propranolol

2014
Successful treatment of pulmonary hemangioma with propranolol.
    Pediatric pulmonology, 2014, Volume: 49, Issue:8

    Topics: Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Lung Neoplasms; Propranolol; Radiog

2014
[The effectiveness of propranolol therapy of subfold hemangioma in the children during the first year of life].
    Vestnik otorinolaringologii, 2014, Issue:1

    Topics: Adrenergic beta-Antagonists; Dose-Response Relationship, Drug; Female; Glottis; Hemangioma; Humans;

2014
Successful treatment of multifocal intracerebral and spinal hemangiomas with propranolol.
    Journal of the American Academy of Dermatology, 2014, Volume: 70, Issue:4

    Topics: Brain Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies;

2014
Propranolol targets the contractility of infantile haemangioma-derived pericytes.
    The British journal of dermatology, 2014, Volume: 171, Issue:5

    Topics: Adrenergic beta-Antagonists; Animals; Blood Volume; Cell Proliferation; Endothelial Cells; Epinephri

2014
A retrospective analysis of systemic propranolol for the treatment of complicated infantile haemangiomas.
    Acta paediatrica (Oslo, Norway : 1992), 2014, Volume: 103, Issue:9

    Topics: Female; Hemangioma; Humans; Infant; Male; Propranolol; Retrospective Studies; Skin Neoplasms; Treatm

2014
Retrospective analysis of beta-blocker instituted for treatment of hemangiomas (RABBIT study).
    Clinical pediatrics, 2014, Volume: 53, Issue:11

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; In

2014
The role of propranolol in the treatment of infantile hemangioma.
    Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology, 2014, Volume: 33, Issue:5

    Topics: Child; Child, Preschool; Female; Hemangioma; Humans; Infant; Male; Propranolol; Prospective Studies;

2014
Successful treatment of diffuse neonatal hemangiomatosis with propranolol: a case report.
    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2014, Volume: 12, Issue:7

    Topics: Administration, Oral; Hemangioma; Humans; Infant, Newborn; Joint Instability; Male; Phimosis; Propra

2014
Safety profile of a divided dose of propranolol for heart rate in children with infantile haemangioma during 16 weeks of treatment.
    The British journal of dermatology, 2015, Volume: 172, Issue:2

    Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Case-Control Studies; Child; Dose-Response Rela

2015
Oral propranolol (Hemangeol) for infantile hemangioma.
    The Medical letter on drugs and therapeutics, 2014, Jul-21, Volume: 56, Issue:1447

    Topics: Administration, Oral; Antineoplastic Agents; Hemangioma; Humans; Infant; Propranolol

2014
Propranolol promotes accelerated and dysregulated adipogenesis in hemangioma stem cells.
    Annals of plastic surgery, 2014, Volume: 73 Suppl 1

    Topics: Adipogenesis; Hemangioma; Humans; Neoplastic Stem Cells; Propranolol; Time Factors; Tumor Cells, Cul

2014
Propranolol enhanced adipogenesis instead of induction of apoptosis of hemangiomas stem cells.
    International journal of clinical and experimental pathology, 2014, Volume: 7, Issue:7

    Topics: Adipogenesis; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Differentiation; Cells, Cult

2014
Propranolol for infantile haemangiomas: single centre experience of 250 cases and proposed therapeutic protocol.
    Archives of disease in childhood, 2014, Volume: 99, Issue:12

    Topics: Adrenergic beta-Antagonists; Child; Child, Preschool; Female; Hemangioma; Humans; Infant; Male; Prop

2014
[Effectiveness of external propranolol gel for treatment of superficial infantile hemangioma].
    Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 2014, Volume: 16, Issue:8

    Topics: Child, Preschool; Female; Gels; Hemangioma; Humans; Infant; Male; Propranolol

2014
[Clinical analysis for treatment of 1 080 cases of infantile hemangiomas with oral propranolol].
    Zhonghua yi xue za zhi, 2014, Jun-24, Volume: 94, Issue:24

    Topics: Administration, Oral; Female; Hemangioma; Humans; Male; Propranolol; Retrospective Studies; Treatmen

2014
Increased apoptosis and secretion of tryptase by mast cells in infantile haemangioma treated with propranolol.
    Pathology, 2014, Volume: 46, Issue:6

    Topics: Apoptosis; Biopsy; Case-Control Studies; Cell Degranulation; Endothelial Cells; Extracellular Matrix

2014
Glucose transporter 1-positive endothelial cells in infantile hemangioma exhibit features of facultative stem cells.
    Stem cells (Dayton, Ohio), 2015, Volume: 33, Issue:1

    Topics: Cell Differentiation; Cell Proliferation; Child; Child, Preschool; Endothelial Cells; Female; Glucos

2015
Intractable choroidal effusion with exudative retinal detachment in Sturge-Weber syndrome.
    JAMA ophthalmology, 2014, Volume: 132, Issue:9

    Topics: Administration, Oral; Antihypertensive Agents; Child, Preschool; Choroid Neoplasms; Exudates and Tra

2014
Ultrasound in assessing the efficacy of propranolol therapy for infantile hemangiomas.
    Ultrasound in medicine & biology, 2014, Volume: 40, Issue:11

    Topics: Adrenergic beta-Antagonists; Child, Preschool; Female; Follow-Up Studies; Hemangioma; Humans; Infant

2014
Allergic contact dermatitis caused by topical propranolol in a 5-month-old baby.
    Contact dermatitis, 2014, Volume: 71, Issue:4

    Topics: Administration, Cutaneous; Adrenergic beta-Antagonists; Dermatitis, Allergic Contact; Female; Hand;

2014
Is propranolol compounding from tablet safe for pediatric use? Results from an experimental test.
    Minerva pediatrica, 2014, Volume: 66, Issue:5

    Topics: Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Dermatologic Agents; Drug Compoundi

2014
[Subglottic haemangioma].
    Ugeskrift for laeger, 2014, Aug-04, Volume: 176, Issue:32

    Topics: Female; Glottis; Hemangioma; Humans; Infant; Laryngeal Neoplasms; Laryngoscopy; Propranolol; Rare Di

2014
Monitoring propranolol treatment in periocular infantile haemangioma.
    Eye (London, England), 2014, Volume: 28, Issue:11

    Topics: Administration, Oral; Adolescent; Adrenergic beta-Antagonists; Amblyopia; Child; Child, Preschool; D

2014
Successful treatment of tufted angioma with propranolol.
    The Journal of dermatology, 2014, Volume: 41, Issue:12

    Topics: Hemangioma; Humans; Infant; Male; Propranolol; Skin; Skin Neoplasms; Vasodilator Agents

2014
Diode laser for the treatment of telangiectasias following hemangioma involution.
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2015, Volume: 152, Issue:2

    Topics: Child; Child, Preschool; Female; Hemangioma; Humans; Infant; Lasers, Semiconductor; Male; Propranolo

2015
Giant cranial and cerebellar hemangioma treated with propranolol.
    Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 2015, Volume: 31, Issue:5

    Topics: Adrenergic beta-Antagonists; Cerebellar Neoplasms; Female; Hemangioma; Humans; Infant, Newborn; Prop

2015
[Expression of serum and urinary vascular endothelial growth factor-A and epidermal growth factor-like domain 7 in proliferating hemangioma treated with propranolol].
    Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology, 2014, Volume: 32, Issue:5

    Topics: EGF Family of Proteins; Enzyme-Linked Immunosorbent Assay; Hemangioma; Humans; Infant; Propranolol;

2014
Nadolol for the treatment of infantile hemangioma.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2015, Jan-01, Volume: 72, Issue:1

    Topics: Adrenergic beta-Antagonists; Blood Pressure; Child, Preschool; Female; Heart Rate; Hemangioma; Human

2015
Comprehensive therapy for hemangioma presenting with Kasabach-Merritt syndrome in the maxillofacial region.
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2015, Volume: 73, Issue:1

    Topics: Blood Coagulation Tests; Combined Modality Therapy; Embolization, Therapeutic; Female; Follow-Up Stu

2015
Topical treatment with propranolol gel as a supplement to the existing treatment of hemangiomas.
    World journal of pediatrics : WJP, 2014, Volume: 10, Issue:4

    Topics: Administration, Topical; Female; Gels; Hemangioma; Humans; Infant; Male; Propranolol; Retrospective

2014
[Effects of propranolol on proliferation of hemangioma-derived mesenchymal stem cells ].
    Zhonghua zheng xing wai ke za zhi = Zhonghua zhengxing waike zazhi = Chinese journal of plastic surgery, 2014, Volume: 30, Issue:5

    Topics: Adipogenesis; Antigens; Cell Differentiation; Cell Proliferation; Cells, Cultured; Endothelium, Vasc

2014
Treatment of severe infantile hemangiomas with propranolol: an evaluation of the efficacy and effects of cardiovascular parameters in 25 consecutive patients.
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2015, Volume: 73, Issue:3

    Topics: Administration, Oral; Blood Glucose; Blood Pressure; Echocardiography; Electrocardiography; Facial N

2015
[Clinical case of treatment of hepatic haemangioma by propranolol in the newborn].
    Vestnik Rossiiskoi akademii meditsinskikh nauk, 2014, Issue:5-6

    Topics: Adrenergic beta-Antagonists; Dose-Response Relationship, Drug; Drug Monitoring; Female; Hemangioma;

2014
Propranolol for infantile haemangiomas: certain chances, potential risks.
    The British journal of dermatology, 2015, Volume: 172, Issue:1

    Topics: Adrenergic beta-Antagonists; Hemangioma; Humans; Propranolol; Skin Neoplasms

2015
Is cardiovascular evaluation necessary prior to and during beta-blocker therapy for infantile hemangiomas?: A cohort study.
    Journal of the American Academy of Dermatology, 2015, Volume: 72, Issue:3

    Topics: Adrenergic beta-Antagonists; Cardiovascular Diseases; Child, Preschool; Cohort Studies; Drug Monitor

2015
Propranolol and prednisolone combination for the treatment of segmental haemangioma in PHACES syndrome.
    The British journal of dermatology, 2015, Volume: 173, Issue:1

    Topics: Abnormalities, Multiple; Adrenergic beta-Antagonists; Antineoplastic Agents, Hormonal; Blepharoptosi

2015
Intralesional injection of diprospan is effective for infantile hemangioma.
    The Journal of craniofacial surgery, 2015, Volume: 26, Issue:2

    Topics: Betamethasone; Drug Combinations; Female; Follow-Up Studies; Glucocorticoids; Head and Neck Neoplasm

2015
Evidence and nuances of propranolol safety.
    The British journal of dermatology, 2015, Volume: 172, Issue:2

    Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Female; Heart Rate; Hemangioma; Humans; Male; P

2015
[Infantile hemangiomas: the revolution of beta-blockers].
    La Revue du praticien, 2014, Volume: 64, Issue:10

    Topics: Adrenergic beta-Antagonists; Dermatologic Agents; Early Medical Intervention; Esthetics; Follow-Up S

2014
Efficacy of propranolol for cutaneous hemangiomas in premature children.
    Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia, 2016, Volume: 151, Issue:5

    Topics: Adrenergic beta-Antagonists; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hemangioma

2016
Oral propranolol for parotid infantile hemangiomas.
    The Journal of craniofacial surgery, 2015, Volume: 26, Issue:2

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Color; Female; Follow-Up Studies; Hemangioma; Hum

2015
Propranolol induces regression of hemangioma cells via the down-regulation of the PI3K/Akt/eNOS/VEGF pathway.
    Pediatric blood & cancer, 2015, Volume: 62, Issue:8

    Topics: Adrenergic beta-Antagonists; Angiogenesis Inhibitors; Cell Cycle Checkpoints; Cell Proliferation; Ce

2015
[Propranolol in infantile hemangiomas].
    Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 2015, Volume: 22, Issue:4

    Topics: Adrenergic beta-Antagonists; Child, Preschool; Facial Neoplasms; Hemangioma; Humans; Propranolol; Sk

2015
Delayed-onset of multiple cutaneous infantile hemangiomas due to propranolol: a case report.
    Pediatrics, 2015, Volume: 135, Issue:4

    Topics: Dose-Response Relationship, Drug; Heart Defects, Congenital; Hemangioma; Humans; Infant; Infant, New

2015
A novel topical nano-propranolol for treatment of infantile hemangiomas.
    Nanomedicine : nanotechnology, biology, and medicine, 2015, Volume: 11, Issue:5

    Topics: Administration, Topical; Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Hydrogels; Infant;

2015
Diffuse neonatal hemangiomatosis in a very low-birthweight infant treated with erythropoietin.
    Pediatrics international : official journal of the Japan Pediatric Society, 2015, Volume: 57, Issue:2

    Topics: Adrenergic beta-Antagonists; Anemia, Neonatal; Erythropoietin; Gestational Age; Hemangioma; Humans;

2015
Propranolol represses infantile hemangioma cell growth through the β2-adrenergic receptor in a HIF-1α-dependent manner.
    Oncology reports, 2015, Volume: 33, Issue:6

    Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; He

2015
Propranolol to treat infantile hemangioma (IH) in patients with congenital heart disease.
    Journal of the American Academy of Dermatology, 2015, Volume: 72, Issue:5

    Topics: Female; Heart Defects, Congenital; Hemangioma; Humans; Infant; Male; Propranolol; Prospective Studie

2015
[Combination of pulsed dye laser and propranolol in the treatment of ulcerated infantile haemangioma].
    Anales de pediatria (Barcelona, Spain : 2003), 2016, Volume: 84, Issue:2

    Topics: Hemangioma; Humans; Infant; Lasers, Dye; Propranolol; Retrospective Studies; Skin Neoplasms; Treatme

2016
Open airway surgery for subglottic hemangioma in the era of propranolol: Is it still indicated?
    International journal of pediatric otorhinolaryngology, 2015, Volume: 79, Issue:7

    Topics: Adrenergic beta-Antagonists; Child, Preschool; Female; Hemangioma; Humans; Laryngeal Neoplasms; Lary

2015
Infantile Hemangioma in the Airway.
    Anesthesiology, 2015, Volume: 123, Issue:6

    Topics: Airway Obstruction; Biopsy; Hemangioma; Humans; Infant; Laryngoscopy; Propranolol; Respiratory Sound

2015
Propanolol effectively treats significant infantile hemangiomas.
    The Journal of pediatrics, 2015, Volume: 167, Issue:1

    Topics: Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Male; Propranolol

2015
[Hepatic hemangiomas: Spectacular response to treatment with propranolol].
    Anales de pediatria (Barcelona, Spain : 2003), 2015, Volume: 83, Issue:6

    Topics: Abdominal Neoplasms; Hemangioma; Humans; Infant; Propranolol; Treatment Outcome

2015
Multicenter Evaluation of the Effectiveness of Systemic Propranolol in the Treatment of Airway Hemangiomas.
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2015, Volume: 153, Issue:3

    Topics: Airway Obstruction; Endoscopy; Female; Hemangioma; Humans; Infant; Infant, Newborn; Laryngeal Neopla

2015
Risk of neurodevelopmental abnormalities in children treated with propranolol.
    The British journal of dermatology, 2015, Volume: 173, Issue:6

    Topics: Adrenergic beta-Antagonists; Animals; Child, Preschool; Female; Hemangioma; Humans; Infant; Male; Ne

2015
Propranolol during pregnancy for large chorioangioma.
    Medical hypotheses, 2015, Volume: 85, Issue:4

    Topics: Adult; Female; Hemangioma; Humans; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome

2015
DIFFUSE CHOROIDAL HEMANGIOMA MASQUERADING AS CENTRAL SEROUS CHORIORETINOPATHY TREATED WITH ORAL PROPRANOLOL.
    Retinal cases & brief reports, 2016,Winter, Volume: 10, Issue:1

    Topics: Adolescent; Adrenergic beta-Antagonists; Central Serous Chorioretinopathy; Choroid Neoplasms; Diagno

2016
Use of propranolol on a nasal hemangioma in an extremely low birthweight premature infant.
    The Journal of dermatology, 2015, Volume: 42, Issue:11

    Topics: Child, Preschool; Hemangioma; Humans; Infant; Infant, Extremely Low Birth Weight; Infant, Extremely

2015
Oral Propranolol for Infantile Hemangioma.
    The New England journal of medicine, 2015, 07-16, Volume: 373, Issue:3

    Topics: Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Male; Propranolol

2015
Oral Propranolol for Infantile Hemangioma.
    The New England journal of medicine, 2015, 07-16, Volume: 373, Issue:3

    Topics: Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Male; Propranolol

2015
Large Doses of Propranolol for the Treatment of Infantile Cephalic and Facial Hemangiomas: A Clinical Report of 38 Cases.
    The Journal of clinical pediatric dentistry, 2015,Spring, Volume: 39, Issue:3

    Topics: Antineoplastic Agents; Blood Glucose; Blood Pressure; Drug Administration Schedule; Facial Neoplasms

2015
Propranolol (Hemangiol) and severe infantile haemangiomas. The drug of first choice.
    Prescrire international, 2015, Volume: 24, Issue:162

    Topics: Adrenergic beta-Antagonists; Clinical Trials as Topic; Hemangioma; Humans; Prednisolone; Propranolol

2015
Propranolol-responsive cranial nerve palsies in a patient with PHACES syndrome.
    International journal of pediatric otorhinolaryngology, 2015, Volume: 79, Issue:10

    Topics: Aortic Coarctation; Bell Palsy; Eye Abnormalities; Hemangioma; Humans; Infant; Neurocutaneous Syndro

2015
Commentary on Moodley S et al. "Shouldn't Propranolol be Used to Treat All Hemangiomas?".
    Aesthetic plastic surgery, 2015, Volume: 39, Issue:6

    Topics: Animals; Cadaver; Evidence-Based Medicine; Hemangioma; Humans; Propranolol

2015
[Making hemangiomas disappear with cardiac agents: pediatric surgeons greet the new study results].
    Kinderkrankenschwester : Organ der Sektion Kinderkrankenpflege, 2015, Volume: 34, Issue:4

    Topics: Child; Child, Preschool; Controlled Clinical Trials as Topic; Drug Approval; Germany; Hemangioma; Hu

2015
Characterization of Endothelial Microparticles Induced by Different Therapeutic Drugs for Infantile Hemangioma.
    Journal of cardiovascular pharmacology, 2015, Volume: 66, Issue:3

    Topics: Cells, Cultured; Dexamethasone; Endothelium, Vascular; Flow Cytometry; Hemangioma; Human Umbilical V

2015
[Oral propranolol effective for hemangioma].
    MMW Fortschritte der Medizin, 2015, Sep-10, Volume: 157, Issue:15

    Topics: Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Male; Propranolol

2015
Shouldn't Propranolol Be Used to Treat All Haemangiomas?
    Aesthetic plastic surgery, 2015, Volume: 39, Issue:6

    Topics: Female; Hemangioma; Humans; Infant; Male; Propranolol; Retrospective Studies; Skin Neoplasms

2015
Propranolol for Treatment of Genital Infantile Hemangioma.
    The Journal of urology, 2016, Volume: 195, Issue:3

    Topics: Adolescent; Child; Child, Preschool; Female; Genital Neoplasms, Female; Genital Neoplasms, Male; Hem

2016
Evaluation of the efficacy and safety of propranolol, timolol maleate, and the combination of the two, in the treatment of superficial infantile haemangiomas.
    The British journal of oral & maxillofacial surgery, 2015, Volume: 53, Issue:9

    Topics: Adrenergic beta-Antagonists; Drug Combinations; Hemangioma; Humans; Propranolol; Prospective Studies

2015
Clinical Characteristics and Treatment Options of Infantile Vascular Anomalies.
    Medicine, 2015, Volume: 94, Issue:40

    Topics: Adrenal Cortex Hormones; Age Factors; China; Combined Modality Therapy; Female; Hemangioma; Humans;

2015
Propranolol in the treatment of infantile haemangiomas: lessons from the European Propranolol In the Treatment of Complicated Haemangiomas (PITCH) Taskforce survey.
    The British journal of dermatology, 2016, Volume: 174, Issue:3

    Topics: Administration, Oral; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Hemangioma; H

2016
Haemangioma in an infant whose mother was receiving long-term propranolol treatment during pregnancy.
    The British journal of dermatology, 2016, Volume: 174, Issue:2

    Topics: Adrenergic beta-Antagonists; Hemangioma; Humans; Propranolol; Skin Neoplasms

2016
Conservative Management of Cardiac Hemangioma for 11 Years.
    Texas Heart Institute journal, 2015, Volume: 42, Issue:5

    Topics: Adrenergic beta-Antagonists; Adult; Coronary Angiography; Drug Therapy, Combination; Echocardiograph

2015
Reply of the authors.
    Pediatric endocrinology reviews : PER, 2015, Volume: 13, Issue:1

    Topics: Adrenergic beta-Antagonists; Hemangioma; Humans; Hypoglycemia; Propranolol

2015
Response to "Propranolol Induced Hypoglycemia" by Amir Horev, MD, Alon Haim, MD, Alex Zvulunov, MD.
    Pediatric endocrinology reviews : PER, 2015, Volume: 13, Issue:1

    Topics: Adrenergic beta-Antagonists; Hemangioma; Humans; Hypoglycemia; Propranolol

2015
Propranolol Targets Hemangioma Stem Cells via cAMP and Mitogen-Activated Protein Kinase Regulation.
    Stem cells translational medicine, 2016, Volume: 5, Issue:1

    Topics: Animals; Apoptosis; Cell Proliferation; Cyclic AMP; Dose-Response Relationship, Drug; Hemangioma; Hu

2016
[Effect of propranolol gel on plasma VEGF, bFGF and MMP-9 in proliferating infantile hemangiomas of superficial type].
    Zhonghua zheng xing wai ke za zhi = Zhonghua zhengxing waike zazhi = Chinese journal of plastic surgery, 2015, Volume: 31, Issue:4

    Topics: Administration, Topical; Case-Control Studies; Child; Enzyme-Linked Immunosorbent Assay; Fibroblast

2015
Treatment for Infantile Hemangiomas: Selection Criteria, Safety, and Outcomes Using Oral Propranolol During the Early Phase of Propranolol Use for Hemangiomas.
    The Journal of craniofacial surgery, 2016, Volume: 27, Issue:1

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Antineoplastic Agents; Body Weight; Cohort Studie

2016
Use of propranolol for parotid hemangioma.
    Head & neck, 2016, Volume: 38 Suppl 1

    Topics: Administration, Oral; Female; Hemangioma; Humans; Infant; Infant, Newborn; Male; Neoplasm Recurrence

2016
[Fast response of subglottic haemangiomas to propranolol].
    Anales de pediatria (Barcelona, Spain : 2003), 2016, Volume: 85, Issue:4

    Topics: Child, Preschool; Female; Glottis; Hemangioma; Humans; Infant; Infant, Newborn; Laryngeal Neoplasms;

2016
Safety of Propranolol Therapy for Severe Infantile Hemangioma.
    JAMA, 2016, Jan-26, Volume: 315, Issue:4

    Topics: Administration, Oral; Antineoplastic Agents; Causality; Child; Child, Preschool; Compassionate Use T

2016
Commentary on Moodley S et al. "Shouldn't Propranolol be Used to Treat All Hemangiomas?" and Dr. Blei's Invited Commentary.
    Aesthetic plastic surgery, 2016, Volume: 40, Issue:2

    Topics: Hemangioma; Humans; Propranolol

2016
The embryo-placental CD15-positive "vasculogenic zones" as a source of propranolol-sensitive pediatric vascular tumors.
    Placenta, 2016, Volume: 38

    Topics: Age of Onset; Cell Lineage; Child; Drug Resistance, Neoplasm; Embryo, Mammalian; Endothelial Cells;

2016
Propranolol was effective in treating cutaneous infantile haemangiomas in Thai children.
    Acta paediatrica (Oslo, Norway : 1992), 2016, Volume: 105, Issue:6

    Topics: Adrenergic beta-Antagonists; Anti-Inflammatory Agents; Female; Hemangioma; Humans; Infant, Newborn;

2016
Rebound Growth of Infantile Hemangiomas After Propranolol Therapy.
    Pediatrics, 2016, Volume: 137, Issue:4

    Topics: Adrenergic beta-Antagonists; Cohort Studies; Drug Administration Schedule; Female; Hemangioma; Human

2016
Hemangiomas and β-Blockers: On the Rebound.
    Pediatrics, 2016, Volume: 137, Issue:4

    Topics: Adrenergic beta-Antagonists; Hemangioma; Infant; Propranolol

2016
Treatment of infantile hemangioma by intralesional injection of propranolol combined with compound betamethasone.
    European review for medical and pharmacological sciences, 2016, Volume: 20, Issue:4

    Topics: Betamethasone; Drug Therapy, Combination; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Inj

2016
The treatment of problematic hemangiomas in children with propranolol and 940nm diode laser.
    Journal of pediatric surgery, 2016, Volume: 51, Issue:5

    Topics: Administration, Oral; Antineoplastic Agents; Child, Preschool; Combined Modality Therapy; Female; He

2016
Propranolol for infantile hemangioma: Effect on plasma vascular endothelial growth factor.
    Pediatrics international : official journal of the Japan Pediatric Society, 2016, Volume: 58, Issue:11

    Topics: Administration, Oral; Adolescent; Adrenergic beta-Antagonists; Child; Child, Preschool; Dose-Respons

2016
Oral Propranolol for the Treatment of Infantile Hemangiomas in the Post-Proliferative Phase: A-Single Center Retrospective Study of 31 Cases.
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2016, Volume: 74, Issue:8

    Topics: Administration, Oral; Child, Preschool; Female; Head and Neck Neoplasms; Hemangioma; Humans; Infant;

2016
[Effects of topical propranolol hydrochloride gel for treatment of infantile hemangioma in nude mice].
    Zhonghua zheng xing wai ke za zhi = Zhonghua zhengxing waike zazhi = Chinese journal of plastic surgery, 2015, Volume: 31, Issue:6

    Topics: Animals; Gels; Hemangioma; Humans; Immunohistochemistry; Mice; Mice, Nude; Propranolol; Skin Neoplas

2015
[Subsequent therapy for infantile hemangiomas after discontinuation of oral propranolol].
    Shanghai kou qiang yi xue = Shanghai journal of stomatology, 2015, Volume: 24, Issue:6

    Topics: Administration, Oral; Bleomycin; Child, Preschool; Face; Female; Hemangioma; Humans; Hyperplasia; Hy

2015
[Changes in ambulatory electrocardiographic findings after oral administration of low-dose propranolol in infants with hemangioma].
    Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 2016, Volume: 18, Issue:4

    Topics: Administration, Oral; Electrocardiography; Female; Heart Rate; Hemangioma; Humans; Infant; Male; Pro

2016
Hepatic Hemangioma with Kasabach-Merritt Syndrome in an Adult Patient.
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2016, Apr-25, Volume: 67, Issue:4

    Topics: Abdomen; Ecchymosis; Female; Gastrointestinal Hemorrhage; Hemangioma; Humans; Kasabach-Merritt Syndr

2016
Serum and tissue profile of VEGF and its receptors VGFR1/R2 in children with infantile hemangiomas on systemic propranolol treatment.
    Immunology letters, 2016, Volume: 175

    Topics: Angiogenesis Inhibitors; Female; Gene Expression Profiling; Hemangioma; Humans; Immunohistochemistry

2016
3D photography is a reliable method of measuring infantile haemangioma volume over time.
    Journal of pediatric surgery, 2016, Volume: 51, Issue:9

    Topics: Adrenergic beta-Antagonists; Aftercare; Female; Follow-Up Studies; Hemangioma; Humans; Imaging, Thre

2016
Clinical Outcomes of Infants With Periorbital Hemangiomas Treated With Oral Propranolol.
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2016, Volume: 74, Issue:11

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Drug Administration Schedule; Eye; Female; Follow

2016
Role of oral propranolol in the treatment of infantile subglottic hemangioma.
    International journal of clinical pharmacology and therapeutics, 2016, Volume: 54, Issue:9

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Female; Glottis; Hemangioma; Humans; Infant; Infa

2016
Multifocal infantile haemangioma: a diagnostic challenge.
    BMJ case reports, 2016, Jun-17, Volume: 2016

    Topics: Adrenergic beta-Antagonists; Anemia; Diagnosis, Differential; Hemangioma; Humans; Infant; Infant, Ne

2016
Low Dose Propanolol for Infantile Haemangioma.
    Journal of paediatrics and child health, 2016, Volume: 52, Issue:5

    Topics: Dose-Response Relationship, Drug; Hemangioma; Humans; Infant; Propranolol

2016
Propranolol treatment for infantile hemangioma: a case series of sixty-two patients.
    La Pediatria medica e chirurgica : Medical and surgical pediatrics, 2016, Jun-27, Volume: 38, Issue:2

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Child, Preschool; Female; Hemangioma; Humans; Inf

2016
Reevaluating the Need for Electrocardiograms Prior to Initiation of Treatment With Propranolol for Infantile Hemangiomas.
    JAMA pediatrics, 2016, 09-01, Volume: 170, Issue:9

    Topics: Contraindications, Drug; Electrocardiography; Fee-for-Service Plans; Heart Diseases; Hemangioma; Hum

2016
Response to propranolol in infantile hemangioma.
    Pediatrics international : official journal of the Japan Pediatric Society, 2016, Volume: 58, Issue:7

    Topics: Adrenergic beta-Antagonists; Biopsy; Dose-Response Relationship, Drug; Female; Hemangioma; Humans; I

2016
The Role of the Pharmacist in the Treatment of Patients with Infantile Hemangioma Using Propranolol.
    Advances in therapy, 2016, Volume: 33, Issue:10

    Topics: Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Hemangioma; H

2016
Effective treatment for infantile hemangioma with long-pulsed dye laser with oral propranolol medication: a preliminary report.
    Pediatric surgery international, 2016, Volume: 32, Issue:9

    Topics: Administration, Oral; Combined Modality Therapy; Female; Hemangioma; Humans; Infant; Lasers, Dye; Ma

2016
Corticosteroids as an adjunct to propranolol for infantile haemangiomas complicated by recalcitrant ulceration.
    The British journal of dermatology, 2017, Volume: 176, Issue:4

    Topics: Administration, Oral; Chronic Disease; Drug Therapy, Combination; Glucocorticoids; Hemangioma; Human

2017
Topical Timolol Maleate Treatment of Infantile Hemangiomas.
    Pediatrics, 2016, Volume: 138, Issue:3

    Topics: Administration, Oral; Administration, Topical; Adrenergic beta-Antagonists; Cohort Studies; Female;

2016
Topical Treatment of Infantile Haemangiomas: A Comparative Study on the Selection of a Semi-Solid Vehicle.
    Skin pharmacology and physiology, 2016, Volume: 29, Issue:4

    Topics: Administration, Cutaneous; Drug Carriers; Drug Delivery Systems; Hemangioma; Humans; Organ Culture T

2016
Use of Propranolol for Treating Hemangiomas in Infants with Previously Diagnosed Hypoglycemic Conditions.
    Pediatric dermatology, 2016, Volume: 33, Issue:6

    Topics: Administration, Oral; Female; Hemangioma; Humans; Hypoglycemia; Infant, Newborn; Infant, Premature,

2016
Is Routine Electrocardiography Necessary Before Initiation of Propranolol for Treatment of Infantile Hemangiomas?
    Pediatric dermatology, 2016, Volume: 33, Issue:6

    Topics: Adrenergic beta-Antagonists; Electrocardiography; Hemangioma; Hemangioma, Capillary; Humans; Infant;

2016
[Chinese experts consensus on the use of oral propranolol for treatment of infantile hemangiomas].
    Shanghai kou qiang yi xue = Shanghai journal of stomatology, 2016, Volume: 25, Issue:3

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Consensus; Female; Hemangioma; Humans; Infant; La

2016
Cardiac evaluation in children with hemangiomas.
    Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2016, Volume: 44, Issue:6

    Topics: Contraindications; Echocardiography; Female; Heart Diseases; Heart Ventricles; Hemangioma; Humans; I

2016
Expression of β-Adrenergic Receptor Subtypes in Proliferative, Involuted, and Propranolol-Responsive Infantile Hemangiomas.
    JAMA facial plastic surgery, 2017, Mar-01, Volume: 19, Issue:2

    Topics: Blotting, Western; Case-Control Studies; Facial Neoplasms; Female; Hemangioma; Humans; Infant; Male;

2017
Cardiovascular Profile of Propranolol after Multiple Dosing in Infantile Hemangioma.
    Pharmacology, 2017, Volume: 99, Issue:1-2

    Topics: Adrenergic beta-Antagonists; Blood Pressure; Dose-Response Relationship, Drug; Drug Monitoring; Fema

2017
Nd:YAG and pulsed dye laser therapy in infantile haemangiomas: a retrospective analysis of 271 treated haemangiomas in 149 children.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2017, Volume: 31, Issue:8

    Topics: Adrenergic beta-Antagonists; Child; Combined Modality Therapy; Female; Hemangioma; Humans; Infant; L

2017
Oral propranolol for infantile hemangiomas: a prospective study on the role of 48-hour Holter monitoring in additional safety assessment.
    The Journal of dermatological treatment, 2017, Volume: 28, Issue:6

    Topics: Administration, Oral; Blood Pressure; Drug Dosage Calculations; Electrocardiography, Ambulatory; Fem

2017
Propranolol as first-line treatment for life-threatening diffuse infantile hepatic hemangioma: A case report.
    Hepatology (Baltimore, Md.), 2017, Volume: 66, Issue:1

    Topics: Female; Hemangioma; Humans; Infant; Liver Neoplasms; Propranolol; Remission Induction; Severity of I

2017
Cytochrome P450 isoform genotyping in poor propranolol responders for hemangioma treatment.
    Pediatrics international : official journal of the Japan Pediatric Society, 2017, Volume: 59, Issue:1

    Topics: Cytochrome P-450 Enzyme System; Genotype; Hemangioma; Humans; Infant; Propranolol; Protein Isoforms;

2017
Downregulation of miR-382 by propranolol inhibits the progression of infantile hemangioma via the PTEN-mediated AKT/mTOR pathway.
    International journal of molecular medicine, 2017, Volume: 39, Issue:3

    Topics: Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Gene Expression Regulation, Neoplast

2017
Propranolol, infantile haemangiomas, and serendipity: new use for an old drug.
    The Libyan journal of medicine, 2011, Volume: 6, Issue:1

    Topics: Adrenergic beta-Antagonists; Hemangioma; Humans; Infant; Propranolol

2011
Propranolol treatment of infantile hemangioma is not associated with psychological problems at 7 years of age.
    Journal of the American Academy of Dermatology, 2017, Volume: 77, Issue:1

    Topics: Child; Female; Hemangioma; Humans; Male; Mental Disorders; Propranolol; Prospective Studies; Psychol

2017
Prolonged tumour growth after treatment of infantile haemangioma with propranolol.
    The Medical journal of Australia, 2017, Feb-20, Volume: 206, Issue:3

    Topics: Child; Child, Preschool; Disease Progression; Female; Hemangioma; Humans; Infant; Infant, Newborn; M

2017
When to stop propranolol for infantile hemangioma.
    Scientific reports, 2017, 02-22, Volume: 7

    Topics: Administration, Oral; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Female

2017
Image Gallery: PELVIS syndrome.
    The British journal of dermatology, 2017, Volume: 176, Issue:2

    Topics: Antineoplastic Agents; Female; Hemangioma; Humans; Infant; Magnetic Resonance Imaging; Meningomyeloc

2017
Propranolol treatment for infantile hemangioma does not increase risk of childhood wheezing.
    Pediatric pulmonology, 2017, Volume: 52, Issue:8

    Topics: Adrenergic beta-Antagonists; Asthma; Case-Control Studies; Child, Preschool; Female; Hemangioma; Hos

2017
[Chinese expert consensus on the use of topical timolol maleate treatment of infantile hemangiomas].
    Shanghai kou qiang yi xue = Shanghai journal of stomatology, 2016, Volume: 25, Issue:6

    Topics: Administration, Topical; Adrenergic beta-Antagonists; Asian People; Consensus; Expert Testimony; Hem

2016
Molecular and immunohistochemical expression of apoptotic proteins Bax, Bcl-2 and Caspase 3 in infantile hemangioma tissues as an effect of propranolol treatment.
    Immunology letters, 2017, Volume: 185

    Topics: Angiogenesis Inhibitors; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Cells, Cultured; Female;

2017
Successful propranolol treatment for diffuse neonatal hemangiomatosis.
    The Journal of dermatology, 2017, Volume: 44, Issue:6

    Topics: Administration, Oral; Female; Hemangioma; Humans; Infant, Newborn; Liver Neoplasms; Magnetic Resonan

2017
A New Perspective for Infantile Hepatic Hemangioma in the Age of Propranolol: Experience at Baskent University.
    Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 2017, Volume: 15, Issue:Suppl 2

    Topics: Age of Onset; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Critical Pathways; Female;

2017
67th annual meeting of the American Academy of Dermatology: San Francisco, California, USA, 6-10 March 2009.
    American journal of clinical dermatology, 2009, Volume: 10, Issue:3

    Topics: Acne Vulgaris; Dermatology; Hemangioma; Humans; Keratosis, Actinic; Melanoma; Methicillin-Resistant

2009
Life-threatening infantile haemangioma: a dramatic response to propranolol.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2009, Volume: 23, Issue:12

    Topics: Female; Hemangioma; Humans; Infant, Newborn; Propranolol

2009
Role of Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma.
    International journal of pediatric otorhinolaryngology, 2009, Volume: 73, Issue:8

    Topics: Abnormalities, Multiple; Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Laryngeal

2009
Role of Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma.
    International journal of pediatric otorhinolaryngology, 2009, Volume: 73, Issue:8

    Topics: Abnormalities, Multiple; Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Laryngeal

2009
Role of Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma.
    International journal of pediatric otorhinolaryngology, 2009, Volume: 73, Issue:8

    Topics: Abnormalities, Multiple; Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Laryngeal

2009
Role of Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma.
    International journal of pediatric otorhinolaryngology, 2009, Volume: 73, Issue:8

    Topics: Abnormalities, Multiple; Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Laryngeal

2009
[Treatment of infantile hemangioma with propranolol].
    Anales de pediatria (Barcelona, Spain : 2003), 2010, Volume: 72, Issue:2

    Topics: Antihypertensive Agents; Hemangioma; Humans; Infant; Male; Propranolol

2010
[Treatment of infantile hemangioma with propranolol].
    Anales de pediatria (Barcelona, Spain : 2003), 2010, Volume: 72, Issue:2

    Topics: Antihypertensive Agents; Hemangioma; Humans; Infant; Male; Propranolol

2010
[Treatment of infantile hemangioma with propranolol].
    Anales de pediatria (Barcelona, Spain : 2003), 2010, Volume: 72, Issue:2

    Topics: Antihypertensive Agents; Hemangioma; Humans; Infant; Male; Propranolol

2010
[Treatment of infantile hemangioma with propranolol].
    Anales de pediatria (Barcelona, Spain : 2003), 2010, Volume: 72, Issue:2

    Topics: Antihypertensive Agents; Hemangioma; Humans; Infant; Male; Propranolol

2010
Propranolol for airway hemangiomas: case report of novel treatment.
    The Laryngoscope, 2009, Volume: 119, Issue:10

    Topics: Adrenergic beta-Antagonists; Antineoplastic Agents, Phytogenic; Bronchoscopy; Disease Progression; F

2009
Propranolol for severe infantile hemangiomas: follow-up report.
    Pediatrics, 2009, Volume: 124, Issue:3

    Topics: Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Male; Propranolo

2009
Propranolol for severe infantile hemangiomas: follow-up report.
    Pediatrics, 2009, Volume: 124, Issue:3

    Topics: Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Male; Propranolo

2009
Propranolol for severe infantile hemangiomas: follow-up report.
    Pediatrics, 2009, Volume: 124, Issue:3

    Topics: Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Male; Propranolo

2009
Propranolol for severe infantile hemangiomas: follow-up report.
    Pediatrics, 2009, Volume: 124, Issue:3

    Topics: Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Male; Propranolo

2009
Propranolol for severe infantile hemangiomas: follow-up report.
    Pediatrics, 2009, Volume: 124, Issue:3

    Topics: Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Male; Propranolo

2009
Propranolol for severe infantile hemangiomas: follow-up report.
    Pediatrics, 2009, Volume: 124, Issue:3

    Topics: Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Male; Propranolo

2009
Propranolol for severe infantile hemangiomas: follow-up report.
    Pediatrics, 2009, Volume: 124, Issue:3

    Topics: Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Male; Propranolo

2009
Propranolol for severe infantile hemangiomas: follow-up report.
    Pediatrics, 2009, Volume: 124, Issue:3

    Topics: Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Male; Propranolo

2009
Propranolol for severe infantile hemangiomas: follow-up report.
    Pediatrics, 2009, Volume: 124, Issue:3

    Topics: Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Male; Propranolo

2009
Propranolol for severe infantile hemangiomas: follow-up report.
    Pediatrics, 2009, Volume: 124, Issue:3

    Topics: Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Male; Propranolo

2009
Propranolol for severe infantile hemangiomas: follow-up report.
    Pediatrics, 2009, Volume: 124, Issue:3

    Topics: Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Male; Propranolo

2009
Propranolol for severe infantile hemangiomas: follow-up report.
    Pediatrics, 2009, Volume: 124, Issue:3

    Topics: Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Male; Propranolo

2009
Propranolol for severe infantile hemangiomas: follow-up report.
    Pediatrics, 2009, Volume: 124, Issue:3

    Topics: Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Male; Propranolo

2009
Propranolol for severe infantile hemangiomas: follow-up report.
    Pediatrics, 2009, Volume: 124, Issue:3

    Topics: Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Male; Propranolo

2009
Propranolol for severe infantile hemangiomas: follow-up report.
    Pediatrics, 2009, Volume: 124, Issue:3

    Topics: Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Male; Propranolo

2009
Propranolol for severe infantile hemangiomas: follow-up report.
    Pediatrics, 2009, Volume: 124, Issue:3

    Topics: Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Male; Propranolo

2009
[Use of beta blockers--a new perspective in therapy of infantile hemangiomas of the head and neck area].
    Laryngo- rhino- otologie, 2010, Volume: 89, Issue:4

    Topics: Adrenergic beta-Antagonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Female;

2010
Successful treatment of a large hemangioma with propranolol.
    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2010, Volume: 8, Issue:3

    Topics: Female; Hemangioma; Humans; Infant, Newborn; Infant, Premature; Propranolol; Thoracic Neoplasms; Tre

2010
Successful treatment of isolated subglottic haemangioma with propranolol alone.
    International journal of pediatric otorhinolaryngology, 2009, Volume: 73, Issue:12

    Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Glottis;

2009
[Propranolol and haemangiomas].
    Anales de pediatria (Barcelona, Spain : 2003), 2009, Volume: 71, Issue:5

    Topics: Child; Hemangioma; Humans; Propranolol

2009
[Propranolol therapy to treat problematic hemangiomas : a new standard therapy makes its debut].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2009, Volume: 60, Issue:12

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Blood Pressure; Facial Neoplasms; Female; Follow-

2009
[Response to oral propranolol therapy for ulcerated hemangiomas in infancy].
    Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 2009, Volume: 16, Issue:12

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Female; Forearm; Hemangioma; Humans; Infant; Prop

2009
Propranolol as first-line treatment for infantile hemangiomas.
    Plastic and reconstructive surgery, 2010, Volume: 125, Issue:1

    Topics: Adrenergic beta-Antagonists; Hemangioma; Humans; Propranolol

2010
[Angiomas].
    La Revue du praticien, 2009, Dec-20, Volume: 59, Issue:10

    Topics: Adrenergic beta-Antagonists; Hemangioma; Humans; Lasers, Dye; Propranolol; Skin Neoplasms

2009
Propranolol for the treatment of a life-threatening subglottic and mediastinal infantile hemangioma.
    The Journal of pediatrics, 2010, Volume: 156, Issue:2

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Airway Obstruction; Antineoplastic Agents, Hormon

2010
Propranolol for isolated orbital infantile hemangioma.
    Archives of ophthalmology (Chicago, Ill. : 1960), 2010, Volume: 128, Issue:2

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Biomarkers, Tumor; Female; Hemangioma; Humans; In

2010
Propranolol may become first-line treatment in obstructive subglottic infantile hemangiomas.
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2010, Volume: 142, Issue:3

    Topics: Adrenergic beta-Antagonists; Hemangioma; Humans; Laryngeal Neoplasms; Propranolol

2010
[Treatment of infantile hemangiomas with low-dose propranolol: evaluation of short-term efficacy and safety].
    Zhonghua yi xue za zhi, 2009, Dec-01, Volume: 89, Issue:44

    Topics: Dose-Response Relationship, Drug; Female; Hemangioma; Humans; Infant; Male; Propranolol; Prospective

2009
[Infantile hemangioma. Successful treatment with propranolol].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2010, Volume: 61, Issue:4

    Topics: Female; Hemangioma; Humans; Infant, Newborn; Propranolol; Skin Neoplasms; Treatment Outcome; Vaginal

2010
Successful treatment of ulcerated haemangioma with propranolol.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2010, Volume: 24, Issue:9

    Topics: Female; Hemangioma; Humans; Infant; Infant, Newborn; Male; Propranolol; Ulcer

2010
Use of propranolol to treat multicentric airway haemangioma.
    The Journal of laryngology and otology, 2010, Volume: 124, Issue:12

    Topics: Adrenergic beta-Antagonists; Airway Obstruction; Anti-Inflammatory Agents; Dexamethasone; Endoscopy;

2010
Propranolol as a novel treatment for congenital visceral haemangioma.
    Neonatology, 2010, Volume: 98, Issue:3

    Topics: Abdominal Neoplasms; Hemangioma; Humans; Infant, Newborn; Male; Propranolol; Umbilical Cord; Vascula

2010
[Propranolol in the therapy of infantile hemangioma--fascinating, but not with risk].
    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2010, Volume: 8, Issue:3

    Topics: Child; Hemangioma; Humans; Propranolol; Vasodilator Agents

2010
Efficacy of propranolol in hepatic infantile hemangiomas with diffuse neonatal hemangiomatosis.
    The Journal of pediatrics, 2010, Volume: 157, Issue:2

    Topics: Adrenal Cortex Hormones; Female; Heart Failure; Hemangioma; Humans; Infant; Liver Neoplasms; Male; P

2010
Successful treatment of infantile haemangiomas of the orbit with propranolol.
    Clinical & experimental ophthalmology, 2010, Volume: 38, Issue:6

    Topics: Adrenergic beta-Antagonists; Child, Preschool; Female; Hemangioma; Humans; Infant; Magnetic Resonanc

2010
Innovative therapeutics in pediatric dermatology.
    Dermatologic clinics, 2010, Volume: 28, Issue:3

    Topics: Adolescent; Adrenal Cortex Hormones; Alopecia Areata; Autoimmune Diseases; Child; Child, Preschool;

2010
Propranolol in the management of periorbital infantile haemangioma.
    Clinical & experimental ophthalmology, 2010, Volume: 38, Issue:6

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Astigmatism; Eyelid Neoplasms; Female; Hemangioma

2010
Management of infantile subglottic hemangioma: acebutolol or propranolol?
    International journal of pediatric otorhinolaryngology, 2010, Volume: 74, Issue:8

    Topics: Acebutolol; Adrenergic beta-Antagonists; Dose-Response Relationship, Drug; Drug Administration Sched

2010
Outpatient treatment of periocular infantile hemangiomas with oral propranolol.
    Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus, 2010, Volume: 14, Issue:3

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Humans; Infant; Infant, Newborn; Orbi

2010
Low-dose propranolol for infantile haemangioma.
    Journal of plastic, reconstructive & aesthetic surgery : JPRAS, 2011, Volume: 64, Issue:3

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Breast Neoplasms; Ear Neoplasms; Female; Follow-U

2011
Effectiveness of propranolol in a newborn with liver hemangiomatosis.
    European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift fur Kinderchirurgie, 2010, Volume: 20, Issue:6

    Topics: Cardiovascular Agents; Female; Hemangioma; Humans; Infant; Liver Neoplasms; Propranolol

2010
Hypoglycemia in children taking propranolol for the treatment of infantile hemangioma.
    Archives of dermatology, 2010, Volume: 146, Issue:7

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Blood Glucose; Dose-Response Relationship, Drug;

2010
Hypoglycemia in children taking propranolol for the treatment of infantile hemangioma.
    Archives of dermatology, 2010, Volume: 146, Issue:7

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Blood Glucose; Dose-Response Relationship, Drug;

2010
Hypoglycemia in children taking propranolol for the treatment of infantile hemangioma.
    Archives of dermatology, 2010, Volume: 146, Issue:7

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Blood Glucose; Dose-Response Relationship, Drug;

2010
Hypoglycemia in children taking propranolol for the treatment of infantile hemangioma.
    Archives of dermatology, 2010, Volume: 146, Issue:7

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Blood Glucose; Dose-Response Relationship, Drug;

2010
Hypoglycemia in children taking propranolol for the treatment of infantile hemangioma.
    Archives of dermatology, 2010, Volume: 146, Issue:7

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Blood Glucose; Dose-Response Relationship, Drug;

2010
Hypoglycemia in children taking propranolol for the treatment of infantile hemangioma.
    Archives of dermatology, 2010, Volume: 146, Issue:7

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Blood Glucose; Dose-Response Relationship, Drug;

2010
Hypoglycemia in children taking propranolol for the treatment of infantile hemangioma.
    Archives of dermatology, 2010, Volume: 146, Issue:7

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Blood Glucose; Dose-Response Relationship, Drug;

2010
Hypoglycemia in children taking propranolol for the treatment of infantile hemangioma.
    Archives of dermatology, 2010, Volume: 146, Issue:7

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Blood Glucose; Dose-Response Relationship, Drug;

2010
Hypoglycemia in children taking propranolol for the treatment of infantile hemangioma.
    Archives of dermatology, 2010, Volume: 146, Issue:7

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Blood Glucose; Dose-Response Relationship, Drug;

2010
Propranolol in the management of airway infantile hemangiomas.
    Archives of otolaryngology--head & neck surgery, 2010, Volume: 136, Issue:7

    Topics: Adrenal Cortex Hormones; Airway Obstruction; Combined Modality Therapy; Drug Therapy, Combination; F

2010
[Treatment of infantile parotid hemangioma with propranolol].
    Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese journal of stomatology, 2010, Volume: 45, Issue:5

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; In

2010
Propranolol for the treatment of airway hemangiomas: a case series and treatment algorithm.
    International journal of pediatric otorhinolaryngology, 2010, Volume: 74, Issue:9

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Airway Obstruction; Female; Hemangioma; Humans; I

2010
Role of propranolol in the management of periocular hemangiomas.
    Plastic and reconstructive surgery, 2010, Volume: 126, Issue:2

    Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Eye; Facial Neoplasms; Female; Follo

2010
Propranolol for infantile haemangiomas and neuroglycopenic seizures.
    Acta paediatrica (Oslo, Norway : 1992), 2010, Volume: 99, Issue:12

    Topics: Adrenergic beta-Antagonists; Blood Glucose; Hemangioma; Humans; Hyperphagia; Hypoglycemia; Infant; L

2010
Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma: A preliminary retrospective study of French experience.
    International journal of pediatric otorhinolaryngology, 2010, Volume: 74, Issue:11

    Topics: Adrenergic beta-Antagonists; Airway Obstruction; Drug Resistance; Hemangioma; Humans; Infant; Infant

2010
Management of complicated facial hemangiomas with beta-blocker (propranolol) therapy.
    Plastic and reconstructive surgery, 2010, Volume: 126, Issue:3

    Topics: Adrenergic beta-Antagonists; Facial Neoplasms; Female; Hemangioma; Humans; Infant; Propranolol

2010
Case report: Treatment failure using propanolol for treatment of focal subglottic hemangioma.
    International journal of pediatric otorhinolaryngology, 2010, Volume: 74, Issue:8

    Topics: Female; Follow-Up Studies; Glottis; Hemangioma; Humans; Infant; Laryngeal Neoplasms; Laryngoscopy; L

2010
Expression of components of the renin-angiotensin system in proliferating infantile haemangioma may account for the propranolol-induced accelerated involution.
    Journal of plastic, reconstructive & aesthetic surgery : JPRAS, 2011, Volume: 64, Issue:6

    Topics: Adrenergic beta-Antagonists; Angiotensins; Biomarkers, Tumor; Cell Proliferation; Disease Progressio

2011
[Documented good enough?].
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2010, Sep-23, Volume: 130, Issue:18

    Topics: Adrenergic beta-Antagonists; Documentation; Evidence-Based Medicine; Hemangioma; Humans; Propranolol

2010
Research in infantile haemangioma: local perspectives.
    Hong Kong medical journal = Xianggang yi xue za zhi, 2010, Volume: 16, Issue:5

    Topics: Adrenergic beta-Antagonists; Hemangioma; Hong Kong; Humans; Infant; Propranolol; Radiography; Resear

2010
Use of propranolol in infantile haemangioma among Chinese children.
    Hong Kong medical journal = Xianggang yi xue za zhi, 2010, Volume: 16, Issue:5

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Child, Preschool; Dose-Response Relationship, Dru

2010
Efficacy and safety of propranolol as first-line treatment for infantile hemangiomas.
    European journal of pediatrics, 2011, Volume: 170, Issue:4

    Topics: Adrenergic beta-Antagonists; Blood Pressure; Drug Administration Schedule; Female; Heart Rate; Heman

2011
Invited commentary.
    Journal of plastic, reconstructive & aesthetic surgery : JPRAS, 2011, Volume: 64, Issue:3

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Hemangioma; Humans; Infant; Infant, Newborn; Prop

2011
Mature infantile haemangiomas role for propranolol.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2011, Volume: 25, Issue:11

    Topics: Hemangioma; Humans; Infant; Propranolol; Treatment Outcome

2011
Hyperkalemia complicating propranolol treatment of an infantile hemangioma.
    Pediatrics, 2010, Volume: 126, Issue:6

    Topics: Adrenergic beta-2 Receptor Agonists; Adrenergic beta-Antagonists; Albuterol; Female; Fluid Therapy;

2010
Hepatic haemangioma of infancy: role of propranolol.
    Annals of tropical paediatrics, 2010, Volume: 30, Issue:4

    Topics: Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant, Low Birth Weight; Infant, Newborn;

2010
Hemangiomas of the nasal tip: an approach to a therapeutic challenge.
    International journal of pediatric otorhinolaryngology, 2011, Volume: 75, Issue:3

    Topics: Adrenergic beta-Antagonists; Child, Preschool; Cicatrix; Cryotherapy; Esthetics; Female; Follow-Up S

2011
Propranolol treatment for subglottic haemangioma.
    Archives of disease in childhood. Fetal and neonatal edition, 2011, Volume: 96, Issue:4

    Topics: Adrenergic beta-Antagonists; Hemangioma; Humans; Infant; Laryngeal Neoplasms; Laryngoscopy; Laryngos

2011
Propranolol for severe hemangioma of infancy.
    Journal of cardiovascular medicine (Hagerstown, Md.), 2011, Volume: 12, Issue:1

    Topics: Facial Neoplasms; Female; Hemangioma; Humans; Infant; Propranolol; Vasoconstrictor Agents

2011
Propranolol for severe hemangioma of infancy.
    Journal of cardiovascular medicine (Hagerstown, Md.), 2011, Volume: 12, Issue:1

    Topics: Angiotensin-Converting Enzyme Inhibitors; Diuretics; Facial Neoplasms; Female; Hemangioma; Humans; I

2011
Treatment of vascular anomalies of the upper extremity.
    The Journal of hand surgery, 2011, Volume: 36, Issue:2

    Topics: Child; Child, Preschool; Female; Hemangioma; Humans; Male; Propranolol; Radiography; Risk Assessment

2011
Efficacy and safety of propranolol in the treatment of parotid hemangioma.
    Cutaneous and ocular toxicology, 2011, Volume: 30, Issue:3

    Topics: Adrenergic beta-Antagonists; Female; Hemangioendothelioma; Hemangioma; Humans; Infant; Liver Neoplas

2011
Propranolol, a very promising treatment for ulceration in infantile hemangiomas: a study of 20 cases with matched historical controls.
    Journal of the American Academy of Dermatology, 2011, Volume: 64, Issue:5

    Topics: Adrenergic beta-Antagonists; Female; Head and Neck Neoplasms; Hemangioma; Humans; Infant; Male; Prop

2011
Propranolol for treatment of ulcerated infantile hemangiomas.
    Journal of the American Academy of Dermatology, 2011, Volume: 64, Issue:5

    Topics: Adrenergic beta-Antagonists; Child; Child, Preschool; Female; Head and Neck Neoplasms; Hemangioma; H

2011
Low-dose propranolol for multiple hepatic and cutaneous hemangiomas with deranged liver function.
    Pediatrics, 2011, Volume: 127, Issue:3

    Topics: Adrenergic beta-Antagonists; Dose-Response Relationship, Drug; Follow-Up Studies; Hemangioma; Humans

2011
Use of propranolol in treating hemangiomas.
    Canadian family physician Medecin de famille canadien, 2011, Volume: 57, Issue:3

    Topics: Adrenergic beta-Antagonists; Child; Hemangioma; Humans; Propranolol

2011
Management of complicated facial hemangiomas with Beta-blocker (propranolol) therapy.
    Plastic and reconstructive surgery, 2011, Volume: 127, Issue:4

    Topics: Adrenergic beta-Antagonists; Facial Neoplasms; Hemangioma; Humans; Infant; Propranolol

2011
Diffuse neonatal hemangiomatosis: a case report.
    International journal of dermatology, 2012, Volume: 51, Issue:10

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Gastrointestinal Neop

2012
Initial experience with a multidisciplinary strategy for initiation of propranolol therapy for infantile hemangiomas.
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2011, Volume: 144, Issue:1

    Topics: Adrenergic beta-Antagonists; Blood Pressure; Cardiovascular System; Child, Preschool; Dose-Response

2011
Initial experience with a multidisciplinary strategy for initiation of propranolol therapy for infantile hemangiomas.
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2011, Volume: 144, Issue:1

    Topics: Adrenergic beta-Antagonists; Blood Pressure; Cardiovascular System; Child, Preschool; Dose-Response

2011
Initial experience with a multidisciplinary strategy for initiation of propranolol therapy for infantile hemangiomas.
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2011, Volume: 144, Issue:1

    Topics: Adrenergic beta-Antagonists; Blood Pressure; Cardiovascular System; Child, Preschool; Dose-Response

2011
Initial experience with a multidisciplinary strategy for initiation of propranolol therapy for infantile hemangiomas.
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2011, Volume: 144, Issue:1

    Topics: Adrenergic beta-Antagonists; Blood Pressure; Cardiovascular System; Child, Preschool; Dose-Response

2011
Propranolol: useful therapeutic agent for the treatment of ulcerated infantile hemangiomas.
    Journal of pediatric surgery, 2011, Volume: 46, Issue:4

    Topics: Adrenergic beta-Antagonists; Female; Follow-Up Studies; Hemangioma; Humans; Infant; Male; Propranolo

2011
[Propranolol for the treatment of severe hemangiomas of infancy: results from a series of 28 patients].
    Actas dermo-sifiliograficas, 2011, Volume: 102, Issue:7

    Topics: Administration, Oral; Child, Preschool; Female; Hemangioma; Humans; Infant; Male; Propranolol; Sever

2011
β-blockers for infantile hemangiomas: a single-institution experience.
    Clinical pediatrics, 2011, Volume: 50, Issue:8

    Topics: Administration, Oral; Administration, Topical; Adrenergic beta-Antagonists; Drug Monitoring; Female;

2011
[Hemangiomas in childhood].
    Praxis, 2011, May-11, Volume: 100, Issue:10

    Topics: Adrenergic beta-Antagonists; Disease Progression; Female; Hemangioma; Hemangioma, Cavernous; Humans;

2011
Propranolol as first-line treatment of head and neck hemangiomas.
    Archives of otolaryngology--head & neck surgery, 2011, Volume: 137, Issue:5

    Topics: Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Child, Preschool; Female; Head and Neck Neopla

2011
Infantile intraspinal and extensive cutaneous hemangiomas: excellent response to propranolol.
    Neurology, 2011, May-17, Volume: 76, Issue:20

    Topics: Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Female; Hemangioma; Hemangioma, Cavernous, Cen

2011
Adverse effects of propranolol when used in the treatment of hemangiomas: a case series of 28 infants.
    Journal of the American Academy of Dermatology, 2011, Volume: 65, Issue:2

    Topics: Adrenergic beta-Antagonists; Biopsy, Needle; Bronchial Hyperreactivity; Cohort Studies; Dose-Respons

2011
Comment on efficacy and safety of propranolol in the treatment of parotid hemangioma.
    Cutaneous and ocular toxicology, 2011, Volume: 30, Issue:4

    Topics: Adrenergic beta-Antagonists; Female; Hemangioendothelioma; Hemangioma; Humans; Liver Neoplasms; Neop

2011
[Past, present, and future of propranolol for hemangiomas of infancy].
    Actas dermo-sifiliograficas, 2011, Volume: 102, Issue:7

    Topics: Forecasting; Hemangioma; Humans; Infant; Propranolol; Skin Neoplasms

2011
The Cyrano nose: different treatment approaches to management of hemangiomas of the nasal tip.
    Plastic and reconstructive surgery, 2011, Volume: 127, Issue:6

    Topics: Hemangioma; Humans; Infant; Nose Neoplasms; Propranolol; Rhinoplasty

2011
Successful treatment of infantile subglottic hemangioma with oral propranolol.
    Clinical pediatrics, 2012, Volume: 51, Issue:10

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Laryngeal Neo

2012
Atenolol: a promising alternative to propranolol for the treatment of hemangiomas.
    Journal of the American Academy of Dermatology, 2011, Volume: 65, Issue:2

    Topics: Atenolol; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies;

2011
Giving propranolol tablets to infants with hemangiomas - solubility in water.
    Journal of paediatrics and child health, 2011, Volume: 47, Issue:7

    Topics: Adrenergic beta-Antagonists; Dosage Forms; Hemangioma; Humans; Infant; Propranolol; Solubility

2011
[Oral propranolol in the management of periorbital proliferating phase infantile hemangioma].
    Zhonghua zheng xing wai ke za zhi = Zhonghua zhengxing waike zazhi = Chinese journal of plastic surgery, 2011, Volume: 27, Issue:3

    Topics: Child; Child, Preschool; Female; Hemangioma; Humans; Infant; Male; Orbital Neoplasms; Propranolol; R

2011
Propranolol vs corticosteroids for infantile hemangiomas: a multicenter retrospective analysis.
    Archives of dermatology, 2011, Volume: 147, Issue:12

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Cost-Benefit Analysis; Female; Glucocorticoids; H

2011
Failure of propranolol in the treatment of childhood haemangiomas of the head and neck.
    The Journal of laryngology and otology, 2011, Volume: 125, Issue:11

    Topics: Adrenal Cortex Hormones; Airway Obstruction; Anti-Inflammatory Agents; Combined Modality Therapy; Co

2011
Evolving treatments in the management of laryngotracheal hemangiomas: will propranolol supplant steroids and surgery?
    International journal of pediatric otorhinolaryngology, 2011, Volume: 75, Issue:11

    Topics: Cohort Studies; Female; Follow-Up Studies; Hemangioma; Hospitals, Pediatric; Humans; Immunohistochem

2011
Propranolol for the treatment of subglottic hemangiomas.
    International journal of pediatric otorhinolaryngology, 2011, Volume: 75, Issue:12

    Topics: Administration, Oral; Female; Hemangioma; Humans; Infant; Laryngeal Neoplasms; Male; Propranolol; Re

2011
Oral propranolol for exudative retinal detachment in diffuse choroidal hemangioma.
    Archives of ophthalmology (Chicago, Ill. : 1960), 2011, Volume: 129, Issue:10

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Choroid Neoplasms; Exudates and Transudates; Fema

2011
In brief: oral propranolol infantile hemangiomas.
    The Medical letter on drugs and therapeutics, 2011, Oct-31, Volume: 53, Issue:1376

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Child, Preschool; Hemangioma; Humans; Infant; Pro

2011
Use of propranolol for treatment of hemangiomas in PHACE syndrome.
    Journal of perinatology : official journal of the California Perinatal Association, 2011, Volume: 31, Issue:11

    Topics: Abnormalities, Multiple; Adrenergic beta-Antagonists; Facial Neoplasms; Female; Hemangioma; Humans;

2011
New treatment strategy for granulomatous epulis: intralesional injection of propranolol.
    Medical hypotheses, 2012, Volume: 78, Issue:2

    Topics: Adrenergic beta-Antagonists; Female; Gingiva; Gingival Diseases; Granuloma; Hemangioma; Humans; Infa

2012
Propranolol for infantile haemangiomas: initiating treatment on an outpatient basis.
    Cardiology in the young, 2012, Volume: 22, Issue:4

    Topics: Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Male; Outpatients; Propranolol; Ret

2012
Childhood wheeze while taking propranolol for treatment of infantile hemangiomas.
    Pediatric pulmonology, 2012, Volume: 47, Issue:7

    Topics: Adrenergic beta-Antagonists; Androstadienes; Antineoplastic Agents; Dermatologic Agents; Face; Fluti

2012
Giving propranolol tablets to infants with hemangiomas.
    Journal of paediatrics and child health, 2011, Volume: 47, Issue:12

    Topics: Adrenergic beta-Antagonists; Hemangioma; Humans; Propranolol

2011
[The change of serum vascular endothelial growth factor and matrix metalloproteinases-9 in proliferative hemangioma treated with propranolol].
    Zhonghua zheng xing wai ke za zhi = Zhonghua zhengxing waike zazhi = Chinese journal of plastic surgery, 2011, Volume: 27, Issue:5

    Topics: Female; Hemangioma; Humans; Infant; Male; Matrix Metalloproteinase 9; Propranolol; Serum; Vascular E

2011
Reply to the letter to the Editor on "Low-dose propranolol for infantile haemangioma".
    Journal of plastic, reconstructive & aesthetic surgery : JPRAS, 2012, Volume: 65, Issue:8

    Topics: Adrenergic beta-Antagonists; Hemangioma; Humans; Propranolol

2012
Adrenal suppression following steroid treatment of infantile hemangiomas: expediting the move toward propranolol?
    Plastic and reconstructive surgery, 2012, Volume: 129, Issue:2

    Topics: Adrenal Insufficiency; Glucocorticoids; Hemangioma; Humans; Infant; Prednisolone; Propranolol; Prosp

2012
Treatment of subglottic hemangiomas with propranolol: initial experience in 10 infants.
    ANZ journal of surgery, 2011, Volume: 81, Issue:6

    Topics: Adrenergic beta-Antagonists; Female; Follow-Up Studies; Glottis; Hemangioma; Humans; Infant; Larynge

2011
Initial experiences with propranolol treatment of infantile hemangiomas: report of three cases.
    Medicinski arhiv, 2011, Volume: 65, Issue:6

    Topics: Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Male; Propranolol; Skin Neoplasms;

2011
[Pediatrics].
    Revue medicale suisse, 2012, Jan-11, Volume: 8, Issue:323

    Topics: Adrenergic beta-Agonists; Bacterial Infections; Breast Feeding; Enterocolitis, Necrotizing; Fever; G

2012
Use of propranolol for infantile hemangiomas.
    Pediatric hematology and oncology, 2012, Volume: 29, Issue:3

    Topics: Adrenergic beta-Antagonists; Bronchial Spasm; Hemangioma; Humans; Infant; Infant, Newborn; Propranol

2012
Propranolol for problematic head and neck hemangiomas: an analysis of 37 consecutive patients.
    International journal of pediatric otorhinolaryngology, 2012, Volume: 76, Issue:4

    Topics: Age Factors; Cohort Studies; Drug Administration Schedule; Female; Head and Neck Neoplasms; Hemangio

2012
[Hemangioma. New aspects of pathogenesis, differential diagnosis and therapy].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2012, Volume: 63, Issue:2

    Topics: Child; Child, Preschool; Cryotherapy; Female; Hemangioma; Humans; Infant, Newborn; Male; Propranolol

2012
Decreased eNOS protein expression in involuting and propranolol-treated hemangiomas.
    Archives of otolaryngology--head & neck surgery, 2012, Volume: 138, Issue:2

    Topics: Adolescent; Blotting, Western; Child; Child, Preschool; Cross-Sectional Studies; Female; Hemangioma;

2012
Comparison of efficacy of intralesional bleomycin and oral propanolol in management of hemangiomas.
    Plastic and reconstructive surgery, 2012, Volume: 129, Issue:4

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Antibiotics, Antineoplastic; Bleomycin; Child, Pr

2012
Treatment with propranolol for infantile hemangioma in 13 Taiwanese newborns and young infants.
    Pediatrics and neonatology, 2012, Volume: 53, Issue:2

    Topics: Female; Hemangioma; Humans; Infant; Infant, Newborn; Male; Propranolol; Taiwan

2012
How "unsafe" is propranolol when used in the treatment of infantile hemangioma?
    Journal of the American Academy of Dermatology, 2012, Volume: 66, Issue:5

    Topics: Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Male; Propranolol; Skin Neoplasms

2012
Topical propranolol for treatment of superficial infantile hemangiomas.
    Journal of the American Academy of Dermatology, 2012, Volume: 67, Issue:6

    Topics: Administration, Topical; Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Male; Oint

2012
Difficult treatment of consumptive hypothyroidism in a child with massive parotid hemangioma.
    Journal of pediatric endocrinology & metabolism : JPEM, 2012, Volume: 25, Issue:1-2

    Topics: Adrenal Cortex Hormones; Congenital Hypothyroidism; Female; Hemangioma; Humans; Hypothyroidism; Infa

2012
Propranolol induces regression of hemangioma cells through HIF-1α-mediated inhibition of VEGF-A.
    Annals of surgery, 2012, Volume: 256, Issue:1

    Topics: Adrenergic beta-Antagonists; Cell Migration Assays; Cell Survival; Dose-Response Relationship, Drug;

2012
Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon.
    Pediatric blood & cancer, 2012, Volume: 59, Issue:5

    Topics: Adrenergic beta-Antagonists; Child, Preschool; Female; Hemangioendothelioma; Hemangioma; Humans; Inf

2012
Propranolol reduces infantile hemangioma volume and vessel density.
    Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2012, Volume: 147, Issue:2

    Topics: Child, Preschool; Female; Hemangioma; Humans; Infant; Male; Propranolol; Skin Neoplasms

2012
A clue on the face...
    BMJ case reports, 2010, May-06, Volume: 2010

    Topics: Bronchoscopy; Diagnosis, Differential; Female; Hemangioma; Humans; Infant; Laryngeal Neoplasms; Lary

2010
Expanding the therapeutic repertoire of infantile haemangiomas: cohort-blinded study of oral nadolol compared with propranolol.
    The British journal of dermatology, 2013, Volume: 168, Issue:1

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Drug Administration Schedule; Feasibility Studies

2013
Propranolol as the first-line therapy for infantile hemangiomas: preliminary results of two centers.
    Journal of drugs in dermatology : JDD, 2012, Volume: 11, Issue:7

    Topics: Adrenergic beta-Antagonists; Child, Preschool; Feasibility Studies; Female; Follow-Up Studies; Heman

2012
Treating hemangioma of infancy with beta-blockers: is there really a risk of hypotension?
    Journal of the American Academy of Dermatology, 2012, Volume: 67, Issue:2

    Topics: Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Male; Propranolol; Skin Neoplasms

2012
Propranolol treatment for severe infantile hemangiomas: a single-centre 3-year experience.
    Acta paediatrica (Oslo, Norway : 1992), 2012, Volume: 101, Issue:10

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Male; Photogr

2012
Early growth of infantile hemangiomas: what parents' photographs tell us.
    Pediatrics, 2012, Volume: 130, Issue:2

    Topics: Adrenal Cortex Hormones; Age Factors; Diseases in Twins; Facial Neoplasms; Female; Hemangioma; Human

2012
Airway hemangiomas in PHACE syndrome.
    The Laryngoscope, 2012, Volume: 122, Issue:10

    Topics: Aortic Coarctation; Bronchoscopy; Disease-Free Survival; Eye Abnormalities; Female; Follow-Up Studie

2012
Management of adult onset orbital hemangioma by oral propranalol: a case report.
    Orbit (Amsterdam, Netherlands), 2012, Volume: 31, Issue:5

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Diagnosis, Differential; Female; Hemangioma; Huma

2012
Use of propranolol for treatment of infantile haemangiomas in an outpatient setting.
    Journal of paediatrics and child health, 2012, Volume: 48, Issue:10

    Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents; Child; Child, Preschool; Drug Administ

2012
Efficacy of propranolol treatment in thyroid dysfunction associated with severe infantile hepatic hemangioma.
    Hormone research in paediatrics, 2012, Volume: 78, Issue:4

    Topics: Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Liver Neoplasms; Propranolol; Sever

2012
Propranolol for infantile haemangioma: striking effect in the first weeks.
    International journal of pediatric otorhinolaryngology, 2012, Volume: 76, Issue:12

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Cohort Studies; Dose-Response Relationship, Drug;

2012
Propranolol as first-line treatment of a severe subglottic haemangioma.
    European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 2013, Volume: 43, Issue:1

    Topics: Bronchoscopy; Constriction, Pathologic; Female; Hemangioma; Humans; Infant; Laryngeal Neoplasms; Pro

2013
Propranolol accelerates adipogenesis in hemangioma stem cells and causes apoptosis of hemangioma endothelial cells.
    Plastic and reconstructive surgery, 2012, Volume: 130, Issue:5

    Topics: Adipogenesis; Adrenergic beta-Antagonists; Annexin A5; Apoptosis; Cell Proliferation; Dose-Response

2012
[Treatment of infantile subglottic hemangioma with oral propranolol].
    Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery, 2012, Volume: 47, Issue:9

    Topics: Female; Glottis; Hemangioma; Humans; Infant; Laryngeal Neoplasms; Male; Propranolol; Treatment Outco

2012
[Infantile hepatic hemangiomas: first-line propranolol monotherapy as new treatment strategy?].
    Klinische Padiatrie, 2012, Volume: 224, Issue:6

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Beckwith-Wiedemann Syndrome; Female; Follow-Up St

2012
Adverse effects of propranolol treatment for infantile hemangiomas in China.
    The Journal of dermatological treatment, 2014, Volume: 25, Issue:5

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Bronchial Hyperreactivity; China; Female; Hemangi

2014
Effects of propranolol on the proliferation and apoptosis of hemangioma-derived endothelial cells.
    Journal of pediatric surgery, 2012, Volume: 47, Issue:12

    Topics: Analysis of Variance; Apoptosis; Blotting, Western; Caspases; Cell Proliferation; Down-Regulation; E

2012
Propranolol for hemangiomas.
    Pediatric surgery international, 2013, Volume: 29, Issue:3

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Child; Child, Preschool; Dose-Response Relationsh

2013
Topical propranolol hydrochloride gel for superficial infantile hemangiomas.
    Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban, 2012, Volume: 32, Issue:6

    Topics: Female; Gels; Hemangioma; Humans; Infant; Infant, Newborn; Male; Propranolol

2012
Effect of propranolol on the treatment of infantile hemangiomas: a single tertiary center 3-year experience.
    The Journal of dermatological treatment, 2014, Volume: 25, Issue:5

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Female; Hemangioma; Humans; Infant; Male; Photogr

2014
Propranolol in a case series of 174 patients with complicated infantile haemangioma: indications, safety and future directions.
    The British journal of dermatology, 2013, Volume: 168, Issue:4

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Drug Administration Schedule; Female; Hemangioma;

2013
Propranolol given orally for proliferating infantile haemangiomas: analysis of efficacy and serological changes in vascular endothelial growth factor and endothelial nitric oxide synthase in 35 patients.
    The British journal of oral & maxillofacial surgery, 2013, Volume: 51, Issue:7

    Topics: Administration, Oral; Adrenergic beta-Antagonists; Analysis of Variance; Endothelium, Vascular; Enzy

2013
Preliminary experience on treatment of infantile hemangioma with low-dose propranolol in China.
    European journal of pediatrics, 2013, Volume: 172, Issue:5

    Topics: Adrenergic beta-Antagonists; Aldosterone; Angiotensin II; China; Female; Hemangioma; Humans; Infant;

2013
Great Ormond Street Hospital treatment guidelines for use of propranolol in infantile isolated subglottic haemangioma.
    The Journal of laryngology and otology, 2013, Volume: 127, Issue:3

    Topics: Constriction, Pathologic; Glottis; Hemangioma; Humans; Infant; Laryngeal Neoplasms; Practice Guideli

2013
Congenital disseminated tufted angioma.
    Journal of cutaneous pathology, 2013, Volume: 40, Issue:4

    Topics: Capillaries; Drug Substitution; Female; Glucocorticoids; Hemangioma; Humans; Infant; Prednisone; Pro

2013
Congenital primarily ulcerated hemangioma mimicking cleft lip.
    The Journal of pediatrics, 2013, Volume: 162, Issue:4

    Topics: Cleft Lip; Diagnosis, Differential; Hemangioma; Humans; Infant; Infant, Newborn; Propranolol; Treatm

2013
Nevus anemicus. Donor-dominant defect.
    Archives of dermatology, 1977, Volume: 113, Issue:1

    Topics: Hemangioma; Humans; Male; Middle Aged; Phentolamine; Propranolol; Skin Neoplasms; Skin Transplantati

1977